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ABSTRACT 
 
Colorectal cancer (CRC) is an important public health concern worldwide, especially 
among populations that adopt Western-style diets. Thus, it becomes important to 
investigate new prevention and therapeutic approaches for CRC. The use of 
nutraceuticals have been described as a new strategy in this context by the use of 
dietary Propionibacteria, found in fiber-rich food and dairy products, which produce 
short-chain fatty acids (SCFA). SCFA, namely butyrate, propionate and acetate 
have been described as anti-neoplastic agents, being recognized as an optimal 
strategy for prevention/treatment of CRC. Little was known about the role of acetate, 
but like the other SCFAs, acetate is also able to induce apoptosis in CRC cells. It 
has been previously demonstrated that acetic acid induces apoptosis in 
Sacharomyces cerevisiae. Thus, we aimed to understand the mechanisms 
underlying acetate-induced cell death in CRC cells taking into account the results 
obtained in the yeast model. We also aimed to study acetate transport in CRC cells, 
investigating the involvement of monocarboxylate transporters (MCTs) as well as 
regulation of MCTs expression in response to acetate. Moreover, we wanted to 
verify the effects of acetate in glycolytic metabolism and to explore the combined 
use of acetate with the glycolysis inhibitor 3-bromopyruvate (3BP) as a new strategy 
to potentiate the effect of acetate in CRC cells. Furthermore, we aimed to assess 
the effect of acetate in the main signalling pathway activated in CRC: RAS-RAF-
MEK-ERK. 
Three cell lines derived from human CRC, harbouring different genetic mutations 
namely RKOBRAFV600E, HCT-15KRASG13D and HCT116KRASG13D; PI3KCA were used as 
models. We showed that acetate treatment in CRC cells decreased cell proliferation 
and induced apoptosis. The apoptosis process was characterized by DNA 
fragmentation, caspase-3 activation and phosphatidylserine exposure to the leaflet 
of the plasma membrane and appearance of sub-G1 population. In addition, we 
found that acetate induced partial lysosome membrane permeabilization with 
cathepsin D (CatD) release to the cytosol and that this protease, but not CatB and 
CatL, has an anti-apoptotic role in acetate-induced apoptosis in CRC cells. We next 
showed that acetate treatment induced several mitochondrial dysfunctions as well 
as reactive oxygen species (ROS, total and mitochondrial) accumulation and an 
increase in mitochondrial mass accompanied by mitochondrial membrane 
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depolarization. We could also demonstrate that, like acetic acid in yeast, acetate-
induced apoptosis is not associated with autophagy induction in CRC cells. 
Moreover, inhibition of CatD (with siRNA or pepstatin A) enhanced apoptosis 
associated with higher mitochondrial dysfunction and increased mitochondrial 
mass. This effect seems to be specific of CatD, since inhibition of CatB and CatL 
had no effect, nor were these proteases significantly released to the cytosol during 
acetate-induced apoptosis. Summing up, these results identified a novel function of 
CatD in the degradation of damaged mitochondria when autophagy is impaired, 
protecting CRC cells from acetate-induced apoptosis. 
Furthermore, we showed that acetate enters CRC cells by a sodium dependent 
monocarboxylate transporter (SMCT-1) and passive diffusion by aquaporins. MCT-
1 is also involved in acetate uptake, accompanied by an increase in expression of 
both MCT-1, MCT-4, as well as of the glycosylated form of CD147, the MCT1/4 
chaperone in the presence of acetate. Additionally, we found that acetate promotes 
plasma membrane re-localization of MCT-1 and further triggers changes in glucose 
metabolism (decreasing both glucose consumption and lactate production). Further, 
we explored the combined treatment of acetate with 3BP and we demonstrated that 
3BP potentiates acetate-induced apoptosis in CRC cells.  
Taken together, this work demonstrates a protective role of CatD in acetate-induced 
apoptosis which could negatively impact the efficacy of acetate and probably of 
other therapeutic compounds. Thus, the use of CatD inhibitors in combination with 
strategies to increase acetate concentrations in the colon, namely nutraceuticals, is 
proposed as a new strategy to prevent/treat CRC. Our findings also show a novel 
approach for CRC therapy based on the elimination of CRC cells through their 
sensitization to acetate by association with 3BP and/or other chemotherapeutic 
agent which transport is mediated by MCTs. 
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RESUMO 
 
O cancro colorretal (CCR) é uma importante questão de saúde pública em todo o 
mundo, especialmente nas populações com um estilo de dieta-ocidental. Torna-se 
assim importante investigar novas abordagens de prevenção e terapia para o CCR. 
A utilização de nutracêuticos, tem sido descrita como uma possível abordagem 
neste contexto, nomeadamente o uso das Propionibactérias da dieta, encontradas 
em alimentos ricos em fibras e laticínios, que produzem ácidos gordos de cadeia 
curta (AGCC). Os AGCC, nomeadamente butirato, propionato e acetato têm sido 
descritos como agentes anti-neoplásicos, reconhecidos na prevenção/tratamento 
do CCR. O papel do acetato era pouco conhecido, mas tal como os outros AGCC, 
também é capaz de induzir apoptose em células de CCR. Foi previamente 
demonstrado que o ácido acético induz apoptose em Saccharomyces cerevisiae. 
Deste modo, tivemos como objetivo compreender os mecanismos subjacentes à 
morte celular induzida pelo acetato em células de CCR, tendo em conta os 
resultados obtidos no modelo da levedura. Também tivemos como objetivo estudar 
o transporte do acetato em células de CCR, investigando o envolvimento dos 
transportadores de monocarboxilatos (MCTs) bem como a regulação da sua 
expressão em resposta ao acetato. Além disso, quisemos avaliar os efeitos do 
acetato no metabolismo glicolítico e explorar o uso combinado do acetato com o 
inibidor da glicólise 3-bromopiruvato (3BP) como uma nova estratégia para 
potenciar o efeito do acetato em células de CCR. Procurou-se também avaliar o 
efeito do acetato na principal via de sinalização ativada no CCR: RAS-RAF-MEK-
ERK. 
Foram utilizadas como modelo três linhas celulares derivadas de CCR humano: 
RKOBRAFV600E, HCT-15KRASG13D e HCT116KRASG13D; PI3KCA. Mostramos que o 
tratamento com acetato diminuiu a proliferação celular e induziu a apoptose em 
células de CCR. O processo de apoptose foi caracterizado pela fragmentação de 
DNA, activação de caspase-3, exposição de fosfatidilserina para o folheto externo 
da membrana plasmática e o surgimento de uma população sub-G1. Além disso, 
verificou-se que o acetato induziu permeabilização parcial da membrana lisossomal 
com libertação de catepsina D (CatD) para o citosol, e que esta protease, mas não 
a CatB e a CatL, tem um papel anti-apoptótico na apoptose induzida pelo acetato 
em células de CCR. Em seguida, mostramos que o tratamento com acetato induziu 
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disfunções mitocondriais, assim como a acumulação de espécies reativas de 
oxigênio (nível de ROS, total e mitocondrial) e um aumento da massa mitocondrial 
acompanhado por uma despolarização da membrana. Foi também possível 
demonstrar que, tal como o ácido acético em levedura, a apoptose induzida pelo 
acetato não está associada com a indução de autofagia em células de CCR. Além 
disso, a inibição da CatD (com siRNA ou pepstatina A) aumentou a apoptose 
associada a uma disfunção mitocondrial mais proeminente, bem como a massa 
mitocondrial. Este efeito, parece ser específico da CatD, uma vez que a inibição da 
CatB e CatL não teve nenhum efeito, não havendo libertação destas proteases para 
o citosol durante a apoptose induzida pelo acetato. Resumindo, estes resultados 
identificaram uma nova função da CatD na degradação das mitocôndrias 
danificadas quando a autofagia é perturbada, protegendo assim as células de CCR 
da apoptose induzida pelo acetato.  
Além disso, mostramos que o acetato entra nas células de CCR por um 
transportador de monocarboxilato tipo 1 dependente de sódio (SMCT-1) e por 
difusão passiva mediada por aquaporinas. O MCT-1 está também envolvido no 
transporte do acetato havendo, na presença de acetato, um aumento na expressão 
de MCT-1 e MCT-4, bem como da forma glycosilada da CD147, a chaperona do 
MCT1/4. Adicionalmente, verificou-se que o acetato promove a re-localização do 
MCT-1 para a membrana plasmática desencadeando alterações no metabolismo 
da glicose (diminuindo o consumo de glucose e produção de lactato). Além disso, 
exploramos o tratamento combinado do acetato com o 3BP e demonstramos que o 
3BP potencia a apoptose induzida pelo acetato em células de CCR. 
Neste trabalho demonstramos um papel protetor da CatD na apoptose induzida 
pelo acetato que pode afetar a eficácia do acetato e de outros compostos 
terapêuticos. Propomos assim uma nova estratégia para prevenir e/ou tratar o CCR 
que inclui a utilização de inibidores da CatD em combinação com outras 
abordagens para aumentar as concentrações de acetato no cólon, como o uso de 
nutracêuticos. Os nossos resultados também sugerem uma nova abordagem para 
a terapia do CCR baseada na eliminação de células de CCR através da sua 
sensibilização ao acetato pelo 3BP ou por um outro agente quimioterapêutico cujo 
transporte seja mediado pelo MCT-1. 
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THESIS OUTLINE 
 
The present thesis is organized in five different chapters as follows: 
Chapter 1 is a general introduction and comprises parts of two review articles 
presenting an overview of the literature related with the scope of the thesis, divided 
in three main parts. The first part focuses on the current knowledge on colorectal 
cancer (CRC) (general aspects, incidence, types, the main genetic alterations 
involved in CRC carcinogenesis, risk factors, available treatment options for 
pacients with CRC and the use of nutraceuticals as a strategy to prevent/treat CRC). 
The second part explores the difference between the microbiota from normal colon 
epithelium to CRC, focusing on short-chain fatty acids (SCFAs, especially butyrate, 
propionate and acetate), with respect to their production and metabolism at the 
intestinal level, transporters/receptors and their physiological functions in intestinal 
epithelial cells. The effect of SCFAs in CRC cells is also described, focusing on how 
these compounds can be useful in the prevention or treatment of CRC. The last part 
comprises an overall review about the lysosome as an important player in cancer 
cell death regulation exploring the role of cathepsins (lysosome proteases), namely 
cathepsin D (CatD) in this context. 
Chapters 2, 3 and 4 describe the experimental work and are part of three articles: 
Chapter 2 describes the matherial and methodos used to develop all the 
experimental work, subdivided according to the type of technique. 
In Chapter 3 the results of the thesis are presented, subdivided in subchapters as 
follows: 
3.1: Acetate-induced apoptosis in colorectal carcinoma cells involves 
lysosomal membrane permeabilization and cathepsin D release. 
3.2: Cathepsin D protects colorectal cancer cells from acetate-induced 
apoptosis through autophagy-independent degradation of damaged mitochondria. 
3.3: The role of acetate on monocarboxylate transporter (MCT) expression and 
glucose metabolism in colorectal cancer cells: therapeutic implications. 
3.4: Acetate induces downregulation of ERK1/2 pathway in colorectal cancer 
cells. 
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Chapter 4 comprises a general discussion of the work. 
 
Chapter 5 presents the overall conclusions of the thesis as well as suggestions for 
future work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: 
General introduction 
_________________________________________________________________ 
 
This chapter comprises parts from the following publications: 
 
Pereira H, Oliveira CSF, Castro L, Preto A, Chaves SR, Côrte-Real M (2015). Yeast 
as a tool to explore cathepsin D function. Microbial Cell, 2(7):225-234. 
(In this publication I have participated in the writing of the section regarding cathepsins, its role in 
physiology and pathology and the role of cathepsin D in cancer). 
 
Oliveira CSF, Barreto J, Pereira H, Chaves SR, Baltazar, F, Côrte-Real M, Preto A. 
The role of diet related short-chain fatty acids in colorectal cancer: prevention or 
therapeutic strategy? Paper submitted to Current Pharmaceutical Design.  
(In this publication I am the first author responsible for the design and writing of the manuscript) 
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General introduction  
 
1. Colorectal cancer  
Colorectal cancer (CRC) is a malignant neoplasia localized in the large intestine 
(that comprise the colon), vermiform appendix or rectum (Figure 1). CRC is also 
referred as colon cancer or rectal cancer, depending on where the cancer arises 
and usually have many features in common, which explain the reason why these 
cancers are generally discussed together.  
 
Figure 1: Ilustration of the large intestine. Front of abdomen showing the respective regions of 
the colon, appendix, rectum and anus. 
CRC is among the most common cancers, accounting for over 1 million cases (1.23 
million cases, 9.7% of overall cancer) and about half a million deaths annually 
representing an important health issue worldwide (Zhu, Michelle Luo et al. 2011; 
Cappellani, Zanghi et al. 2013; Stigliano, Sanchez-Mete et al. 2014). CRC is 
currently the third most frequent cancer in men, after lung and prostate cancer, and  
the second most frequent cancer in women, after breast cancer (Samuel Constant 
2013; Mudassar, Khan et al. 2014; Tarraga Lopez, Albero et al. 2014). 
Epidemiological studies have shown that rates of CRC incidence and mortality vary 
substantially across regions of the world (Table 1) (Cotter 2013; Bishehsari, 
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Mahdavinia et al. 2014; Raskov, Pommergaard et al. 2014; Stigliano, Sanchez-Mete 
et al. 2014), with a higher incidence in North America, Europe, Australia and New 
Zeland (Raskov, Pommergaard et al. 2014). Almost 60% of cases occur in 
developed regions, particularly in the United States (where CRC is the third most 
common cancer) and in Europe (Stigliano, Sanchez-Mete et al. 2014), where CRC 
is the second cause of death from all cancer types in both genders, with ~446.000 
new cases arising each year (Altobelli, Lattanzi et al. 2014; Tarraga Lopez, Albero 
et al. 2014). In the particular case of Portugal, CRC is the third most common 
cancer, accounting for 3800 deaths in Portugal in 2013 (Ferreira and Riphaus 2014). 
In Portugal, like in most European countries, CRC incidence is steadily increasing, 
and the number of deaths from CRC increased by 3% per year between 2000 and 
2005 (Cotter 2013; Ferreira and Riphaus 2014). 
Table 1: Estimated rate of incidence and mortality for colorectal cancer, in 2008 in a population of 
100 000 persons, for both sexes, in different regions of the world. 
Region of the world Incidence Mortality 
Norther America 30.1 9.1 
Europe 28.1 12.8 
Eastern Asia 18.0 8.0 
Western Asia 17.9 7.9 
Latin America 11.4 6.6 
South East Asia 6.9 4.8 
Africa 5.9 4.8 
 
 
Adapted from Cotter J, 2013. 
As mentioned above, both incidence and mortality rates are not equally distributed 
among the world, varying according to diferent primary and secondary CRC 
prevention strategies, which can be correlated with the differences in health 
insurance systems and budgets (Cotter 2013). In addition, higher CRC rates have 
been reported especially among populations that adopt Western-style diets, strongly 
linked to changes in lifestyle and exposure to carcinogens (Zhu, Michelle Luo et al. 
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2011; Kim, Coelho et al. 2013; Sobhani, Amiot et al. 2013; Bishehsari, Mahdavinia 
et al. 2014).  
CRC is generally classified into three types: hereditary, familial and sporadic. 
Hereditary/familial CRC derive, in part, from germline mutations comprising 
approximately 10-30% of all CRC cases (Jasperson, Tuohy et al. 2010). 
Hereditary/familial CRC present a well-characterized cancer predisposition 
syndromes including Lynch syndrome, Familial adenomatous polyposis (FAP),  
MUTYH-associated polyposis (MAP), hamartomatous polyposis syndromes 
and hyperplastic polyposis (Jasperson, Tuohy et al. 2010; Tarraga Lopez, Albero 
et al. 2014). Most CRC cases are sporadic (about 70%) and derive from somatic 
mutations, not associated with family history, but linked mainly to environmental 
causes (Kim, Coelho et al. 2013; Sobhani, Amiot et al. 2013; Bishehsari, Mahdavinia 
et al. 2014; Tarraga Lopez, Albero et al. 2014). 
Usually, CRC develops slowly over a period of 10 to 15 years. It is generally due to 
an abnormal growth of cells (polyps) from the intestinal mucosa (Figure 2), with 
approximately 90% of CRCs classified as adenocarcinomas (colon polyps) 
(Tannapfel, Neid et al. 2010; Fleming, Ravula et al. 2012). These polyps are very 
common and most are benign, generally located in the rectum or in the sigmoid 
colon (66% to 77% of cases) (Tannapfel, Neid et al. 2010). If the polyp/adenoma is 
not removed, cells continue to proliferate and may become cancerous and/or 
progress into CRC with the ability to invade or metastasize to other parts of the body 
(Figure 2) (Tannapfel, Neid et al. 2010; Cappellani, Zanghi et al. 2013). Only a small 
percentage of adenomas progress to CRC (Cappellani, Zanghi et al. 2013) through 
the involvement of several genetic alterations that require the accumulation of 
mutations in particular genes that induce genetic and epigenetic changes 
responsible for cell proliferation, apoptosis, angiogenesis and invasion (Tannapfel, 
Neid et al. 2010; Gonsalves, Mahoney et al. 2014). 
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1.1 Genetic alterations associated with colorectal cancer 
A genetic model has been proposed to explain the stepwise formation of CRC from 
normal colonic tissue, a well-known adenoma-carcinoma sequence (Mudassar, 
Khan et al. 2014), which postulates that: 
 CRC is the result of mutations of genes with important functions in regulating 
cell proliferation, repair of DNA damage and apoptosis. 
 Mutations in several genes are required over the years. 
 The sequence of mutations is very important in determining the eventual 
formation of CRC. 
 
Genes involved in the genetic paradigm of CRC can be divided into two main 
classes: tumour suppressor genes (TSGs) and oncogenes (Mudassar, Khan et al. 
2014). TSGs are often inactivated and encode proteins that either inhibit cell 
proliferation or promote apoptosis. In contrast, oncogenes are activated versions of 
protooncogenes, which are often involved in promoting cell proliferation and cancer 
development. Once activated, oncogenes can lead to accelerated cell growth and 
contribute to tumour formation. The main molecular changes involved in the CRC 
carcinogenesis are illustrated in Figure 2.  
Figure 2: Colorectal carcinogenesis from normal epithelium to colon cancer. The main 
mutations in CRC development are shown: Adenomatous polyposis coli (APC), K-RAS, BRAF, p53, 
SMAD4, Microsatellite instability (MSI), Mismatch repair (MMR), Chromosomal instability (CIN). 
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The primary genetic alteration in CRC carcinogenesis involves the adenomatous 
polyposis coli (APC) gene mutation. Secondary genetic alterations occur with 
activation of the KRAS or BRAF oncogenes, followed by inactivation of the TSG 
p53, as well as microsatellite and chromosomal instability (MSI) (Tannapfel, Neid et 
al. 2010; Mudassar, Khan et al. 2014). 
APC is a tumour supressor gene mutated both in inherited and sporadic CRC forms 
(Smith, Carey et al. 2002; Waldner and Neurath 2010). Germline mutations in this 
gene lead to development of a high number of premalignant polyps in the colon of 
individuals affected with familial adenomatous polyposis (FAP) (Aoki and Taketo 
2007; Waldner and Neurath 2010; Raskov, Pommergaard et al. 2014). In cases of 
sporadic CRC, APC mutations are present in microscopic adenomas (~50-60%) 
(Smith, Carey et al. 2002; Aoki and Taketo 2007). The APC gene product is a protein 
(~312 kDa) that functions as a “gatekeeper” that regulates the entry of intestinal 
epithelial cells into the adenoma-cancer progression (Smith, Carey et al. 2002). At 
the molecular level, APC is a negative regulator of the Wnt-signalling pathway, 
which is critical during cellular proliferation and differentiation (Raskov, 
Pommergaard et al. 2014; Russo, Catania et al. 2014). APC is a multi-domain 
protein that contains binding sites for numerous other proteins, including 
microtubules components, Wnt pathways regulators – axin, β-catenin and the 
cytoskeletal regulators EB1 (Smith, Carey et al. 2002; Aoki and Taketo 2007). Most 
APC mutations occur in a region referred to as the mutation cluster region (MCR), 
resulting in C-terminal truncations that cause loss of the protein domain required for 
binding to β-catenin and microtubules (Aoki and Taketo 2007). This leads to 
accumulation of nuclear β-catenin and activation of targets of the canonical Wnt 
signalling pathway (Aoki and Taketo 2007; Raskov, Pommergaard et al. 2014).  
Other mutations implicated in CRC development are activation of KRAS and BRAF 
oncogenes frequently found in sporadic CRC - in approximately 35-40% and 5-10% 
of the CRC cases, respectively (Figure 3) (Velho, Moutinho et al. 2008; Yokota 
2012; Gonsalves, Mahoney et al. 2014; Raskov, Pommergaard et al. 2014; 
Sridharan, Hubbard et al. 2014). KRAS (Kirsten rat sarcoma) belongs to the 
RAS protein family. It is a proto-oncogene on chromosome 12 and encodes a GTP-
binding protein (21 kDa) capable of receiving signals from tyrosine kinase receptors, 
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integrating mitogenic messages from the outside of the cell; when KRAS is 
stimulated, it anchors GTP (releasing GDP), which turns on its active state that 
triggers a signalling cascade known as RAS-RAF-MEK-ERK (Smith, Carey et al. 
2002; Yokota 2012).  KRAS hotspot mutations are found most commonly at codons 
12 or 13, dominated by G→A transitions at the second base of the respective codon 
resulting in G12D or G13D mutations(Figure 3) (Prior, Lewis et al. 2012). These 
mutations can usually lead to abnormal cell proliferation and malignant cell 
transformation (Smith, Carey et al. 2002). It is known that mutated KRAS is 
constitutively activated, permanently stimulating growth and differentiation in CRC 
cells (Bos 1989). Altered KRAS is found both in CRC and in large colorectal 
adenomas, but less frequently in small adenomas, which suggests that the mutation 
appears before the acquisition of the malignant state and that its presence confers 
a growth advantage (Leslie et al., 2002). In recent years, it has been described that 
KRAS mutations limit the effects of anti-EGFR therapy (Tannapfel, Neid et al. 2010; 
Waldner and Neurath 2010; Yokota 2012), and the use of agents such as Cetuximab 
have to be limited to patients with KRAS wild-type CRC (Waldner and Neurath 2010; 
Yokota 2012; Raskov, Pommergaard et al. 2014). Our group has also studied the 
role of KRAS in CRC and recently demonstrated that KRAS hotspot mutations play 
a role in autophagy regulation, which might have important therapeutic implications 
(Alves, Castro et al. 2015). 
Like in the case of KRAS, mutated BRAF is also involved in the alteration of RAS-
RAF-MEK-ERK pathway in CRC cases (Velho, Moutinho et al. 2008).  BRAF 
encodes a protein (94 kDa) of the RAF family of kinases and operates by binding to 
RAS (Tannapfel, Neid et al. 2010; Yokota 2012). The most common mutation found 
in CRC carcinogenesis is the classic GTG→GAC substitution at position 1799 of 
exon 15, which results in the V600E amino acid change and the subsequent 
constitutive activation of the EGFR signalling pathway (Yokota 2012). In addition, 
BRAF mutations have been described as a strong negative prognostic marker in 
patients with CRC, since patients have demonstrated very poor response to 
conventional chemotherapy, especially to anti-EGFR therapy (Yokota 2012). Preto 
et al have demonstrated that BRAF might be an important therapeutic target in CRC 
harbouring a BRAFV600E mutation (Preto, Figueiredo et al. 2008). 
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Furthermore, experimental evidence has shown that KRAS and BRAF mutations do 
not overlap in colorectal cancer (Rajagopalan et al., 2002), but both lead to the 
constitutive activation of the pathway (MEK-ERK), which suggests that this is an 
important hit in the development of this type of cancer. 
 
Figure 3: Frequence of KRAS, NRAS and BRAF mutations in CRC cases. The image also shows 
the main codons mutaded in these genes. (Adapted from Sridharan et al. 2014). 
Another important step in colon carcinogenesis is the loss of p53 function which has 
been reported to occur relatively late in the development of CRC tumors (Smith, 
Carey et al. 2002).  The TP53 gene, located on chromosome 17p, is mutated in 70% 
of all CRC tumors (Smith, Carey et al. 2002). The gene encodes the p53 protein, a 
well-known “guardian of the genome” (Raskov, Pommergaard et al. 2014), 
responsible for inhibiting cell proliferation whenever DNA damage exists. If the repair 
mechanisms fail, p53 initiates an apoptotic programme, preventing cell to proliferate 
(Hollstein, Sidransky et al. 1991). However, if p53 is mutated and DNA damage is 
not repaired, damage is spread to the daughter cells. In this case, it has been 
demonstrated that mutation in the TP53 gene is crucial to progression from non-
invasive to invasive disease, found in the following frequences: adenomas (5%), 
malignant polyps (50%) and invasive CRC (75%) with a increasing frequency 
correlated to the extent of malignancy (Raskov, Pommergaard et al. 2014). 
SMAD4 is another tumor suppressor gene often mutated in colorectal cancer. The 
SMAD4 protein is part of the transforming growth factor β (TGF-β) signalling 
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pathway, which is responsible for controlling the expression of cell cycle regulators, 
differentiation factors and cell adhesion factors (Massaous and Hata 1997). SMAD4 
forms heterodimers with other SMAD proteins, acting as transcription factors (Hahn, 
Schutte et al. 1996; Imamura, Takase et al. 1997). However, mutation of SMAD4 
impairs its regulatory activity, blocking the transcription of important genes 
necessary for cell cycle control and apoptosis (Woodford-Richens, Rowan et al. 
2001). As cancer progresses, the mutation rate in this gene increases; it is found 
mutated in about 31% of the metastatic colorectal cancer (mCRC) cases (Miyaki, 
Iijima et al. 1999; Maitra, Molberg et al. 2000), suggesting that loss of this gene is 
important for the development of the metastatic state. 
Following these key genetic alterations, a number of acquired genetic mutations in 
other genes, including PIK3CA, FBXW7, SMAD2, TCF7L2, NRAS, FAM123B 
CTNNB1, have also been described to contribute to colorectal carcinogenesis 
(Keku, Dulal et al. 2015).  
Moreover, genetic instability termed as microsatellite instability (MSI) appears in 12-
15% of the CRC cases (Raskov, Pommergaard et al. 2014). Microsatellites are 
repeated mono to tetra-nucleotide sequences distributed throughout the genome 
arising from a mismatch repair (MMR) deficiency. During DNA amplification, these 
sequences can be repeated many times (~10-60) and replication errors in those 
sequences may occur naturally (Tannapfel, Neid et al. 2010). There are various 
proteins which recognize incorrect base pairs within DNA and “repair” DNA damage. 
However, if one of these proteins is altered, incorrect pairs can accumulate in the 
form of mutations in genes involved in tumor progression (Tannapfel, Neid et al. 
2010).  
Data have also shown the presence of chromosomal instability (CIN) as a result of 
structural or numerical chromosomal changes in about 65-70% of CRCs (Waldner 
and Neurath 2010). These changes can lead to uncontrolled growth and 
differentiation associated with CRC development (Tannapfel, Neid et al. 2010; 
Mudassar, Khan et al. 2014). 
In addition to these somatic mutations, CRC progression is also due to epigenetic 
modifications in the expression of genes that regulate proliferation, apoptosis and 
DNA repair (Cappellani, Zanghi et al. 2013). These epigenetic alterations are 
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characterized mainly by hypermethylation of the cytosine residues in CpG-rich 
sequences (CpG-islands) located within the promoter regions of expressed genes. 
It is important to note that this does not alter DNA integrity, but methylation of these 
sequences can induce progressive silencing of DNA-repair genes and tumor 
suppressor genes promoting abnormal cell proliferation (Cappellani, Zanghi et al. 
2013).  
1.1.2 Colorectal cancer risk factors 
CRC has been characterized as a multifactorial disease process which may include 
hereditary/familial factors, age, environmental lifestyle-related risk factors (diet, 
physic inactivity, obesity, smoking, alcohol consumption) as well as inflammatory 
conditions of the digestive tract and, more recently, changes in intestinal microbiota 
composition (Figure 4) (Bishehsari, Mahdavinia et al. 2014; Mudassar, Khan et al. 
2014; Kumar, Sastry et al. 2015). According to the Centre for Disease Control and 
Prevention, patients with family history of CRC have a higher risk of developing CRC 
themselves (Mudassar, Khan et al. 2014).  
Regarding age, CRC is commonly found in patients aged 50 years and over 
(Mudassar, Khan et al. 2014). Interestingly, the most common risk factor includes 
dietary regimen rich in sugar and proteins, especially with high intake of red meat, 
processed meat, animal fats and usually poor in whole grain, vitamin D, fruits, 
vegetables, cereals and fibers (Cappellani, Zanghi et al. 2013; Kim, Coelho et al. 
2013; Bishehsari, Mahdavinia et al. 2014). The association between high red and 
processed meat intake and CRC risk includes the content of the meat and 
compounds generated by the cooking process (e.g. N-nitroso compounds) (Kim, 
Coelho et al. 2013). These factors can affect the large intestine mucosa with 
genotoxicity and metabolic disturbances contributing to colon carcinogenesis (Kim, 
Coelho et al. 2013; Raskov, Pommergaard et al. 2014).  
Obesity is another risk factor associated with CRC development (Cappellani, Zanghi 
et al. 2013). One of the mechanisms involved in the obesity-CRC relationship seems 
to be an asymptomatic chronic inflammation of the colonic mucosa associated with 
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an alteration of the dominant phyla of bacteria in the gut and of body weight both in 
humans and in animal models (Zhu, Michelle Luo et al. 2011). 
Another emerging risk factor involved in CRC is altered intestine microbiota 
composition (Zhu, Michelle Luo et al. 2011; Kumar, Sastry et al. 2015). Since the 
microbiota impacts numerours physiological functions in the gut, some studies have 
shown that significant changes in the microbiota composition, especially of some 
bacterial groups that are able to produce metabolites which cause inflammation, 
correlated with tumor initiation/progression (Cappellani, Zanghi et al. 2013; Kumar, 
Sastry et al. 2015). 
Tobacco smoking acts on the mucosa though the production of carcinogenic agents 
(such as acetaldehyde, benzopyrenes, aromatic amines and N-nitrosamines) and 
also increases the risk of microsatellite instability (Bishehsari, Mahdavinia et al. 
2014; Raskov, Pommergaard et al. 2014). Furthermore, excessive alcohol 
consumption can also accelerate CRC initiation and progression by triggering 
inflammation and epigenetic changes (Bishehsari, Mahdavinia et al. 2014).  
 
Figure 4: Main factors contributing to the risk of CRC development (Adapted from Kumar et al. 
2015). 
It has been demonstrated that CRC may be highly amenable to prevention through 
a dietary fiber consumption (Zeng, Lazarova et al. 2014). Many of these benefits 
can be attributed to the fermentation of dietary fiber into short chain fatty acids 
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(SCFAs) (Zeng, Lazarova et al. 2014), described as anti-tumorigenic agents in the 
colon (Tang, Chen et al. 2011; Adom and Nie 2013; Marques, Oliveira et al. 2013; 
Zeng, Lazarova et al. 2014). Likewise, primary and secondary prevention, in 
attention to a healthy lifestyle, physical activity and screening should be enhanced 
in the general population to decrease the risk of CRC as well as its incidence and 
mortality. 
1.1.2 Colorectal cancer therapy 
The main symptoms of CRC are changes in bowel habits, rectal bleeding, 
abdominal pain, anemia, weight loss and feeling tired all the time. Due to the slow 
progression of CRC, early detection of polyps and smaller lesions in the colon 
through several available screening methods, including rectal exam, fecal blood 
test, colonoscopy and sigmoidoscopy, is possible (Delavari, Mardan et al. 2014).  
The majority of CRC cases would benefit from surgical treatment if diagnosed early 
or at the stage of the premalignant polyps (Pawa, Arulampalam et al. 2011). 
However, at diagnostic, about 20% of patients are already in a metastatic state; 
when the disease is considered incurable, palliative care (“best supportive care”) is 
selected as the best strategy to treat the patient (Lucas, O'Neil et al. 2011). At 
previous stages of the disease, many therapeutic strategies may be adopted, 
generally starting with tumor resection, either endoscopically or surgically. In some 
cases, the tumor is removed completely and no further treatment is needed except 
follow-up visits. After characterization of the CRC stage and in the case of advanced 
cancer with lymph nodes or any other tissue metastization, additional treatment is 
required.  
The chemotherapeutic options for this type of cancer may be divided in two main 
groups. The first group, cytotoxic chemotherapy, englobes classical 
chemotherapeutic agents (5-fluorouracil, 5-FU), Capecitabine, Irinotecan and 
Oxaliplatin) (Sridharan, Hubbard et al. 2014). The other group is known as targeted 
therapy, and is divided into three main classes of biological agents: (1) monoclonal 
antibodies against the epidermal growth factor receptor (EGFR) on the surface of 
tumor cells (Cetuximab and Panitumumab); (2) inhibitors of the vascular endotelial 
General introduction 
38 
growth factor (VEGF) proangiogenic system (Bevacizumab and Aflibercept) and (3) 
small-molecule inhibitor of intracellular kinases involved in various signalling 
cascades (Regorafenib) (Sridharan, Hubbard et al. 2014). The use of glycolysis 
inhibitors as potential anticancer agents has also been proposed, since most cancer 
cells, including CRC cells, exhibit increased glycolysis and use this metabolic 
pathway for ATP generation as the main source of their energy supply, a 
phenomenon known as Warburg effect (Pelicano, Martin et al. 2006; Pedersen 
2012; Amorim, Pinheiro et al. 2015). 
These chemotherapeutic modalities may use one drug at a time (as single-agent 
chemotherapy) or several drugs at once (combination chemotherapy) (Sridharan, 
Hubbard et al. 2014). An overview regarding the different treatment options for CRC 
available today is presented in Table 2. Their main advantages, modes of action 
and side effects are described in the next sections. 
1.1.3.1 Classical chemotherapy relies on cytotoxic agents  
Traditional chemotherapeutic agents are cytotoxic i.e, they act by targeting cells that 
divide rapidly, one of the main properties of most cancer cells. However, cytotoxic 
agents also harm cells that divide rapidly under normal circumstances: cells in 
the bone marrow, digestive tract, and hair follicles, resulting in the most common 
side effects of chemotherapy: myelosuppression (decreased production of blood 
cells, hence also immunosuppression), mucositis (inflammation of the lining of the 
digestive tract), and alopecia (hair loss). Despite these severe side effects, these 
agents have been extensively used in CRC chemotherapy. 
The approved conventional cytotoxic agents are classified into three main classes: 
fluoropyrimidines (5-fluorouracil and capecitabine), topoisomerase I inhibitors 
(irinotecan) and platinum-containing compounds (oxaliplatin) (Sridharan, Hubbard 
et al. 2014). 
5-fluorouracil (5-FU) is the main anticancer agent used in CRC therapy, and one 
of the most effective (Gill, Thomas et al. 2003; Lucas, O'Neil et al. 2011). 5-FU 
abrogates DNA synthesis by inhibiting thymidylate synthase (TS), an enzyme that 
is essential for de novo synthesis of thymidine, the precursor of thymine nucleotide 
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(Papamichael 1999; Gill, Thomas et al. 2003). This agent is usually administered in 
combination with other chemical compounds, particularly with folinic acid 
(leucovorin, LV), which  stabilizes the interaction between 5-FU and TS (Lucas, 
O'Neil et al. 2011) improving the anti-metabolite effect of 5-FU, resulting in a faster 
response to this chemotherapy (Gill, Thomas et al. 2003). However, by combining 
5-FU and LV, the toxicity of the first is also enhanced, resulting in the appearance 
of several and more hazardous side effects, though the overall survival time is 
extended in about one year (Lucas, O'Neil et al. 2011). 5-FU treatment raises 
several side effects, particularly myelosuppression (a decrease in production of 
blood cells by bone marrow), diarrhea, stomatitis, nausea, vomiting, alopecia and 
cardiotoxicity, among several others (Board and Valle 2007).  
Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine) (available as 
Xeloda®) is an oral fluoropyrimidine produced as a pro-drug of fluorouracil (FU) 
(Koukourakis, Kouloulias et al. 2008). This drug has provided compelling efficacy 
data for CRC treatment (stage III or IV), both as monotherapy and in combination 
regimens (Koukourakis, Kouloulias et al. 2008). The preferential conversion of 
capecitabine to 5-fluorouracil in neoplastic tissues renders this fluoropyrimidine 
particularly appealing for clinical use (Koukourakis, Zacharias et al. 2010). The 
enzyme thymidine phosphorylase, necessary to convert this pro-drug, is an active 
form expressed in higher concentration in neoplastic compared to healthy tissues, 
which makes capecitabine more tumor-specific than other chemotherapeutic agents 
(Koukourakis, Zacharias et al. 2010). The main side effects of  capecitabine are 
neutropenia, stomatitis and diarrhea, which often occur due to nonselective 
cytotoxicity (Koukourakis, Kouloulias et al. 2008). 
Irinotecan (also known as CPT-11 and available as Camptosar®) is a semi-
synthetic derivative of the natural alkaloid camptothecin which targets the activity of 
topoisomerase I and exerts its cytotoxic effect by causing DNA damage (Gill, 
Thomas et al. 2003). Irinotecan has been approved for CRC patients whose tumors 
did not respond to 5-FU treatment (Oguro, Seki et al. 1990). Normally, this type of 
treatment is combined with other chemotherapeutical agents, including 5-FU/LV, 
increasing the response rate, progression-free survival (about seven months) and 
overall survival (about seventeen months) (Lucas, O'Neil et al. 2011). Irinotecan is 
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also responsible for several secondary effects, namely diarrhea and 
myelosuppression (Xu and Villalona-Calero 2002; Gill, Thomas et al. 2003). 
Oxaliplatin (available as Eloxatin®) was the first platinum-based therapy approved 
for CRC treatment and, like other platinum-based therapies, this compound 
intercalates in DNA, impairing DNA replication and transcription, abrogating cell 
proliferation (Graham, Mushin et al. 2004). Oxaliplatin alone does not have 
important anti-cancer properties, but when combined with other anticancer agents, 
particularly fluoropyrimidines (Lucas et al., 2011) or bevacizumab (Okines and 
Cunningham 2009), its anti-cancer properties are enhanced. By adding this 
platinum-based compound to 5-FU, the progression free survival is increased, but 
the overall survival time remains unaltered (Lucas, O'Neil et al. 2011). The main 
secondary effects that arise due to the treatment with oxaliplatin are nausea, 
vomiting and sensory neuropathy, and the most severe cases may present 
dysesthesia in the hands, feet and in perioral area (Di Francesco, Ruggiero et al. 
2002)  (Di Francesco et al., 2002). 
There are other platinum-based compounds widely used in CRC treatment. In fact, 
oxaliplatin appeared in response to the emerging necessity of overcoming the 
secondary effects induced by cisplatin, another platinum-based therapy widely 
used in cancer treatment (Graham, Mushin et al. 2004), despite the fact that it is not 
the preferred treatment regarding CRC. Cisplatin binds DNA, creating cross-links 
between purine bases, both in the same DNA strand or between different DNA 
strands, inducing DNA damage responses (Oliver, Mercer et al. 2010). Likewise, 
cisplatin treatment also leads to severe side effects, including neurotoxicity, 
nephrotoxicity, myelotoxicity, nausea, vomiting and auditory impairment (Di 
Francesco, Ruggiero et al. 2002).  
As cytotoxic chemotherapeutic agents target cells in rapid proliferation, normal cells 
within the organism may also be affected, resulting in the appearance of adverse 
effects that affect the quality of life (Gerber 2008). To overcome these effects 
caused by cytotoxic chemotherapy, specific targeted therapies started to be 
explored. 
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1.1.3.2 Targeted therapies for colorectal cancer treatment 
Targeted therapies comprise chemical agents that interfere specifically with 
molecules necessary for the appropriate tumor development and growth. Those 
agents usually have antibody specificity and normally inhibit signalling pathways that 
are important for cancer development and maintenance, resulting in diminished 
toxicity for normal tissues (Cohen, Cohen et al. 2005). Furthermore, in normal cells, 
the targeted molecules are expressed at lower levels than those found in cancer 
cells, or are not expressed at all. The progress in this field opened the possibility of 
creating more personalized CRC treatments, since patients can be administered 
with specific drugs depending on the mutations found (Gerber 2008). 
Two types of chemical agents used as targeted therapies have been distinguished: 
monoclonal antibodies and small molecule inhibitors. The first are large, water-
soluble molecules, with a molecular weight of about 150.000 Da and act by binding 
to the extracellular part of the cells that contain their receptors (Gerber 2008; Tol 
and Punt 2010). The latter are small molecule inhibitors which block signals by 
interfering with intracellular molecules that intervene in signalling transduction 
pathways in response to extracellular stimuli; these inhibitors have a lower 
molecular weight (about 500 Da) and must enter the cells to perform their function 
(Gerber 2008). 
The role of targeted therapies on CRC therapy will be explored, focusing particularly 
on monoclonal antibodies, since they are used widely in CRC treatment. The 
targeted biologic therapies available for CRC fall into three groups: monoclonal 
antibodies against the epidermal growth factor receptor (EGFR), inhibitors of the 
vascular endothelial growth factor (VEGF) proangiogenic system and an oral small-
molecule inhibitor of intracellular kinases involved in various signalling cascades.  
1.1.3.2.1 Monoclonal antibodies in colorectal cancer treatment 
The main targets of the antibodies used in CRC therapy are molecules important in 
cell proliferation, invasion, migration and angiogenesis. An example is the Epidermal 
Growth Factor Receptor (EGFR, also known as ErB1 or HER1), a member of the 
ERbB transmembrane receptor family with tyrosine kinase activity responsible for 
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stimulating several signalling pathways. Therefore its activation results in a wide 
range of cellular responses, including mitogenic stimulation, changes in cell 
adhesion that eventually allow motility or, in some cases, cell death (Mendelsohn 
and Baselga 2006; Sridharan, Hubbard et al. 2014). The RAS-RAF-MEK-ERK 
pathway is triggered by activation of EGFR, resulting in cell proliferation and 
survival, and hence it is not surprising that EGFR plays important roles in cancer 
development (Alroy and Yarden 1997). EGFR is normally present in epithelial cells, 
found, for example in skin and mucosa (Gerber 2008), and is overexpressed in 25 
to 77% of CRC cases (Hoy and Wagstaff 2006), particularly the most aggressive.  
Overexpression of EGFR therefore carries a negative prognostic value (Spano, 
Lagorce et al. 2005). Monoclonal antibodies targeting EGFR have already been 
developed; cetuximab and panitumumab are two examples of FDA-approved 
agents for CRC treatment (Tol and Punt 2010).  
Cetuximab (commercially available as Erbitux®) inhibits tumor development by 
binding to the extracellular domain of EGFR, impairing activation of the receptor 
(Blick and Scott 2007). This human-mouse chimeric monoclonal antibody exhibits 
anti-tumor properties in mCRC cells expressing EGFR that do not harbor mutations 
in KRAS or BRAF by inducing cell-cycle arrest and apoptosis, inhibiting 
angiogenesis and metastasis (Blick and Scott 2007; Tol and Punt 2010). As KRAS 
and BRAF are downstream of EGFR in the signalling pathway, mutations in those 
molecules can trigger activation of the signalling pathway even without ligand-
dependent stimulation, circumventing the action of cetuximab (Khambata-Ford, 
Garrett et al. 2007). Cetuximab can be used both combined with classical 
chemotherapeutical agents (such as irinotecan) or in monotherapy. Evidence has 
shown that 22.5% of patients that no longer respond to treatments based on 
irinotecan start responding to treatments with cetuximab and irinotecan combined, 
and 10% positively respond to treatments based only on cetuximab (Mendelsohn 
and Baselga 2006). 
EGFR is also present in normal tissues, and inhibition of its downstream signalling 
pathways may lead to local undesired side effects. In fact, several secondary effects 
due to cetuximab treatment are reported, particularly associated with dermatological 
and gastrointestinal toxicities. The most severe secondary effects include 
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cutaneous rash, diarrhea, nausea and vomiting (Gerber 2008). Normally, the 
appearance of a cutaneous rash suggests that the treatment is working (Agero, 
Dusza et al. 2006).  
Panitumumab (commercially available as Vectibix®) is another monoclonal 
antibody highly selective for EGFR, also responsible for blocking the activation of 
this receptor. Unlike cetuximab, panitumumab is a fully human monoclonal antibody 
and is used to impair cell proliferation and survival, as well as to diminish pro-
inflammatory cytokine production due to EGFR activation (Hoy and Wagstaff 2006). 
As with cetuximab, this type of treatment is only effective in tumors with non-mutated 
KRAS (Amado, Wolf et al. 2008). Panitumumab is used as a therapeutic agent both 
in monotherapy (when the patient fails to respond to other types of chemotherapy, 
such as fluoropyrimidines and irinotecan) or combined with other 
chemotherapeutical agents (Kohne, Hofheinz et al. 2012). Several secondary 
effects are associated with panitumumab treatment, including skin rash, fatigue, 
abdominal pain, nausea, vomiting, diarrhea, constipation and hypomagnesaemia 
(Hoy and Wagstaff 2006). 
There are many other players in colon carcinogenesis, and thus EGFR is not the 
only possible target for antibody-based treatments. It is known that angiogenesis is 
fundamental for tumor development, and some evidence shows that tumors are 
unable to grow more than 3 millimeters away from the surrounding vasculature 
(Gerber 2008). 
Vascular endothelial growth factor (VEGF) comprises a family of key molecules that 
regulate angiogenesis and vascular permeability. Their expression is negligible in 
adult tissues, except in the process of wound healing and in female sexual cycle 
related processes, such as endometrial development (Rosen 2002). VEGF is 
overexpressed in about 50% of CRC cases, and it is minimally expressed or absent 
in normal colon mucosa and in adenomas (Bendardaf, Buhmeida et al. 2008). VEGF 
overexpression is correlated both with disease progression and with negative 
prognostic, because tumors that highly express this molecule tend to be more lethal 
than those that do not (Bendardaf, Buhmeida et al. 2008). 
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Expression of VEGF is triggered, among other circumstances, under hypoxic 
conditions and through the activation of EGFR-related pathways (Niu, Wright et al. 
2002). The major importance of VEGF overexpression in mCRC lays on the fact that 
tumor cells need to reach the bloodstream in order to metastasize (Sridharan, 
Hubbard et al. 2014).  
The rationale for targeting VEGF lies on the fact that, by inhibiting its action, tumor 
growth is circumscribed due to the limited access to blood vessels and nutrients 
(Gerber 2008). However, it is believed that the mode of action of anti-VEGF agents 
is far more complex and may involve several other mechanisms (Ellis and Hicklin, 
2008). Some side effects may arise due to this type of treatment, namely bleeding, 
thrombosis and hypertension (Gerber 2008).  
In CRC treatment, bevacizumab (available as Avastin®) was the first anti-
angiogenic agent approved by US Food and Drug Administration (FDA), and is the 
most common anti-VEGF therapy used today (Sridharan, Hubbard et al. 2014). 
Bevacizumab is used in mCRC treatment in combination with classical 
chemotherapeutic agents, including 5-FU/LV, irinotecan and oxaliplatin (Okines and 
Cunningham 2009). This type of treatment appears to improve the progression free 
survival time, but has no significant impact in the overall survival time (Okines and 
Cunningham 2009).  
Bevacizumab appears to induce apoptosis, blocking VEGF-mediated stimulation of 
endothelial progenitor cells and normalizing tumor vasculature, which has significant 
impact in chemotherapeutic delivery improvement (Okines and Cunningham 2009). 
Moreover, evidence has shown that by targeting VEGF the immune response 
against cancer cells is improved by enhancing differentiation of dendritic cells; 
VEGF appears to inhibit their differentiation, which impairs the ability to present 
antigens and affects the immune response against cancer cells in VEGF-positive 
cancers (Ellis and Hicklin 2008). Despite all these advantageous features, targeted 
treatments against VEGF raise several secondary effects that may compromise the 
treatment success including hypertension, thrombosis, intestinal perforation and 
wound healing impairment (Okines and Cunningham 2009). 
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Due to the success of bevacizumab, several compounds targeting VEGF-signalling 
such as sunitinib, cediranib and sorafenib have been developed and are currently 
being tested in clinical trials on human cancers, including CRC (Ferrarotto and Hoff 
2013). These compounds include specific anti-VEGF agents, multitargeted agents 
that selectively inhibit VEGF receptors, and multikinase inhibitors that target VEGF 
receptors and other kinases that contribute to tumor development (Ferrarotto and 
Hoff 2013). 
1.1.3.2.2 New anti-angiogenesis therapies 
Like bevacizumab, another active agent against angiogenesis was recently 
appoved by the FDA as a second-line therapy for the treatment of mCRC (Wang 
and Lockhart 2012). Aflibercept (available as Zaltrap®) is a recombinant protein 
consisting of the key domains of VEGF receptors 1 and 2. This agent captures and 
blocks the isoforms of VEGF-A and VEGF-B, and therefore inhibits angiogenesis 
(Wang and Lockhart 2012). It has been used particularly in combination with 
cytotoxic chemotherapy, such as FOLFOX (Leucovirin/5-FLU/Oxaliplatin) and 
ILV5FU2 (5-FLU/Leucovirin/Irinotecan) (Wang and Lockhart 2012). The most 
common adverse symptoms are hypertension, proteinuria, fatigue, and diarrhea 
(Wang and Lockhart 2012).  
Regorafenib (available as Stivarga®) is an oral multikinase inhibitor that has shown 
antitumor activity against a range of solid tumors, including CRC (De Wit, Boers-
Doets et al. 2014). Studies have demonstrated that this compound targets cell 
signalling pathways such as RAF/MEK/ERK signalling and is also involved in the 
inhibition of protein kinases associated with angiogenesis (e.g., VEGFR 1–3) (Yan 
and Grothey 2015). In particular, regorafenib blocks several protein kinases that 
either prompt tumor cells to grow or help form new blood vessels to feed the tumor. 
This agent is generally used in patients with advanced CRC that cannot be surgically 
removed and no longer respond to other appropriate treatments (De Wit, Boers-
Doets et al. 2014; Yan and Grothey 2015). Common side effects include fatigue, 
decreased appetite, hand-foot syndrome (redness and irritation of the hands and 
feet), diarrhea, sores in the mouth and throat, weight loss, infections, and high blood 
pressure (De Wit, Boers-Doets et al. 2014). Some serious side effects that can occur 
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include liver damage, severe bleeding and perforations in the stomach or intestines 
(De Wit, Boers-Doets et al. 2014). 
So far, chemotherapeutic agents have been used as the first choice for CRC 
treatment and also to prolong the survival of pacients. However, as previously 
mentioned, these chemical anticancer drugs have important adverse effects. To 
overcome these problems, nutraceuticals have been extensively investigated for the 
prevention and/or therapy of CRC. These nutritional compounds have the additional 
benefit of improving the overall health of the patient. 
Table 2: FDA-Approved Agents and indications in Metastatic Colorectal Cancer (Dezember 2013). 
Class of 
Agent (s) 
 Trade name Target 
Approved 
as single 
agent 
Approved in 
combination 
with other 
agents 
 
 
Cytotoxic 
chemoterapy 
Fluoracil 
Efudex 
Adrucil 
Flouroplex 
DNA 
synthesis 
+ + 
Capecitabine Xeloda 
DNA 
synthesis 
+  
Irinotecan Camptosar 
DNA 
synthesis 
+ + 
Oxaliplatin Eloxatin 
DNA 
synthesis 
 
+ 
 
EGFR 
antibody 
Cetuximab Ertibix 
Blocks EGFR 
pathway 
+ + 
Panitumumab Vectibix 
Blocks EGFR 
pathway 
+ 
 
 
VEGF 
inhibitor 
Bevacizumab Avastin Blocks VEGF   
Aflibercep Zaltrap Blocks VEGF  
+ 
 
Multikinase 
inhibitor 
Regorafenib Stivarga 
Inhibits 
VEGFR (1-3) 
+  
Adapted from Sridhran et al. 2014. 
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1.2 The role of nutraceuticals in colorectal cancer 
The term nutraceutical is known as a food (or part of the food) that provides medical 
or health benefits for the consumer (Arora and Baldi 2015). It is also defined as 
functional food, ranging from natural diets (medicinal plants, marine organisms, 
vegetables, fruits) and herbal products to genetically engineered foods and 
processed products such as cereals, soups and beverages providing the body with 
the required amount of vitamins, fiber, proteins, carbohydrates, microrganisms, etc., 
needed for body health (Figure 4) (Singh and Sinha 2012). At present, these 
compounds are available in foods, dietary supplements and as pharmaceutical 
formulations (capsules, tablets and powders) by the medicinal and commercial 
industries (Arora and Baldi 2015).  
 
Figure 4: Different classes of nutraceuticals and their uses. Adapted from Kuppusamy, 2014. 
Dairy products that contain nutraceuticals have represented a new research area in 
the last decade due to their presumed safety and potential nutritional properties, 
especially in the gastrointestinal tract, namely in the prevention of diarrhea or 
obstipation, stimulation of mineral adsorption, modulation of the metabolism of the 
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intestinal flora, effects on lipid metabolism, immunomodulatory properties and 
cancer prevention (Kuppusamy, Mashitah et al. 2014). 
It has been suggested that consumption of nutraceuticals (especially fibers and 
some mircrorganisms) may decrease the risk of colon cancer development 
(Fotiadis, Stoidis et al. 2008). In this case, the beneficial effects of these 
components in retarding carcinogenesis is attributed to their anti-carcinogenic 
activity, which provides a strong support for the acceptance of these nutraceuticals 
as chemopreventive agents (Cencic and Chingwaru 2010; Kuppusamy, Mashitah et 
al. 2014). At present, they are classified into three main groups: probiotics, 
prebiotics and synbiotics (Fotiadis, Stoidis et al. 2008). 
Probiotics are characterized by the Food and Agricultural Organization/World 
Health Organization (FAO/WHO) as “live micro-organisms that, when administered 
in adequate amounts, confer a health benefit on the host” (Arora and Baldi 2015). 
Additionaly, they are also known as live microorganisms (especially bacterial) 
belonging to natural microbiota with low or no pathogenicity, but with functions of 
prime importance to the health and well being of the host. Numerous 
microorganisms from different genera like Lactobacillus, Bifidobacterium, 
Propionibacterium, Pedicoccus, Leuconostoc, Enterococus and the yeast 
Saccharomyces boulardii are recognised as probiotics (Fotiadis, Stoidis et al. 2008). 
These bioactive components can be used in probiotic foods, particularly in 
fermented milk products, and others are being investigated with regard to their 
medicinal use (Cencic and Chingwaru 2010; Arora and Baldi 2015). Usually, 
probiotics have high antimicrobial and immunomodulatory capabilities. It has also 
been demonstrated that their members produce short-chain fatty acids (SCFAs) as 
fermentation products, which possess several anti-neoplastic properties, especially 
in the human colon (Cencic and Chingwaru 2010; Zeng, Lazarova et al. 2014). 
Prebiotic is "a selectively fermented ingredient, or a fiber that allows specific 
changes, particularly in activity of the gastrointestinal microbiota, conferring benefits 
on the well being and health of host” (Cencic and Chingwaru 2010). A number of 
prebiotics include certain fibers and resistant starches, but the most widely 
described prebiotics are non-digestible oligosaccharides which upon fermentation 
of beneficial microorganisms produce different amounts of SCFAs in the colon  
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(Fotiadis, Stoidis et al. 2008). Furthermore, a mixture of probiotics and prebiotics 
can result in additive or synergistic effects on gastrointestinal function. The term 
used, in this case, is synbiotic - “a combination of probiotics and prebiotics that 
beneficially affects the host by improving the survival and implantation of live 
microbial dietary supplements in the gastrointestinal tract, by selectively stimulating 
the growth and activating the metabolism of one or a limited number of health 
promoting bacteria, and thus improving host welfare”(Fotiadis, Stoidis et al. 2008). 
In summary, it has been established that gut microbiota interact with the host at 
multiple levels to maintain intestinal homeostasis and disruption in this symbiotic 
interaction can result in many physiological alterations associated with the onset 
and progression of chronic intestinal diseases including CRC (Fotiadis, Stoidis et al. 
2008). Moreover, scientific evidence (in vitro and in vivo studies) has shown that 
modulation of the host gut microbial environment by the use of nutraceuticals (pro, 
pre and/or synbiotics)  is a protective approach for proper maintenance of healthy 
gut microbiota and reduce the development of colon cancer risk (Fotiadis, Stoidis et 
al. 2008; Zeng, Lazarova et al. 2014). It is thus important to understand the “normal” 
gut microbiota and its changes during CRC development to understand how the use 
of nutraceuticals, notably by increasing the production of short-chain fatty acids, 
could function as a new strategy to prevent/treat CRC. 
1.3 Normal colon microbiota and short-chain fatty acids 
The human intestine harbours as many as 1012 microorganisms from 500 - 1000 
different bacterial species, described by their variation in 16S ribosomal RNA genes 
(Sobhani, Amiot et al. 2013; Zeng, Lazarova et al. 2014; Cipe, Idiz et al. 2015). 
Several studies have proposed that the normal human microbiota is formed mainly 
by strict anaerobes, such as Bacteroides, Eubacterium, Bifidobacterium, 
Fusobacterium, Peptostreptococcus, and Atopobium (Neish 2009; Tiihonen, 
Ouwehand et al. 2010; Liu, Cao et al. 2013), representative of 2 main divisions: 
Bacterodeites and Firmicutes (Neish 2009; Tiihonen, Ouwehand et al. 2010; 
Holmes, Li et al. 2011; Liu, Cao et al. 2013; Zeng, Lazarova et al. 2014). 
Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia were also found, 
but in minor proportions (Liu, Cao et al. 2013; Zeng, Lazarova et al. 2014). It is 
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known that the intestinal microbiota is a very complex system with numerous 
beneficial roles to human health, including protection against pathogens, immune 
system maturation, degradation of toxic substances, digestion of complex 
carbohydrates and production of short-chain fatty acids (SCFAs) (Holmes, Li et al. 
2011; Russell, Hoyles et al. 2013). 
In this case, although the main SCFAs (namely acetate, propionate and butyrate) 
exert multiple beneficial effects in the normal colon physiology, their role as cancer-
preventing/treating agents has received special attention by several researchers 
(Scheppach, Bartram et al. 1995; Kim, Park et al. 2014; Kasubuchi, Hasegawa et 
al. 2015). These microbial compounds are produced by anaerobic microorganisms 
able to ferment polysaccharides, oligosaccharides, proteins, peptides and 
glycoproteins in the colon, including Firmicutes, Clostridium, Bifidobacterium, 
Propionibacterium, Bacteroides and Lactobacillus (Neish 2009; Adom and Nie 
2013; Layden, Angueira et al. 2013; Kim, Park et al. 2014). The ability to produce 
butyrate requires a specific enzymatic process via butyryl-CoA: acetate CoA-
transferase (mainly by Eubacterium, Roseburia, Anaerostipes and Faecalibacterium 
prausnitzii species) or via butyrate kinase (in certain Clostridium and Coprococcus 
species) (Russell, Hoyles et al. 2013; Kim, Park et al. 2014; Zeng, Lazarova et al. 
2014). Firmicutes species are able to produce butyrate by both pathways (Russell, 
Hoyles et al. 2013; Kim, Park et al. 2014; Zeng, Lazarova et al. 2014). Propionate 
is generally produced by Bacteroides, Firmicutes and Propionibacterium species 
which involve the succinate, acrylate and propanediol pathways (Hosseini, 
Grootaert et al. 2011; Russell, Hoyles et al. 2013; Kim, Park et al. 2014), while 
acetate is produced by acetogenic bacteria such as Acetobacterium species, 
Clostridium aceticum and Propionibacterium, able to perform reductive 
acetogenesis from formate (Russell, Hoyles et al. 2013; Kim, Park et al. 2014). 
Normally, these bacteria exist in a mutually beneficial symbiotic relationship in the 
human colon, providing the proper amount of these SCFAs to help maintain colon 
homeostasis (Cipe, Idiz et al. 2015).  
Indeed, it has recently been shown, that some changes in SCFAs production is 
directly associated with alterations in the intestinal microbiota modulated by 
numerous extrinsic factors such as diet, age, medication, treatment (drugs, 
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radiation, surgery), stress and diseases (Zhu, Michelle Luo et al. 2011; Cipe, Idiz et 
al. 2015). These changes in the normal symbiotic state (normobiosis) can be 
associated with many intestinal disorders, such as obesity, inflammatory bowel 
disease and colorectal cancer (Chen, Liu et al. 2012; Di Mauro, Neu et al. 2013; 
Sobhani, Amiot et al. 2013; Zeng, Lazarova et al. 2014).  In this regard, the main 
challenge is to characterize the differences between a “healthy” intestinal microbiota 
and a CRC microbiota and its consequences on SCFAs production. This study 
would facilitate future studies towards the development of novel strategies for the 
diagnosis, treatment, and prevention of colorectal cancer (Cipe, Idiz et al. 2015). 
1.3.1 Intestinal microbiota and short-chain fatty acids in colorectal cancer 
patients 
Several factors (genetic and environmental) are involved in the transformation of 
normal colonic epithelium to adenoma and CRC (Keku, Dulal et al. 2015). It has 
been demonstrated that specific changes in human intestinal microbiota (dysbiosis) 
can also be associated with CRC development, especially in sporadic cases 
(Sobhani, Tap et al. 2011; Sobhani, Amiot et al. 2013; Gao, Guo et al. 2015). These 
changes support the hypothesis that “colon cancer may be a bacteria-related 
disease” (Sobhani, Amiot et al. 2013; Gao, Guo et al. 2015), and that specific 
bacterial species can be involved in CRC pathogenesis (Ohigashi, Sudo et al. 2013; 
Geng, Song et al. 2014; Cipe, Idiz et al. 2015; Gao, Guo et al. 2015)  (Figure 5). 
The majority of studies have shown a significant difference between the bacteria 
genera associated with cancerous and non-cancerous intestinal tissue or fecal 
samples (Sobhani, Amiot et al. 2013; Gao, Guo et al. 2015; Keku, Dulal et al. 2015). 
The intestine microbial composition of CRC patients is usually increased in the 
following genera: Lactococcus, Fusobacterium, Prevotella, Streptococcus, 
Bacteroides (Sobhani, Tap et al. 2011; Gao, Guo et al. 2015; Keku, Dulal et al. 
2015). It has been demonstrated that some bacteria have a complex arsenal of 
virulence factors which allow them to colonize and persist in the intestine, inducing 
chronic inflammation, accumulated mutations by DNA damage through superoxide 
radicals, genotoxin formation, increased T-cell proliferation and biosynthesis of 
procarcinogenic compounds that interfere with cell cycle regulation contributing to 
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colorectal carcinogenesis (Yang and Jobin 2014; Cipe, Idiz et al. 2015; Gao, Guo et 
al. 2015; Leung, Tsoi et al. 2015; Nistal, Fernandez-Fernandez et al. 2015).  
Escherichia coli (E. coli, a member of Enterobacteriaceae family) and 
Fusobacterium nucleatum  (F. nucleatum) are the main bacteria associated with 
CRC cases and commonly over-represented in many tumor tissues from CRC 
patients (Sobhani, Amiot et al. 2013; Yang and Jobin 2014; Gao, Guo et al. 2015; 
Keku, Dulal et al. 2015; Leung, Tsoi et al. 2015). Interestingly, in healthy individuals, 
Enterobacteriaceae constitute only a small fraction (less than 1%) of the gut 
microbiota, but E. coli in particular becomes dominant in the gut microbiota of 
individuals with inflammatory bowel disease (IBD), in several animal models of gut 
inflammation and in CRC cases (Yang and Jobin 2014). An interesting fact is that, 
E. coli strains isolated from individuals with IBD and CRC are often adherent and 
invasive, displaying several pathogenic properties which modulate host cells and 
mediate carcinogenesis, and are in this way classified as inflammation drivers of the 
CRC formation (Leung, Tsoi et al. 2015). Beyond that, F. nucleatum is an 
opportunistic bacterium able to induce chronic inflammation and interact directly or 
indirectly with colonocytes leading to uncontrolled cell proliferation, dysbiosis and 
intestinal tumorigenesis (Kostic, Chun et al. 2013; Leung, Tsoi et al. 2015). 
Recently, F. nucleatum has been considered as an indicator of disease progression 
and tumor severity (Leung, Tsoi et al. 2015). Likewise, it has also been shown that 
Streptococcus gallolyticus/bovis (involved with intestinal inflammatory disorders) is 
present in 20-50% of CRC and in less than 5% of normal colon (Gao, Guo et al. 
2015). 
 In contrast, patterns that preserve microbial intestinal homeostasis, such as 
Bifidobacterium, Lactobacillus, Clostridium and Ruminococcus are under-
represented in CRC patients compared to healthy individuals (Sobhani, Tap et al. 
2011; Chen, Liu et al. 2012; Sobhani, Amiot et al. 2013; Nistal, Fernandez-
Fernandez et al. 2015). 
Changes in the intestinal microbial community of CRC patients affect the amount 
and types of metabolites produced by colonic microbes. In this regard, some studies 
have reported that changes in colon microbiota are associated with a decrease in 
SCFA concentrations accompanied by an elevated pH in patients with CRC 
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compared to healthy individuals (Sobhani, Tap et al. 2011; Ohigashi, Sudo et al. 
2013; Sobhani, Amiot et al. 2013) (Figure 5). However, it is not yet understood if the 
changes in colon microbiota are a cause or a consequence of CRC development. 
In this context, it is important to characterize the possible over- and under-
represented bacteria, exploring the relationship between changes in the colon 
microbiota composition with the production of bacterial metabolites as well as the 
tumorigenesis process of CRC. The relationship between diet, intestinal microbiota, 
SCFA metabolism and colorectal cancer is very complex and remains an important 
area of research. In the following sections, the role of SCFAs in normal conditions 
is discussed (their concentrations, metabolism, beneficial effects, transporters and 
receptors), as well as how these microbial metabolites, namely butyrate, propionate 
and acetate, can be useful in the prevention and/or treatment of CRC. 
 
 
Figure 5: Schematic representation of the most important changes in the microbiota in the 
transition from normal epithelium to colorectal cancer (CRC).  
1.4 Short-chain fatty acid concentrations in colon 
Short chain fatty acids (SCFAs) are the major products of bacterial fermentation of 
undigested dietary fiber and of starches resistant to digestion in the human colon 
(Adom and Nie 2013; Zeng, Lazarova et al. 2014). Indeed, a diet rich in fiber, 
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resistant starches and complex carbohydrates leads to increases the levels of 
colonic SCFAs (Adom and Nie 2013; Layden, Angueira et al. 2013). 
SCFAs are carboxylic acids with aliphatic tails ranging from formic (C1), acetic (C2), 
propionic (C3), butyric (C4), valeric (C5) and caproic (C6) acid (Layden, Angueira et 
al. 2013). SCFAs constitute approximately two-thirds of the colonic anions (~150 
mM). At physiological pH, they predominate in a dissociated form, specifically 
acetate, propionate, butyrate, valerate and caproate (Nedjadi, Moran et al. 2014). 
The rate and amount of SCFAs produced depend on diet composition (which 
determines the type of the substrate fermented), on the microbiota present in the 
colon and on gut transit time (Mortensen and Clausen 1996; Macfarlane and 
Macfarlane 2012; Zeng, Lazarova et al. 2014). SCFAs are usually generated by 
carbohydrate fermentation according to the following equation (Zeng, Lazarova et 
al. 2014) : 
59 C6H12O6 + 38 H2O = 60 CH3COO- (Acetate) + 22 CH5COO- (Propionate) + 18 CH7COO- (Butyrate) 
+ 96 CO2 + 256 H+ + heat + gases 
Acetate, propionate and butyrate are the three major colonic SCFAs. They are found 
in the colon at considerably high concentrations, ranging from 40–80 mM to 10–25 
mM, respectively (Scheppach, Bartram et al. 1995; Alles, Hartemink et al. 1999; 
Jenkins, Kendall et al. 1999; Topping and Clifton 2001). Although not constant, the 
ratio of SCFA concentrations in the colonic lumen is approximately 60% acetate, 
25% propionate and 15% butyrate (Scheppach, Bartram et al. 1995; Canani, 
Costanzo et al. 2011). In addition, the concentration of acetate, propionate and 
butyrate vary along the human intestine as follows: approximately 130 ± 9 mmol/L 
in the cecum (where the amounts of fermentable substrates are higher), ~ 80 ± 11 
mmol/L in the descending colon and ~ 13  ± 6 mmol/L in the rectum (Cummings, 
Pomare et al. 1987; Du, Shi et al. 2014).  This variation in acid concentration is 
linked with pH differences along the human colon, namely: ~ 5.5-6.8 in the cecum 
and ~ 6.6-7 in the descending colon (Figure 6).  The higher acidity is associated with 
more active carbohydrate fermentation in the cecum than in the sigmoid/rectum, 
where the pH is more alkaline (Cummings, Pomare et al. 1987). 
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Figure 6: Regions of the colon and rectum with respective total amount of SCFA 
concentrations and pH. 
1.4.1 Metabolism of short-chain fatty acids in the colon 
It has been demonstrated that SCFAs derived from microbial metabolism in the gut 
play a central role in colon homeostasis (den Besten, Lange et al. 2013; den Besten, 
van Eunen et al. 2013). SCFAs are substrates for energy metabolism by the 
epithelial cells, converted by colonocytes into glucose, ketone bodies, and amino 
acids (Hadjiagapiou, Schmidt et al. 2000; den Besten, Lange et al. 2013; Kasubuchi, 
Hasegawa et al. 2015). Previous studies showed a preferential utilization of SCFAs 
in the order of butyrate ˃  propionate ˃  acetate by colonocytes (Adom and Nie 2013). 
Butyrate is the major energy source for colonocytes, but also for other cells from 
liver and muscle tissues (Ahmad, Krishnan et al. 2000; Adom and Nie 2013; Russell, 
Hoyles et al. 2013; Zeng, Lazarova et al. 2014). Butyrate is usually metabolized to 
acetyl-CoA by colonocytes (Donohoe, Collins et al. 2012) while propionate and 
acetate can modulate lipogenesis and gluconeogenesis (Comalada, Bailon et al. 
2006). It has been demonstrated that propionate is largely metabolized in the liver 
(Russell, Hoyles et al. 2013) and also acts as substrate for gluconeogenesis 
inhibiting cholesterol synthesis in hepatic tissue (Adom and Nie 2013; Scott, Gratz 
et al. 2013). Acetate can be oxidized in the tricarboxylic acid (TCA) cycle, used as 
a substrate for the synthesis of cholesterol, long-chain fatty acids or as a co-
substrate for glutamine and glutamate synthesis by colonocytes (Adom and Nie 
2013; den Besten, Lange et al. 2013; Zeng, Lazarova et al. 2014). This compound 
also enters systemic circulation and can be used by many tissues, including heart, 
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adipose, kidney, liver and muscle (den Besten, Lange et al. 2013; Scott, Gratz et al. 
2013). 
In contrast to normal colonocytes, CRC cells primarily undergo aerobic glycolysis 
instead of oxidative metabolism (Donohoe, Collins et al. 2012). In this case, it has 
been proposed that the preference of CRC cells for glucose metabolism instead 
SCFAs as an energy source explains the opposite effects on the growth of normal 
versus cancerous colonocytes (Donohoe, Collins et al. 2012). However, this 
paradox is still poorly understood and more studies are needed to understand how 
the metabolic differences between normal and cancerous colonocytes can be used 
to inhibit tumorigenesis in CRC. 
1.4.2 Short-chain fatty acid transporters and receptors  
Production of total colonic SCFAs is difficult to determine because more than 95% 
of these SCFAs are water soluble and rapidly absorbed and metabolized by 
colonocytes (Roy, Kien et al. 2006; Kim, Park et al. 2014; Zeng, Lazarova et al. 
2014). Only a small amount of these SCFAs leave the colon intact and can be 
transported via the blood circulation to other organs (Roy, Kien et al. 2006; 
Ganapathy, Thangaraju et al. 2013; Kim, Park et al. 2014).  
Though distinct mechanisms for SCFAs absorption across the plasma membrane 
of colonocytes in various species have been postulated (Hijova and Chmelarova 
2007; Nedjadi, Moran et al. 2014), most studies on SCFAs transporters both show 
in intestinal epithelial cells and CRC cells used butyrate transport as a model 
(Hadjiagapiou, Schmidt et al. 2000; Ganapathy, Thangaraju et al. 2013; Goncalves 
and Martel 2013) and information concerning other SCFAs like propionate or 
acetate transport is still rare. 
SCFAs enter intestinal epithelial cells through passive diffusion of protonated 
SCFAs or mediated transport by monocarboxylate transporters (MCTs) (Goncalves 
and Martel 2013). The MCT family comprises 14 members, however, only the first 
four (MCT-1 - 4) are known to mediate the proton-coupled transport of 
monocarboxylic acids across the plasma membrane (Pinheiro, Longatto-Filho et al. 
2012; Halestrap 2013). The main function of  MCT has been associated with the 
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uptake or efflux of monocarboxilic acids through the plasma membrane, according 
to the cell metabolic needs, characterized by a high affinity transport for L-lactate, 
pyruvate, acetate, propionate, D,L-β-hydroxybutyrate and acetoacetate (Halestrap 
and Meredith 2004). 
SMCT-1 and MCT-1 have been identified as the main monocarboxylate 
transporters, responsible for the uptake of SCFAs across the membrane of intestinal 
cells (den Besten, Lange et al. 2013; Goncalves and Martel 2013; Kim, Park et al. 
2014). SMCT-1 is a Na+-coupled transporter for a variety of SCFAs, especially 
butyrate (Canani, Costanzo et al. 2011; Ganapathy, Thangaraju et al. 2013), while 
MCT-1 is a H+-coupled transporter for SCFAs and related organic acids, which 
transports these molecules across the plasma membrane depending on the H+  
eletrochemical gradient (Kim, Park et al. 2014). MCT-1 is expressed widely in many 
different cell types and has been characterized as the primary butyrate transporter 
in colon epithelial cells (Canani, Costanzo et al. 2011; Fung, Cosgrove et al. 2012).  
MCT-1 also exports lactate to the extracellular milieu, which is a potentially cytotoxic 
metabolic by-product of glycolysis, indicating that it plays a dual role to enhance 
CRC cell survival (Fung, Cosgrove et al. 2012). In contrast, it has been shown that 
CRC cells silence SMCT-1 by DNA methylation (Hadjiagapiou, Schmidt et al. 2000; 
Thangaraju, Cresci et al. 2008; Babu, Ramachandran et al. 2011; Ganapathy, 
Thangaraju et al. 2013; Goncalves and Martel 2013) which confers a selective 
advantage to escape butyrate-induced cell death through limitation of butyrate 
uptake (Li, Myeroff et al. 2003; Ganapathy, Thangaraju et al. 2013). 
In addition to SCFA transporters, their receptors constitute a new and rapidly 
growing field of research, as more functions of SCFA receptors have been 
discovered. SCFAs are able to activate cells through several cell-surface G-protein-
coupled receptors (GPRs), especially GPR41 and GPR43 (Kim, Kang et al. 2013; 
Kuwahara 2014), involved in immune response regulation (Kim, Kang et al. 2013). 
These two GPRs are expressed not only by intestinal epithelial cells where SCFAs 
are produced, but also at multiple other sites considered to be metabolically 
important such as adipose tissue and pancreatic islets (Layden, Angueira et al. 
2013). Recent studies have identified the cell-surface receptors GPR41, GPR43 and 
GPR109A as essential for the biologic effects of SCFAs in the colon (Ganapathy, 
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Thangaraju et al. 2013; Kim, Kang et al. 2013). GPR41 (also called free fatty acid 
receptor 3; FFA3) expressed in colon cells is activated by SCFAs, primarily by 
butyrate and propionate (Layden, Angueira et al. 2013; Kuwahara 2014), while 
GPR43 (free fatty acid receptor 2; FFA2) has a more potent affinity for propionate 
and acetate (Ganapathy, Thangaraju et al. 2013; Layden, Angueira et al. 2013). In 
addition, GPR109A (hydroxycarboxylic acid receptor 2), a receptor for niacin and 
vitamin B3, is also a receptor for butyrate in colon cells (Kim, Park et al. 2014; 
Kuwahara 2014). Nevertheless, the regulation of SCFA transporters and receptors 
in CRC cells is still poorly understood, and more studies are needed to grasp how 
these metabolites can influence the regulation of their transporters and receptors in 
CRC cells.  
1.4.3 Physiological effects of short-chain fatty acids in normal colon 
It is known that SCFAs play a significant role in maintaining the normal physiological 
functions of the colonic mucosa, serving as regulators of intracellular pH, cell volume 
and other functions associated with ion absorption and gut motility of intestinal 
epithelial cells (Kim, Park et al. 2014; Ohtani 2015). SCFAs are the major energy 
source for colonocytes and can also be used for de novo synthesis of lipids as 
referred before (Scharlau, Borowicki et al. 2009; Kim, Kang et al. 2013; Kasubuchi, 
Hasegawa et al. 2015). 
In addition, it has been demonstrated that SCFAs have a suppressive role in 
inflammation and cancer of the intestine (Kim, Park et al. 2014; Keku, Dulal et al. 
2015). Though the anti-inflammatory mechanism of SCFAs is still not adequately 
clarified, a recent study showed that, once absorbed by intestinal epithelial cells 
and/or immune cells, SCFAs (especially butyrate and propionate) inhibit the activity 
of histone deacetylases (HDACs), promoting the hyperacetylation of histones and 
trans-activating gene expression, which results in downregulation of pro-
inflammatory cytokines, such as interleukin-6 (IL-6) and IL-12 (Ohtani 2015). 
Interestingly, it has been demonstrated that total SCFAs and/or local differences in 
SCFA concentrations along the intestinal tract might be implicated in diseases of 
the colon, especially gastrointestinal disorders and colorectal cancer (Wong, de 
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Souza et al. 2006). For example, a decreased level of butyrate in the environment 
of colonocytes has been suggested to contribute to the genesis of ulcerative colitis 
(UC) and to a significantly increased risk of colon cancer (Huda-Faujan, Abdulamir 
et al. 2010). Therefore, increased production and greater distal delivery of SCFAs 
may result in a protective effect against these diseases (Wong, de Souza et al. 
2006). 
SCFAs, especially butyrate, are involved not only in the regulation of expression of 
several genes, cell proliferation, differentiation and apoptosis to promote colonic 
wellbeing in epithelial cells, but in the prevention of colon cancer by promoting 
growth inhibition, cell-cycle arrest and apoptosis in transformed colonocytes (Sakata 
1987; Comalada, Bailon et al. 2006; Fung, Cosgrove et al. 2012; Ganapathy, 
Thangaraju et al. 2013; Kim, Park et al. 2014). Furthermore, as described in more 
detail below, it has been shown that SCFAs exhibit anti-cancer activities acting 
through different mechanisms to induce cell death in CRC cells (Comalada, Bailon 
et al. 2006; Lan, Lagadic-Gossmann et al. 2007; Zhang, Zhou et al. 2010; Adom 
and Nie 2013; Marques, Oliveira et al. 2013; Oliveira, Pereira et al. 2015). 
1.4.4 Mechanisms of action of short-chain fatty acids in colorectal cancer 
cells: prevention and therapeutic implications 
A variety of biological effects of SCFA have been reported, and a vast number of 
experimental studies keep showing new aspects of these molecules.  Most notably, 
it has been shown that the SCFAs butyrate, propionate and acetate induce 
apoptosis in CRC cells but not in normal cells (Sakata 1987; Comalada, Bailon et 
al. 2006; Sauer, Richter et al. 2007; Zhang, Zhou et al. 2010; Tang, Chen et al. 
2011; Imbernon, Whyte et al. 2014). The anti-cancer effect of SCFAs is also 
supported by epidemiological studies suggesting an inverse relation between the 
level of dietary fibers and the incidence of CRC (Scheppach, Bartram et al. 1995; 
Sengupta, Muir et al. 2006; Zeng, Lazarova et al. 2014). These dietary components 
influence the risk of human colon cancer through diverse mechanisms, which 
include activation of cell death through different processes depending on the 
concentration, pH and cell type. The mechanisms by which these SCFA are 
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metabolized and regulate cell proliferation, differentiation, cell death and their role 
in inflammation in CRC cells will be discussed below. 
1.4.4.1 Butyrate 
Butyrate is considered the most potent of the SCFAs regarding prevention and 
inhibition of colon carcinogenesis, and its antitumor effects have been the most 
studied (Scheppach, Bartram et al. 1995; Comalada, Bailon et al. 2006; Scharlau, 
Borowicki et al. 2009; Zhang, Zhou et al. 2010; Matthews, Howarth et al. 2012; 
Goncalves and Martel 2013). Butyrate’s protective effects against human colon 
cancer cells involve inhibition of cell differentiation, promotion of cell-cycle arrest, 
apoptosis and of inhibition of histone deacetylases (HDACs) (Table 3) (Hinnebusch, 
Meng et al. 2002; Comalada, Bailon et al. 2006; Zhang, Zhou et al. 2010; Donohoe, 
Collins et al. 2012; Fung, Cosgrove et al. 2012; Matthews, Howarth et al. 2012).  
Previous studies in CRC cell lines showed that induction of apoptosis and cell cycle 
arrest in G0-G1 or G2-M by butyrate could occur via p53-dependent or p53- 
independent pathways (Archer, Meng et al. 1998; Mariadason, Velcich et al. 2001; 
Matthews, Howarth et al. 2012). Zhang and co-workers analyzed the cytotoxicity 
mechanism of butyrate (0-40 mM) in human colon cancer (RKO cells) and showed 
that it exhibited a strong growth inhibitory effect against RKO cells, inducing the 
intrinsic apoptosis pathway characterized by DNA fragmentation and activation of 
caspase-9 and caspase-3 (Zhang, Zhou et al. 2010). The expression of anti-
apoptotic protein Bcl-2 decreased, whereas the apoptotic protein Bax increased in 
a dose-dependent manner during butyrate-induced apoptosis (Zhang, Zhou et al. 
2010). 
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Table 3: Effects of SCFA butyrate in colorectal cancer cells. 
  Butyrate  
Human 
colorectal 
cancer cell 
lines 
Concentration 
(mM) 
 
Effects 
 
Reference 
    
HCT116 
HT-29 
0 - 20 
p21 is required for butyrate-mediated 
growth arrest 
Archer et 
al, 1998 
Caco-2 
SW620 
2 - 10 
Cell cycle arrest and apoptosis more 
effective in undifferentiated cells, whereas 
differentiated cells were essentially 
resistant to butyrate effects 
Mariadason 
et al, 2001 
HT-29  
Growth inhibition by the downregulation of 
ERK1/2 
Davido et 
al, 2001 
HCT116 
HT-29 
1 
5 
Cell growth arrest, differentiation, 
apoptosis, induction of histone H4 
hyperacetylation 
Hinnebusch 
et al, 2002  
HT-29 1 - 8 Inhibition of cell proliferation, induction of 
differentiation and apoptosis 
Comalada, 
2006 
HT-29 5 - 40 Modulation of histone acetylation 
Kiefer et al, 
2006 
HT-29 5 Downregulation of the GLUT-1 expression 
mediates apoptosis 
He et al, 
2007 
LT92 
HT-29 
0 - 50 
Induction of GSTs as a possible 
mechanism of chemoprevention 
Scharlau et 
al, 2009 
RKO 0 - 40 
Inhibition of cell proliferation involving 
inactivation of ERK MAPK, induction of 
apoptosis via activation of caspase-9 and 
caspase-3 
Zhang et al, 
2010 
Caco-2 5 
Induction of apoptosis, G2-M arrest, 
alterations in the oxidative pentose 
pathway 
Matthews 
et al, 2012 
RAW264.7* 0 – 1.200 µmol/L 
Decrease of proinflammatory factors with 
an increase in the antiinflammatory 
cytokine 
 
Liu et al, 
2012 
 
*Murine macrophage cell line 
Critical tumorigenesis signalling pathways that regulate cell proliferation, cell 
migration and apoptosis, including extracellular signal-regulated protein kinase 1/2 
(ERK1/2), C-Jun N-terminal kinase (JNK) and p38 MAPK (p38) were also studied 
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(Zhang, Zhou et al. 2010). An important point is that a high levels of ERK1/2 
activation/expression are associated with cell proliferation and survival in various 
cancer cells, including CRC (Davido, Richter et al. 2001; Zhang, Zhou et al. 2010). 
However, it was demonstrated that butyrate-induced growth inhibition occurs with 
inactivation or downregulation of ERKs in RKO and HT-29 cells, respectively 
(Davido, Richter et al. 2001; Zhang, Zhou et al. 2010). Moreover, activation of the 
JNK MAPK pathway played an important role in butyrate-induced apoptosis in RKO 
cells (Zhang, Zhou et al. 2010). 
Matthews et al 2012, showed that butyrate (5 mM) induced apoptosis and G2-M 
arrest mediated by alterations in the oxidative pentose pathway, reduction in 
glutathione availability and glucose consumption, and increased levels of reactive 
oxygen species (ROS) (Matthews, Howarth et al. 2012). He et al (2007) observed 
that downregulation of GLUT-1 expression was associated with apoptosis-induced 
by butyrate (5 mM) in HT-29 cells, also correlated with an increase in the expression 
and activity of MCT-1 as a mechanism to maximize intracellular availability of 
butyrate (He, Li et al. 2007). Some authors state that butyrate inhibits CRC cell 
proliferation and induces cell death due to its inefficient metabolism associated with 
the Warburg effect and nuclear accumulation in transformed colonocytes, where it 
acts as a HDAC inhibitor (Shao, Gao et al. 2004; Wong, de Souza et al. 2006; 
Donohoe, Collins et al. 2012). Robert Li and co-workers (2006) confirmed 
accumulation of acetylated histone 3 (H3) as a reslt of butyrate treatment in CRC 
cells. Butyrate further contributes to hyperacetylation through conversion to acetyl-
CoA and stimulation of histone acetyltransferase (HAT) activity (Barshishat, Polak-
Charcon et al. 2000; Li and Li 2006). However, the metabolic state of the cell 
influences the amount of intranuclear butyrate and acetyl-CoA levels determining 
whether butyrate functions as a HDAC inhibitor or stimulate HATs, thus 
epigenetically regulating the expression of different target genes (Mariadason, 
Velcich et al. 2001; Donohoe, Collins et al. 2012). Deregulation of the expression or 
activity of HATs and HDACs may lead to alterations in gene expression profiles, 
associated with reactivation or silencing of important genes for cancer progression, 
differentiation and apoptosis (Sambucetti, Fischer et al. 1999; Iacomino, Tecce et 
al. 2001; Marchion and Munster 2007). In this context, Archer et al 1998, showed 
that butyrate (0-20 mM) increased p21 expression through a process involving 
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histone hyperacetylation, and that p21 was required for butyrate-mediated growth 
arrest in colon cancer cells (HT-29 and HCT116).  
Furthermore, compared to propionate and acetate, butyrate has strong anti-
inflammatory properties, and this effect is mediated mainly by inhibition of TNF-α 
production, nuclear factor-kappa B (NF-κB) activity and IL-8, 10 -12 expression in 
immune and colonic epithelial cells (Tedelind, Westberg et al. 2007; Kim, Park et al. 
2014; Zeng, Lazarova et al. 2014). Yet, little is known about the role of butyrate on 
inflammation in CRC cells. 
The main conclusion is that the exposure of the human colon to butyrate might 
protect against CRC by reducing survival and inducing cell death in CRC cells by 
several mechanisms discussed above. It is worth noting that cells that metabolize 
butyrate at a higher rate, are usually less susceptible to its apoptosis-inducing 
effects. This may explain why normal colonocytes are unaffected by high levels of 
this SCFA in the colon, since they preferentially use butyrate as an energy source, 
in contrast with CRC cells which seem to prefer glucose.  
1.4.4.2 Propionate 
Though propionate exerts an anti-neoplastic effect in colorectal cancer cells and has 
a mechanisms of action similar to butyrate, there are less published studies with this 
SCFA than with butyrate (Kiefer, Beyer-Sehlmeyer et al. 2006; Hosseini, Grootaert 
et al. 2011) (Table 4). 
Jan and co-workers showed that propionate (10 - 40 mM) induced typical signs of 
apoptosis in human CRC cell lines, with loss of mitochondrial membrane potential 
(∆ᴪm), generation of ROS, cytochrome c release, caspase-3-processing and 
nuclear chromatin condensation (Jan, Belzacq et al. 2002). Matthews and co-
workers demonstrated that at lower doses (5 mM) propionate also induced 
apoptosis, characterized by an elevated ROS production and decreased glucose 
oxidation after 48 h of treatment in the Caco-2 colon cancer cell line (Matthews, 
Howarth et al. 2012). Tang et al. showed that propionate treatment (3 -10 mM) 
induces ROS generation and loss of mitochondrial membrane potential (∆ᴪm) with 
autophagy induction to degrade damaged mitochondria in HCT116 cells, showing 
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in this case that propionate-triggered autophagy serves as an adaptive strategy to 
delay mitochondria-mediated cell death in CRC cells (Tang, Chen et al. 2011).  
Table 4: Effects of SCFA propionate in colorectal cancer cells. 
  Propionate  
Human 
colorectal 
cancer cell 
lines 
Concentration 
(mM) 
 
Effects 
 
Reference 
    
HT-29 
 
 
Growth inhibition by the downregulation of 
ERK1/2 
Davido et 
al. 2002 
HT-29 
Caco-2 
0 - 40 
Decrease of viability/apoptosis with 
mitochondrial alterations 
Jan et al. 
2002 
HT-29 20 - 40 Modulation of histone acetylation Kiefer et al, 
2006 
HT-29 2 - 16 Antiproliferative effect 
Comalada, 
2006 
HT-29 30 Apoptosis at pH 7.5 
Necrosis at pH 5.5 
Lan et al, 
2007 
Colo320DM 0,3 - 30 Inhibition of the NF-kB pathway 
Tedelind et 
al, 2007 
HCT116 0 - 10 Mitochondrial defects and autophagy Tang et al, 
2011b 
HCT116 
SW480 
0 - 3 
Two types of programmed cell death 
(autophagy and apoptosis) 
Tang et al, 
2011a 
Caco-2 5 
Induction of apoptosis, G2-M arrest, 
alterations in the oxidative pentose 
pathway. 
Matthews 
et al, 2012 
RAW264.7* 0 – 1.200 µmol/L 
Decrease of proinflammatory factors with 
an increase in the antiinflammatory 
cytokine 
Liu et al, 
2012 
*Murine macrophage cell line 
It has been demonstrated that propionate, like butyrate, also acts as an inducer of 
histone acetylation in CRC cells, which is possibly associated with a modulated 
growth response of tumorigenic lesions in the gut (Kiefer, Beyer-Sehlmeyer et al. 
2006; Hosseini, Grootaert et al. 2011; Kim, Park et al. 2014). In this regard, Kiefer 
et al showed that propionate alone (2.5 – 40 mM) or in combination with butyrate or 
acetate induced significant histone acetylation in HT-29 cells. In addition, another 
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study demonstrated that propionate-induced growth inhibition, like butyrate, 
involves downregulation of ERK1/2 in HT-29 cells (Davido, Richter et al. 2001). 
Furthermore, it has been shown that propionate has anti-inflammatory properties in 
the gut, comparable to those already described for butyrate (Tedelind, Westberg et 
al. 2007; Liu, Li et al. 2012; Kim, Park et al. 2014). Tedelind et al 2007, observed 
that the anti-inflammatory activity of propionate (0.3 - 30 mM) involves the inhibition 
of the NF-κB pathway and suppression of IL-6 release in Colo320DM cells. 
Taken together, these findings suggest that propionate could be effective in the 
prevention and treatment of some colon alterations, including CRC. Nevertheless, 
further studies both in vitro and in vivo are required to understand its real role alone 
and in combination with other SCFAs, as discussed below. 
1.4.4.3 Acetate 
Acetate has been the least studied of the three most relevant SCFAs (table 5). 
Initially, Jan and co-workers showed that acetate (0-40 mM) decreased the viability 
and induced typical signs of apoptosis in the colon adenocarcinoma cell line HT-29, 
including loss of mitochondrial membrane potential, generation of ROS, caspase-3 
processing and nuclear chromatin condensation (Jan, Belzacq et al. 2002).  
As already referred for butyrate and propionate, the mechanism through which 
acetate mediates cell death and its anti-inflammatory effects are currently poorly 
understood. However, it has been shown that acetate also reduces the production 
of pro-inflammatory factors, including TNF-α, IL-1β, IL-6, while enhancing the 
production of the anti-inflammatory cytokine IL-10 (Tedelind, Westberg et al. 2007; 
Liu, Li et al. 2012; Kim, Park et al. 2014) and induces inhibition of the NF-κB pathway 
in CRC cells (Tedelind, Westberg et al. 2007). Although it has been demonstrated 
that acetate can affect the immune response in the colon, more studies are 
necessary in order to understand the precise role of this SCFA and its interaction 
with intestinal microbiota, host immune cells, colonocytes and CRC cells. 
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Table 5: Effects of SCFA acetate in colorectal cancer cells. 
  Acetate  
Human 
colorectal 
cancer cell 
lines 
Concentration 
(mM) 
 
Effects 
 
Reference 
    
HT-29 
Caco-2 0 - 40 
Decrease of viability/Apoptosis with 
mitochondrial alterations 
Jan et al, 
2002 
HT-29 4 - 32 Ineffective in these concentrations Comalada, 
2006 
HT-29 80 Does not induce histone acetylation 
Kiefer et al, 
2006 
Colo320DM 2,4 Inhibition of the NF-kB pathway 
Tedelind et 
al, 2007 
HT-29 15 
Apoptosis at pH 7.5 
Necrosis at pH 5.5 
Lan et al, 
2007 
RAW264.7* 0 – 1.200 µmol/L 
Decrease of proinflammatory factors with 
an increase in the antiinflammatory 
cytokine 
Liu et al, 
2012 
*Murine macrophage cell line 
Studies in the yeast species Saccharomyces cerevisiae first demonstrated that 
acetic acid induced a mitochondria-mediated apoptotic process (Pereira, Silva et al. 
2008; Guaragnella, Zdralevic et al. 2012) with several features similar to apoptosis 
mediated by SCFAs in CRC cells. Indeed, alterations in mitochondria were identified 
in yeast, including production of ROS, mitochondrial swelling, decrease of ΔΨm 
(Ludovico, Rodrigues et al. 2002), mitochondrial fragmentation/degradation 
(Fannjiang, Cheng et al. 2004), mitochondrial outer membrane permeabilization 
(MOMP) with consequent release of pro-apoptotic factors like cytochrome c, yeast 
apoptosis inducing factor 1 (Aif1p) and Nuc1p (yeast ortholog of EndoG) (Ludovico, 
Rodrigues et al. 2002; Wissing, Ludovico et al. 2004; Kroemer, Galluzzi et al. 2007). 
The yeast orthologs of the mammalian VDAC (voltage-dependent anion channel) 
and ANT (adenine nucleotide transporter) were shown to play a role in MOMP and 
cytochrome c release during acetic acid-induced apoptosis in yeast (Pereira, 
Camougrand et al. 2007) Later, vacuolar membrane permeabilization (VMP) and 
release of Pep4p, yeast cathepsin D (CatD), from the lysosome-like vacuole to the 
cytosol, were observed in yeast cells exhibiting apoptotic cell death induced by 
acetic acid (Pereira, Chaves et al. 2010). In that study, it was also shown that, once 
General introduction 
67 
in the cytosol, Pep4p played an important role in mitochondrial degradation through 
an autophagic-independent process, which protected yeast cells from acetic acid-
induced apoptosis. Recently, it was demonstrated that both the protective function 
of Pep4p and its role in mitochondrial degradation during acetic acid-induced 
apoptosis in yeast depend on Pep4p proteolytic activity, and is complemented by 
heterologous expression of human CatD (Pereira, Azevedo et al. 2013; Oliveira, 
Pereira et al. 2015). 
Taking into account the aforementioned results, we hypothesized that similar 
cellular events could occur in response to acetate in CRC cells. As mentioned 
before, acetate, like butyrate and propionate, may be useful as a chemopreventive 
agent, but more studies are necessary to understand the mechanisms underlying 
acetate-induced apoptosis in CRC cells. 
1.4.4.4 Combined effects of short-chain fatty acids 
Neither butyrate, propionate or acetate are available as the only metabolite present 
in the human colon, and therefore their combined effect should be taken into 
consideration.  Although there are few studies on the combined effect of SCFAs 
performed in CRC cells, Tang et al 2011a, using a combination of butyrate and 
propionate (1-3 mM), showed for the first time that SCFAs orchestrate two types of 
programmed cell death in colon cancer cells (HCT116 and SW480). Butyrate and 
propionate treatment induced autophagy to dampen apoptosis, whereas inhibition 
of autophagy potentiated SCFA-induced apoptosis (Tang, Chen et al. 2011). 
Matthews and co-workers demonstrated that the combination (butyrate and 
propionate: 5 mM) induced cell cycle arrest in G2-M associated with a rapid and 
extensive apoptosis with changes in redox state and D-glucose metabolism in Caco-
2 cells, compared to single treatments (Matthews, Howarth et al. 2012). In addition, 
Kiefer et al. showed that mixtures of acetate, butyrate and propionate (at molar 
ratios 75: 11 : 14, 69 : 16 : 15 and 43 : 24 : 33, respectively) which mimic the relative 
concentrations occurring in the gut, modulated histone acetylation. However, they 
concluded that the histone acetylation was mainly due to additive effects of butyrate 
and propionate, but not due to acetate (Kiefer, Beyer-Sehlmeyer et al. 2006). Lan 
and co-workers showed that acetate and propionate (15 mM and 30 mM, 
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respectively) produced by Propionibacterium freudereichii decreased proliferation 
and induced cell cycle arrest in G2/M, followed by a sequence of cellular events 
characteristic of apoptosis at pH 7.7, but induced necrosis at pH 5.5 in colon cancer 
cells (HT-29) (Lan, Lagadic-Gossmann et al. 2007). This study demonstrated for the 
first time the impact of the extracellular pH prevailing within the colon (from 5.5 to 
7.5) on the mode of cell death triggered by propionibacteria-produced SCFA in CRC 
cells (Lan, Lagadic-Gossmann et al. 2007). In this regard, our group has recently 
characterized the potential of P. freudenreichii subsp. freudenreichii DSM 20271 as 
a producer of SCFAs (propionate and acetate) using several culture media to 
simulate the digestive stress process and the composition of digested products 
present in the colon (Marta et al unpublished results). Pure SCFAs, as well as the 
bacterial fermented broth, inhibited CRC cell proliferation and increased cell death. 
The results showed that co-culture of P. freudenreichii and CRC cells is possible 
and favourable for the bacteria and that P. freudenreichii could potentially be used 
as a probiotic in CRC prevention and/or treatment through its ability to produce 
SCFAs (Marta et al unpublished results).  
Although studies on the combined effects of SCFAs are still few, it seems that they 
have a greater effect in colorectal cancer cells compared with treatment with each 
SCFA separately. In summary, there is increasing evidence of the anti-neoplastic 
effects of SCFAs in CRC cells, which may be modulated by several aspects, namely 
the cell type, SCFA concentration/availability, extracellular pH, time of exposure to 
SCFAs, their absorption and metabolism. 
1.5 Lysosomes, lysosomal membrane permeabilization and its role in cell 
death regulation 
The role of lysosomes as regulators of cell death in cancer cells has been a subject 
of increased interest in the last years.  Lysosomes (greek: digestive body) are 
cytoplasmic membrane-enclosed organelles that contain hydrolytic enzymes 
(Cesen, Pegan et al. 2012). The primary function of lysosomes is to degrade 
macromolecules; for this purpose, lysosomes contain more than 50 acid hydrolases, 
including phosphatases, nucleases, glycosidases, proteases, peptidases, 
sulphatases and lipases (Johansson, Appelqvist et al. 2010). For this reason, 
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lysosomes have an acidic environment (pH 4.6–5.0), which allows a maximal 
enzymatic activity (Boya and Kroemer 2008; Cesen, Pegan et al. 2012). In addition, 
over the last years, the lysosome has emerged as a significant player of the cellular 
death machinery (Johansson, Appelqvist et al. 2010; Repnik, Hafner Cesen et al. 
2014). The major hallmark of the lysosomal cell death pathway is characterized by 
the partial/selective loss of lysosomal membrane integrity, which allows the release 
of lysosomal hydrolases into the cytosol,a  process known as lysosomal membrane 
permeabilization (LMP) (Groth-Pedersen and Jaattela 2013; Repnik, Hafner Cesen 
et al. 2014). 
Depending of the initial stimuli, dose and cell type, LMP can initiate different cell 
death pathways (Figure 7), characterized by the release of lysosomal proteases, 
especially cathepsins into the cytosol (Repnik, Stoka et al. 2012; Repnik, Cesen et 
al. 2013). Lysosomal cathepsins translocate from the lysosomal lumen into the 
cytosol in response to a variety of signals such as TNF receptor ligation (the best-
studied inducer of LMP) (Groth-Pedersen and Jaattela 2013),  sphingosine (Cesen, 
Pegan et al. 2012; Repnik, Hafner Cesen et al. 2014), staurosporine (Johansson, 
Steen et al. 2003), reactive oxygen species (Johansson, Appelqvist et al. 2010) p53 
(Johansson, Appelqvist et al. 2010), lysosomotropic agents (ciprofloxacin, 
norfloxacin and hydroxychlotoquine) and some cancer drugs (resveratrol and 
etoposide) (Trincheri, Nicotra et al. 2007; Hsu, Wu et al. 2009).  
Accumulated data have shown that a partial or moderate LMP with subsequent 
release of cathepsins into the cytosol can activate either the intrinsic caspase-
dependent apoptosis pathway or the caspase-independent alternative cell death 
pathway (Jaattela, Cande et al. 2004; Boya and Kroemer 2008; Groth-Pedersen and 
Jaattela 2013). In the case of necrosis, LMP is an early event associated with a 
massive release of contents to the cytosol (Boya and Kroemer 2008; Groth-
Pedersen and Jaattela 2013; Repnik, Cesen et al. 2013). In the necroptosis process, 
LMP is a late process, which coincides with the disintegration phase through 
proteolysis (Groth-Pedersen and Jaattela 2013; Repnik, Cesen et al. 2013). 
Moreover, some studies have reported the involvement of cathepsins in autophagy 
to enhance cell survival under some death stimuli (Hsu, Wu et al. 2009; Hah, Noh 
et al. 2012; Tan, Peng et al. 2013). 
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LMP is still incompletely understood. The hallmark of LMP is considered to be the 
reversible or irreversible loss of membrane integrity with the release of luminal 
contents into the cytosol (Repnik, Stoka et al. 2012; Repnik, Cesen et al. 2013). The 
release of lysosomal components through a mediated process involving pores or 
translocators has not been precluded yet. It has been demonstrated that LMP can 
be a result of osmotic lysis or direct membranolytic activity of the compounds that 
accumulate in the lumen of lysosomes (Cesen, Pegan et al. 2012; Repnik, Hafner 
Cesen et al. 2014). 
 
Figure 7: Regulation of lysosome membrane permeabilization (LMP) and the role of lysosomal 
proteins in cell death. LMP can be induced by death receptor-mediated pathway, DNA damages, 
intracellular calcium, ROS and other cellular stress factors. Cathepsins and other hydrolases 
released to the cytosol are involved in different types of cell death, depending of the LMP intensity. 
(Adapted from Tang et al. 2008). 
Likewise, the lysosomal membrane composition, including sphingolipid and 
cholesterol levels, plays a key role in the maintenance of lysosomal integrity 
(Repnik, Hafner Cesen et al. 2014). In this case, a high content of sphingolipid and 
cholesterol makes the lysosomal membrane more ordered, rigid and thicker 
(Repnik, Stoka et al. 2012; Repnik, Hafner Cesen et al. 2014). It is known that 
damage in lysosomal membrane components or changes in the membrane 
structure and fluidity could result in lysosomal destabilization (Johansson, 
Appelqvist et al. 2010; Repnik, Hafner Cesen et al. 2014). An example is the LMP 
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induced by oxidative stress characterized by an increase of hydrogen peroxide 
diffusion into the lysosome. In the lysosome lumen, the acidic milieu and the 
presence of low-molecular-weight iron, derived from degraded iron- containing 
protein, promote reduction of iron and generation of hydroxyl radicals. The hydroxyl 
radicals induce peroxidation of membrane lipids and thereby cause leakage of 
lysosomal constituents into the cytosol (Johansson, Appelqvist et al. 2010).  
In this regard, it has been demonstrated that cancer cell lysosomes are more prone 
to LMP than normal cells (Boya and Kroemer 2008; Groth-Pedersen and Jaattela 
2013), but the reasons are still poorly understood. Some authors indicate that the 
susceptibility of cancer cells to LMP is due to the abnormal size of the lysosomes, 
which could make them more fragile than normal-sized lysosomes (Boya and 
Kroemer 2008). Another possibility is that higher metabolic rates and an increased 
turnover of iron-containing proteins in cancer cells lead to an accumulation of iron 
in the lysosomal compartment, with consequent sensitization to ROS-induced LMP 
(Boya and Kroemer 2008). Remarkably, induction of LMP has emerged as an 
effective way to kill resistant cancer cells, which could have multiple implications for 
the future treatment of apoptosis-defective and multidrug resistant cancer cells, 
including CRC cells. 
1.6 Cathepsins 
Cathepsins are members of a large protease family, which can be subdivided 
according to their structure and active-site amino acid into cysteine (cathepsins B, 
C, F, H, K, L, O, S, V, W, and X), serine (cathepsins A and G), and aspartic 
cathepsins (cathepsins D and E). While cathepsins B, L, H, C and D are ubiquitously 
expressed in human tissues, expression of cathepsins A, G, K, S, V, X and W is 
tissue and cell type specific (Wex, Levy et al. 1998; Bromme, Li et al. 1999; Turk, 
Turk et al. 2000; Lecaille, Kaleta et al. 2002). In general, cathepsins are found in 
acidic cellular organelles, lysosomes and endosomes. Initially, their function was 
though to be limited to bulk degradation of proteins delivered to the lysosome by 
endocytosis or autophagocytosis. However, it was later demonstrated that 
cathepsins possess highly specific and directed proteolytic activity, and that they 
can be found in other cellular compartments (Brix, Dunkhorst et al. 2008; Duncan, 
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Muratore-Schroeder et al. 2008; Pratt, Sekedat et al. 2009; Hook, Funkelstein et al. 
2012; Turk, Stoka et al. 2012). Numerous physiological functions of cathepsins have 
been uncovered, including a role in hormone and antigen processing, bone and 
tissue remodeling, growth factor and proenzyme activation and, more recently, in 
the immune response (Brix, Dunkhorst et al. 2008; Conus and Simon 2010; Reiser, 
Adair et al. 2010; Turk, Stoka et al. 2012; Jacobson, Lima et al. 2013). Cathepsins 
also participate in apoptosis through LMP in response to a variety of apoptotic 
signals (Boya and Kroemer 2008; Cesen, Pegan et al. 2012; Repnik, Hafner Cesen 
et al. 2014). These lysosomal proteases can also be secreted from the cell and 
degrade extracellular matrix proteins such as collagen, fibronectin, proteoglycans 
and laminin (Fonovic and Turk 2014). 
In addition to their physiological function, cathepsins also have been associated with 
several pathologies such as cardiovascular diseases, osteoporosis, rheumatoid 
arthritis, artherosclerosis and cancer (Benes, Vetvicka et al. 2008; Reiser, Adair et 
al. 2010; Turk, Stoka et al. 2012; Fonovic and Turk 2014). Elucidating the 
mechanisms underlying the involvement of cathepsins in the pathogenesis of these 
diseases, and how they can be modulated to develop new prevention and 
therapeutic strategies, has therefore taken center stage. Among cathepsins, 
cathepsin D (CatD) has attracted increased attention in recent years due to its 
importance in the mediation of lysosomal cell death pathways and in cancer. In the 
next part, it will be given special attention to the physiological and pathological 
functions of CatD, focusing in their role in cancer such as in apoptosis process. 
1.6.1 Role of cathepsin D in cellular physiology and pathology 
CatD is a soluble aspartic endopeptidase found in the lysosomes of most 
mammalian cells. Like other cathepsins, CatD is activated by proteolytic cleavage 
of the synthetized inactive zymogen (preproCatD), which is composed of an N-
terminal signal peptide, a propeptide, and a catalytic domain (Gieselmann, 
Pohlmann et al. 1983; Erickson 1989). The signal peptide directs the nascent chain 
to the endoplasmic reticulum, where it is cleaved in the lumen. ProCatD is then N-
glycosylated and transported to the Golgi, where the N-glycan structures acquire 
mannose-6phosphate (Man-6P) residues that can bind to Man-6P receptor(s) (Man-
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6PR), and the complex is directed to the lysosomal compartment (Baranski, Koelsch 
et al. 1991). In the acidic milieu, proCatD (52 kDa) undergoes further proteolytic 
processing by cleavage of the proregion, resulting in the 48 kDa single chain 
intermediate active form. Finally, this chain is processed into mature active CatD, 
composed of heavy (34 kDa) and light (14 kDa) chains linked by non-covalent 
interactions (Erickson, Conner et al. 1981; Gieselmann, Hasilik et al. 1985; Conner 
and Richo 1992). It has been shown that CatD processing involves cysteine 
cathepsins (Gieselmann, Hasilik et al. 1985) and, more recently, that it is 
independent of its catalytic function and auto-activation but requires CatL and CatB 
(Laurent-Matha, Derocq et al. 2006). Although proCatD and CatD are mostly 
intracellular, they can also localize in the extracellular matrix and synovial fluid of 
cartilage (Poole, Hembry et al. 1974; Bjelle and Osterlin 1976; Vittorio, Crissman et 
al. 1986). ProCatD/CatD are also found in human, bovine and rat milk (Vetvicka, 
Vagner et al. 1993; Larsen and Petersen 1995; Benes, Koelsch et al. 2002), serum, 
sweat and urine (Zuhlsdorf, Imort et al. 1983; Baechle, Flad et al. 2006), and 
extracellularly in macrophage-rich regions of atherosclerotic lesions (Hakala, 
Oksjoki et al. 2003). ProCatD secretion by human keranocytes (Vashishta, 
Saraswat Ohri et al. 2007), mammalian epithelial cells (Lkhider, Castino et al. 2004) 
and different types of cancer cells (Benes, Vetvicka et al. 2008; Masson, Bach et al. 
2010) was also demonstrated. 
It is widely accepted that the major function of CatD is its involvement in general 
protein degradation and turnover within the lysosomal compartment. However, CatD 
has also emerged as an important regulator and signalling molecule with numerous 
physiological functions. These include activation of enzymatic precursors, 
prohormones and growth factors, processing of brain-specific antigens, tissue 
homeostasis, and participation in apoptosis (Minarowska, Minarowski et al. 2007; 
Benes, Vetvicka et al. 2008). CatD has also been associated with different 
pathological scenarios such as Alzheimer’s disease, artherosclerosis some 
inflammatory disorders, cancer progression and metastasis (Conus and Simon 
2010; Masson, Bach et al. 2010; Reiser, Adair et al. 2010; Tan, Peng et al. 2013), 
being considered now as a specific biomarker for several pathologies. Although the 
involvement of CatD in both physiological and pathological processes in multiple 
studies, a detailed description of the role of CatD in cancer is given below. 
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1.6.2 The role of cathepsin D in cancer 
Numerous reports have demonstrated that CatD is overexpressed in several cancer 
types (Gyrd-Hansen, Nylandsted et al. 2004; Leto, Tumminello et al. 2004; Benes, 
Vetvicka et al. 2008; Palermo and Joyce 2008; Masson, Bach et al. 2010; Tan, Peng 
et al. 2013), often correlating with poor prognosis. In particular, CatD is considered 
an independent prognostic marker in breast cancer associated with metastatic risk 
(Bossard, Descotes et al. 2003; Liaudet-Coopman, Beaujouin et al. 2006) and in 
colorectal cancer (CRC)  (Kirana, Shi et al. 2012; Shin, Sung et al. 2014). 
Mechanistically, the majority of reports attribute its role in cancer to overexpression 
of proCatD. As an example, transfection of rat tumor cells with human proCatD 
cDNA leads to increased proliferation, invasion and metastasis in vitro and in vivo 
(Berchem, Glondu et al. 2002). Accordingly, anti-proCatD antibodies can inhibit 
tumor growth both in vitro and in vivo (Fusek and Vetvicka 1994; Bazzett, Watkins 
et al. 1999; Vetvicka, Vetvickova et al. 2000). Overexpressed proCatD escapes 
normal targeting routes and is hypersecreted to the extracellular milieu, where it can 
act in multiple fashions (Figure 8) (Masson, Bach et al. 2010). On one hand, it can 
exert an autocrine effect, inducing cancer cell growth by interacting with cell surface 
receptors (Mathieu, Rochefort et al. 1990; Fusek and Vetvicka 1994; Vetvicka, 
Benes et al. 2002; Vetvicka, Vetvickova et al. 2004). This autocrine role has so far 
been observed in breast, prostate, ovarian and lung cancer cells (Fusek and 
Vetvicka 1994; Bazzett, Watkins et al. 1999; Vetvicka, Vetvickova et al. 2000). In 
addition, proCatD can plays a crucial paracrine role in the tumor microenvironment 
by stimulating fibroblast outgrowth and tumor angiogenesis (Berchem, Glondu et al. 
2002; Hu, Roth et al. 2008), as well as inhibiting anti-tumor responses (Wolf, Clark-
Lewis et al. 2003). When in the tumor microenvironment, proCatD may also affect 
stromal cell behavior and/or degrade components from the extracellular matrix 
(Vetvicka, Vashishta et al. 2010; Khalkhali-Ellis and Hendrix 2014), including the 
release of growth factors (Briozzo, Badet et al. 1991). Although it has been 
suggested that proCatD can be processed in the acidic extracellular space to 
catalytically active CatD (Achour, Bridiau et al. 2013), the enzymatic activity of CatD 
is reportedly not required for its mitogenic role. Indeed, a proteolytically inactive 
mutant of CatD (D231N) is still mitogenic for fibroblasts (Laurent-Matha, Maruani-
Herrmann et al. 2005), as well as for cancer cells both in vitro, in three-dimensional 
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matrices, and in athymic nude mice (Glondu, Coopman et al. 2001; Berchem, 
Glondu et al. 2002). Similarly, proCatD stimulates angiogenesis in tumor xenografts 
of athymic nude mice independently on its catalytic activity (Laurent-Matha, 
Maruani-Herrmann et al. 2005), also suggesting that CatD can signal through 
protein-protein interactions.  
 
Figure 8: Localization of CatD in cancer cells. In cancer cells, overexpressed CatD accumulates 
intracellularly, which may affect the cell degradative capacities. The proCatD (52 kDa) is also hyper-
secreted into the tumor micro-environment thus affecting it through the modulation of stromal cell 
behavior and/or of components of the extracellular matrix. CatD hyper-secreted by cancer cells may 
be captured back by both cancer and stromal cells. After lysosomal membrane permeabilization 
(LMP) during apoptosis, lysosomal mature CatD (34 kDa) is released into the cytosol and there may 
interact with and/or degrade pro-apoptotic or anti-apoptotic proteins. A cytoplasmic form of CatD may 
also be involved in the regulation of transcription in cancer cells by interacting with nuclear proteins 
and modulating their activity. Adapted from Masson et al. 2010.  
Though less extensive, there are also examples of CatD roles in cancer cells that 
are not attributed to proCatD. For instance, intracellular CatD can stimulate cancer 
cell growth by inactivating secreted growth inhibitors (Liaudet, Derocq et al. 1995; 
Nirde, Derocq et al. 2010). Moreover, mature CatD released into the cytosol as a 
consequence of the reportedly higher susceptibility of cancer cells to LMP 
(Fehrenbacher, Gyrd-Hansen et al. 2004; Boya and Kroemer 2008) may interact 
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with and/or degrade pro- and anti-apoptotic proteins, modulating cell death 
(Minarowska, Minarowski et al. 2007).  
Targeting CatD is a promising strategy in the clinic, but requires further detailed 
elucidation of its mechanisms of action. In the following section, we focus on the 
role of CatD in the apoptotic process, of particular relevance for cancer research. 
These studies may however also offer clues into the function of CatD in other 
physiological and pathological scenarios. 
1.6.3 Opposing functions of cathepsin D in apoptosis 
In recent years, multiple studies have shown that CatD is a central player in the 
apoptotic response, both under physiological and pathological conditions. In fact, 
depending on the cell type and context, CatD can induce or inhibit apoptosis, acting 
through different mechanisms (Minarowska, Minarowski et al. 2007). In this regard, 
CatD can directly induce apoptosis triggered by several stimuli such as 
staurosporine (Johansson, Steen et al. 2003), etoposide, 5-fluorouracil and cisplatin 
(Emert-Sedlak, Shangary et al. 2005), as well as resveratrol (Trincheri, Nicotra et 
al. 2007) and others, mediated by intrinsic or extrinsic pathways (Minarowska, 
Minarowski et al. 2007). In the intrinsic pathway, the role of CatD is linked to the 
release of mature CatD (34 kDa) into the cytosol and cleavage of Bid to form tBid, 
triggering insertion of the pro-apoptotic protein Bax into the mitochondrial membrane 
(Boya and Kroemer 2008). Subsequent mitochondrial outer membrane 
permeabilization leads to the release of pro-apoptotic molecules such as 
cytochrome c and apoptosis inducing factor (AIF) to the cytosol (Boya and Kroemer 
2008). For instance, it has been shown that CatD mediates cytochrome c release 
and caspase activation in human fibroblasts undergoing staurosporine-induced 
apoptosis (Johansson, Steen et al. 2003), and cleaves Bid and promotes apoptosis 
via oxidative stress-induced LMP in human neutrophils (Blomgran, Zheng et al. 
2007). In addition, Pepstatin A and/or knockdown of CatD expression by RNA 
interference prevent resveratrol toxicity, impeding Bax oligomerization, 
mitochondrial membrane permeabilization, cytochrome c release and caspase 3 
activation in DLD1 and HT29 CRC cell lines (Trincheri, Nicotra et al. 2007). One 
study also reports that CatD mediates selective release of AIF in T lymphocytes 
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entering the apoptosis early commitment phase through activation of Bax in a Bid-
independent manner (Bidere, Lorenzo et al. 2003). This shows that CatD can be 
involved in caspase-independent apoptosis by activating Bax independently of Bid 
cleavage. Other studies strongly suggest that cytosolic CatD may have an additional 
role involving protein-protein interactions (Masson, Bach et al. 2010). As examples, 
it has been shown that overexpression of either catalytically active or inactive CatD 
by cancer cells enhances apoptosis-dependent chemo-sensitivity (Beaujouin, 
Baghdiguian et al. 2006), and that stress-induced apoptosis is not affected in 
fibroblasts synthesizing a catalytically inactive CatD (Tardy, Tyynela et al. 2003). 
Additionally, microinjection of inactive proCatD into the cytosol of both human 
fibroblasts and HeLa cells induces apoptosis (Schestkowa, Geisel et al. 2007). 
Interestingly, one report also indicates that cytosolic mature CatD may reach the 
nucleus during cell death (Zhao, Aviles et al. 2010). 
In contrast with the multiple studies showing CatD is pro-apoptotic, other studies 
describe an anti-apoptotic function of CatD. Most of these suggest it plays an anti-
apoptotic role in cancer cells. For example, CatD downregulation sensitizes human 
neuroblastoma cells to doxorubicin-induced apoptosis, while CatD overexpression 
has the opposite effect (Sagulenko, Muth et al. 2008).  Accordingly, inhibition of 
CatD with pepstatin A induces caspase-dependent apoptosis in neuroblastoma cell 
lines (Castino, Bellio et al. 2007). Moreover, overexpression of intracellular CatD in 
mouse xenografs using rat-derived cell lines inhibits apoptosis (Berchem, Glondu et 
al. 2002) and expression of wild type or a catalytic mutant of CatD promotes survival 
and invasive growth of CatD‐deficient fibroblasts (Laurent-Matha, Maruani-
Herrmann et al. 2005). Another study in glioblastoma cells proposes that CatD 
stimulates autophagy induction, inhibiting apoptotic cell death under genotoxic 
conditions (Hah, Noh et al. 2012). An anti-apoptotic role of CatD has also been 
described under physiological conditions using CatD-deficient mice (Saftig, Hetman 
et al. 1995; Koike, Nakanishi et al. 2000; Koike, Shibata et al. 2003). Indeed, mutant 
mice developed apoptosis in the thymus, thalamus and retina. 
In summary, it is documented that CatD plays an important role in apoptosis 
regulation, both with and without involvement of its proteolytic activity. However, the 
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exact role of CatD in apoptosis in CRC cells, particularly what determines whether 
this protease plays an anti-or pro-apoptotic function remains poorly understood.  
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Rationale 
 
Colorectal cancer (CRC) is one of the most common causes of cancer-related 
mortality, and thus finding new prevention and therapeutic approaches is of prime 
importance. Propionibacteria, found in fiber-rich food and dairy products, produce 
short-chain fatty acids (SCFAs), namely butyrate, propionate and acetate. It has 
been demonstrated that SCFAs induce apoptosis in human CRC cells (Jan, Belzacq 
et al. 2002; Lan, Bruneau et al. 2008) to a higher extent than in normal intestinal 
cells (Lan, Lagadic-Gossmann et al. 2007). In the present thesis, we proposed to 
further characterize the effect of acetate in CRC cells. 
In cancer cells, lysosomes have emerged as key players in apoptosis through 
selective lysosomal membrane permeabilization (LMP) with subsequent release of 
cathepsins into cytosol (Kirkegaard and Jaattela 2009; Groth-Pedersen and Jaattela 
2013). However, the role of this pathway in cancer is controversial. In a previous 
study, it was demonstrated in Sacharomyces cerevisiae that acetic acid-induced 
apoptosis involves partial vacuole permeabilization with release of Pep4p, the yeast 
ortholog of lysosomal human cathepsin D (CatD), into the cytosol, which has a 
protective role in this process (Pereira, Chaves et al. 2010). Indeed, this protease 
was required for cell survival in a manner depedent on its catalytic activity and for 
efficient mitochondrial degradation indendently of autophagy (Pereira, Azevedo et 
al. 2013). These results raised the possibility that partial LMP and consequent CatD 
release could also be involved in acetate-induced apoptosis in CRC cells. 
Furthermore, understanding the mechanisms underlying acetate-induced cell death 
may provide the possibility to use acetate with specific cathepsin inhibitors as a 
novel prevention/therapeutic strategy in CRC. 
In addition, it is known that monocarboxylate transporters (MCTs), namely MCT-1 
to 4, are transmembrane proteins involved in intracellular pH regulation by the 
transmembrane transport of lactate, pyruvate and some SCFAs, especially butyrate 
in normal colon cells and CRC cells (Pinheiro, Longatto-Filho et al. 2008). There is 
also evidence that MCTs are upregulated in colorectal cancer (Pinheiro, Longatto-
Filho et al. 2008; Sonveaux, Vegran et al. 2008) to maintain the glycolytic 
metabolism. Thus, we thought it was important to study the role of MCTs in acetate 
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transport into CRC cells, as well as MCT regulation and cellular localization in 
presence of acetate in CRC cells. Finally, since the majority of cancer cells, 
including CRC, have a glycolytic phenotype, it was important to assess the effects 
of acetate on glucose metabolism and explore the combined use of acetate with a 
glycolysis inhibitor like 3-bromopyruvate (3BP) as a potentiator of acetate effects in 
CRC cells.  
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Aims 
 
The general aim of the present study was to elucidate the mechanisms by which 
acetate mediates cell death, focusing on LMP induction, the main cathepsins 
involved, and in the crosstalk between the lysosome and mitochondria such as the 
involvement of autophagy in this process. We also aimed to study acetate transport 
in CRC cells, characterizing the involvement of monocarboxylate transporters 
(MCTs) as well as MCT regulation in response to acetate treatment. Moreover, we 
aimed to verify the effects of acetate in the glycolytic metabolism and to explore the 
combined use of acetate with the glycolysis inhibitor 3BP in CRC cells as a new 
strategy to potentiate the effect of acetate in CRC cells. Furthermore, we aimed to 
understand the effect of acetate in the main signalling pathway activated in CRC: 
RAS-RAF-MEK-ERK. 
 
The specific aims of the present thesis are as follows: 
 
 To ascertain whether lysosomal membrane permeabilization (LMP) and CatD 
are involved in acetate-induced apoptosis in CRC cells. 
 
 To assess the role of CatD in acetate-induced mitochondrial alterations and the 
involvelment of autophagy in acetate-induced apoptosis in CRC cells. 
 
 To investigate the mechanism of acetate transport as well as the role of acetate 
on MCT expression/regulation and glucose metabolism. To explore the use of 
3BP and acetate as a possible therapeutic approach for CRC. 
 
 To determine the role of acetate in the regulation of the RAS-RAF-MEK-ERK 
signalling pathway in acetate-induced apoptosis in CRC cells.  
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2. Materials and methods 
 
2.1 Cell lines and culture conditions 
We used three cell lines derived from human CRC, namely RKOBRAFV600E, HCT-
15KRASG13D and HCT116KRASG13D; PI3KCA. Cells were maintained at 37 ºC under a 
humidified atmosphere containing 5% CO2. HCT-15 cells were grown in Roswell 
Park Memorial Institute (RPMI, Biowest) medium with L-glutamine and HEPES. 
RKO cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Biowest) 
with high-glucose and supplemented with 1 mM sodium pyruvate and 1.5 g/l sodium 
bicarbonate. HCT116 cells were grown in McCoy’s 5A medium (Biowest). All culture 
media were supplemented with 10% fetal bovine serum (FBS) and 100 U/ml 
penicillin/streptomycin. For autophagy studies, we used HBSS (Gibco) medium 
supplemented with 7.5% sodium bicarbonate. Cells were seeded and adhered onto 
appropriate sterile plates for 24 h prior to the onset of any treatments. 
2.1.1 Cell treatments with acetate 
Cells were seeded and adhered onto appropriate sterile plates for 24 hours before 
treatments in all experiments. We previously determined the half-maximal inhibitory 
concentration (IC50), IC intermediate (IC inter) and 2×IC50 of acetate after 48 hours 
of treatment: 70 mM, 100 mM and 140 mM for HCT-15; 110 mM, 140 mM and 220 
mM for RKO cell lines, respectively (Marques, Oliveira et al. 2013). In addition, in 
some experiences we used values for the IC30, 45 mM and 75 mM, respectively for 
HCT-15 and RKO cells. The IC50, IC inter and 2×IC50 values for HCT116 (100 mM, 
150 mM and 200 mM, respectively) were calculated from the mean values of 
sulforhodamine B (SRB) reduction (Supplementary Figure S3) (Oliveira, Pereira et 
al. 2015). The HCT116 cells were used only in the autophagic studies. 
2.1.2 Cell treatments to inhibit the activity of Cathepsins (B, L and D) 
Before the treatments, cells were pre-incubated with 10 µM (2S,3S)-trans-
Epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E-64d; Sigma-Aldrich) (a 
cathepsin B and cathepsin L inhibitor) for 1 hour or with 100 µM Pepstatin A (PstA; 
Materials and metods 
88 
Sigma-Aldrich) (a CatD inhibitor) for 16 hours, respectively, and then co-incubated 
without or with or different acetate concentrations or etoposide for 12, 24 or 48 hours 
to perform the assays. 
2.1.3 Cell treatments with acetate and 3-bromopyruvate (3BP) 
Cells were treated during 48 hours, using the concentration (IC) of acetate 
previously determined (Marques, Oliveira et al. 2013): 45 mM, 70 mM, for HCT-15 
and 75 mM, 110 mM for RKO cell lines (values for the IC30 and IC50, respectively). 
The concentrations of 3-bromopyruvate (3BP) used (17,5 µM, 35 µM and 75 µM, 
150 µM; IC25 and IC50, respectively for HCT-15 and RKO cells) in the assay were 
calculated from the mean values obtained in the SRB assays. For the assays with 
acetate and 3BP, the 3BP was co-incubated 16 hours before completing 48 hours 
of acetate treatment.  
2.2 Cell viability assay 
2.2.1 MTT reduction assay 
Cells were incubated with different concentrations of sodium acetate, henceforth 
referred to as acetate, for 48 hours. Freshly prepared 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) was added at a final concentration of 0.5 
mg/ml in PBS pH 7.4 and plates incubated in the dark for 2 hours at 37ºC. To 
dissolve the formazan crystals, 500 µl of acidic isopropanol (0.04 M HCl in absolute 
isopropanol) was added to each well, followed by 30 min of orbital shaking in the 
dark, to solubilise the formazan crystals. Absorbance was read at 570 nm in a 
microplate reader (Spectra Max 340PC, Molecular Devices). Results were 
expressed as a percentage of sample absorbance in relation to the negative control 
(untreated cells). 
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2.3 Cell proliferation assays 
2.3.1 Sulforhodamine B (SRB) assay 
After the treatments, the cells were fixed in ice-cold methanol containing 1% acetic 
acid, and incubated with 0.5% (w/v) sulforhodamine B dissolved in 1% acetic acid 
for 1.5h at 37°C. After washing with 1% acetic acid, SRB was solubilised with 10 
mM Tris, pH 10. Absorbance was read at 540 nm in a microplate reader 
(Spectromax 340 PC, Molecular Devices). Results were expressed relatively to the 
negative control (untreated cells), which was considered as 100% of cell 
proliferation.  
2.3.2 BrdU incorporation 
Cells were seeded in plates containing glass coverslips, exposed to acetate for 48 
h and incubated with 10 mM BrdU for 1 h. Cells were fixed with 4% 
paraformaldehyde and nuclear incorporation of BrdU was detected by 
immunofluorescence. Coverslips were mounted on Vectashield Mounting Medium 
with DAPI (4’,6-diamidino-2-phenylindole) and the percentage of positive nuclei 
(BrdU index) was determined from ˃ 500 cells/datum point. 
2.3.3 Colony formation assay (CFA) 
Cells were seeded in 6-well plates at 600 cells/mL, 300 cells/mL (respectively for 
HCT-15 and RKO cell lines) and incubated 24 h at 37º C with 5% CO2 before the 
treatments. Cells were treated as described for the SRB assay (the same 
conditions). After 48 hours of treatment, the medium was replaced by fresh medium 
twice per week during 14 days. To evaluate the colony numbers formed for each 
condition, the cells were washed with 1x PBS and then fixed with 6% 
glutaraldehyde/0.5% crystal violet solution for 30 min, at room temperature (RT). 
The cells were then washed with water and air-dried.  
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2.4  Cell death assays 
2.4.1 TUNEL assay 
Cells were exposed to DMSO control, etoposide or different concentrations of 
acetate for 48 hours. When cathepsin inhibitors were used, cells were pre-incubated 
with pepstatinA (Pst A) or (2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-
methylbutane ethyl ester (E64d) for 16 hours and 1 hour, respectively, and then co-
incubated with acetate or etoposide for 48 hours. Cytospins of both floating and 
attached cells, from each sample, were fixed with 4% paraformaldehyde for 15 min 
at room temperature (RT). Cells were washed in PBS and permeabilized with ice-
cold 0.1% Triton X-100 in 0.1% sodium citrate. TdT-mediated dUTP Nick End 
Labelling (TUNEL) was performed following the manufacturer’s instructions (“In situ 
cell death detection kit, fluorescein”, Roche, Mannheim, Germany). Slides were 
mounted on Vectashield Mounting Medium with DAPI and maintained at -20ºC until 
visualization in a fluorescence microscope (Leica  DM  5000B, Leica Microsystems, 
Wetzlar, Germany).  
2.4.2 Caspase 3 activity assay  
Cells were exposed to etoposide or acetate for 48h. Both floating cells and attached 
cells were collected from each sample, washed twice with PBS, and lysed in Lysis 
Buffer (10 mM Tris, pH 7.5, 0.1 M NaCl, 1 mM EDTA, 0.01% Triton X-100) through 
3 freeze/thaw cycles. In all, 50 µl of total extracts (1 mg/ml) were incubated with 50 
µl 200 µM z-DEVD-AFC (Biomol, Plymouth Meeting, PA, USA) in 2× reaction buffer 
(20 mM PIPES, pH 7.4, 4 mM EDTA, 10 mM DTT) and fluorescence of cleaved AFC 
was measured using a microplate reader (Flouroskan Ascent FL, Thermo Scientific 
Inc., Waltham, MA, USA). 
2.4.3  Annexin V/ Propidium iodide by flow cytometry 
After the treatments, both floating and attached cells were collected from each 
sample and washed in PBS. 1×106  cells were resuspended in 200 µl 1× binding 
buffer and incubated with 8 µl Annexin V-FITC (BD Biosciences, San Jose, CA, 
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USA) and 15 µl 50 µg/ml propidium iodide (PI) for 15 min in the dark. Samples were 
analysed in a ﬂow cytometer (Epics XL, Beckman Coulter, Miami, FL, USA) 
equipped with an argon-ion laser emitting a 488 nm beam at 15 mW. 
Monoparametric detection of red ﬂuorescence was performed using FL-3 (488/620 
nm) and detection of green ﬂuorescence was performed using FL-1 (488/525 nm).  
Cell viability or cell death were categorized by the level of Annexin-V FITC and/or 
PI fluorescence: viable cells (AV-/PI-), early apoptotic cells (AV+/PI-), late apoptotic 
cells (AV+/PI+) or necrotic cells (AV-/PI+). In all, 20 000 cells were analysed per 
sample and data analysed using FlowJo software (version 7.6) or Flowing software 
(version 2.5.1).  
 2.4.4 Sub-G1 cell population analysis by flow cytometry 
Cells were treated with DMSO, etoposide or acetate for 48 hours. When PstA was 
used, cells were pre-incubated as described above. Both floating and attached cells 
were collected from each sample, washed with PBS, and incubated with 70% cold 
ethanol for 15 minutes. Cells were then washed twice with PBS, incubated with 
RNase A (200 µg/ml) for 15 minutes in the dark at 37ºC and with propidium iodide 
(0.5 mg/ml) for 30 minutes at RT before analysis on a flow cytometer, as described 
above. FlowJo software was used to generate DNA content frequency histograms 
and quantify the amount of cells in the individual cell cycle phases, including the 
sub-G1 population assumed as corresponding to apoptotic cells.  
2.5 Lysosome membrane permeabilization (LMP) assessment 
2.5.1 Acridine Orange staining analysis by fluorescence microscopy 
Cells were seeded in 6-well plates containing glass coverslips, and exposed to 
etoposide or acetate for 48 hours. Cells were then incubated with 1 µM Acridine 
Orange (AO) for 15 minutes at 37ºC and washed with PBS. Coverslips were 
mounted over glass slides with PBS and immediately observed and photographed 
using a fluorescence microscope (Leica DM 5000B). 
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2.5.2 Acridine Orange staining analysis by flow cytometry  
Cells were exposed to etoposide or acetate for 48 hours. Both floating and attached 
cells were collected from each sample, washed with PBS, and ressuspended in PBS 
to a final concentration of 1×106 cells in 1.5 ml. Cells were then incubated with 1 µM 
AO (or without AO to measure autofluorescence) for 15 minutes at 37ºC.  
2.6 Preparation of extracts to immunoblot detections 
2.6.1 Total protein extracts 
After the treatments, both floating and attached cells were collected, washed with 
PBS and centrifuged at 650 x g for 5 min at 4 ºC. The supernatant was discarded 
and cells lysed in 80 ml Ripa Buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM 
EDTA, 1% NP-40) supplemented with 20 mM NaF, 20 mM Na3VO4, 1 mM PMSF 
and 40 µl/ml Protease inhibitor cocktail. Supernatants were cleared by centrifugation 
at 4500 x g for 10 min. Total protein extracts were stored at - 80 ºC. 
2.6.2 Cytosolic protein extracts  
Cells were exposed to etoposide or acetate for 48 h. Both floating and attached cells 
were collected, washed with PBS and centrifuged at 650 x g for 10 min at 4 ºC. All 
subsequent steps were performed at 4 ºC. Cells were resuspended in 1 ml PBS, 
centrifuged at 1500 x g for 5 min and washed twice in 800 ml Isotonic Buffer (200 
mM mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM HEPES) by centrifugation at 
3000 x g for 5 min. The cell pellet was then resuspended in 300 ml Isotonic Buffer 
with 20 mM NaF, 20 mM Na3VO4, 1 mM PMSF and 40 ml/ml Protease inhibitor 
cocktail and homogenized by passing through a 26-G needle 70 times. Nuclei and 
unbroken cells were removed by centrifugation at 1000 x g for 5 min, followed by 
two consecutive centrifugations, first at 10 000 x g for 15 min to remove lysosomes 
and mitochondria and then at 100 000 x g for 1 h in an ultracentrifuge. Cytosolic 
protein extracts were stored at - 80 ºC. 
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2.7 Western blot analysis 
Protein samples (25 µg) were separated by sodium dodecyl sulfate 12,5% 
polyacrylamide gel electrophoresis and electroblotted onto PVDF (polyvinylidene 
difluoride) membranes. All the primary antibodies were incubated overnight at 4º C. 
The primary antibodies used are represented in Table 1.   
Secondary antibodies used were peroxidase conjugated AffiniPure goat anti-rabbit 
IgG (Jackson ImmunoResearch, West Grove, PA, USA) and horseradish 
peroxidase-labeled goat anti-mouse immunoglobulin IgG (Jackson 
ImmunoResearch). Subsequent chemiluminescence detection was performed 
using the ECL detection system (Amersham, Biosciences, Buckinghamshire, UK) 
and a molecular imager by Chemi-Doc XRS system (Bio-Rad, Laboratories Inc., 
Hercules, CA, USA). When performed, densitometry analysis of protein bands was 
performed using the Quantity One software (version 4.6.9) and levels of actin used 
as a normalization control for protein loading. 
Table 1 – List of primary antibodies used in the present study. 
Protein Primary antibody (Company, dilution)    
Cathepsin D Calbiochem, 1:100    
Cathepsin B Abcam, 1:300    
Cathepsin L Abcam, 1:1000    
Beclin-1 Cell Signalling, 1:3000    
Atg-5 Sigma-Aldrich, 1:5000    
LC3I/II Sigma-Aldrich, 1:3000    
AIF Chemicon International, 1:500    
VDAC-1 MitoSciences, 1:2000    
TOM22 Santa Cruz Biotechnology, 1:1000    
MCT-1 Santa Cruz Biotechnology, 1:500    
MCT-2 Santa Cruz Biotechnology, 1:200    
MCT-4 Santa Cruz Biotechnology,1:500    
SMCT-1 Santa Cruz Biotechnology, 1:250    
CD147 Santa Cruz Biotechnology, 1:500    
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2.8 RNA interference-mediated inhibition of cathepsin D  
RKO cells were plated in 6 well plates at a density of 3×104 cells per well. After 24 
hours, about 70% confluence was confirmed before transfection with small 
interfering RNA (siRNA) oligonucleotides. Cells were transfected with 100 nM on-
target plus SMART pool siRNA against CatD (A-003649-16; Thermo Fisher 
Scientific, Lafayette, CO, USA). Transfection performance was monitored using a 
validated Silencer Select Negative Control (scrambled siRNA control, nº 4390843; 
Life Technologies, CARLSBAD, CA, USA). Transfection was performed with 6 µl 
Lipofectamine 2000 (Invitrogen Corp., Paisley, UK). After 14 hours, the transfection 
mixture was removed and cells were left untreated (blank) or treated with acetate 
(110 mM) or etoposide (50 µM) and incubated for a further 48 hours in fresh medium. 
MitoSOx, Dihydroethidium (DHE) and double staining with MitoTracker Green and 
Mitotracker Red CMXRos were performed as described below. The experiments 
were carried out in three replicates, and CatD levels were monitored by Western 
blotting.  
2.9  Determination of Intracellular Reactive Oxygen Species (ROS) 
2.9.1 Dichlorofluorescein (DCF) assay 
Cells were seeded in a 12-well plate at a density of 1.4×105 cells/well and 1.8×105 
cells/well (RKO and HCT-15 cells respectively). When indicated, cells were pre-
incubated with PstA for 16 hours and then co-incubated with PstA without and with 
different acetate concentrations for 12, 24 and 48 hours. After treatment, cells were 
washed twice with 1x PBS and 2’,7’-dihydrodichlorofluorescein diacetate (H2DCF-
DA; Sigma-Aldrich) was added to the culture plates at a final concentration of 100 
µM. Plates were incubated at 37 ºC for 30 min in the dark. Then, cells were lysed 
with 500 µL of 90% DMSO/10 % PBS (lysis solution) for 10 min at room temperature 
in the dark, with agitation. H2O2 (500 μM or 1 mM for HCT-15 or RKO cell lines, 
respectively) was used as positive control. H2DCF-DA fluorescence intensity was 
detected with emission wavelength at 538 nm and excitation wavelength at 485 nm 
using a fluorescence microplate reader (Fluoroskan Ascent FL, Thermo Fisher 
Scientific Inc., Waltham, MA, USA). Values are expressed as the mean fluorescence 
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intensity normalized to the cell number in each condition at the end of the 
experiment. Three independent experiments were performed. 
2.9.2 Dihydroethidium (DHE) assay 
Non-treated cells (negative control) or cells exposed to different acetate 
concentrations for 12, 24 and 48 hours were analyzed. When used, cells were pre-
incubated with PstA for 16 hours and then co-incubated with PstA without and with 
different acetate concentrations for 24 hours. Inhibition of cathepsin D in RKO cells 
was performed as described above. Approximately 1×106 floating and attached cells 
were collected, washed with 1x PBS, centrifuged at 1500 x g for 5 minutes and 
incubated with 150 nM dihydroethidium (DHE) (Molecular Probes, Eugene, USA) 
(30 minutes, 37ºC, in the dark) to detect superoxide anion (O2-). Fluorescence 
emission of oxidized DHE was analyzed by flow cytometry. H2O2 (500 μM or 1 mM 
for HCT-15 or RKO cell lines, respectively) was used as positive control. Values are 
expressed as the mean of fluorescence intensity normalized to T0 (control for ROS 
level before the treatment). Three independent experiments were carried out and 
data were analyzed using Flowing software (version 2.5.1).  
2.9.3 MitoSOX assay 
MitoSOX Red (Molecular Probes) was used to detect mitochondrial superoxide. 
Approximately 1×106 floating and attached cells were collected, washed with 1x 
PBS, centrifuged at 1500 x g for 5 minutes and incubated with 2.5 µM MitoSOX Red 
for 30 min at room temperature. Fluorescence emission of oxidized MitoSOX Red 
was analyzed by flow cytometry. H2O2 (1 mM) was used as a positive control. Values 
are expressed as the percentage of cells with positive staining normalized to T0 
(control for ROS level before the treatment). 
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2.10 Analysis of mitochondrial alterations 
2.10.1 Mitochondrial mass and mitochondrial membrane potential (ΔΨm) analysis 
MitoTracker Green FM (Molecular Probes) was used to analyze the relative 
mitochondrial mass. MitoTracker Green is a green-fluorescent dye that localizes to 
the mitochondrial matrix regardless of the ΔΨm and covalently binds to 
mitochondrial proteins by reacting with free thiol groups of cysteine residues. 
MitoTracker Red CMXRos (Molecular Probes) was used simultaneously, to monitor 
the changes in ΔΨm. MitoTracker Red CMXRos is a red-fluorescent dye that stains 
mitochondria in live cells through accumulation in mitochondria in a membrane 
potential-dependent manner. Untreated cells (negative control), exposed to 
etoposide (50 µM), an inducer of LMP, or different acetate concentrations were 
analyzed at different time points. When used, cells were pre-incubated and co-
incubated with E-64d and PstA without and with different acetate concentrations as 
described before. Both floating cells and attached cells were collected, washed with 
1x PBS, centrifuged at 1500 x g for 5 minutes and incubated with 400 nM 
MitoTracker Green FM and 200 nM MitoTracker Red CMXRos (30 minutes, 37ºC, 
in the dark). The uncoupling agent CCCP (50 μM, 30 min) was used as positive 
control for mitochondrial membrane depolarization. Fluorescence emission was 
analyzed by flow cytometry. The values of mitochondrial mass for each time point 
were expressed as the ratio between the mean green fluorescence intensity and the 
one correspondent to time zero (T0). The values of the ΔΨm for each time point 
were expressed as the ratio between the mean red fluorescence intensity and the 
mean green fluorescence intensity normalized to the correspondent one at T0. 
Three independent experiments were carried out.  
2.10.2 Fluorescence microscopy studies  
Cells were seeded in 6-well plates containing glass coverslips and exposed to 
acetate for 48 hours. At the end of the experiment, cells were washed with 1x PBS 
and incubated with 20 nM DiOC6(3) (Molecular Probes, Eugene, OR) or with 400 
nM MitoTracker Green and 200 nM MitoTracker Red CMXRos for 30 minutes, at 
37ºC, in the dark. CCCP (50 μM, 30 min) was also used as a positive control for 
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mitochondrial membrane potential loss. Coverslips were mounted in 1x PBS and 
immediately observed under the fluorescence microscope (Leica DM 5000B, Leica 
Microsystems, Wetzlar, Germany). Three coverslips were prepared for each 
experimental condition and representative images are shown. 
2.11 Flow cytometry analysis 
Samples were analyzed in a flow cytometer (Epics XL, Beckman Coulter, Miami, 
FL, USA) equipped with an argon-ion laser emitting a 488-nm beam at 15mW. 
Detection of red ﬂuorescence was performed using FL-4 (488/620 nm) and 
detection of green ﬂuorescence was performed using FL-1 (488/525 nm). 30 000 or 
20. 000 cells were acquired per sample and data were analyzed using FlowJo 
software (version 7.6) or Flowing software (version 2.5.1).  
2.12 Assessing autophagy in CRC cell lines 
Cell lines untreated (Blank) or treated with IC50, IC intermediate (IC inter) or 2×IC50 
acetate concentrations were incubated for 42 hours in complete medium. 
Afterwards, cells were incubated in HBSS medium for 6 hours in the presence or 
absence of 20 nM Bafilomycin A1 (BafA1, Acros Organics, Geel, Belgium) and in 
the presence or absence of acetate. After the treatments, were performed total 
protein extracts and Western blotting to detect some proteins involved with 
autophagy, such as Beclin-1, LC3I/II and Atg-5.  
2.13 Measurement of acetate uptake 
The protocol for [14C] acetate uptake was adapted from Kobayashi et al. (Kobayashi, 
Itagaki et al. 2004) as described in Azevedo-Silva et al. (Azevedo-Silva, Queiros et 
al. 2015). Briefly, cells were seeded in 24-well plates at 2–3×105 cells/well, 
incubated overnight at 37◦C with 5% CO2, washed twice and incubated with HEPES 
buffer (pH 7.4) for 10min at 37ºC. HEPES buffer was removed and cells were 
incubated in MES buffer (pH 6.0) with the radiolabelled [14C] acetate (4000 
d.p.m./nmol) for the appropriate period of time at 37◦C. Afterwards, the [14C] acetate 
solution was removed, the plate was incubated on ice and the cultures washed with 
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ice-cold HEPES buffer, pH 7.4. Cells were then solubilized with 1% SDS/0.2 M 
NaOH and mixed with scintillation liquid for measuring radioactivity in a Packard Tri-
Carb 2200 CA liquid scintillation spectrophotometer with d.p.m. correction. For 
normalization, protein of all samples was quantified using a BCA Protein Assay Kit 
(Pierce). As [14C] acetate uptake was linear up to 5 min, 3 min of incubation of the 
cells with the radiolabelled substrate was adopted in the present study. The effect 
of distinct inhibitors AR-C155858, CHC, DIDS, CCCP, monensin, valinomycin and 
HgCl2 was evaluated in cells incubated for 3 min with each compound in MES buffer, 
pH 6.0, prior to incubation with 1.0 mM [14C] acetate for 3 min.  
2.14 Immunofluorescence microscopy analysis of MCT-1, MCT-4 and CD147  
Cells were seeded in 12-well plates containing glass coverslips and exposed to 
acetate for 48 hours (IC30 and IC50 acetate doses for both cell lines). As negative 
control, cells with fresh medium were used. At the end of the experiment, cells were 
washed with 1x PBS and fixed with 4% paraformaldehyde for 15 min at RT. Then, 
coverslips were washed in 1x PBS and permeabilised with 0,1% Triton X-100 in 1x 
PBS for 2 min. After this, coverslips were washed in 1x PBS and blocked with 5% 
BSA for 30 min. Coverslips were incubated with anti-MCT-1 (1:250, Santa Cruz 
Biotechnology) or anti-MCT-4 (1:500, Santa Cruz Biotechnology) or anti-CD147 
(1:250, Santa Cruz Biotechnology) diluted in 5% BSA, overnight. At the end, 
coverslips were washed twice with 1x PBS and incubated with fluorescence anti-
rabbit (for MCT-4, 1:500, Alexa Fluor® 488, Invitrogen A-11008) and fluorescence 
anti-mouse (MCT-1 and CD147, 1:250, Alexa Fluor® 594, Invitrogen A-11032) for 
1 h. So, the coverslips were washed twice with 1x PBS and finally mounted on 
Vectashield Mounting Medium with DAPI and immediately observed under the 
fluorescence microscope (Olympus BX61 fluorescence microscope, Tokyo, Japan). 
Three coverslips were prepared for each experimental condition and representative 
images are shown. 
2.15 Glucose consumption and lactate production assays 
Cells cultured in 48-well plates were pre-incubated in glucose-free media for 2 h. 
Then, cells were washed with 1x PBS and incubated with the doses of acetate - IC30 
Materials and methods 
99 
and IC50, as mentioned before). Non-treated cells (negative control) or exposed to 
acetate concentrations were analyzed. After incubation, conditioned medium was 
collected at 3, 6, 12, 24 and 48 hours. Glucose consumption and extracellular lactate 
were measured by the enzymatic colorimetric kits: Glucose Assay Kit (Roche, 
Mannheim, Germany) and Lactate Assay kit (SpinReact, Sant Esteve de Bas, 
Girona, Spain), following the manufacturer’s instructions. Glucose and lactate 
fluorescence intensity were detected with absorbance emission at 490 nm using a 
fluorescence microplate reader. Values are expressed as the mean of fluorescence 
intensity normalized to T0 (control for glucose and lactate levels before the 
treatment with acetate) and the cell biomass for each condition (by Sulforhodamine 
(SRB) assay). The SRB protocol was performed as previously described (Marques, 
Oliveira et al. 2013). 
2.16 Statistical analysis 
Statistical significance analysis was determined by two-way ANOVA or by one-way 
ANOVA followed by Dunnett or Bonferroni’s test for multiple comparisons using 
Prism software version 6 (GraphPad La Jolla, CA, USA). Kinetic parameters were 
determined using GraphPad for the non-linear regression of the plots of the initial 
uptake rates of acetate as a function of the acid concentration. All results are 
presented as mean ± standard deviation (SD) of three independent experiments. 
Differences were considered significant for P values lower than 0.05. 
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CHAPTER 3: 
Results 
_________________________________________________________________ 
 
This chapter includes part of the results presented in the following publications: 
 
Marques C*, Oliveira CSF*, Alves S, Chaves SR, Coutinho OP, Côrte-Real M, Preto 
A (2013). Acetate-induced apoptosis in colorectal carcinoma cells involves 
lysosomal membrane permeabilization and cathepsin D release. Cell death & 
disease, 4: e507. *These authors contributed equally to this article. 
 
Oliveira CSF, Pereira H, Alves S, Castro L, Baltazar F, Chaves SR, Preto A, Côrte-
Real M (2015). Cathepsin D protects colorectal cancer cells from acetate-induced 
apoptosis through autophagy-independent degradation of damaged mitochondria. 
Cell death & disease, 6: e1788. 
 
Oliveira CSF, Azevedo-Silva J, Casal M, Côrte-Real M, Baltazar F, Preto A. The 
role of acetate on monocarboxylate transporter (MCT) expression and glucose 
metabolism in colorectal cancer cells: therapeutic implications. Submitted to Cancer 
Letters. 
 
# In all these publications I actively participated in the design, laboratory work, such as in the writing 
of the manuscript and in the process of journal submission.  
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3.1: Acetate-induced apoptosis in colorectal carcinoma cells involves 
lysosomal membrane permeabilization and cathepsin D release 
 
One of the goals of this thesis project was to further characterize the previously 
described apoptotic death pathway in colorectal cancer (CRC) cells induced by 
acetate (Jan, Belzacq et al. 2002; Lan, Lagadic-Gossmann et al. 2007). 
Furthermore, as we previously reported that acetic acid-induced apoptosis in 
Saccharomyces cerevisiae cells involves partial vacuole permeabilization and 
release of Pep4p, the yeast cathepsin D (CatD), showing a protective role in this 
process, we also aimed to investigate whether lysosomal membrane 
permeabilization (LMP) and CatD could be involved in acetate-induced apoptosis in 
CRC cells.  
Our results showed that acetate per se inhibits proliferation and induces apoptosis 
in HCT-15 and RKO (colon cancer cell lines selected in the present sudy). More 
importantly, we uncovered that acetate triggers LMP and CatD release to the 
cytosol. Pepstatin A (a CatD inhibitor) but not E64d (a cathepsin B and L inhibitor) 
increased acetate-induced apoptosis of CRC cells, suggesting that CatD has a 
protective role in this process. Our data indicate that acetate induces LMP and 
subsequent release of CatD in CRC cells undergoing apoptosis, and suggest 
exploiting novel strategies using acetate as a prevention/therapeutic agent in CRC, 
through simultaneous treatment with CatD inhibitors. 
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3.1.1 Acetate induces apoptosis and inhibits cell proliferation in CRC cell lines 
CRC-derived cell lines HCT-15 and RKO were treated with different concentrations 
of acetate for 24 and 48 h and cell viability assessed with the 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) reduction test. After 24 h, there was no 
statistically significant decrease in viability of acetate-treated cells in either cell line, 
in comparison with untreated cells (not shown). The half-maximal inhibitory 
concentration (IC50) of acetate was therefore calculated from the mean values of 
MTT reduction after 48 h of treatment: 70mM and 110mM for HCT-15 and RKO 
cells, respectively (Figure 1a). IC50, 2xIC50 and an intermediate concentration of 
acetate were used in subsequent studies. 
The decrease in cell viability determined by MTT assay might be due to decreased 
cell proliferation, increased cell death or both. We therefore assessed cell 
proliferation after exposure to acetate using sulforhodamine B (SRB) and 
bromodeoxyuridine (BrdU) assays and apoptosis using Annexin V/propidium iodide 
(AV/PI), caspase activity and terminal deoxynucleotidyl transferase-mediated 
dUTP-fluorescein nick end labeling (TUNEL) assays, as well as sub-G1 population 
analysis by flow cytometry. The IC50 of acetate reduced cell proliferation by 
approximately 30% and 65% in HCT-15 and RKO cells, respectively, as determined 
by SRB assay (Figure 1b). In HCT-15 cells, IC50 and 2xIC50 of acetate reduced 
proliferation by approximately 17% and 75%, respectively, as determined by BrdU 
assay (Figures 1c and d). 
We next analysed cell death through AV/PI staining and found that acetate induced 
exposure of phosphatidylserine to the outer leaflet of the plasma membrane in HCT-
15 cells in a dose-dependent manner (Figure 2a). The number of cells stained with 
AV (AV+PI- plus AV+PI+) increased from 3.9% in the untreated control to 8.0, 18.2 
and 47.9% after exposure to 70, 100 and 140 mM acetate, respectively, and to 
49.1% when cells were exposed to etoposide for 48 h (Figure 2b). Levels of necrotic 
cells (AV- PI+) after exposure to 70 or 100mM acetate were very low. .A higher dose 
of acetate (140 mM) increased the number of necrotic cells (4% AV-/PI+), similarly 
to etoposide, although the majority of the population (~48%) was in early and late 
apoptosis (AV+PI- plus AV+PI+) (Figure 2b). These results led us to conclude that 
acetate induces apoptosis rather than necrosis. 
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Figure 1: Determination of acetate IC50 values and proliferation analysis in CRC cell lines 
treated with acetate. (a) HCT-15 and RKO cells were incubated with different concentrations of 
acetate for 48 h or with fresh complete medium as a negative control, and IC50 values determined 
by MTT reduction assay. (b) Cell proliferation analysis by SRB assay in CRC cells treated with 
acetate. Cells were incubated with IC50 and 2xIC50 concentrations of acetate (respectively, 70 mM 
and 140 mM for HCT-15 and 110 mM and 220 mM for RKO) for 48 h. Values represent mean ± 
S.E.M. of at least three independent experiments. ***P ≤ 0.001, compared with negative control cells. 
(c) Cell proliferation analysis by BrdU incorporation assay in HCT-15 cells treated with acetate (70 
mM and 140 mM) for 48 h; values represent mean ± S.E.M. of at least three independent experiments 
*P ≤ 0.05; ***P ≤ 0.001, compared with negative control cells. (d) Representative photographs of 
BrdU incorporation assay in HCT-15 cells treated with acetate (70 mM and 140 mM) for 48 h. phase 
contrast (PC; x 100); DAPI (4’,6-diamidino-2-phenylindole), FITC (fluorescein isothiocyanate) and 
merged (x 200) were obtained by fluorescence microscopy. (Some of these results were obtained in 
collaboration with C. Marques). 
Accordingly, caspase 3 was also activated in HCT-15 cells, as cleavage of the 
fluorogenic caspase 3 substrate z-DEVD-AMC, expressed in arbitrary fluorescence 
units/min/mg protein, increased from 3.6 in HCT-15 control cells (untreated) to 24.4 
after exposure to 140 mM acetate (Figure 2c). Similar results were obtained when 
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activation of total caspases was assessed by labelling with the fluorescent pan-
caspase inhibitor FICT-VAD-fmk (not shown). 
 
Figure 2: Acetate induces apoptosis and not necrosis in CRC cells. Apoptosis determined by 
Annexin V fluorescein isothiocyanate (AV-FITC) and propidium iodide (PI) assay in HCT-15 cells 
after incubation with 70 mM, 100 mM and 140 mM of acetate for 48 h. Cells were incubated with 
fresh complete medium or etoposide (50 µM) as a negative and positive control, respectively. (a) 
Representative histograms of HCT-15 cells double-labeled with AV and PI. Percentages of apoptotic 
cells (positive for AV) are the sum of the lower and upper right panels. (b) Quantitative analysis of 
AV/PI staining in HCT-15 cells. Values represent mean ± S.E.M. of at least three independent 
experiments. *P ≤ 0.05; ***P ≤ 0.001, comparing each subset of cells (AV- PI -, AV - PI +, AV + PI -, 
AV + PI +) to the respective negative control cells.(c) Quantitative analysis of caspase 3 activity in 
HCT-15 cells after incubation with 70 mM, 100 mM and 140 mM of acetate for 48 h. Values represent 
mean ± S.E.M. of three independent experiments. *P ≤ 0 .05; **P ≤ 0.01; ***P ≤ 0.001, compared 
with negative control cells. 
We also assessed the levels of DNA strand breaks in both the cell lines by TUNEL 
assay. In comparison to the negative control, there were no significant differences 
in the number of HCT-15 apoptotic cells after 48 h of treatment with 70 mM acetate 
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(IC50) (0.5% versus 1.6%; Figure 3a), though phenotypic alterations typical of 
apoptosis (such as apoptotic bodies) were observed (Figure 3b).  
 
Figure 3: Acetate increases levels of TUNEL-positive cells. Apoptosis analysis in HCT-15 and 
RKO cells by TUNEL assay, after incubation with IC50 and 2xIC50 acetate concentrations (70 mM 
and 140 mM for HCT-15; 110 mM and 220 mM for RKO) for 48 h. (a) Analysis of TUNEL assay in 
HCT15 and RKO cells. Values represent mean ± S.E.M. of at least three independent experiments. 
*P ≤ 0.05; ***P ≤ 0.001 compared with negative control cells. (b) Representative images (x 200) of 
DAPI (4’,6- diamidino-2-phenylindole), FITC (fluorescein isothiocyanate) and merged were obtained 
by fluorescence microscopy. PC, phase contrast. (These results were obtained in collaboration with 
C. Marques). 
However, the number of apoptotic cells increased significantly (7.2%) after 48 h of 
treatment with 140 mM acetate (2xIC50) (Figure 3a). Exposure to 110 mM acetate 
(IC50) induced a minor increase in the number of apoptotic RKO cells, compared 
with low basal apoptotic levels (1.6% versus 0.3%; Figure 3a), but again with evident 
phenotypic alterations (Figure 3b). When treated with 220 mM acetate (2xIC50), the 
number of apoptotic RKO cells increased significantly (65.5%; Figure 3a). Acetate 
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also led to a dose-dependent increase in the sub-G1 peak of HCT-15 cells, 
indicative of an apoptotic sub-population, and similar to that of cells treated with 
etoposide (Figure 5b). Two peaks corresponding to the G1 and G2/M phases of the 
cell cycle were evident in DNA content histograms of HCT-15 control (untreated) 
cells, with very few cells in the hypodiploid sub-G1 cell-cycle phase (2% of the total 
events acquired). Exposure to etoposide or 140 mM acetate greatly increased the 
percentage of hypodiploid cells to approximately 70% and 35%, respectively (Figure 
5b). It has been reported that the pH influences the cell death pathway induced by 
SCFA produced by propionibacteria, that is, SCFA trigger apoptosis at pH 7.5 in HT-
29 cells but necrosis at pH 5.5.1 In our study, the pH of the culture medium after 48 
h of incubation with acetate was closer to 7.5 than to 5.5 in both HCT-15 and RKO 
cell lines and was similar to that of the control culture (Table 1). In RKO cells, the 
pH of the control culture medium (pH = 8.00) was higher than that of HCT-15 cells 
(pH = 7.45), probably due to the different composition of the growth medium (DMEM, 
Dulbecco’s Modified Eagle’s Medium) for RKO cells and RPMI for HCT-15 cells) 
and to the different growth rates of these cell lines. Taken together, our results show 
that, under our experimental conditions, acetate induced apoptosis. 
Table 1: Measurements of pH in acetate-treated cells.
 
Determination of pH values in the culture medium of CRC cells, after incubation with acetate for 48 h. Untreated cells were 
incubated with fresh complete medium. Data represent means of at least three independent experiments. (These results were 
obtained in collaboration with C. Marques). 
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3.1.2 Acetate induces lysosomal permeabilization and cathepsin D release to 
the cytosol 
We next investigated whether the lysosomal pathway was involved in acetate-
induced apoptosis in CRC cells. We measured LMP both by staining with the 
lysosomotropic agent Acridine Orange (AO) and by immunoblot detection of CatD 
in cytosolic fractions. AO is a weak base that moves freely across membranes when 
uncharged and accumulates in acidic compartments like lysosomes in its protonated 
form, where it forms aggregates that fluoresce bright red. 
LMP is associated with proton release, which renders lysosomes more alkaline and 
hence with decreased red fluorescence. LMP was monitored qualitatively by 
fluorescence microscopy and quantitatively by flow cytometry, by measuring the 
percentage of cells with loss of lysosomal AO red fluorescence. Etoposide was used 
as a positive control, as it destabilizes lysosomes and induces LMP through CatD 
release to the cytosol (Emert-Sedlak, Shangary et al. 2005; Groth-Pedersen, 
Ostenfeld et al. 2007; Fehrenbacher, Bastholm et al. 2008). Fluorescence 
microscopy analysis of both the cell lines stained with AO showed that a high 
percentage of control cells exhibited intact acidic lysosomes (i. e., high levels of red 
fluorescence corresponding to accumulation of AO in acidic lysosomes) and a 
reduced percentage of cells with diffused green fluorescence (corresponding to non-
lysosomal AO) (Figure 4a). By contrast, exposure to acetate led to a decrease in 
the percentage of cells with red fluorescence, associated with an increase in the 
percentage of cells with green fluorescence, indicative of LMP (Figure 4a). Similar 
results were obtained in cells treated with etoposide. These differences were more 
pronounced in cells treated with 2xIC50 acetate than in cells treated with IC50 
concentrations. Quantification of AO-stained cells was performed by flow cytometry; 
cells with red fluorescence levels lower than the threshold of AO-positive staining of 
untreated cells were considered to exhibit LMP. Cells with LMP increased from 
approximately 3.6% in untreated cells to 11.7, 25.8 and 49.1% in cells exposed to 
70 mM (IC50), 100 mM and 140 mM (2xIC50) acetate, respectively (Figure 4c). 
These results demonstrate that acetate induces LMP in a dose-dependent manner. 
As lysosomal proteases such as CatD are released from lysosomes to the cytosol 
after LMP, their detection in the cytosolic fraction is indicative of LMP. We therefore 
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treated HCT-15 and RKO CRC cells with two concentrations of acetate (IC50 and 
2xIC50 for each cell line), or with etoposide, and detected CatD in whole-cell 
extracts and in cytosolic fractions by western blot (Figure 4d). We found that CatD 
is expressed in whole-cell lysates and that untreated cells exhibited very low levels 
of CatD in the cytosol. Notably, we found that exposure to etoposide and to IC50 
and 2xIC50 concentrations of acetate led to CatD release to the cytosol, indicating 
that acetate induces LMP in a concentration-dependent manner and further 
suggesting that acetate induces a lysosomal pathway of apoptosis in both the cell 
lines. We also observed that exposure to acetate increased Pro-CatD levels in the 
cytosol of both the cell lines (Figure 4d). The apparent decrease in cytosolic Pro-
CatD levels in RKO cells treated with 2xIC50 compared with IC50 concentrations of 
acetate seems to be due to increased processing to mature CatD. 
3.1.3 Cathepsin D release protects cells from acetate-induced apoptosis 
To test whether the apoptotic phenotype of HCT-15 and RKO cells exposed to 
acetate depends on CatD, we inhibited lysosomal CatD with pepstatin A (PstA) 
and cathepsins B (CatB) and L (CatL) with (2S,3S)-trans-Epoxysuccinyl-L-
leucylamido-3-methylbutane ethyl ester (E64d). PstA, but not E64d, increased 
apoptotic levels induced by acetate (Figure 5a). Indeed, incubation of HCT-15 cells 
and RKO with PstA before incubation with the 2xIC50 concentration of acetate 
increased the number of TUNEL-positive cells, though only reaching statistical 
significance in HCT-15. E64d did not significantly alter apoptotic levels of either cell 
line under the same conditions (Figure 5a). PstA-treated HCT-15 cells exposed to 
acetate also exhibited a higher percentage of cells with sub-G1 DNA content than 
cells treated with acetate alone, indicative of higher apoptotic levels (Figures 5b and 
c). By contrast, inhibition of CatD in cells exposed to etoposide decreased the sub-
G1 population (Figures 5b and c), in agreement with previous reports showing that 
CatD has a pro-apoptotic role in etoposide-induced cell death (Emert-Sedlak, 
Shangary et al. 2005). These results therefore indicate that CatD has a protective 
role in acetate-induced apoptosis in CRC cells, as has been observed in S. 
cerevisiae cells for Pep4p, the human CatD ortholog (Pereira, Chaves et al. 2010). 
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Figure 4: Acetate induces LMP, analyzed by lysosomal pH alterations and CatD release to the 
cytosol. (a) HCT-15 and RKO cells were incubated with acetate (70 mM, 100 mM and 140 mM, for 
HCT-15 cells; 110 mM, 140 mM and 220 mM, for RKO cells) for 48 h or with fresh complete medium 
or etoposide (50 µM) as a negative and positive control, respectively. LMP was detected by AO 
staining and visualization by fluorescence microscopy. Representative images (x400) are shown. (b) 
Representative images of monoparametric histograms of green fluorescence (FL3 area (log)) in 
HCT-15 cells treated as in (a). (c) Percentage of HCT-15 and RKO cells displaying LMP quantified 
by flow cytometry analysis of AO staining after exposure to acetate as described in (a). Values 
represent mean ± S.E.M. of three independent experiments. *P ≤ 0.05; **P ≤ 0.01 compared with 
negative control cells. (d) Effect of acetate on the expression and release of cathepsin D to the 
cytosol in HCT-15 and RKO cells, comparing whole-cell lysates (total) and cytosolic fractions (cyto). 
Cells were treated with IC50 and 2xIC50 acetate concentrations (respectively, 70 mM and 140 mM 
for HCT-15 cells and 110 mM and 220 mM for RKO cells) for 48 h or with fresh complete medium or 
etoposide (50 µM) as a negative and positive control, respectively. Actin was used as a loading 
control. (Some of these results were obtained in collaboration with C. Marques). 
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Figure 5: CatD has a protective role in acetate-induced apoptosis. Effect of the specific CatD 
inhibitor (PstA) and CatB and CatL inhibitor (E64d) on apoptosis in HCT-15 and RKO cells treated 
with acetate. PstA (100 µM) was pre-incubated for 16 h and then co-incubated with acetate for 48 h. 
E64d (10 µM) was pre-incubated for 1 h and then co-incubated with acetate for 48 h. (a) Apoptosis 
analysis by TUNEL assay. Values represent mean ± S.E.M. of at least three independent 
experiments. **P ≤ 0.01; ***P ≤ 0.001 compared with negative control cells. # P ≤ 0.05; ## P ≤ 0.01; 
### P ≤ 0.001 comparing acetate treatment with or without PstA or E64d. (b) Analysis of the effect 
PstA on the sub-G1 subpopulation of acetate-treated HCT-15 cells by flow cytometry. Representative 
histograms corresponding to HCT-15 cells treated with 100 mM and 140 mM acetate with or without 
PstA. Percentage of sub-G1 cells are shown. Cells were incubated with fresh complete medium or 
etoposide (50 µM) as a negative and positive control, respectively. (c) Analysis of the distribution of 
cell-cycle phases in HCT-15 cells after acetate treatment in absence/presence of PstA. Values 
represent mean ± S.E.M. of at least three independent experiments. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 
0.001 comparing the percentage of sub-G1 populations of treated cells with that of untreated cells 
(negative control/dimethyl sulfoxide (DMSO)). (Some of these results were obtained in collaboration 
with C. Marques). 
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3.2: Cathepsin D protects colorectal cancer cells from acetate-induced 
apoptosis through autophagy-independent degradation of damaged 
mitochondria 
 
As we previously established that acetate induces lysosome membrane 
permeabilization (LMP) in CRC cells, associated with release of the lysosomal 
protease Cathepsin D (CatD), which has a well-established role in the mitochondrial 
apoptotic cascade. Unexpectedly, we showed that CatD plays an anti-apoptotic role 
in this process, since pepstatin A (a CatD inhibitor) increased acetate-induced 
apoptosis. These results mimicked our previous data in the yeast system showing 
that acetic acid activates a mitochondria-dependent apoptosis process associated 
with vacuolar membrane permeabilization and release of the vacuolar protease 
Pep4p, ortholog of mammalian CatD. Indeed, this protease was required for cell 
survival in a manner dependent on its catalytic activity and for efficient mitochondrial 
degradation independently of autophagy. In this study, we therefore assessed the 
role of CatD in acetate-induced mitochondrial alterations. We found that, like acetic 
acid in yeast, acetate-induced apoptosis is not associated with autophagy induction 
in CRC cells. Moreover, inhibition of CatD with siRNA or pepstatin A enhanced 
apoptosis associated with higher mitochondrial dysfunction and increased 
mitochondrial mass. This effect seems to be specific, since inhibition of Cathepsins 
B and L with E-64d had no effect, nor were these proteases significantly released 
to the cytosol during acetate-induced apoptosis. Using yeast cells, we further show 
that the role of Pep4p in mitochondrial degradation depends on its protease activity 
and is complemented by CatD, indicating this mechanism is conserved. 
In summary, the clues provided by the yeast model unveiled a novel CatD function 
in the degradation of damaged mitochondria when autophagy is impaired, which 
protects CRC cells from acetate-induced apoptosis. CatD inhibitors could therefore 
enhance acetate-mediated cancer cell death, presenting a novel strategy for 
prevention or therapy of CRC. 
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3.2.1 Acetate leads to oxidative stress, changes in ΔΨm and increased 
mitochondrial mass in CRC cells  
Acetate-induced apoptosis has been associated with mitochondrial dysfunction, 
including increased ROS and ΔΨm alterations, though only in HT-29 cells (Jan, 
Belzacq et al. 2002; Lan, Lagadic-Gossmann et al. 2007). We also previously 
showed that CRC-derived cells HCT-15 and RKO exposed to physiological 
concentrations of acetate exhibit characteristic apoptotic markers (Marques, 
Oliveira et al. 2013). However, an effect on mitochondrial mass, as suggested by 
our studies in yeast (Pereira, Chaves et al. 2010) has never been described. We 
therefore sought to comprehensively determine how acetate affects mitochondrial 
function in HCT-15 and RKO cells, in particular ROS accumulation and changes in 
ΔΨm and mitochondrial mass. For this purpose, cells exposed to different 
concentrations of acetate were stained with the reactive oxygen species (ROS) 
probes 2,7-dihydrodichlorofluorescein diacetate (H2DCF-DA) or dihydroethidium 
(DHE), to detect hydrogen peroxide (H2O2) or superoxide anion (O2-), respectively. 
ROS levels in HCT-15 and RKO cells consistently increased in response to acetate 
in a dose-dependent manner after 12 and 24 hours of exposure, and then slightly 
decreased after 48h (H2O2 in HCT-15 (Figure 1a) and RKO cells (not shown), and 
O2- in RKO cells (Figure 1b)). To determine if the acetate-induced ROS 
accumulation could be due to inhibition of cellular antioxidant defenses, we used a 
qualitative assay to measure catalase activity (Iwase, Tajima et al. 2013). We found 
that exposure to IC50 concentrations of acetate slightly decreased catalase activity 
in HCT-15 and RKO cells, though more evidently in the latter (Supplementary Figure 
S1). 
In addition to resulting from a decrease in antioxidant defenses, ROS accumulation 
can be an early event of the apoptotic process, associated with other mitochondrial 
dysfunctions.(Handy and Loscalzo 2012) We therefore assessed if acetate induces 
further mitochondrial alterations in CRC cells. We found that acetate, like CCCP, 
decreased the mitochondrial potential - ΔΨm, as it lowered mitochondrial 
accumulation of DiOC6(3) and of MitoTracker® Red CMXRos in RKO cells and of 
DiOC6(3) in HCT-15 cells (Supplementary Figure S2), while increasing cytosolic 
fluorescence of the probes. Since changes in ΔΨm can result from changes in 
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mitochondrial mass, we quantitatively assessed these two parameters 
simultaneously in RKO cells stained with both MitoTracker® Red CMXRos and 
MitoTracker® Green FM, by flow cytometry. In addition to a decrease in the mean 
red fluorescence, indicative of decreased ΔΨm (Figure 1c), acetate increased the 
mean green fluorescence, indicative of an increase in mitochondrial mass (Figures 
1c and d). After normalizing acetate-induced changes in ΔΨm to mitochondrial 
mass, and in relation to time zero (Figure 1e), it became evident that a short 
exposure to acetate induces a small increase in ΔΨm (Figure 1e). This 
hyperpolarization was apparent after 12 hours of exposure to 110 and 140 mM but 
not to 220 mM acetate. For longer exposure times, this ratio significantly decreased 
for all concentrations, indicative of ΔΨm dissipation (as verified for the control CCCP 
treatment). We also investigated the effect of acetate on the levels of mitochondrial 
proteins, namely the apoptosis inducing factor (AIF), the voltage dependent anion 
channel (VDAC1), and a subunit of the outer mitochondrial membrane translocator 
(TOM22). We found all doses of acetate, as well as etoposide, increased the levels 
of AIF and VDAC1 in RKO and, to a higher extent, in HCT-15 cells (Supplementary 
Figure S3). In addition, acetate, but not etoposide, led to increased levels of TOM22.  
Our results indicate that acetate causes mitochondrial dysfunction, increasing ROS 
accumulation, perturbing ΔΨm and increasing mitochondrial mass in a time- and 
dose-dependent manner, suggesting that acetate impairs the turnover of harmful 
mitochondria. 
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Figure 1: Acetate induces oxidative stress and mitochondrial dysfunction in CRC cells. (a) 
and (b) HCT-15 and RKO cells were incubated with acetate (70, 100 or 140 mM for HCT-15 cells; 
110, 140 or 220 mM for RKO cells) for 12, 24 and 48 hours. HCT-15 and RKO negative control cells 
were incubated with fresh complete medium for the same times, while positive control cells were 
incubated with 500 µM and 1 mM H2O2, respectively. (a) Accumulation of hydrogen peroxide (H2O2) 
in HCT-15 cells was detected with 2’,7’-dihydrodichlorofluorescein diacetate (H2DCF-DA) using a 
fluorescence microplate reader. (b) Accumulation of superoxide anion (O2-) in RKO cells was 
detected with dihydroethidium (DHE) and quantified by flow cytometry. (c), (d) and (e) Detection of 
mitochondrial dysfunction in RKO cells using MitoTracker® Green FM and MitoTracker® Red 
CMXROs double staining. Cells were incubated with 110, 140 or 220 mM of acetate for 48 hours and 
then stained with 400 nM MitoTracker® Green and 200 nM MitoTracker® Red for 30 min at 37º in the 
dark. (c) Representative histograms of mitochondrial dysfunction in cell exposed to 110, 140 or 220 
mM of acetate for 48 hours. There was a significant increase in the green mean fluorescence intensity 
(MitoTracker® Green), indicative of an increase in mitochondrial mass, and a decrease in the mean 
red fluorescence intensity (Mito Tracker® Red CMXRos), indicative of changes in the mitochondrial 
membrane potential. (d) Acetate treatment induces an increase in the mean green fluorescence 
intensity normalized to the green mean fluorescence intensity at time 0 (T0), indicating an increase 
in mitochondrial mass. (e) Acetate treatment induces an alteration in the mitochondrial membrane 
potential normalized to mitochondrial mass, assessed by the ratio between the mean red 
fluorescence intensity (FL-4) and the mean green fluorescence intensity (Fl-1) normalized to T0. For 
each time point, the values of at least three independent experiments are represented. Bonferroni’s 
test *P ≤ 0.05; **P ≤ 0.01 and ***P ≤ 0.001 compared to negative control cells. In (c), (d) and (e), 
cells incubated with fresh complete medium or with 50 µM CCCP were used as a negative and 
positive control, respectively. 
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3.2.2 Acetate inhibits basal autophagy and impairs autophagy induction  
To determine if the increased mitochondrial mass resulting from acetate exposure 
could be due to autophagy inhibition, we monitored how it affects the levels of 
Beclin-1, a well-known autophagic player that is part of the class III PI3K complex 
(PI3KC3). Acetate lowered Beclin-1 levels in both RKO and HCT-15 cells, consistent 
with inhibition of autophagy and possibly explaining the increased levels of 
mitochondrial proteins in acetate-treated cells (Figure 2a). We next determined 
whether acetate affects autophagy induction. We monitored starvation-induced 
autophagy (in HBSS medium) by assessing an autophagy hallmark: conversion of 
LC3-I to LC3-II (in the presence and absence of bafilomycin A1 (Baf. A1) (Mathew 
et al., 2007), a specific inhibitor of vacuolar type H+ -ATPase used to inhibit the 
fusion of autophagosomes with lysosomes (Yamamoto, Tagawa et al. 1998). 
HCT-15 and RKO cell lines had high basal autophagy levels and did not induce 
autophagy in response to starvation, evidenced by the increased accumulation of 
LC3-II in the presence of Baf. A1 already in control cells, which was not altered in 
response to starvation (Figure 2b, c and d). Therefore, we could not determine 
whether acetate affects autophagy induction in these cells. For that purpose, we 
instead used the HCT116 cell line, which displays increased autophagic flux in 
response to starvation (Figure 2b, c and d). We found that a 48h exposure of 
HCT116 cells to half maximal inhibitory concentration (IC50), intermediate 
concentration and 2x IC50 of acetate (Supplementary Figure S4) decreased 
conversion of LC3-I to LC3-II in the presence of Baf. A1, which was even more 
pronounced under starvation conditions (Figure 2e and 2f). Increasing doses of 
acetate also progressively decreased the levels of Beclin1 and Atg5 proteins, 
essential for autophagosome completion (Xie and Klionsky 2007; Mehrpour, 
Esclatine et al. 2010) in both complete and starvation media (Figure 2g). Taken 
together, our results indicate not only that exposure to acetate does not induce 
autophagy under our experimental conditions, but also that it can inhibit both basal 
autophagy and autophagy induction. 
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Figure 2: Acetate impairs autophagy in CRC cells. (a) Levels of Beclin-1 in cells exposed to 
acetate for 48h (110 and 220 mM; 70 and 140 mM for RKO and HCT-15 cells respectively). (b) 
Immunoblot analysis of LC3-I/II in HCT116, RKO and HCT-15 cell lines. Cells were maintained in 
complete medium or incubated in HBSS medium (starvation) for 6h in the presence and absence of 
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20 nM Bafilomycin A1 (Baf. A1). The HCT116 cell line exhibited the strongest autophagic response 
to nutrient limitation (starvation) and thus was chosen to address the effect of acetate on starvation-
induced autophagy. (c) LC3-II/Actin ratios of HCT116, RKO and HCT-15 cells were determined using 
Quantity One software. (d) The autophagic flux was determined by subtracting the normalized LC3-
II levels in the presence of Baf. A1 from the corresponding levels obtained in the absence of Baf. A1. 
(e) Levels of LC3-I/II and (g) of Beclin-1 and Atg5 in HCT116 cells exposed to acetate. Cells were 
left untreated (Blank) or treated with 100, 150 or 200 mM acetate for 42 hours. Afterwards, cells were 
maintained in complete medium or HBSS medium (starvation) with acetate for another 6 hours in 
presence or absence of 20 nM Baf. A1. These data demonstrate that acetate decreases the 
autophagic flux in CRC cells in a dose-dependent manner, as shown by the decrease in LC3-II 
delivery to the lysosome, and in Beclin-1 and Atg5 protein levels. (f) The LC3-II/Actin ratios of 
HCT116 cells were determined using Quantity One software. Actin was used as a loading control. 
Values are mean ± SEM of three independent experiments. Representative immunoblots are shown 
in (a), (b), (e) and (g). One-way ANOVA followed by Bonferroni’s test, ## P ≤ 0.01 and ### P ≤  0.001 
compared to control cells treated with HBSS (starvation medium). 
 
3.2.3 Active Cathepsin D mediates mitochondrial degradation and protects 
CRC cells from acetate-induced mitochondrial dysfunction  
The cellular event or signal that determines whether mitochondrial degradation in 
cancer cells undergoing apoptosis occurs through selective or non-selective 
autophagy or by an autophagy-independent process, and which are the 
consequences to cell fate, is still unclear. In a previous study in Saccharomyces 
cerevisiae, we showed that the yeast CatD (Pep4p) plays an anti-apoptotic role in 
acetic acid-induced cell death that depends on its proteolytic activity, and is required 
for mitochondrial degradation independently of autophagy (Pereira, Azevedo et al. 
2013). We therefore hypothesized that CatD, like Pep4p, is required for efficient 
degradation of damaged mitochondria. To test this hypothesis, we assessed how 
CatD affects mitochondrial dysfunctions induced by acetate in CRC cells.  
We first analyzed whether Pepstatin A (PstA), a known specific pharmacological 
inhibitor of CatD, or transfection with specific RNA interference (siRNA) targeting 
CatD interfered with acetate-induced accumulation of ROS in RKO cells. We found 
that PstA increased total O2- and H2O2 accumulation in cells exposed to the three  
acetate concentrations for 24h (Figure 3a and 3b). Down-regulation of CatD was 
even more effective, as it significantly increased total and mitochondrial O2- 
accumulation in cells treated with 110 mM acetate (detected with DHE or MitoSOX, 
respectively) (Figure 3c and 3d). In contrast, inhibition of CatD did not significantly 
affect etoposide-induced ROS accumulation (Figure 3c and 3d).  
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We next tested the effect of depleting CatD on mitochondrial mass. Transfection 
with CatD siRNA clearly increased the levels of the mitochondrial protein AIF in both 
acetate- and etoposide-treated RKO cells, though not in untreated controls (Figure 
4a). Using the double staining protocol described above, we also found that 
depletion of CatD in acetate-treated RKO cells significantly increased mitochondrial 
mass and decreased ΔΨm. In contrast, it had no significant effect in cells treated 
with etoposide (Figure 4b and 4c). Altogether, these data indicate that CatD protects 
RKO cells from mitochondrial dysfunction induced by acetate through its 
involvement in the degradation of damaged mitochondria. 
To further analyze whether the role of CatD in mitochondrial degradation depends 
on its proteolytic activity, we assessed how this parameter was affected by inhibition 
with PstA. PstA significantly increased the mitochondrial mass of RKO cells exposed 
to 110 and 140 mM acetate for 48 hours, but decreased the ΔΨm (Figure 4d and 
4e). In contrast, inhibition of CatD in RKO cells exposed to etoposide did not affect  
mitochondrial mass or the ΔΨm. Moreover, E-64d, an inhibitor of CatB and CatL 
(also over-expressed in CRC cells) (Troy, Sheahan et al. 2004) had no effect in the 
mitochondrial mass or ΔΨm of either acetate- or etoposide-treated cells (Figure 4d 
and 4e). We confirmed E-64d was active under our experimental conditions 
because it decreased caspase-3 activity in cells exposed to etoposide (not shown), 
confirming the previously described pro-apoptotic function of CatB and CatL in this 
process (Oberle, Huai et al. 2010). These results indicate CatD, but not CatL or 
CatB, is involved in mitochondrial degradation in response to acetate. Accordingly, 
we found that only the active form of CatD, but not CatL and only trace amounts of 
CatB, is released to the cytosol after acetate treatment (Figure 5). 
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Figure 3: CatD protects CRC cells from oxidative stress. (a) and (b) Effect of Pepstatin A (PstA), 
a specific inhibitor of CatD catalytic activity, on ROS levels of RKO cells treated with acetate. PstA 
(100 µM) was pre-incubated for 16 hours and then co-incubated with acetate for 24 hours. (a) 
Accumulation of superoxide anion (O2-) in RKO cells was detected with dihydroethidium (DHE) and 
quantified by flow cytometry. (b) Accumulation of H2O2 in RKO cells was detected with H2DCF-DA 
using a fluorescence microplate reader. (c) and (d) Effect of CatD silencing on mitochondrial 
superoxide and total superoxide production in RKO cells treated with acetate (110 mM) or etoposide 
(50 µM) for 48 hours. As controls, RKO cells were not transfected (blank), transfected with scrambled 
control siRNA or transfected with CatD siRNA. 1 mM H2O2 was used as a positive control for ROS 
production. (c) Accumulation of mitochondrial superoxide in RKO cells was detected with MitoSOX™ 
and quantified by flow cytometry. (c) Downregulation of CatD induces a significant increase in 
mitochondrial superoxide production normalized to time 0 (T0) in RKO cells treated with 110 mM 
acetate and (d) a significant accumulation of total superoxide, normalized to T0 cells. Values 
represent mean ± S.E.M. of at least three independent experiments. *P ≤ 0.05, **P ≤ 0.01 and ***P 
≤ 0.001 compared with control cells. # P ≤ 0.05 and ## P ≤ 0.001 comparing acetate treatment with 
acetate/PstA or acetate treatment with acetate/ CatD siRNA. 
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Figure 4: CatD is involved in autophagy-independent mitochondrial degradation in CRC cells. 
(a) Western blot of CatD isoforms (Pro-Cathepsin D, Intermediate form and mature CatD) and AIF 
with or without CatD silencing in the absence or presence of acetate (110 mM) or etoposide (50 µM). 
As controls, RKO cells were not transfected (blank), transfected with scrambled control siRNA or 
transfected with CatD siRNA. Actin was used as a loading control. (b) and (c) effect of CatD silencing 
on mitochondrial dysfunction in RKO cells treated with acetate (110 mM) or etoposide (50 µM) for 48 
hours. (b) Downregulation of CatD induces a significant increase in mitochondrial mass normalized 
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to time 0 (T0) in RKO cells treated with 110 mM acetate and (c) a significant mitochondrial membrane 
depolarization normalized to mitochondrial mass, in relation to T0. For each bar, the mean value for 
at least three independent experiments is represented. Bonferroni’s test *P ≤ 0.05; **P ≤ 0.01 and 
***P ≤ 0.001 compared to negative control cells. # P ≤ 0.05, ## P≤ 0.01 comparing acetate treatment 
with acetate/CatD siRNA. (d) and (e) effect of the specific CatD inhibitor (PstA) and the CatB and 
CatL inhibitor (E-64d) on mitochondrial dysfunction in RKO cells treated with acetate (110 and 140 
mM) or etoposide (50 µM) for 48 hours. E-64d (10 uM) and PstA (100 µM) were pre-incubated for 1 
or 16 hours, respectively, and then co-incubated with acetate or etoposide for 48 hours. Cells were 
incubated with fresh complete medium or with 50 µM CCCP as a negative and positive control, 
respectively. Cells were then double stained with 400 nM MitoTracker® Green and 200 nM 
MitoTracker® Red CMXRos for 30 min at 37º in the dark and analyzed by flow cytometry. Inhibition 
of Cathepsin D activity with PstA induces an increase in mitochondrial mass (d) and membrane 
depolarization normalized to mitochondrial mass in relation to time 0 (T0) in RKO cells (e). For each 
bar, the mean value for at least three independent experiments is represented. Bonferroni’s test *P 
≤ 0.05; **P ≤ 0.01 and ***P ≤ 0.001 compared to negative control cells. # P ≤ 0.05 comparing acetate 
treatment with acetate/PstA. 
 
 
 
Figure 5: Acetate induces specific CatD release to the cytosol in CRC cells.  Effect of acetate 
on the expression and release of CatL, CatB and CatD to the cytosol in RKO cells. Cells were treated 
with 110 mM acetate or 50 uM etoposide for 48 hours, or with fresh medium as negative control. 
Total and cytosolic fractions (Cyto) are showed. Actin was used as a loading control.  
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Supplementary figures 
 
 
 
Figure S1: Acetate decreases catalase activity in CRC cells. RKO and HCT-15 cells were treated 
with 110 or 70 mM of acetate, respectively, or with medium fresh as negative control. After 48 hours, 
cells were washed with PBS and 4 different cell concentrations per condition in a final volume of 500 
ul were added to glass tube. Subsequently, 100 ul of Triton X-100 and 100 ul of undiluted hydrogen 
peroxide (30%) were added, mixed and tubes were incubated at room temperature for 15 min. 
 
 
 
 
 
 
 
Results 
125 
 
Figure S2: Representative fluorescence microscopy images of changes in DYm of RKO and 
HCT-15 cells. Cells were plated on coverslips and incubated with different acetate concentrations 
for 48 hours, or with fresh medium or CCCP as negative and positive controls, respectively. Cells 
were then stained with (a) 20 nM DiOC6(3) or (b) 200 nM MitoTracker®  Red and 400 nM 
MitoTracker®Green (30 min, 37º in the dark). 
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Figure S3: Acetate causes accumulation of mitochondrial proteins in RKO and HCT-15 cells. 
RKO and HCT-15 cells were treated with 110, 140 and 220 mM or 70, 100 and 140 mM of acetate, 
respectively, for 48 hours, or with fresh medium as a negative control, or etoposide (50 µM) as a 
positive control. Levels of AIF, VDAC1 and TOM22 were assessed by Western Blot. Actin was used 
as a loading control. 
 
 
Figure S4: Acetate inhibits proliferation of HCT116 cells. HCT116 cells were seeded (7x104 
cells/well) and incubated for 48 hours with acetate, or with fresh medium or H2O2 used as positive 
and negative controls, respectively. The half-maximal inhibitory concentration (IC50), IC inter and 
2×IC50 values were determined using the sulforhodamine B assay.  
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3.3: The role of acetate on monocarboxylate transporter (MCT) expression and 
glucose metabolism in colorectal cancer cells: therapeutic implications 
 
Acetate is a short-chain fatty acid relevant in the regulation of colorectal cancer 
(CRC) cells survival. Monocarboxylate transporters (MCTs) have gained increased 
interest in cancer contributing to their metabolic phenotype and to the uptake of 
drugs such as 3-bromopyruvate (3BP). The mechanism by which acetate enters 
CRC cells is not well understood. Here, we aimed to investigate the mechanism of 
acetate transport as well as the role of acetate on MCTs expression and glucose 
metabolism. We further wanted to explore the use of 3BP and acetate as a possible 
therapeutic approach for CRC. 
Our results show that the transport of acetate occurs through the sodium dependent 
monocarboxylate transporter (SMCT-1) and by passive diffusion via aquaporins. 
MCT-1 and MCT-2 are also involved in acetate uptake, indeed acetate increased 
the expression of MCT-1, MCT-4 and of the highly glycosylated CD147 chaperone, 
promoting membrane re-localization of MCT-1 and changes in glucose metabolism. 
We further verified that 3BP potentiates acetate-induced apoptosis in CRC cells. 
Altogether we provide new evidences for the role of acetate in the regulation of 
MCTs expression and glycolytic profile, which influence acetate transport and 
increases the sensitivity of CRC cells to 3BP therapy. 
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3.3.1 Kinetics and energetics of acetate uptake across the plasma membrane 
of CRC cells 
The initial uptake rates of [14C] acetate were evaluated at pH 6.0 in HCT-15 and 
RKO cell lines (Figure 1a and b). The non-linear regression analysis shows that 
HCT-15 cells transport acetate follows a second order kinetics with an affinity 
constant (Km) of 1.97 ± 0.57 mM and a transport capacity (Vmax) of 62 ± 9 nmol/mg 
of protein/min. In RKO cells, acetate follows a first order kinetics with a diffusion 
constant of 5.19 ± 0.16 µL/mg of protein/min.  
To evaluate the energetics of [14C] acetate transport we tested the influence of 
agents known to disrupt different ion membrane electrochemical potentials (Figure 
1c), such as CCCP (a protonophore which disrupts both the pH and the electric 
potentials), monensin (an ionophore that specifically disrupts a Na+ gradient) and 
valinomycin (an ionophore which preferentially affects a K+ gradient and, to a lesser 
extent, a Na+ gradient across biological membranes). We also tested the inhibition 
of acetate transport using monocarboxylate transporters (MCTs) inhibitors such as 
CHC (inhibitor of MCT-1 and SMCT-1), DIDS (inhibitor of MCTs and anion 
exchangers) and AR-C155858 (specific inhibitor of MCT-1 and MCT-2). We also 
used HgCl2, which is described as an inhibitor of aquaporin activity (Yukutake, Tsuji 
et al. 2008; Hirano, Okimoto et al. 2010). Our results showed that CCCP inhibited 
significantly acetate transport in both HCT-15 (71%) and RKO (52%) cells; 
monensin also inhibited acetate uptake in HCT-15 (78%) and RKO (36%) and 
valinomycin presented only a small inhibitory effect in both cell lines (22% inhibition 
in HCT-15 and 21% in RKO cells). Regarding MCT inhibitors, CHC inhibited both 
HCT-15 (30%) and RKO cells (35%) but DIDS and AR-C155858 did not prevent 
acetate uptake. Interestingly, HgCl2 (aquaporin inhibitor) inhibited acetate uptake in 
HCT-15 (51%) and RKO (56%) cells indicating the contribution of aquaporins in 
acetate diffusion into CRC cells. 
We further investigated if this inhibition was independent of the inhibition detected 
for CCCP or monensin. HCT-15 and RKO cells were used to evaluate the inhibition 
of acetate uptake using double combinations of CCCP (1 µM), HgCl2 (5 µM) and 
monensin (20 µM) (Figure 2a and b). However, in these assays lower concentrations 
than described above were used. We verified that in HCT-15 cells CCCP inhibited 
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34%, HgCl2 37% and monensin 69% of acetate transport. Combination of CCCP 
and HgCl2 resulted in a 56% inhibition of acetate uptake, HgCl2 and monensin in 
76%, and CCCP with monensin inhibited 75%. In RKO cells acetate uptake was 
inhibited in 37% with CCCP, 28% with HgCl2 and 68% with monensin. Combination 
of CCCP with HgCl2 and monensin with HgCl2 resulted in 46% inhibition of acetate 
transport while CCCP with monensin inhibited 81%.  
In conclusion, these results point for the involvement of at least two mechanisms of 
transport in CRC cells: a secondary active transport dependent on electrochemical 
Na+ gradient and diffusion mediated by aquaporins. 
 
Figure 1: Characterization of acetate uptake in CRC cells.  (a) and (b) Plots of the initial uptake 
rates of labeled acetate, as a function of the acid concentration at pH 6.0 in HCT-15 and RKO, 
respectively. Kinetic parameters, as affinity constant (Km) and transport capacity (Vmax) or Diffusion 
constant (Kd) for the uptake of acetate were based on the non-linear regression for the Michaelis-
Menten equation f [V]=(Vmax x [Acetate])/(Km + [Acetate]) and Passive diffusion equation f[V] = 
Kd.[Acetate]. In HCT-15 a transporter system exists with a Km of 1.97 ± 0.57 mM and a Vmax of 62 ± 
9 nmol/ mg of protein/ min. In RKO acetate enters cells by passive diffusion with a Kd of 5.19 ± 0.16. 
(c) Effect of CCCP (100 µM), Monensin (100 µM), Valinomycin (100 µM), AR-C155858 (1 µM), CHC 
(10 mM), DIDS (1 mM) and HgCl2 (100 µM) in the uptake of 1 mM of acetate. Statistical analysis was 
performed by two-way ANOVA: ***, ** and * indicate significant differences with a respective P-values 
of <0.001, <0.01 and <0.05 (n=3). (These results were obtained in collaboration with J. Azevedo-
Silva). 
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Figure 2: Inhibition of 1 mM of acetate uptake by CCCP (1 µM), HgCl2 (5 µM) and Monensin (20 
µM) alone or in combination in HCT-15 (a) and RKO (b) cells. Statistical analysis was performed 
by two-way ANOVA: ***, ** and * indicate significant differences with a respective P-values of <0.001, 
<0.01 and <0.05 (n=3). (These results were obtained in collaboration with J. Azevedo-Silva). 
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3.3.2 Acetate pre-treatment alters the kinetics and the energetics of acetate 
uptake by CRC cells  
To evaluate if acetate treatment could influence the kinetics and energetics of 
acetate, we tested the influence of CCCP, monensin, AR-C155858 and HgCl2 in the 
uptake of 1 mM of acetate in cells treated with IC30 of acetate for 48h (Figure 3). 
Untreated cells of HCT-15 and RKO cell lines behaved as expected with acetate 
transport being inhibited with CCCP (HCT-15: 54%; RKO: 62%), monensin (HCT-
15: 60%; RKO: 59%) and HgCl2 (HCT-15: 51%; RKO: 56%) but not with AR-
C155858. Cell treated with the IC30 of acetate for 48 hours also presented inhibition 
for acetate uptake using CCCP (HCT-15: 52%; RKO: 53%), monensin (HCT-15: 
60%; RKO: 38%) and HgCl2 (HCT-15: 60%; RKO: 55%). Acetate transport in HCT-
15 (29%) and RKO (23%) cells treated with acetate was significantly inhibited by 
AR-C155858. These results led us to conclude that in cells treated with acetate, 
MCT-1 and MCT-2, besides other transport mechanisms described above, are also 
involved in acetate transport. 
3.3.3 Acetate upregulates MCT-1, MCT-4 and CD147 expression in CRC cells  
We wanted to study if acetate influences the expression of MCTs as it was already 
reported by us for butyrate in breast cancer cells (Queiros, Preto et al. 2012; 
Azevedo-Silva, Queiros et al. 2015). We assessed the expression profile for the 
SMCT-1, MCT-1, MCT-2, MCT-4 and the chaperone CD147 (an important protein 
for MCT activity) in response to acetate by western blot analysis of cell extracts 
(Figure 4). We analyzed CRC cells treated with both IC30 and IC50 acetate doses (45 
mM and 70 mM; 75 mM and 110 mM, respectively for HCT-15 and RKO) after 24 
and 48 hours of incubation. We found that both CRC cell lines express SMCT-1 and 
MCT-2 but no difference in expression after acetate treatment was observed in both 
cell lines. We found an elevated expression of MCT-1 and MCT-4 after 48 hours but 
not after 24 hours acetate treatment in both cell lines compared to the negative 
control (Figure 4). The increase of MCT-1 and MCT-4 expression was accompanied 
by an increased expression of the chaperone cluster of differentiation (CD)147, 
important for MCT-1 and MCT-4 activity. The chaperone CD147, was present in 
both fully (FG) and core-glycosylated forms in both CRC cell lines after 48 hours of 
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acetate treatment compared to the negative control. A higher level of CD147 
expression was observed in RKO compared to HCT-15 cells (Figure 4). We also 
evaluated the expression of GLUT-1 after acetate treatment. GLUT-1 is responsible 
for basal glucose transport across the plasma membrane into the cytosol in many 
cancer cells (Zhang, Zhao et al. 2015). We observed that both cells expressed 
GLUT-1 transporter, but no difference in the expression of this transporter was 
observed after acetate treatment. Our results suggest that acetate regulates MCT-
1, MCT-4 and CD147 expression in CRC cells. 
 
Figure 3: Inhibition of acetate (1 mM) uptake in HCT-15 and RKO cell lines treated with IC30 of 
acetate for 48h with CCCP (100 µM), Monensin (100 µM), AR-C155858 (1 µM) and HgCl2 (100 
µM). Statistical analysis was performed by two-way ANOVA: ***, ** and * indicate significant 
differences with a respective P -values of <0.001, <0.01 and <0.05 (n=3). (These results were 
obtained in collaboration with J. Azevedo-Silva). 
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Figure 4: Characterization of MCTs expression and other glycolytic markers in CRC cells after 
acetate treatment. HCT-15 and RKO cells were incubated with acetate (45 mM and 70 mM for HCT-
15 cells; 75 mM and 110 mM for RKO cells, respective doses for the IC30 and IC50) or with fresh 
medium (as negative control) for 24 and 48 hours. Western blotting images of the SMCT-1, MCT-1, 
MCT-2, MCT-4, CD147 and GLUT-1 expression. β-actin was used as loading control. A 
representative experiment of at least three independent experiments is shown. 
3.3.4 Acetate induces MCT-1 plasma membrane localization in CRC cells  
We analyzed by immunofluorescence the cellular localization changes induced by 
acetate in MCT-1, MCT-4 and CD147. CRC cells were treated with acetate IC30 and 
IC50 doses during 48 hours, as described above for immunodetection. In agreement 
with the western blot analysis we could observe that acetate treatment leads to an 
elevated expression of these transporters and an increase in MCT-1 localization at 
the plasma membrane in comparison to the cytoplasm in both cell lines (Figure 5), 
being more evident in HCT-15 than in RKO cells. Moreover, we found no differences 
between MCT-4 and CD147 co-localization after acetate treatment. Our results 
suggest that acetate treatment (in physiological concentrations) induces MCT-1 
plasma membrane localization, which might explain that the plasma membrane 
transport of acetate also occurs by MCT-1 in CRC cells. 
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Figure 5: Localization of MCT-1, MCT-4 and CD147 in CRC cells after acetate treatment. HCT-
15 and RKO cells were incubated with acetate (45 mM and 70 mM for HCT-15 cells; 75 mM and 110 
mM for RKO cells, respective doses for the IC30 and IC50) or with fresh medium (as negative control) 
for 48 hours. Representative images of immunofluorescence are shown (400× magnification). 
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3.3.5 Acetate treatment induces changes in the glycolytic metabolic profile in 
CRC cells 
MCTs are known to be overexpressed in cancer cells to maintain high glycolytic 
rates by performing lactate efflux from glycolysis as well as pH regulation by the co-
transport of protons (Pinheiro, Longatto-Filho et al. 2012). Herein, we showed that 
acetate increases MCT-1 localization at the plasma membrane upon acetate 
treatment being accompanied by an increase in MCT-1, MCT-4 and CD147 
expression. We therefore wonder if acetate might induce metabolic changes like 
glucose consumption and lactate production. To test this hypothesis, CRC cell lines 
were exposed to IC30 and IC50 doses of acetate and the relative rate of glucose 
consumption and extracellular lactate production were measured at 3, 6, 12, 24 and 
48 hours in triplicate and normalized to T0 (amount of glucose and lactate at time 
0) and to cell biomass (by SRB assay). We found that CRC cells in response to 
acetate, exhibited a higher consumption of glucose (p ˂  0.05) and lactate production 
(p ˂ 0.05; p ˂ 0.01) up to 24 hours in a dose-dependent manner and then 
significantly decreased at 48 hours (Figure 6). RKO cells appear to be more 
glycolytic than HCT-15 cells since they exhibited a higher consumption of glucose 
(p ˂ 0.01) and lactate production up to 12 hours after acetate treatment. 
Glycolytic metabolism is a well-known characteristic of cancer cells which 
contributes to their aggressive phenotype, such as increased proliferation, 
suppression of anti-cancer immune response, invasion, angiogenesis and 
metastasis (Pelicano, Martin et al. 2006; Amorim, Pinheiro et al. 2015). Our results 
indicate that there is an increase in the glycolytic metabolism in response to short 
incubation periods of acetate, although after 48 hours of treatment, acetate induces 
a significant decrease in the glycolytic metabolism of CRC cells. 
3.3.6 3BP potentiates acetate-induced apoptosis 
It has been demonstrated that cancer cells exhibit the Warburg effect switching their 
metabolism to anaerobic glycolysis, characterized by glucose conversion into 
lactate even in the presence of oxygen (Jones and Bianchi 2015). Regarding our 
results on the metabolic profile and the elevated expression of MCT-1 and MCT-4 
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in CRC cells after acetate treatment we decided to study the effect of 3-
bromopyruvate (3BP) in combination with acetate. 3BP is a small molecule 
analogue of lactate and pyruvate that acts as a glycolysis inhibitor and which is 
transported by MCTs in cancer cells (Ko, Smith et al. 2004; Pedersen 2012; 
Azevedo-Silva, Queiros et al. 2015). It was previously described by us the capability 
of butyrate to sensitize breast cancer cells to 3BP by increasing the expression and 
activity of MCTs (Queiros, Preto et al. 2012; Azevedo-Silva, Queiros et al. 2015). 
Our present results indicate that acetate have a similar effect in CRC cells regarding 
the expression of MCTs and thus we hypothesize that acetate could also sensitize 
these cells to 3BP. 
To test this hypothesis, we used the colony formation assay (CFA) to analyze CRC 
cells treated with IC25 and IC50 values for the 3BP (17,5 µM, 35 µM and 75 µM, 150 
µM, respectively for HCT-15 and RKO cells) alone or in combination with acetate 
treatment (only with the IC50 value for acetate: 70 mM, for HCT-15 and 110 mM for 
RKO cell lines) after 48 hours of incubation. We found that the combined treatment 
(IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of acetate) decreases cell 
proliferation (number of colonies formed) in both CRC cell lines in a 3BP dose-
dependent manner in comparison to the negative control and to the same dose of 
3BP or acetate alone (Figure 7a). The effect of the combined treatment was more 
evident in RKO cells compared to HCT15 cells.   
Analysis of cell proliferation by SRB assay (Figure 7b) showed that IC25 and IC50 of 
3BP reduced proliferation of HCT-15 and RKO cell being only significant with IC50 
of 3BP. In addition, we found that combination of IC25 of 3BP/ IC50 of acetate and 
IC50 of 3BP/IC50 of acetate also reduced cell proliferation in both cell lines with a 
significant difference compared to the negative control. We also observed a 
significant difference between acetate treatment alone compared with the 
3BP+acetate combination in both CRC cell lines (p ˂ 0.01 and p ˂ 0.0001), being 
more evident in RKO cells as reported previously. 
We next analyzed cell death through AV/PI staining (Figure 7c) and found that the 
number of apoptotic (early and late) cells stained with AV (AV + PI - plus AV + PI +) 
were 11%, 13% and 7% for IC25 of 3BP, IC50 of 3BP and IC50 of acetate, respectively 
for HCT-15 cells in comparison to 3% in the negative control.  In RKO cells the levels 
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of apoptotic cells stained with AV were 4%, 13% and 18% for IC25 of 3BP, IC50 of 
3BP and IC50 of acetate, respectively in comparison to 2% in the negative control. 
In addition, the treatment with 3BP alone induces a significant increase (p ˂ 0.05 
and p ˂ 0.01) in cells stained with AV – PI + in a dose-dependent manner in both 
CRC cells. We could observe that the combined treatment of 3BP and acetate (IC25 
of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of acetate) potentiates apoptosis, as the 
number of cells stained with AV + PI - and AV + PI + showed a significant increase 
comparing with acetate alone (p ˂ 0.01 and p ˂ 0.001) in both CRC cells, being 
more evident in RKO cells. In summary, our results show that the combination 
treatments (acetate in physiologic concentration + 3BP) potentiate apoptosis in CRC 
cells.  
 
Figure 6: Acetate induces metabolic changes in CRC cells. HCT-15 and RKO cells were 
incubated with acetate (45 mM and 70 mM for HCT-15 cells; 75 mM and 110 mM for RKO cells, 
respective doses for the IC30 and IC50) or with fresh medium (as negative control). Extracellular 
amounts of glucose consumption and lactate production overtimes 3, 6, 12, 24 and 48 hours are 
shown. Values are expressed as mean ± SD of at least three independent experiments. *P ≤ 0.05, 
**P ≤ 0.01 and ***P ≤ 0.001 compared with control cells and # P ≤ 0.05, ## P ≤ 0.01 and ### P ≤ 
0.001 comparing acetate treatment at 24 h with acetate treatment at 48 h. 
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Figure 7: Effect of acetate with 3-bromopyruvate (3BP; a glycolysis inhibitor) in CRC cells. (a, 
b and c) CRC cells were treated with IC25 and IC50 values for the 3BP (17,5 uM, 35 uM and 75 uM, 
150 uM, respectively for HCT-15 and RKO cells). The treatments were performed with 3BP alone or 
with acetate treatment combination (only the IC50 value for the acetate: 70 mM for HCT-15 and 110 
mM for RKO cell line) after 48 h of incubation. 3BP was added 16 hours before to complete 48 hours 
of the treatment. As negative control, cells were treated with fresh medium. H2O2 (500 uM or 1 mM 
for HCT-15 or RKO cell lines, respectively) was used as positive control. (a) Colony formation assay 
shows that the combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of acetate) 
decreases cell proliferation (number of colony formed at the end of the assay) in both CRC cell lines 
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in a dose-dependent manner compared to the negative control and with the same dose of the 3BP 
or acetate alone. (b) Sulforhodamine B (SRB) assay analyzes the cell proliferation of the same 
conditions. Values represent mean ± SD of at least three independent experiments. **P ≤ 0.01, ***P 
≤ 0.001 and ***P ≤ 0.0001 compared with negative control cells and ## P ≤ 0.01 and #### P ≤ 0.0001 
comparing acetate alone with combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 
of acetate). (c) Quantitative analysis of AV/PI staining in HCT-15 and RKO cells. Values represent 
mean ± SD (AV – PI -, AV + PI -, AV + PI + and AV – PI +) of each condition (n=3). *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001 and ***P ≤ 0.0001 compared with negative control cells and ## P ≤ 0.01 and #### 
P ≤ 0.0001 comparing acetate alone with combined treatment (IC25 of 3BP/IC50 of acetate and IC50 
of 3BP/IC50 of acetate). 
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3.4: Acetate induces downregulation of ERK1/2 in colorectal cancer cells 
 
CRC arises from a multistep process involving several genes and in particular 
alterations in the KRAS-BRAF-ERK signalling pathway. High levels of extracellular 
signal-regulated kinases 1/2 (ERK1/2) activation/expression is associated with cell 
proliferation and cell survival in various cancer cells, including CRC. SCFAs, namely 
butyrate and propionate inhibit cell proliferation through the inactivation or 
downregulation of ERK1/2 in colon cancer cells. However, little is know about how 
acetate regulates this pathway. Here, we aimed to study the effects of acetate on 
the levels of ERK expression in CRC cells. Our preliminary results show that acetate 
downregulates the levels of active ERKs in these cells, which is in accordance with 
previous published results using butyrate and propionate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
141 
Preliminary results and discussion 
3.4.1 Acetate treatment decreases the levels of ERKs in CRC cells 
Activating mutations of KRAS and BRAF are frequently found in sporadic CRC - in 
approximately 35-40% and 5-10% of CRC cases, respectively (Velho, Moutinho et 
al. 2008; Yokota 2012). These mutation proteins are constitutively activated and 
trigger activation of the signalling cascade RAS-RAF-MEK-ERK, which 
permanently stimulates growth and differentiation of CRC cells (Yokota 2012). 
Furthermore, it has been described that ERK1 and ERK2 are key signalling 
molecules in the regulation of cell proliferation, transformation and cancer cell 
metastasis (Lee, Lee et al. 2015). It has been demonstrated that butyrate and 
propionate inhibit cell proliferation through the inactivation or downregulation of 
ERK1/2 in colon cancer cells HT-29 and RKO (Davido, Richter et al. 2001; Zhang, 
Zhou et al. 2010). Little is known about how acetate regulates ERK levels in CRC 
cell lines harbouring different genetic backgrounds.  For this purpose, we used two 
CRC-derived cell lines, with a KRASG13D mutation (HCT15) or a BRAFV600E mutation 
(RKO), and analysed the levels of phosphorylated ERKs in response to acetate 
treatment. 
We found that acetate decreased the levels of phosphorytated ERKs in a dose-
dependent manner in both CRC cell lines after 48 hours of acetate treatment (Figure 
1). This result can be correlated with the decreased proliferation induced by acetate 
in CRC cells reported previously by us and others (Jan, Belzacq et al. 2002; Lan, 
Lagadic-Gossmann et al. 2007; Marques, Oliveira et al. 2013) and prompt for a 
possible role of acetate in the regulation of the ERK signalling pathway.  Our results 
are in accordance with the results already obtained with butyrate and propionate in 
colon cancer cells (Davido, Richter et al. 2001; Zhang, Zhou et al. 2010). It would 
be interesting to assess the levels of MAPK/ERK kinase MEK (1/2) dual-specificity 
protein kinases which activate ERK1/2, to confirm our results that acetate is involved 
in the regulation of the RAS-RAF-MEK-ERK signalling pathway in CRC cells.  
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Figure 1: Acetate decreases the levels of ERKs in CRC cells. HCT-15 and RKO cells were treated 
with 70, 100 and 140 mM or 110, 140 and 220 mM of acetate, respectively, for 48 hours, or with 
fresh medium as a negative control. Representative immunoblot shows the levels of phosphorylated 
ERKs (pERKs) and total ERKs (tERKs). Total ERKs were used as a loading control.  
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General discussion  
Colorectal cancer is one of the most common solid tumors worldwide (Goncalves 
and Martel 2013; Altobelli, Lattanzi et al. 2014). Worldwide variations in colorectal 
cancer incidence suggest that dietary and lifestyle factors contribute to its etiology 
and are important risk factors for CRC. CRC is most susceptible to dietary influence, 
and a higher intake of dietary fibers can reduce the risk of CRC (Bingham, Day et 
al. 2003). Some of the significant health benefits of dietary fiber can be attributed to 
its microbial fermentation, namely by Propionibacteria in the colon into short-chain 
fatty acids (SCFAs: acetate, propionate and butyrate) (Comalada, Bailon et al. 2006; 
Macfarlane, Steed et al. 2008; Tang, Chen et al. 2011; Tang, Chen et al. 2011; Zhu, 
Michelle Luo et al. 2011). Both pure SCFA and propionibacteria culture 
supernatants from the dairy species Propionibacterium freudenreichii and 
Propionibacterium acidipropionici induce apoptosis in CRC cells in vitro (Jan, 
Belzacq et al. 2002; Ruemmele, Schwartz et al. 2003; Lan, Lagadic-Gossmann et 
al. 2007). Moreover, administration of P. freudenreichii in vivo significantly increased 
the number of apoptotic epithelial cells damaged by 1,2-dimethylhydrazine, a 
carcinogenic agent, without affecting the survival of healthy normal colonic mucosa 
(Lan, Bruneau et al. 2007; Lan, Bruneau et al. 2008). Indeed, many studies suggest 
these SCFAs protect against carcinogenesis, since they reduce human colon 
cancer cell growth and differentiation and stimulate apoptosis in CRC cells 
(Comalada, Bailon et al. 2006; Lan, Lagadic-Gossmann et al. 2007; Janku, 
McConkey et al. 2011; Zeng, Lazarova et al. 2014). These characteristics indicate 
that propionibacteria might have a protective role against colon cancer, acting as a 
probiotic, and point to a useful role of propionibacteria and their metabolites 
propionate, butyrate and acetate as powerful agents for CRC prevention or therapy. 
Acetate is one of the most important SCFAs, but has been less investigated than 
propionate and butyrate. For this purpose, we showed that acetate per se induces 
apoptosis in CRC-derived cell lines HCT-15 and RKO, by inducing DNA 
fragmentation, caspase activation, phosphatidylserine exposure to the outer leaflet 
of the plasma membrane and the appearance of a sub-G1 population. The 
concentrations used in our study were in the physiological range; total SCFA 
concentrations from 50–200 mM have been reported in the intestinal lumen of a 
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wide range of vertebrates and in most cases remain at constant high levels 
throughout the bowel length (Titus and Ahearn 1988; Scharrer, Amstutz et al. 1999). 
Our results are thus in agreement with previous reports showing that 
propionibacteria supernatants, as well as pure acetate and/or propionate, induce 
apoptosis in HT-29 and CACO-2 CRC cell lines (Jan, Belzacq et al. 2002). In these 
cells, a mixture of acetate and propionate induced caspase 3 activation, nuclei 
shrinkage, chromatin condensation and nuclei fragmentation into apoptotic bodies.  
Furthermore, the cell microenvironment may be a determinant for the type of cell 
death induced by toxic stimuli. The pH of the human colon lumen ranges from 5.5–
7.5. SCFA produced by P. freudenreichii trigger apoptosis in HT-29 cells at pH 7.5 
but necrosis at pH 5.5. At pH 7.5, propionibacterial SCFA were shown to induce 
cell-cycle arrest in the G2/M phase and morphological characteristics of apoptotic 
cell death, like membrane blebbing, chromatin condensation and fragmentation, 
phosphatidylserine exposure and formation of apoptotic bodies (Lan, Lagadic-
Gossmann et al. 2007). In accordance with these reports, we showed that acetate 
induces apoptosis in HCT-15 and RKO cells without altering the extracellular pH 
(complete medium). We also demonstrated that acetate alone inhibits proliferation 
in both the cell lines, in agreement with previous reports (Lan, Lagadic-Gossmann 
et al. 2007). 
We have previously demonstrated in the yeast S. cerevisiae that acetic acid induces 
a mitochondria-mediated apoptotic process (Pereira, Chaves et al. 2010) with 
several features similar to apoptosis induced by SCFA in CRC cells. Notably, the 
mitochondrial inner membrane AAC carrier, the yeast ortholog of mammalian ANT, 
was required for mitochondrial outer membrane permeabilization and cytochrome c 
release in yeast cells committed to apoptosis induced by acetic acid. We also 
observed that Pep4p, the yeast CatD, was released from the lysosome-like vacuole 
to the cytosol in response to acetic acid (Pereira, Chaves et al. 2010). As acetic acid 
and acetate trigger apoptosis through an analogous pathway in both yeast and CRC 
cells, respectively, we hypothesized that partial LMP with CatD release might also 
be involved in acetate-induced apoptosis in CRC cells. The involvement of 
lysosomes in apoptotic cell death, mainly through partial LMP, has gained increased 
attention (Guicciardi, Leist et al. 2004). It is now established that they are important 
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contributors to cancer cell death, increasing interest in exploiting lysosomal cell 
death pathways as a potential target in cancer therapy (Kirkegaard and Jaattela 
2009). LMP followed by release of lysosomal contents to the cytosol, especially 
cathepsins, seems to be the critical step of the lysosomal death pathway. The most 
relevant human cathepsins are the proteases CatB and CatL and the sole lysosomal 
aspartic protease CatD. They are most abundant in the lysosome (Turk, Stoka et al. 
2002) and remain active at a neutral pH (Boya and Kroemer 2008). Overexpression 
of cathepsins often occurs in human cancers, and high levels of their expression 
can be associated with increased risk of relapse and poor prognosis (Palermo and 
Joyce 2008). However, besides the tumor-promoting effects of these proteases, 
there is evidence that cathepsins may also function as tumor suppressors (Lopez-
Otin and Matrisian 2007). 
Little is known about the role of the lysosomal pathway in cell death regulation in 
CRC. It has been shown that resveratrol, a naturally occurring polyphenol, triggers 
a caspase-dependent intrinsic pathway of apoptosis involving lysosomal CatD in 
CRC cells. The authors provide evidence that CatD, though not CatB or CatL, 
mediates resveratrol cytotoxicity in DLD1 and HT29 cell lines, inducing lysosome 
leakage with increased cytosolic CatD (Trincheri, Nicotra et al. 2007). In this study, 
we aimed to investigate the mechanisms underlying acetate induced apoptosis in 
CRC cells, focusing on the role of the lysosomal pathway through LMP and CatD 
release. We showed, for the first time, by different approaches that exposure of CRC 
cells to acetate leads to LMP, release of CatD to the cytosol and accumulation of 
Pro-CatD and mature CatD. We also showed that inhibiting CatD with PstA, a widely 
used specific inhibitor of CatD enzymatic activity (Emert-Sedlak, Shangary et al. 
2005; Trincheri, Nicotra et al. 2007)  increased acetate-induced apoptosis in CRC 
cells. Interestingly, in yeast, deletion of Pep4p confers higher susceptibility to acetic 
acid, while cells overexpressing Pep4p display higher resistance (Pereira, Chaves 
et al. 2010). Recently, it has also been demonstrated that Pep4p has a dual 
cytoprotective function, anti-apoptotic and anti-necrotic, during S. cerevisiae 
chronological aging via the polyamine pathway (Carmona-Gutierrez, Bauer et al. 
2011). Our data in CRC cells are thus in agreement with the results obtained in 
yeast. Taken together, our results point to a function of CatD in cell protection rather 
than in the execution of acetate-induced cell death, in both CRC and yeast. 
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The role of CatD expression in colon carcinogenesis is controversial and poorly 
understood. Likewise, CatD has emerged as an important molecular target in cancer 
therapy, since it is overexpressed and secreted by cells of various tumor types, 
including CRC (Talieri, Papadopoulou et al. 2004; Kirana, Shi et al. 2012). CatD 
plays a vital role in extracellular matrix degradation and cancer cell survival, and 
actively participates in the invasion of carcinoma cells during both local invasion and 
metastasis formation (Szajda, Snarska et al. 2008; Carmona-Gutierrez, Bauer et al. 
2011). However, its role in apoptosis depends on cellular types, specific contexts, 
stimulus and catalytic activity (Carmona-Gutierrez, Bauer et al. 2011; Hah, Noh et 
al. 2012). As SCFAs, and in particular acetate, have garnered increased interest as 
potential prevention/therapeutic agents in CRC, we sought to further understand the 
mechanism underlying the anti-apoptotic role of this lysosomal protease under this 
specific cellular and stimulus context. Based on data from our group and others, as 
well as on the present study, we propose that the lysosome and mitochondria 
communicate during acetate-induced apoptosis in CRC cells through 
permeabilization of both organelles and selective leakage of proteins. Indeed, we 
show that acetate triggers release of CatD to the cytosol, but not of CatL and only a 
small amount of CatB, which does not seem to have major consequences. Besides 
lysosomal alterations, acetate triggered mitochondrial dysfunction in a dose- and 
time-dependent-manner, characterized by increased mitochondrial ROS, changes 
in ΔΨm and an increase in mitochondrial mass, which were enhanced when CatD 
was inhibited. This mitochondrial dysfunction is in agreement with that reported 
during apoptosis induction by acetate and a mixture of acetate and propionate 
produced by Propionibacterium freudenreichii in other CRC cells (HT-29), including 
increased ROS and ΔΨm dissipation, as well as swelling in isolated mitochondria 
(Lan, Lagadic-Gossmann et al. 2007). However, the role of CatD or the lysosome in 
that context was not evaluated. 
The increase in mitochondrial mass observed after exposure of cells to acetate led 
us to investigate whether the presumed decrease in mitochondrial turnover was 
associated with modulation of autophagy by this SCFA. Previous studies 
demonstrated that apoptosis triggered by low doses (1-10 mM) of propionate and 
butyrate can be delayed because autophagy is also induced, which can potentially 
impair the therapeutic efficacy of SCFAs in colon cancer (Tang, Chen et al. 2011; 
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Tang, Chen et al. 2011; Adom and Nie 2013). Indeed, autophagy has been 
implicated in cancer progression, used by cells for autophagic degradation of 
damaged organelles, long-lived proteins and pathogens, and in this way maintain 
homeostasis (Klionsky 2005; Mathew, Karantza-Wadsworth et al. 2007; Janku, 
McConkey et al. 2011). Further assays are required to ascertain whether low 
concentrations of acetate can cause a similar adaptive response in CRC cells. 
However, we previously showed that autophagy is not induced during acetic acid-
induced apoptosis in yeast (Pereira, Chaves et al. 2010). In the present study, we 
demonstrate that acetate impairs the autophagic flux of HCT116 cells and 
decreases Beclin-1 levels in all three cell lines. Therefore, we show that 
concentrations of acetate normally present in the human intestine have a previously 
uncharacterized effect in CRC cells: inhibition of autophagy, most likely through 
impairment of autophagosome and lysosome fusion during acetate induced-
apoptosis.  
It is known that malfunctioning mitochondria are selectively targeted for autophagic 
degradation (Tang, Chen et al. 2011). However, it is conceivable that cells use 
alternative pathways to clear damaged mitochondria when autophagy is inactive. 
We therefore investigated if CatD is involved in mitochondrial degradation, like 
Pep4p in yeast, possibly playing a pro-survival role through elimination of 
dysfunctional mitochondria. We show that CatD protects RKO cells from acetate-
induced oxidative stress and mitochondrial depolarization, since its inhibition with 
PstA or down-regulation with siRNA cause a significant increase in the levels of 
H2O2 and O2- and a decrease in ΔΨm. Hah et al. 2012 have previously suggested 
that CatD has a protective role in H2O2-induced cell death in M059J glioblastoma 
cells through its involvement in autophagy, which enhances cell survival under 
oxidative stress. Accordingly, we had shown that Pep4p deletion increased the 
sensitivity of yeast cells to acetic acid associated with increased ROS accumulation 
(Pereira, Azevedo et al. 2013), though autophagy was not induced (Pereira, Chaves 
et al. 2010). These data, together with our results, support the notion that reduced 
CatD activity leads to increased ROS accumulation and mitochondrial 
depolarization. We therefore proceeded to determine whether CatD is involved in 
the degradation of damaged mitochondria, as we presumed to be the case during 
acetate-induced apoptosis in CRC cells. We found that down-regulation of CatD in 
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acetate-treated RKO cells increased mitochondrial mass, as well as the cellular pool 
of AIF. These findings corroborate our hypothesis that CatD is involved in the 
degradation of damaged mitochondria during acetate induced-apoptosis through an 
autophagy-independent process. Though not sufficiently efficient to maintain 
mitochondrial mass homeostasis, as an acetate-induced increase in mitochondrial 
mass is still observed, this alternative degradation process allows the cell to dispose 
of dysfunctional mitochondria and delay cell death. It will be interesting in the future 
to determine if CatD is also released and is involved in mitochondrial degradation in 
response to other SCFAs, either directly or through downstream substrates. 
Inhibition of CatD with PstA mimicked the results obtained with CatD siRNA, 
indicating the catalytic activity of CatD is required for this function, as we previously 
found for the anti-apoptotic role of both yeast and human CatD (Marques, Oliveira 
et al. 2013; Pereira, Azevedo et al. 2013). We now also show that the role of yeast 
CatD in acetic acid-induced mitochondrial degradation depends on its proteolytic 
activity and can be complemented by human CatD, indicating this mechanism is 
conserved through evolution. 
 As discussed above, partial LMP followed by a release of lysosomal hydrolases 
into the cytosol can activate intrinsic caspase-dependent apoptosis or a caspase-
independent alternative cell death pathway (Repnik, Stoka et al. 2012; Groth-
Pedersen and Jaattela 2013). Thus, disabling lysosome function is under 
investigation as an adjuvant therapeutic approach to sensitize cells to apoptosis-
inducing agents (Repnik, Stoka et al. 2012). Destabilization of the lysosomal 
membrane has been proposed as a promising strategy, since it would promote 
apoptosis through initiation of the lysosomal pathway in cancer cells (Groth-
Pedersen and Jaattela 2013). However, our results show that the release of 
lysosomal proteases, in particular of CatD (Marques, Oliveira et al. 2013), may 
enable a degradation process alternative to autophagy with a similar protective role 
in cell survival, thus counteracting activation of the lysosomal death pathway. This 
would negatively impact the efficacy of acetate, and probably of other therapeutic 
compounds that trigger LMP and impair autophagy, and would require inhibiting 
CatD in combination treatments.  
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In summary, these first findings based on the clues provided by the yeast system 
unveiled a novel pro-survival function of CatD in autophagy-independent 
mitochondrial degradation, which can enhance cell survival in CRC cells undergoing 
acetate-induced apoptosis. These results offer new perspectives in the intricate 
regulation of life and death, and suggest using CatD inhibitors as adjunct therapy 
with SCFAs for prevention/therapy of colorectal cancer. 
In addition to these findings, acetate is a monocarboxylic acid, which figures among 
the most abundant SCFA in the human organism and is absorbed at the intestinal 
level being able to reach distant organs (Moschen, Broer et al. 2012; Kasubuchi, 
Hasegawa et al. 2015). Acetate transport across biological membranes in the colon 
model is not well understood, thus here we deepen the study of the kinetics and 
energetics of acetate transport across CRC cells. Our results indicate the 
participation of sodium dependent transporters such as SMCT-1 or anion-
exchangers (AE-1 for example) in the uptake of acetate in CRC cells. These results 
are in accordance with several reports showing that SMCT-1 transport 
monocarboxylic acids such as butyrate, 3BP and dichloroacetate in cancer cells 
(Thangaraju, Cresci et al. 2008; Thangaraju, Karunakaran et al. 2009; Babu, 
Ramachandran et al. 2011) and it has also been described that anion-exchangers 
might be involved in acetate transport in HT29-18-C1, a CRC cell line (Rowe, Lesho 
et al. 1994). 
Our results also show that at pH 6.0 (similar to the gut environment) acetate 
transport across CRC cells membrane occurs preferentially via a sodium-dependent 
mechanism possibly by SMCT-1. Indeed this is in agreement to the fact that 
monocarboxylate transport family members (MCT 1-4) are proton symporters, 
involved in the uptake and/or efflux of pyruvate, lactate, ketone bodies and SCFA 
through the plasma membrane (Pinheiro, Longatto-Filho et al. 2012; Kim, Park et 
al. 2014). The literature on acetate transport is scarce and little is known about 
SCFA transport mediated by MCTs in CRC cells, being that the majority of the 
studies use butyrate as model to study SCFA transport, both in normal intestinal 
epithelial and CRC cells (Hadjiagapiou, Schmidt et al. 2000; Ganapathy, Thangaraju 
et al. 2013; Goncalves and Martel 2013).  In this regard, some studies demonstrated 
that butyrate can be transported into colon cancer cells mainly by MCT-1 
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(Hadjiagapiou, Schmidt et al. 2000; He, Li et al. 2007; Goncalves and Martel 2013). 
It has also been reported that MCT-1 is responsible for acetate transport in mouse 
cancer cells with an affinity constant of 3.7 mM (Carpenter and Halestrap 1994). 
Herein we showed for the first time that MCT-1 participates actively in the transport 
of acetate into CRC cells. 
Interestingly our data suggest that other transport mechanisms such as passive 
diffusion through aquaporins might also contribute to acetate uptake. Aquaporins 
are important membrane proteins for cellular homeostasis, being known to be 
upregulated in different types of cancer including CRC (Papadopoulos and Saadoun 
2014), suggesting their capacity to transport not only water but other compounds. 
To the best of our knowledge, this is also the first report suggesting that aquaporins 
might play a novel role in acetate transport in colorectal cancer.   
Acetate is an important messenger in the symbiotic relationship between intestinal 
microbiota and colonocytes and is thus predictable that may play an important role 
in the regulation of transporters expression and metabolism of colon human cells 
(Moschen, Broer et al. 2012; Kasubuchi, Hasegawa et al. 2015). These issues are 
poorly understood and needed further understanding namely in CRC cells. Our data 
suggest that acetate might interfere with MCT-1 expression and with its cellular 
localization influencing the total acetate uptake/transport. Accordingly, it has been 
reported that butyrate and other SCFA, may modulate cell behavior by activation of 
several specific proteins depending of concentration and cell models used 
(Hadjiagapiou, Schmidt et al. 2000; Canani, Costanzo et al. 2011; Kasubuchi, 
Hasegawa et al. 2015). 
Despite the controversy in the literature concerning MCT expression in CRC, it has 
been shown that MCTs (especially MCT-1, MCT-2 and MCT-4) are usually 
upregulated in CRC tumors compared to normal epithelium samples (Pinheiro, 
Longatto-Filho et al. 2008; Pinheiro, Reis et al. 2010; Pinheiro, Longatto-Filho et al. 
2012). We have previously shown that butyrate led to an increase in MCT-1, MCT-
4 and CD147 expression with an increased localization of MCT-1 expression at the 
plasma membrane in breast cancer cells (Queiros, Preto et al. 2012; Azevedo-Silva, 
Queiros et al. 2015). Our results on CRC cells demonstrated that acetate is also 
capable of inducing the expression of MCT-1, MCT-4 and CD147 with an increase 
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in plasma membrane localization of MCT-1. Our observations suggest that MCT-1 
might be involved in acetate transport across the membrane by regulating MCT-1 
expression and activation at the plasma membrane. 
The mechanisms involved in the regulation of MCTs in CRC cells in response to 
SCFA (especially acetate), are not well clarified, being the majority of the reports 
focused in the role of butyrate in CRC cells (Hadjiagapiou, Schmidt et al. 2000; He, 
Li et al. 2007; Ganapathy, Thangaraju et al. 2013; Goncalves and Martel 2013). 
Some studies have reported that MCT-1, MCT-4, MCT-5 and MCT-6 isoforms are 
also expressed in CRC cells (Hadjiagapiou, Schmidt et al. 2000). In this regard, it 
has been shown that upon butyrate treatment, MCT-1 is the most abundant MCT 
isoform expressed in Caco-2, a CRC derived cell line (Hadjiagapiou, Schmidt et al. 
2000). Furthermore, some investigators have shown that SMCT-1 was silenced by 
DNA methylation in CRC cells (Thangaraju, Cresci et al. 2008; Babu, 
Ramachandran et al. 2011; Ganapathy, Thangaraju et al. 2013; Goncalves and 
Martel 2013), which conferred a selective advantage to escape butyrate-induced 
cell death (Li, Myeroff et al. 2003; Ganapathy, Thangaraju et al. 2013). Taking into 
account our results, we cannot exclude the involvement of SMCT-1 as the Na+-
linked symporter for acetate in CRC cells, since SMCT-1 was expressed after 
acetate treatment in CRC cells. To the best of our knowledge, this is the first report 
showing that the SCFA acetate leads to an increase in MCTs expression and to a 
cellular re-localization of MCT-1 in CRC cells. Our results put forward a possible 
regulatory role of acetate at both MCT-1 expression and localization in CRC cells, 
similarly to what was described by us with butyrate in breast cancer cells (Azevedo-
Silva, Queiros et al. 2015). 
Our data also show that MCT-1 re-localization to the plasma membrane is 
associated with increased expression of MCT-1 and CD147 in response to acetate 
treatment. Indeed it has been described that MCT-1 and MCT-4 require the 
presence of CD147, for proper localization and function (Halestrap and Meredith 
2004).  
MCT-4 expression has been associated with highly glycolytic tissues (including 
CRC), where it is essentially responsible for lactate efflux (Pinheiro, Longatto-Filho 
et al. 2012; Baltazar, Pinheiro et al. 2014). We observed an elevated MCT-4 
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expression after 48 hours of acetate treatment that can be related with the increased 
glucose consumption and lactate production upon 24h of acetate treatment in CRC 
cells. Our findings are in agreement with Matthews and co-workers, which described 
that butyrate and propionate, alone or in combination, significantly increased 
glucose consumption at 24 hours with a considerable decrease 48 hours after 
treatment (Matthews, Howarth et al. 2012). The authors explained the increased 
rate in glucose consumption as a way to provide energy efficiently and then the 
decreased rate in glucose consumption associated with the use of butyrate as 
second source of energy in CRC cells (Matthews, Howarth et al. 2012).  
It is known that CRC cells use 30 to 40 times more glucose for energy metabolism 
than normal colon cells (He, Li et al. 2007). As glucose becomes the primary source 
in CRC cells, we also evaluated the expression of GLUT-1, the main glucose 
transporter detected in colorectal cancer tissues (Lambert, Wood et al. 2002; He, Li 
et al. 2007; Amorim, Pinheiro et al. 2015). Interestingly, we found that both CRC 
cells express GLUT-1 but the levels remain unchanged after acetate treatment over 
the time. Therefore the decrease in glucose consumption is not due to a decrease 
uptake and further studies are required to assess whether it relates to inhibition of 
the glycolytic flux as already reported in yeast in response to acetic acid (Pampulha 
and Loureiro-Dias 2000).  
It is known that cancer cells usually express high levels of MCTs to maintain a highly 
glycolytic profile and an appropriate pH environment essential for tumor growth. 
MCTs became attractive targets in cancer therapy, especially in cancer with a hyper-
glycolytic phenotype (Halestrap 2013; Baltazar, Pinheiro et al. 2014). Furthermore, 
MCTs can also be seen as Trojan horses and recent reports have demonstrated 
that MCTs are also involved in the transport of drugs such as 3BP (Pedersen 2012; 
Azevedo-Silva, Queiros et al. 2015). In this case, the elevated MCT expression is 
used to mediate the entry of the chemotherapeutic agent 3BP into the cells and then 
selectively kill cancer cells (Baltazar, Pinheiro et al. 2014; Azevedo-Silva, Queiros 
et al. 2015). 3BP is an anti-cancer agent that targets energy metabolism of cancer 
cells (Azevedo-Silva, Queiros et al. 2015). Our results showed that the combination 
of acetate and 3BP potentiates the effect of acetate or 3BP alone in cell proliferation 
inhibition and apoptosis induction in CRC cells. This result is in agreement with our 
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previous data showing that butyrate also sensitize breast cancer cancer cells to 3BP 
treatment (Queiros, Preto et al. 2012; Azevedo-Silva, Queiros et al. 2015).  
Summing up, here we show that acetate uptake involves at least two mechanisms 
of transport in CRC cells: mediated by MCTs and diffusion by aquaporins. Indeed, 
acetate induces changes in glycolytic metabolism, upregulation of MCT-1, MCT-4 
and CD147 and plasma membrane localization of MCT-1. These findings may 
provide a novel strategy for CRC therapy based on the elimination of CRC cells in 
the presence of acetate through their sensitization by 3BP or other glycolytic 
metabolism inhibitor whose transport is mediated by MCTs. 
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5.1 Concluding remarks  
The main conclusions of the results addressed in the present study are represented 
as a squematic model in Figure 1. In summary the results obtained in this thesis 
allowed us to conclude that: 
 
I. Acetate inhibits cell proliferation and induces apoptosis in CRC cells. Acetate-
induced apoptosis is characterized by DNA fragmentation, caspase activation, 
phosphatidylserine exposure to the plasma membrane leaflet and the appearance 
of a population with sub-G1 DNA content. 
 
II. Acetate-induced apoptosis also involves the lysosomal pathway, with 
lysosome membrane permebilization (LMP), lysosome pH variation and specific 
release of CatD into the cytosol in CRC cells. CatD, but not CatB and CatL, has a 
protective role in this process. 
 
III.  Acetate-induced apoptosis in CRC cells involves a crosstalk between the 
lysosome and mitochondria, characterized by mitochondrial alterations, such as 
Reactive Oxygen Species (ROS) (H2O2 and O2-) accumulation, an increase in 
mitochondrial mass, mitochondrial membrane depolarization, elevated expression 
of mitochondrial proteins, namely the apoptosis inducing factor (AIF), the voltage 
dependent anion channel (VDAC1) and a subunit of the outer mitochondrial 
membrane translocator (TOM22). Active CatD, but not CatB and CatL, mediates 
the degradation of damaged mitochondria protecting CRC cells from acetate-
induced apoptosis. 
 
IV. Autophagy is impaired during acetate-induced apoptosis in CRC cells. 
 
V. The plasma membrane transport of acetate is mediated by a sodium 
dependent transporter (SMCT-1) and might also occur through passive diffusion 
by aquaporins. MCT-1 is also involved in acetate uptake. 
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VI.Acetate increases the expression of MCT-1, MCT-4 and CD147 with an increase 
in MCT-1 localization at the plasma membrane of CRC cells, which can be 
correlated with the regulation of acetate transport. 
 
VII.Acetate induces significant changes in glycolytic metabolism (decreasing glucose 
consumption and lactate production). 
 
VIII.The combination treatment of acetate in a physiologic concentration and the 
glycolysis inhibitor 3BP potentiates acetate-induced apoptosis in CRC cells.   
 
IX.Although preliminary, our results also suggest that acetate decreases ERK levels 
in CRC cells, which is consistent with its role in inhibition of proliferation and a 
possible role of acetate in the regulation of the ERK signalling pathway. 
 
Taken together, our findings led us to conclude that the use of CatD inhibitors in 
combination with strategies to increase acetate concentrations in the colon, namely 
emerging nutraceuticals, could potentiate acetate-mediated cancer cell death, 
presenting a novel strategy for prevention or therapy of CRC. Furthermore, as 
acetate increase MCTs membrane expression, the use of  chemotherapeutic agents 
transported by MCTs like 3BP may be as a new way to increase the sensitivity of 
CRC cells to 3BP therapy or similar drugs. 
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Figure 1: Schematic representation of different cell processes involved in apoptosis triggered 
by acetate in colorectal cancer cells. Different transporter systems which may mediate acetate 
uptake by CRC cells are represented. Acetate transport can be mediated by mocarboxylate 
transporters (MCT), such as SMCT-1 and MCT-1 (only in acetate pre-treated cells) or via passive 
diffusion by aquaporins. Acetate induces an increase in the expression of MCT-1, MCT-4 as well as 
of CD147 that after glycosylation leads to plasma membrane re-localization of MCT-1 and glycolysis 
perturbation. Acetate also induces partial lysosome membrane permeabilization (LMP) with specific 
release of cathepspin D (CatD) into the cytosol, which protects cells from acetate-induced apoptosis. 
DNA fragmentation and mitochondrial dysfunctions (accumulation of reactive oxygen species ROS; 
increase of mitochondrial mass, decrease of mitochondrial membrane potential, ∆ᴪm; caspase 3 
activation, and increase in the levels of different mitochondrial proteins such as apoptosis inducing 
factor, AIF; voltage dependent anion channel, VDAC1 and outer mitochondrial membrane 
translocator, TOM22) are other cellular events associated with acetate-induced apoptosis. Under 
these conditions autophagy is not induced and the inhibition of CatD (with pepstatin A or siRNA) 
enhanced acetate-induced apoptosis associated with a higher mitochondrial dysfunction. CatD plays 
a role in the degradation of damaged mitochondria when autophagy is impaired in CRC cells. 
Combined treatment (acetate + 3-bromopyruvate, 3BP, a well-known glycolysis inhibitor) potentiates 
the acetate effects, decreasing cell proliferation and inducing elevated rate of apoptosis.  
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5.2 Future perspectives  
Our results identified several mechanisms involved in acetate-induced apoptosis in 
CRC cells, but more studies are still needed to understand how acetate (alone or in 
combination with other SCFAs) can be used as a nutraceutical approach in CRC. In 
order to pursue the work here presented, the following studies are suggested: 
 
I.Although the main SCFAs (butyrate, propionate and acetate) are not produced 
alone at the intestine level, there are still few studies using the combination of these 
compounds in CRC cells. Thus, it is important to explore their combinatory effects 
as a strategy to prevent and/or to treat CRC. 
 
II.To determine if the lysosome pathway is involved in butyrate and propionate-
induced cell death in CRC cells, since these two SCFAs also induce apoptosis with 
mitochondrial alterations/dysfunctions (Jan, Belzacq et al. 2002; Comalada, Bailon 
et al. 2006; Lan, Lagadic-Gossmann et al. 2007; Tang, Chen et al. 2011; Tang, 
Chen et al. 2011). It will also be important to define the role of cathepsins, 
especially CatD, CatB and CatL in apoptosis induced by butyrate and propionate 
in CRC cells. We have already determined the inhibitory concentration (IC50) for 
butyrate and propionate in CRC cells (see Supplementary results, Figures 1 and 
2). 
 
III.Our group recently demonstrated that expression of CatD in yeast compensates 
the loss of Pep4p (the yeast ortholog of human CatD), indicating that these two 
proteins have a similar role in mitochondrial degradation independently of 
autophagy (Oliveira, Pereira et al. 2015). This finding provides new perspectives 
by using yeast expressing CatD to explore the role of CatD in degradation of 
damaged mitochondria and to uncover possible CatD partners in this process. 
 
IV.It has been demonstrated that hypoxia (oxygen deficiency) is a feature of solid 
tumors, including CRC, often resistant to conventional cancer therapies and 
correlated with advanced stages of malignancy (Kim, Lin et al. 2009; Foster, Wong 
et al. 2014). Thus, regarding our results in normal conditions, it could be important 
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to study the effects of acetate focusing in the role of CatD under hypoxia conditions 
in CRC cells.  
 
V.It has been demonstrated that acetylation of histones in cancer cells is usually 
associated with the reactivation or silencing of genes critical for cancer 
progression, differentiation and apoptosis (Kiefer, Beyer-Sehlmeyer et al. 2006). 
In this regard, it has been shown that SCFAs, namely butyrate and propionate, 
induce hyperacetylation of H3 and H4 core histones by inhibiting histone 
deacetylases (HDACs) in CRC cells (Hinnebusch, Meng et al. 2002; Kiefer, Beyer-
Sehlmeyer et al. 2006), but little is know about the effect of acetate in that process. 
Thus, we suggest assessing the role of acetate as an inhibitor of histone 
deacetylases by evaluating H3 and H4 acetylation using immunoblot analysis in 
CRC cells.   
 
VI.Regarding our results showing downregulation of ERKs upon acetate treatment, it 
could be interesting to verify the levels of MEKs under the same conditions, to 
confirm that acetate is also involved in the regulation of the RAS-RAF-MEK-ERK 
signalling pathway in CRC cells. Furthermore, to understand the role of KRAS and 
BRAF oncogenes signalling pathway in acetate-induced apoptosis by 
downregulating their expression using RNAi in CRC cells. 
 
VII.According to our results regarding acetate transport, it is necessary to study the 
rates of acetate uptake by downregulation (RNAi) of the main MCTs involved in 
that process, namely SMCT-1 and MCT-1 to verify the dependence of acetate in 
use these transporters. This, coud be useful in future works to explore the use of 
combined treatment (acetate and chemotherapeutic agents which use the same 
transporters as acetate) to potentiate its effects in CRC cells.  
 
VIII.It is know that 5-fluorouracil (5-FU) is the main anticancer agent used in CRC 
treatment, but resistance to this drug in CRC patients still occurs (Zhang, Yin et al. 
2008). Taking our results into consideration, we suggest evaluating several 
combination treatments (such as 5-FU plus acetate, 5-FU plus CatD inhibitors – 
Pepstatin A or the downregulation of CatD by RNAi and 5-FU plus acetate and 
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CatD inhibitors) as new possible strategy to improve CRC treatment reducing the 
chemoresistance described by the use of 5-FU.  
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Supplementary results 
5.2.1 Determination of half-maximal inhibitory concentration (IC50) values for 
butyrate and propionate in CRC cells. 
We determined the values of half-maximal inhibitory concentration (IC50) for butyrate 
and propionate in HCT-15 and RKO cells, important for future studies. The IC50 
values of butyrate and propionate were calculated by SRB assay after 48 hours of 
treatment (Figure S1 and S2). The IC50 values for butyrate were: 14 mM and 48.7 
mM for HCT-15 and RKO cells, respectively (Figure S1). The IC50 values for 
propionate were 20 mM and 59 mM for HCT-15 and RKO cells, respectively (Figure 
S2). We could observe that both butyrate and propionate led to a decrease in cell 
proliferation, like acetate (but in lower concentrations than acetate). Since these 
SCFAs are also produced and have an important role at the intestine level, it 
becomes important to study their effect alone and in combination to gain 
understanding of the role of these compounds in the CRC context. 
 
 
 
 
 
 
 
 
Figure S1: Effect of butyrate on cell proliferation, determined by SRB assay. HCT-15 and RKO 
cells were seeded at a density of 7x104 and 5x104cells/well, respectively, and incubated with different 
concentrations of butyrate (48 hours). As positive control were used 500 µM and 1mM of H2O2, 
respectively for HCT-15 and RKO cells. As a negative control cells were incubated with fresh 
complete medium. For each bar, the mean for at least three indepent experiments is represented. 
(Bonferroni’s test; **P ≤ 0.01 and ***P ≤ 0.001 compared to control cells). 
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Figure S2: Effect of propionate on cell proliferation, determined by SRB assay. HCT-15 and 
RKO cells were seeded at a density of 7x104 and 5x104cells/well, respectively, and incubated with 
different concentrations of propionate (48 hours). As positive control were used 500 µM and 1mM of 
H2O2, respectively for HCT-15 and RKO cells. As a negative control cells were incubated with fresh 
complete medium. For each bar, the mean for at least three indepent experiments is represented. 
(Bonferroni’s test; **P ≤ 0.01 and ***P ≤ 0.001 compared to control cells).  
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Acetate-induced apoptosis in colorectal carcinoma
cells involves lysosomal membrane permeabilization
and cathepsin D release
C Marques1,2, CS F Oliveira1,2, S Alves1, SR Chaves1, OP Coutinho1, M Coˆrte-Real1 and A Preto*,1
Colorectal carcinoma (CRC) is one of the most common causes of cancer-related mortality. Short-chain fatty acids secreted by
dietary propionibacteria from the intestine, such as acetate, induce apoptosis in CRC cells and may therefore be relevant in CRC
prevention and therapy. We previously reported that acetic acid-induced apoptosis in Saccharomyces cerevisiae cells involves
partial vacuole permeabilization and release of Pep4p, the yeast cathepsin D (CatD), which has a protective role in this process.
In cancer cells, lysosomes have emerged as key players in apoptosis through selective lysosomal membrane permeabilization
(LMP) and release of cathepsins. However, the role of CatD in CRC survival is controversial and has not been assessed in
response to acetate. We aimed to ascertain whether LMP and CatD are involved in acetate-induced apoptosis in CRC cells. We
showed that acetate per se inhibits proliferation and induces apoptosis. More importantly, we uncovered that acetate triggers
LMP and CatD release to the cytosol. Pepstatin A (a CatD inhibitor) but not E64d (a cathepsin B and L inhibitor) increased acetate-
induced apoptosis of CRC cells, suggesting that CatD has a protective role in this process. Our data indicate that acetate induces
LMP and subsequent release of CatD in CRC cells undergoing apoptosis, and suggest exploiting novel strategies using acetate
as a prevention/therapeutic agent in CRC, through simultaneous treatment with CatD inhibitors.
Cell Death and Disease (2013) 4, e507; doi:10.1038/cddis.2013.29; published online 21 February 2013
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Colorectal carcinoma (CRC) is a leading cause of cancer
death worldwide (GLOBOCAN 2008), and thus finding new
prevention and therapeutic approaches is of prime impor-
tance. Propionibacteria, found in fiber-rich food and dairy
products, produce short-chain fatty acids (SCFA), mainly
propionate and acetate, which induce apoptosis in CRC cells.
Their potential in cancer prevention and therapy has thus
been proposed by several authors1–6 and understanding the
mechanisms underlying acetate-induced cell death should
provide new prevention/therapeutic strategies in CRC.
The lysosomal pathway of apoptosis involves partial
lysosomal membrane permeabilization (LMP), with subse-
quent release of proteases (such as cathepsins) into the
cytosol.7,8 However, the role of this pathway in cancer is
controversial. Transformation can lead to several lysosomal
changes, such as increased lysosomal volume, secretion of
proteases and total protease activity,9 and changes in the
subcellular localization of cathepsins B, D and L (CatB, CatD
and CatL, respectively).10 Such alterations become pro-
oncogenic when enhanced secretion of cathepsins initiates
proteolytic pathways that increase neoplastic progression.11
Increased cysteine cathepsin activity is important for
tumor angiogenesis, proliferation, growth and invasion.12
Cathepsins are often overexpressed in human cancers, and
high expression levels have been associated with increased
risk of relapse and poor prognosis.13 In contrast to their tumor-
promoting effects, there is also evidence that they function as
tumor suppressors.14 This opposing role depends on the
context: if cathepsins are released intracellularly they con-
tribute to cancer cell death, but if released extracellularly they
break down the extracellular matrix, stimulating angiogenesis
and migration.10
CatD is a lysosomal aspartyl protease involved in autop-
hagy and apoptosis, thus having a crucial role in cell fate and
tissue homeostasis.15 CatD has emerged as a central player
in the apoptotic response, although its role is cell-type and
context-dependent. Expression patterns of CatD protein are
divergent in CRC, suggesting a complex regulation and
function of this protease,16,17 though its precise role remains
poorly understood.
We previously showed that the vacuolar protease Pep4p,
the Saccharomyces cerevisiae CatD, translocates to the
cytosol during acetic acid-induced apoptosis, suggesting that
the release of a vacuolar protease during regulated cell death
is also conserved in yeast.18 We additionally showed that
Pep4p has a role in cell protection rather than in the execution
1CBMA (Centre of Molecular and Environmental Biology), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
*Corresponding author: A Preto, CBMA (Centre of Molecular and Environmental Biology), Department of Biology, University of Minho, Campus de Gualtar, Braga
4710-057, Portugal. Tel: þ 3512 5360 1511; Fax: þ 3512 5367 8980; E-mail: apreto@bio.uminho.pt
2These authors contributed equally to this work.
Received 12.11.12; revised 23.12.12; accepted 02.1.13; Edited by A Stephanou
Keywords: Cathepsin-D; lysosomal membrane permeabilization (LMP); apoptosis; acetate; colorectal carcinoma
Abbreviations: AO, Acridine Orange; AV, annexin V; BrdU, bromodeoxyuridine; CatB, cathepsin B; CatD, cathepsin D; CatL, cathepsin L; CRC, colorectal carcinoma;
E64d, (2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester; LMP, lysosomal membrane permeabilization; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide; PI, propidium iodide; PstA, pepstatin A; SCFA, short-chain fatty acids; SRB, sulforhodamine B; TUNEL, terminal deoxynucleotidyl
transferase-mediated dUTP-fluorescein nick end labeling
Citation: Cell Death and Disease (2013) 4, e507; doi:10.1038/cddis.2013.29
& 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13
www.nature.com/cddis
of acetic acid-induced cell death. These results raised the
possibility that partial LMP and consequent CatD release was
involved in the response of CRC cells to acetate. Here, we show
that CatD is released from lysosomes and might protect CRC
cells from acetate-induced apoptosis. Our data therefore
establish the lysosome and CatD as novel targets of acetate in
CRC cells and indicate that CatD activity has important
repercussions in the sensitivity of CRC to acetate produced in
the intestine thatmight have prevention/therapeutic implications.
Results
Acetate induces apoptosis and inhibits cell proliferation
in CRC cell lines. CRC-derived cell lines HCT-15 and RKO
were treated with different concentrations of acetate for 24
and 48 h and cell viability assessed with the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
reduction test. After 24 h, there was no statistically significant
decrease in viability of acetate-treated cells in either cell line,
in comparison with untreated cells (not shown). The half-
maximal inhibitory concentration (IC50) of acetate was
therefore calculated from the mean values of MTT reduction
after 48 h of treatment: 70mM and 110mM for HCT-15 and
RKO cells, respectively (Figure 1a). IC50, 2 IC50 and an
intermediate concentration of acetate were used in subse-
quent studies.
The decrease in cell viability determined by MTT assay
might be due to decreased cell proliferation, increased cell
death or both. We therefore assessed cell proliferation after
exposure to acetate using sulforhodamine B (SRB) and
bromodeoxyuridine (BrdU) assays and apoptosis using
Annexin V/propidium iodide (AV/PI), caspase activity and
terminal deoxynucleotidyl transferase-mediated dUTP-fluor-
escein nick end labeling (TUNEL) assays, as well as sub-G1
population analysis by flow cytometry. The IC50 of acetate
reduced cell proliferation by approximately 30% and 65% in
HCT-15 and RKO cells, respectively, as determined by SRB
assay (Figure 1b). In HCT-15 cells, IC50 and 2 IC50 of
acetate reduced proliferation by approximately 17% and 75%,
respectively, as determined by BrdU assay (Figures 1c and d).
We next analyzed cell death through AV/PI staining and
found that acetate induced exposure of phosphatidylserine to
the outer leaflet of the plasma membrane in HCT-15 cells in a
dose-dependent manner (Figure 2a). The number of cells
stained with AV (AVþPI plus AVþPIþ ) increased from
3.9% in the untreated control to 8.0, 18.2 and 47.9% after
exposure to 70, 100 and 140mM acetate, respectively, and to
49.1% when cells were exposed to etoposide for 48 h
(Figure 2b). Levels of necrotic cells (AVPIþ ) after
exposure to 70 or 100mM acetate were very low. A higher
dose of acetate (140mM) increased the number of necrotic
cells (B4% AV /PIþ ), similarly to etoposide, although the
majority of the population (B48%) was in early and late
apoptosis (AVþPI plus AVþPIþ ) (Figure 2b). These
results led us to conclude that acetate induces apoptosis
rather than necrosis. Accordingly, caspase 3 was also
activated in HCT-15 cells, as cleavage of the fluorogenic
caspase 3 substrate z-DEVD-AMC, expressed in arbitrary
fluorescence units/min/mg protein, increased from 3.6 in
HCT-15 control cells (untreated) to 24.4 after exposure to
140mM acetate (Figure 2c). Similar results were obtained
when activation of total caspases was assessed by labeling
with the fluorescent pan-caspase inhibitor FICT-VAD-fmk (not
shown). We also assessed the levels of DNA strand breaks in
both the cell lines by TUNEL assay. In comparison to the
negative control, there were no significant differences in the
number of HCT-15 apoptotic cells after 48 h of treatment with
70mM acetate (IC50) (0.5% versus 1.6%; Figure 3a), though
phenotypic alterations typical of apoptosis (such as apoptotic
bodies) were observed (Figure 3b). However, the number of
apoptotic cells increased significantly (7.2%) after 48 h of
treatment with 140mM acetate (2 IC50) (Figure 3a). Expo-
sure to 110mM acetate (IC50) induced a minor increase in the
number of apoptotic RKO cells, compared with low basal
apoptotic levels (1.6% versus 0.3%; Figure 3a), but again with
evident phenotypic alterations (Figure 3b). When treated with
220mM acetate (2 IC50), the number of apoptotic RKO cells
increased significantly (65.5%; Figure 3a). Acetate also led to
a dose-dependent increase in the sub-G1 peak of HCT-15
cells, indicative of an apoptotic sub-population, and similar to
that of cells treated with etoposide (Figure 5b). Two peaks
corresponding to the G1 and G2/M phases of the cell cycle
were evident in DNA content histograms of HCT-15 control
(untreated) cells, with very few cells in the hypodiploid sub-G1
cell-cycle phase (2% of the total events acquired). Exposure
to etoposide or 140mM acetate greatly increased the
percentage of hypodiploid cells to approximately 70% and
35%, respectively (Figure 5b).
It has been reported that the pH influences the cell death
pathway induced by SCFA produced by propionibacteria, that
is, SCFA trigger apoptosis at pH 7.5 in HT-29 cells but
necrosis at pH 5.5.1 In our study, the pH of the culture medium
after 48 h of incubation with acetate was closer to 7.5 than to
5.5 in both HCT-15 and RKO cell lines and was similar to that
of the control culture (Table 1). In RKO cells, the pH of the
control culture medium (pH¼ 8.00) was higher than that of
HCT-15 cells (pH¼ 7.45), probably due to the different
composition of the growth medium (DMEM (Dulbecco’s
Modified Eagle’s Medium) for RKO cells and RPMI for
HCT-15 cells) and to the different growth rates of these cell
lines. Taken together, our results show that, under our
experimental conditions, acetate induced apoptosis.
Acetate induces lysosomal permeabilization and cathe-
psin D release to the cytosol. We next investigated
whether the lysosomal pathway was involved in acetate-
induced apoptosis in CRC cells. We measured LMP both by
staining with the lysosomotropic agent Acridine Orange (AO)
and by immunoblot detection of CatD in cytosolic fractions.
AO is a weak base that moves freely across membranes
when uncharged and accumulates in acidic compartments
like lysosomes in its protonated form, where it forms
aggregates that fluoresce bright red. LMP is associated with
proton release, which renders lysosomes more alkaline and
hence with decreased red fluorescence. LMP was monitored
qualitatively by fluorescence microscopy and quantitatively
by flow cytometry, by measuring the percentage of cells with
loss of lysosomal AO red fluorescence. Etoposide was used
as a positive control, as it destabilizes lysosomes and
induces LMP through CatD release to the cytosol.19–21
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Fluorescence microscopy analysis of both the cell lines
stained with AO showed that a high percentage of control
cells exhibited intact acidic lysosomes (i. e., high levels of red
fluorescence corresponding to accumulation of AO in acidic
lysosomes) and a reduced percentage of cells with diffused
green fluorescence (corresponding to non-lysosomal AO)
(Figure 4a). By contrast, exposure to acetate led to a
decrease in the percentage of cells with red fluorescence,
associated with an increase in the percentage of cells with
green fluorescence, indicative of LMP (Figure 4a). Similar
results were obtained in cells treated with etoposide. These
differences were more pronounced in cells treated with
2 IC50 acetate than in cells treated with IC50 concentra-
tions. Quantification of AO-stained cells was performed by
flow cytometry; cells with red fluorescence levels lower than
the threshold of AO-positive staining of untreated cells were
considered to exhibit LMP. Cells with LMP increased from
approximately 3.6% in untreated cells to 11.7, 25.8 and
49.1% in cells exposed to 70mM (IC50), 100mM and 140mM
(2 IC50) acetate, respectively (Figure 4c). These results
demonstrate that acetate induces LMP in a dose-dependent
manner.
Figure 1 Determination of acetate IC50 values and proliferation analysis in CRC cell lines treated with acetate. (a) HCT-15 and RKO cells were incubated with different
concentrations of acetate for 48 h or with fresh complete medium as a negative control, and IC50 values determined by MTT reduction assay. (b) Cell proliferation analysis by
SRB assay in CRC cells treated with acetate. Cells were incubated with IC50 and 2 IC50 concentrations of acetate (respectively, 70mM and 140mM for HCT-15 and 110mM
and 220mM for RKO) for 48 h. Values represent mean±S.E.M. of at least three independent experiments. ***Pr0.001, compared with negative control cells. (c) Cell
proliferation analysis by BrdU incorporation assay in HCT-15 cells treated with acetate (70mM and 140mM) for 48 h; values represent mean±S.E.M. of at least three
independent experiments *Pr0.05; ***Pr0.001, compared with negative control cells. (d) Representative photographs of BrdU incorporation assay in HCT-15 cells treated
with acetate (70mM and 140mM) for 48 h. phase contrast (PC;  100); DAPI (4’,6-diamidino-2-phenylindole), FITC (fluorescein isothiocyanate) and merged ( 200) were
obtained by fluorescence microscopy
Acetate induces CatD release in CRC cells
C Marques et al
3
Cell Death and Disease
As lysosomal proteases such as CatD are released from
lysosomes to the cytosol after LMP, their detection in the
cytosolic fraction is indicative of LMP. We therefore treated
HCT-15 and RKOCRC cells with two concentrations of acetate
(IC50 and 2 IC50 for each cell line), or with etoposide, and
detectedCatD inwhole-cell extracts and in cytosolic fractions by
western blot (Figure 4d). We found that CatD is expressed in
whole-cell lysates and that untreated cells exhibited very low
levels of CatD in the cytosol. Notably, we found that exposure to
etoposide and to IC50 and 2 IC50 concentrations of acetate led
to CatD release to the cytosol, indicating that acetate induces
LMP in a concentration-dependentmanner and further suggest-
ing that acetate induces a lysosomal pathway of apoptosis in
both the cell lines. We also observed that exposure to acetate
Figure 2 Acetate induces apoptosis and not necrosis in CRC cells. Apoptosis determined by Annexin V fluorescein isothiocyanate (AV-FITC) and propidium iodide (PI)
assay in HCT-15 cells after incubation with 70mM, 100mM and 140mM of acetate for 48 h. Cells were incubated with fresh complete medium or etoposide (50 mM) as a
negative and positive control, respectively. (a) Representative histograms of HCT-15 cells double-labeled with AV and PI. Percentages of apoptotic cells (positive for AV) are
the sum of the lower and upper right panels. (b) Quantitative analysis of AV/PI staining in HCT-15 cells. Values represent mean±S.E.M. of at least three independent
experiments. *Pr0.05; ***Pr0.001, comparing each subset of cells (AVPI , AVPIþ , AVþ PI , AVþ PIþ ) to the respective negative control cells.
(c) Quantitative analysis of caspase 3 activity in HCT-15 cells after incubation with 70mM, 100mM and 140mM of acetate for 48 h. Values represent mean±S.E.M. of three
independent experiments. *Pr0.05; **Pr0.01; ***Pr0.001, compared with negative control cells
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increased Pro-CatD levels in the cytosol of both the cell lines
(Figure 4d). The apparent decrease in cytosolic Pro-CatD levels
in RKO cells treated with 2 IC50 compared with IC50
concentrations of acetate seems to be due to increased
processing to mature CatD.
Cathepsin D release protects cells from acetate-induced
apoptosis. To test whether the apoptotic phenotype of
HCT-15 and RKO cells exposed to acetate depends on
CatD, we inhibited lysosomal CatD with pepstatin A (PstA)
and cathepsins B (CatB) and L (CatL) with (2S,3S)-trans-
Epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester
(E64d). PstA, but not E64d, increased apoptotic levels
induced by acetate (Figure 5a). Indeed, incubation of
HCT-15 cells and RKO with PstA before incubation with the
2 IC50 concentration of acetate increased the number of
TUNEL-positive cells, though only reaching statistical sig-
nificance in HCT-15. E64d did not significantly alter apoptotic
levels of either cell line under the same conditions
(Figure 5a). PstA-treated HCT-15 cells exposed to acetate
also exhibited a higher percentage of cells with sub-G1 DNA
content than cells treated with acetate alone, indicative of
higher apoptotic levels (Figures 5b and c). By contrast,
inhibition of CatD in cells exposed to etoposide decreased
the sub-G1 population (Figures 5b and c), in agreement with
previous reports showing that CatD has a pro-apoptotic role
in etoposide-induced cell death.21 These results therefore
indicate that CatD has a protective role in acetate-induced
apoptosis in CRC cells, as has been observed in
S. cerevisiae cells for Pep4p, the human CatD ortholog.18
Figure 3 Acetate increases levels of TUNEL-positive cells. Apoptosis analysis in HCT-15 and RKO cells by TUNEL assay, after incubation with IC50 and 2 IC50 acetate
concentrations (70mM and 140mM for HCT-15; 110mM and 220mM for RKO) for 48 h. (a) Analysis of TUNEL assay in HCT15 and RKO cells. Values represent
mean±S.E.M. of at least three independent experiments. *Pr0.05; ***Pr0.001 compared with negative control cells. (b) Representative images ( 200) of DAPI (4’,6-
diamidino-2-phenylindole), FITC (fluorescein isothiocyanate) and merged were obtained by fluorescence microscopy. PC, phase contrast
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Figure 4 Acetate induces LMP, analyzed by lysosomal pH alterations and CatD release to the cytosol. (a) HCT-15 and RKO cells were incubated with acetate
(70mM, 100mM and 140mM, for HCT-15 cells; 110mM, 140mM and 220mM, for RKO cells) for 48 h or with fresh complete medium or etoposide (50mM) as a negative and
positive control, respectively. LMP was detected by AO staining and visualization by fluorescence microscopy. Representative images ( 400) are shown. (b) Representative
images of monoparametric histograms of green fluorescence (FL3 area (log)) in HCT-15 cells treated as in (a). (c) Percentage of HCT-15 and RKO cells displaying LMP quantified
by flow cytometry analysis of AO staining after exposure to acetate as described in (a). Values represent mean±S.E.M. of three independent experiments. *Pr0.05; **Pr0.01
compared with negative control cells. (d) Effect of acetate on the expression and release of cathepsin D to the cytosol in HCT-15 and RKO cells, comparing whole-cell lysates
(total) and cytosolic fractions (cyto). Cells were treated with IC50 and 2 IC50 acetate concentrations (respectively, 70mM and 140mM for HCT-15 cells and 110mM and 220mM
for RKO cells) for 48 h or with fresh complete medium or etoposide (50mM) as a negative and positive control, respectively. Actin was used as a loading control
Acetate induces CatD release in CRC cells
C Marques et al
6
Cell Death and Disease
Discussion
CRC is a leading cause of mortality in Europe, and its global
therapeutics market is worth billions of Euros (GLOBOCAN).
Worldwide variations in colorectal cancer incidence suggest
that dietary and lifestyle factors contribute to its etiology and
are important risk factors for CRC. CRC is most susceptible to
dietary influence, and a higher intake of dietary fibers can
reduce the risk of CRC.22 SCFA, particularly propionate and
acetate, are the end products of fermentation of physiological
bacteria, namely propionibacteria, which are present in dietary
fibers and several dairy products frequently consumed.23 Both
Figure 5 CatD has a protective role in acetate-induced apoptosis. Effect of the specific CatD inhibitor (PstA) and CatB and CatL inhibitor (E64d) on apoptosis in HCT-15 and RKO
cells treated with acetate. PstA (100mM) was pre-incubated for 16 h and then co-incubated with acetate for 48 h. E64d (10mM) was pre-incubated for 1 h and then co-incubated with
acetate for 48 h. (a) Apoptosis analysis by TUNEL assay. Values represent mean±S.E.M. of at least three independent experiments. **Pr0.01; ***Pr0.001 compared with
negative control cells. # Pr0.05; ## Pr0.01; ### Pr0.001 comparing acetate treatment with or without PstA or E64d. (b) Analysis of the effect PstA on the sub-G1 subpopulation
of acetate-treated HCT-15 cells by flow cytometry. Representative histograms corresponding to HCT-15 cells treated with 100mM and 140mM acetate with or without PstA.
Percentage of sub-G1 cells are shown. Cells were incubated with fresh complete medium or etoposide (50mM) as a negative and positive control, respectively. (c) Analysis of the
distribution of cell-cycle phases in HCT-15 cells after acetate treatment in absence/presence of PstA. Values represent mean±S.E.M. of at least three independent experiments.
*Pr0.05; **Pr0.01; ***Pr0.001 comparing the percentage of sub-G1 populations of treated cells with that of untreated cells (negative control/dimethyl sulfoxide (DMSO))
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pure SCFA and propionibacteria culture supernatants from the
dairy species Propionibacterium freudenreichii and Propioni-
bacterium acidipropionici induce apoptosis in CRC cells
in vitro.1–3 Moreover, administration of P. freudenreichii
in vivo significantly increased the number of apoptotic
epithelial cells damaged by 1,2-dimethylhydrazine, a carcino-
genic agent, without affecting the survival of healthy normal
colonic mucosa.4,5 These characteristics indicate that propio-
nibacteria might have a protective role against colon cancer,
acting as a probiotic, and point to a useful role of propioni-
bacteria and their metabolites propionate, butyrate and
acetate as powerful agents for CRC prevention or therapy.
We showed that acetate per se induces apoptosis in
CRC-derived cell lines HCT-15 and RKO, by inducing DNA
fragmentation, caspase activation, phosphatidylserine expo-
sure to the outer leaflet of the plasma membrane and the
appearance of a sub-G1 population. The concentrations used
in our study were in the physiological range; total SCFA
concentrations from 50–200mM have been reported in the
intestinal lumen of a wide range of vertebrates and in most
cases remain at constant high levels throughout the bowel
length.24,25 Our results are thus in agreement with previous
reports showing that propionibacteria supernatants, as well as
pure acetate and/or propionate, induce apoptosis in HT-29
and CACO-2 CRC cell lines.3 In these cells, a mixture of
acetate and propionate induced caspase 3 activation, nuclei
shrinkage, chromatin condensation and nuclei fragmentation
into apoptotic bodies. It was also demonstrated that mito-
chondria have a critical role in this process, evidenced by
increased mitochondrial outer membrane permeability and
enhanced reactive oxygen species accumulation in response
to acetate and propionate, alone or in combination.3 These
authors also identified the mitochondrial adenine nucleotide
translocator (ANT) as a potential SCFA target, suggesting that
mitochondria and ANT are involved in the cell death pathway.3
The cell microenvironment may be a determinant for the
type of cell death induced by toxic stimuli. The pH of the
human colon lumen ranges from 5.5–7.5. SCFA produced by
P. freudenreichii trigger apoptosis in HT-29 cells at pH 7.5 but
necrosis at pH 5.5. At pH 7.5, propionibacterial SCFA were
shown to induce cell-cycle arrest in the G2/M phase and
morphological characteristics of apoptotic cell death, like
membrane blebbing, chromatin condensation and fragmenta-
tion, phosphatidylserine exposure and formation of apoptotic
bodies.1 In accordance with these reports, we showed that
acetate induces apoptosis in HCT-15 and RKO cells without
altering the extracellular pH (complete medium). We also
demonstrated that acetate alone inhibits proliferation in both
the cell lines, in agreement with previous reports.1
We have previously demonstrated in the yeastS. cerevisiae
that acetic acid induces a mitochondria-mediated apoptotic
process18 with several features similar to apoptosis induced
by SCFA in CRC cells. Notably, the mitochondrial inner mem-
brane AAC carrier, the yeast ortholog of mammalian ANT,
was required for mitochondrial outer membrane permeabili-
zation and cytochrome c release in yeast cells committed to
apoptosis induced by acetic acid. We also observed that
Pep4p, the yeast CatD, was released from the lysosome-like
vacuole to the cytosol in response to acetic acid.18 As acetic
acid and acetate trigger apoptosis through an analogous
pathway in both yeast and CRC cells, respectively, we
hypothesized that partial LMP with CatD release might also
be involved in acetate-induced apoptosis in CRC cells. The
involvement of lysosomes in apoptotic cell death, mainly
through partial LMP, has gained increased attention.7 It is now
established that they are important contributors to cancer cell
death, increasing interest in exploiting lysosomal cell death
pathways as a potential target in cancer therapy.10 LMP
followed by release of lysosomal contents to the cytosol,
especially cathepsins, seems to be the critical step of the
lysosomal death pathway. The most relevant human cathe-
psins are the proteasesCatB andCatL and the sole lysosomal
aspartic protease CatD. They are most abundant in the
lysosome26 and remain active at a neutral pH.27 Overexpre-
ssion of cathepsins often occurs in human cancers, and high
levels of their expression can be associated with increased
risk of relapse and poor prognosis.13 However, besides the
tumor-promoting effects of these proteases, there is evidence
that cathepsins may also function as tumor suppressors.14
Little is known about the role of the lysosomal pathway in
cell death regulation in CRC. It has been shown that
resveratrol, a naturally occurring polyphenol, triggers a
caspase-dependent intrinsic pathway of apoptosis involving
lysosomal CatD in CRC cells. The authors provide evidence
that CatD, though not CatB or CatL, mediates resveratrol
cytotoxicity in DLD1 and HT29 cell lines, inducing lysosome
leakage with increased cytosolic CatD.28 In this study, we
aimed to investigate the mechanisms underlying acetate-
induced apoptosis in CRC cells, focusing on the role of the
lysosomal pathway through LMP and CatD release. We
showed, for the first time, by different approaches that
exposure of CRC cells to acetate leads to LMP, release of
CatD to the cytosol and accumulation of Pro-CatD andmature
CatD.We also showed that inhibiting CatD with PstA, a widely
used specific inhibitor of CatD enzymatic activity,21,28–33
increased acetate-induced apoptosis in CRC cells. Interest-
ingly, in yeast, deletion of Pep4p confers higher susceptibility
to acetic acid, while cells overexpressing Pep4p display
higher resistance.18 Recently, it has also been demonstrated
that Pep4p has a dual cytoprotective function, anti-apoptotic
Table 1 Measurement of pH in acetate-treated cells
Condition pH
HCT-15
RPMI 7.45
Untreated cells 7.07
Acetate
70mM 7.18
100mM 6.93
140mM 7.06
RKO
DMEM 8.00
Untreated cells 8.01
Acetate
110mM 8.01
140mM 8.20
220mM 8.16
Determination of pH values in the culture medium of CRC cells, after incubation
with acetate for 48 h. Untreated cells were incubated with fresh complete
medium. Data represent means of at least three independent experiments
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and anti-necrotic, during S. cerevisiae chronological aging via
the polyamine pathway.34 Our data in CRC cells are thus in
agreement with the results obtained in yeast. Taken together,
our results point to a function of CatD in cell protection rather
than in the execution of acetate-induced cell death, in both
CRC and yeast.
The role of CatD expression in colon carcinogenesis is
controversial and poorly understood. CatD protein levels in
CRC clinical cases show divergent expression patterns,
suggesting a complex regulation and function of this
protease.17,28,35–41 One study showed that the average CatD
protein content was not different in 59 CRC when compared
with normal mucosa, but individual tumors demonstrated
marked changes in CatD expression levels.16 Measurement
of protein content of tumor versus normal pairs on western
blots revealed loss of CatD in 450% of CRC. However,
two-fold increases in CatD protein levels were also observed
inB1/3 of tumors, supporting the concept that CRC develop
via divergent molecular pathways and that CatD may function
differently in different cancers.16 Another study analyzed
surgical specimens of 100 primary CRC with different grades
of differentiation and determined that immunoreactivity for
CatD was negative in the cytoplasm of normal colorectal
epithelial cells adjacent to carcinoma. CatD expression in
carcinoma cells was present in 68% of the cases, and CatD
positivity was higher when the grade of differentiation was
higher.17 Yet another study showed that the majority of CRC
(93/106) stained positive for CatD, whereas normal colon was
almost completely negative.35 It is therefore apparent that
some, but not all, CRC cells overexpress CatD in comparison
to normal colon mucosa.
In the present study, we showed that CRC cell lines HCT-15
and RKO express CatD and are sensitive to physiological
levels of acetate, suggesting that the levels of CatD observed
might differ from those of normal colon cells. However, we
could not test this hypothesis ‘in vitro’ because the only
available ‘normal’ human colon mucosal epithelium-derived
cells NCM460 (INCELL Corporation, San Antonio, TX,
USA)42 also express CatD and behave similarly to RKO cells
in response to acetate (data not shown). According to
information provided by INCELL, NCM460 cells have
acquired a tumorigenic phenotype due to their extended time
in culture.
The protective role of CatD demonstrated by our data might
partly explain why CatD is overexpressed in some CRC
clinical cases in comparison to normal colon mucosa. We
therefore hypothesize that increased expression of this
protease might be beneficial to cancer cells and thus that
CatDmight have an ‘oncogenic-like effect’, allowing CRC cells
to survive in the presence of physiological levels of SCFA in
the colon.
In summary, our novel findings show that acetate induces
partial LMP and consequent release of CatD to the cytosol in
CRC cells. Our results also indicate that inhibition of CatD
enzymatic activity sensitizes CRC cells to acetate-induced
apoptosis, suggesting that CatD, like Pep4p in yeast, might
have a protective role in this process. However, the mechan-
ism involved remains elusive and will warrant further
investigation. Our observations indicate that CatD protects
cells from acetate exposure, prompting further exploiting the
differential sensitivity of CRC to acetate. Inhibiting
CatD function therefore emerges as a novel prevention/
therapeutic strategy in CRCs, particularly in the case of
CRCs with decreased levels of CatD. Specifically
increasing the sensitivity of CatD-overexpressing CRCs
without affecting normal colon mucosa cells will likely require
nanodelivery systems of CatD inhibitors such as PstA to
specifically target CRC cells, in combination with strategies to
increase acetate concentrations in the colon, namely emer-
ging nutraceuticals.
Materials and Methods
Cell lines and culture conditions. HCT-15 and RKO cell lines derived
from human CRC were maintained at 37 1C under a humidified atmosphere
containing 5% CO2. HCT-15 cells were grown in RPMI medium with L-glutamine
and HEPES supplemented with 10% heat inactivated fetal bovine serum, 100 U/ml
penicillin/streptomycin. RKO cells were grown in DMEM supplemented with 1mM
sodium pyruvate, 1.5 g/l sodium bicarbonate, 10% fetal bovine serum, 100 U/ml
penicillin/streptomycin. Cells were seeded and adhered onto appropriate sterile
plates for 24 h before treatments.
Assessment of cell viability by MTT reduction assay. Cells were
incubated with different concentrations of sodium acetate, henceforth referred to
as acetate, for 48 h. Freshly prepared MTT was added at a final concentration of
0.5 mg/ml in PBS pH 7.4 and plates incubated in the dark for 2 h at 37 1C.
In all, 500 ml of acidic isopropanol (0.04M HCl in absolute isopropanol)
were added to each well, followed by 30min of orbital shaking in the dark, to
solubilize the formazan crystals. Absorbance was read at 570 nm in a microplate
reader (SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, USA). Results
were expressed as a percentage of sample absorbance in relation to the negative
control (untreated cells).
Cell proliferation assays
SRB: Cells were incubated with different acetate concentrations for 48 h, fixed in
ice-cold methanol containing 1% acetic acid, and incubated with 0.5% (w/v) SRB
dissolved in 1% acetic acid for 1.5 h at 37 1C. After washing with 1% acetic acid,
SRB was solubilized with 10mM Tris, pH 10. Absorbance was read at 540 nm in a
microplate reader (SpectraMax 340PC Molecular Devices). Results were
expressed relatively to the negative control (untreated cells), which was
considered as 100% of cell proliferation.
BrdU incorporation: Cells were seeded in plates containing glass coverslips,
exposed to acetate for 48 h and incubated with 10 mM BrdU for 1 h. Cells were
fixed with 4% paraformaldehyde and nuclear incorporation of BrdU was detected
by immunofluorescence. Coverslips were mounted on Vectashield Mounting
Medium with DAPI (4’,6-diamidino-2-phenylindole) and the percentage of positive
nuclei (BrdU index) was determined from 4500 cells/datum point.
Apoptosis assays
TUNEL: Cells were exposed to DMSO control, etoposide or different concentra-
tions of acetate for 48 h. When cathepsin inhibitors were used, cells were pre-
incubated with PstA or E64d for 16 h and 1 h, respectively, and then co-incubated
with acetate or etoposide for 48 h. Cytospins of both floating and attached cells
were fixed with 4% paraformaldehyde for 15min at room temperature (RT). Cells
were washed in PBS and permeabilized with ice-cold 0.1% Triton X-100 in 0.1%
sodium citrate. TUNEL was performed following the manufacturer’s instructions
(‘In situ cell death detection kit, fluorescein’, Roche, Mannheim, Germany). Slides
were mounted on Vectashield Mounting Medium with DAPI and maintained at
 20 1C until visualization in a fluorescence microscope (Leica DM 5000B, Leica
Microsystems, Wetzlar, Germany).
Caspase 3 activity: Cells were exposed to etoposide or acetate for 48 h. Both
floating cells and attached cells were collected, washed twice with PBS, and lysed
in Lysis Buffer (10mM Tris, pH 7.5, 0.1 M NaCl, 1 mM EDTA, 0.01% Triton X-100)
through three freeze/thaw cycles. In all, 50 ml of total extracts (1 mg/ml) were
incubated with 50ml 200mM z-DEVD-AFC (Biomol, Plymouth Meeting, PA, USA)
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in 2 reaction buffer (20mM PIPES, pH 7.4, 4 mM EDTA, 10mM DTT) and
fluorescence of cleaved AFC was measured using a fluorescence microplate
reader (Fluoroskan Ascent FL, Thermo Fisher Scientific Inc., Waltham, MA, USA).
AV/PI staining: Cells were treated with etoposide or acetate for 48 h. Both floating
and attached cells were collected and washed in PBS. In all, 1 106 cells were
resuspended in 200ml 1 binding buffer and incubated with 8ml AV-fluorescein
isothiocyanate (BD Biosciences, San Jose, CA, USA) and 15ml 50mg/ml PI for
15min in the dark. Samples were analyzed in a flow cytometer (Epics XL, Beckman
Coulter, Miami, FL, USA) equipped with an argon-ion laser emitting a 488-nm beam
at 15mW. Monoparametric detection of red fluorescence was performed using FL-3
(488/620 nm) and detection of green fluorescence was performed using FL-1 (488/
525 nm). In all, 20 000 cells were analyzed per sample and data analyzed using
FlowJo software (version 7.6, Tree Star Inc., Ashland, OR, USA).
Sub-G1 cell population analysis: Cells were treated with DMSO, etoposide or
acetate for 48 h. When PstA was used, cells were pre-incubated as described above.
Both floating and attached cells were collected, washed with PBS and incubated with
70% cold ethanol for 15min. Cells were then washed twice with PBS, incubated with
RNase A (200mg/ml) for 15min in the dark at 37 1C and with propidium iodide
(0.5mg/ml) for 30min at RT before analysis on a flow cytometer, as described above.
FlowJo software was used to generate DNA content frequency histograms and
quantify the amount of cells in the individual cell-cycle phases, including the sub-G1
population assumed as corresponding to apoptotic cells.
LMP assessment
AO staining analysis by fluorescence microscopy : Cells were seeded in six-well
plates containing glass coverslips, and exposed to etoposide or acetate for 48 h.
Cells were then incubated with 1mM AO for 15min at 37 1C and washed with
PBS. Coverslips were mounted over glass slides with PBS and immediately
observed and photographed using a fluorescence microscope (Leica DM 5000B).
AO staining analysis by flow cytometry : Cells were exposed to etoposide or
acetate for 48 h. Both floating and attached cells were collected, washed with PBS
and resuspended in PBS to a final concentration of 1 106 cells in 1.5 ml. Cells
were then incubated with 1 mM AO (or without AO to measure autofluorescence)
for 15min at 37 1C.
Immunoblot detection of cathepsin D
Preparation of cytosolic protein extracts: Cells were exposed to etoposide or
acetate for 48 h. Both floating and attached cells were collected, washed with PBS
and centrifuged at 650 g for 10min at 4 1C. All subsequent steps were
performed at 4 1C. Cells were resuspended in 1 ml PBS, centrifuged at 1500 g
for 5 min and washed twice in 800ml Isotonic Buffer (200mM mannitol, 70 mM
sucrose, 1 mM EGTA, 10mM HEPES) by centrifugation at 3000 g for 5 min. The
cell pellet was then resuspended in 300ml Isotonic Buffer with 20mM NaF, 20mM
Na3VO4, 1mM PMSF and 40ml/ml Protease inhibitor cocktail and homogenized
by passing through a 26-G needle 70 times. Nuclei and unbroken cells were
removed by centrifugation at 1000 g for 5 min, followed by two consecutive
centrifugations, first at 10 000 g for 15min to remove lysosomes and
mitochondria and then at 100 000 g for 1 h in an ultracentrifuge. Cytosolic
protein extracts were stored at  80 1C.
Preparation of total protein extracts: Cells were exposed to etoposide or acetate
for 48 h. Both floating and attached cells were collected, washed with PBS and
centrifuged at 650 g for 5 min at 4 1C. The supernatant was discarded and cells
lysed in 80ml Ripa Buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 2 mM EDTA, 1%
NP-40) supplemented with 20mM NaF, 20mM Na3VO4, 1 mM PMSF and 40ml/ml
Protease inhibitor cocktail. Supernatants were cleared by centrifugation at
4500 g for 10min. Total protein extracts were stored at  80 1C.
Western blot analysis: Protein samples (25mg) were separated by sodium
dodecyl sulfate 12,5% polyacrylamide gel electrophoresis and electroblotted onto
PVDF (polyvinylidene difluoride) membranes. Primary antibodies were anti-
cathepsin D (Calbiochem, San Diego, CA, USA) and anti-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Secondary antibodies were peroxidase-
conjugated AffiniPure goat anti-rabbit IgG (Jackson ImmunoResearch, West
Grove, PA, USA) and horseradish peroxidase-labeled goat anti-mouse
immunoglobulin IgG (Jackson ImmunoResearch). Subsequent chemiluminescence
detection was performed using the ECL detection system (Amersham,
Biosciences, Buckinghamshire, UK) and a molecular imager (Chemi-Doc XRS
system, Bio-Rad, Laboratories Inc., Hercules, CA, USA).
Statistical analysis: Data are expressed as means±S.E.M. of at least three inde-
pendent experiments. Statistical analysis between negative control and treated
samples was performed by one-way ANOVA followed by Dunnett’s test and the
comparison between PstA- or E64d-treated and untreated cells was performed by
unpaired two-tailed Student’s t-test. Differences were considered significant when
Pr0.05.
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Cathepsin D protects colorectal cancer cells from
acetate-induced apoptosis through autophagy-
independent degradation of damaged mitochondria
CSF Oliveira1,2, H Pereira1, S Alves1, L Castro1, F Baltazar3,4, SR Chaves1, A Preto1,5 and M Côrte-Real*,1,5
Acetate is a short-chain fatty acid secreted by Propionibacteria from the human intestine, known to induce mitochondrial apoptotic
death in colorectal cancer (CRC) cells. We previously established that acetate also induces lysosome membrane permeabilization
in CRC cells, associated with release of the lysosomal protease cathepsin D (CatD), which has a well-established role in the
mitochondrial apoptotic cascade. Unexpectedly, we showed that CatD has an antiapoptotic role in this process, as pepstatin A
(a CatD inhibitor) increased acetate-induced apoptosis. These results mimicked our previous data in the yeast system showing
that acetic acid activates a mitochondria-dependent apoptosis process associated with vacuolar membrane permeabilization and
release of the vacuolar protease Pep4p, ortholog of mammalian CatD. Indeed, this protease was required for cell survival in a
manner dependent on its catalytic activity and for efficient mitochondrial degradation independently of autophagy. In this study, we
therefore assessed the role of CatD in acetate-induced mitochondrial alterations. We found that, similar to acetic acid in yeast,
acetate-induced apoptosis is not associated with autophagy induction in CRC cells. Moreover, inhibition of CatD with small
interfering RNA or pepstatin A enhanced apoptosis associated with higher mitochondrial dysfunction and increased mitochondrial
mass. This effect seems to be specific, as inhibition of CatB and CatL with E-64d had no effect, nor were these proteases
significantly released to the cytosol during acetate-induced apoptosis. Using yeast cells, we further show that the role of Pep4p in
mitochondrial degradation depends on its protease activity and is complemented by CatD, indicating that this mechanism is
conserved. In summary, the clues provided by the yeast model unveiled a novel CatD function in the degradation of damaged
mitochondria when autophagy is impaired, which protects CRC cells from acetate-induced apoptosis. CatD inhibitors could
therefore enhance acetate-mediated cancer cell death, presenting a novel strategy for prevention or therapy of CRC.
Cell Death and Disease (2015) 6, e1788; doi:10.1038/cddis.2015.157; published online 18 June 2015
Colorectal cancer (CRC) is one of the most common cancers
worldwide.1,2 In Europe, it is the most diagnosed malignancy
and the second cause of cancer mortality in both genders,2
highlighting the need for novel strategies to prevent and treat
CRC. Short-chain fatty acids (SCFA), namely butyrate,
propionate and acetate, are the major by-products of
anaerobic bacterial fermentation of undigested fibers in the
human colon. As they were reported as antiproliferative and
antineoplastic agents that induce differentiation, growth arrest
and apoptosis in CRC cell lines,3–6 there has been increased
interest in exploiting these natural products in CRC prevention
and therapy. The antitumor effect of SCFAs stems from their
ability to induce cell death involving mitochondria-mediated
apoptosis (caspase-dependent/independent) or necrosis in
colon cancer cells.3,4,6 We also previously implicated another
organelle in acetate-induced apoptosis, the lysosome. Indeed,
lysosomal membrane permeabilization (LMP) and release of
cathepsins into the cytosol can initiate the lysosomal apoptotic
pathway either in a mitochondria-independent manner or
mediated by mitochondrial destabilization with subsequent
release of apoptotic factors.7,8 Among the cathepsins released
by LMP, cathepsin D (CatD), originally considered a ‘house-
keeping enzyme’9 necessary for autophagy10 can act as an
antiapoptotic or proapoptotic mediator depending on the cell
type and context.10–12 However, the exact mechanisms
triggered by CatD following LMP in cancer cells, as well as
the signaling to and/or from mitochondria, remain to be
clarified.
In a previous study, we demonstrated that CatD is released
into the cytosol and protects cells undergoing acetate-induced
apoptosis.5 These results were in agreement with our data
showing that Pep4p, the yeast ortholog of human CatD,
translocates from the vacuole to the cytosol during
mitochondria-mediated acetic acid-induced apoptosis in
Saccharomyces cerevisiae,13 and that it has a protective role
in this process dependent on its catalytic activity.14 However,
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the mechanisms by which CatD protects CRC cells from
acetate exposure are still unknown. It had been shown that
SCFAs (namely butyrate and propionate) induce autophagy in
CRC cells, which serves as an adaptive strategy to delay
mitochondria-mediated apoptotic cell death.15–17 In contrast,
we showed that yeast CatD is involved in acetic acid-induced
mitochondrial degradation independently of autophagy.13
We therefore hypothesized the same would occur in the
response of CRC cells to acetate. In this work, we assessed
how CatD affects the mitochondrial alterations induced by
acetate in CRC cell lines, and specifically evaluated its role in
mitochondrial degradation. Our results indicate that the
antineoplastic mechanism of acetate is characterized by an
accumulation of reactive oxygen species (ROS) and changes
in mitochondrial mass and mitochondrial membrane potential
(ΔΨm). We further show that CatD, but not CatB or CatL, is
involved in the degradation of the dysfunctional mitochondria
to enhance CRC cell survival in response to acetate, which
impairs autophagy. Our data therefore indicate that acetate-
induced apoptosis involves cross-talk between the lysosome
and mitochondria, and support using probiotics and inhibiting
CatD as a prevention or therapeutic strategy in CRC.
Results
Acetate leads to oxidative stress, changes in ΔΨm and
increased mitochondrial mass in CRC cells. Acetate-
induced apoptosis has been associated with mitochondrial
dysfunction, including increased ROS and ΔΨm alterations,
although only in HT-29 cells.3,4 We also previously showed
that CRC-derived cells HCT-15 and RKO exposed to
physiological concentrations of acetate exhibit characteristic
apoptotic markers.5 However, an effect on mitochondrial
mass, as suggested by our studies in yeast,13 has never been
described. We therefore sought to determine comprehen-
sively how acetate affects mitochondrial function in HCT-15
and RKO cells, in particular ROS accumulation and changes
in ΔΨm and mitochondrial mass. For this purpose, cells
exposed to different concentrations of acetate were stained
with the ROS probes 2,7-dihydrodichlorofluorescein diacetate
(H2DCF-DA) or dihydroethidium (DHE), to detect hydrogen
peroxide (H2O2) or superoxide anion (O2
−), respectively. ROS
levels in HCT-15 and RKO cells consistently increased in
response to acetate in a dose-dependent manner after 12
and 24 h of exposure, and then slightly decreased after 48 h
(H2O2 in HCT-15 (Figure 1a) and RKO cells (not shown), and
O2
− in RKO cells (Figure 1b)). To determine if the acetate-
induced ROS accumulation could be due to inhibition of
cellular antioxidant defenses, we used a qualitative assay
to measure catalase activity.18 We found that exposure to a
half-maximal inhibitory concentration (IC50) of acetate slightly
decreased catalase activity in HCT-15 and RKO cells,
although more evidently in the latter (Supplementary Figure
S1).
In addition to resulting from a decrease in antioxidant
defenses, ROS accumulation can be an early event of the
apoptotic process, associated with other mitochondrial
dysfunctions.19 We therefore assessed if acetate induces
further mitochondrial alterations in CRC cells. We found that
acetate, similar to CCCP (carbonyl cyanide m-chlorophenyl-
hydrazone), decreased the ΔΨm, as it lowered mitochondrial
accumulation of DiOC6(3) and of MitoTracker Red CMXRos in
RKO cells and of DiOC6(3) in HCT-15 cells (Supplementary
Figure S2), while increasing cytosolic fluorescence of the
probes. As changes in ΔΨm can result from changes in
mitochondrial mass, we quantitatively assessed these two
parameters simultaneously in RKO cells stained with both
MitoTracker Red CMXRos and MitoTracker Green FM, by
flow cytometry. In addition to a decrease in the mean red
fluorescence, indicative of decreased ΔΨm (Figure 1c),
acetate increased the mean green fluorescence, indicative
of an increase in mitochondrial mass (Figures 1c and d). After
normalizing acetate-induced changes in ΔΨm tomitochondrial
mass, and in relation to time zero (Figure 1e), it became
evident that a short exposure to acetate induces a small
increase in ΔΨm (Figure 1e). This hyperpolarization was
apparent after 12 h of exposure to 110 and 140mM but not to
220mM acetate. For longer exposure times, this ratio
significantly decreased for all concentrations, indicative of
ΔΨm dissipation (as verified for the control CCCP treatment).
We also investigated the effect of acetate on the levels of
mitochondrial proteins, namely the apoptosis-inducing factor
(AIF), the voltage dependent anion channel (VDAC1) and a
subunit of the outer mitochondrial membrane translocator
(TOM22). We found all doses of acetate, as well as etoposide,
increased the levels of AIFand VDAC1 in RKO and, to a higher
extent, in HCT-15 cells (Supplementary Figure S3). In addition,
acetate, but not etoposide, led to increased levels of TOM22.
Our results indicate that acetate causes mitochondrial
dysfunction, increasing ROS accumulation, perturbing ΔΨm
and increasing mitochondrial mass in a time- and dose-
dependent manner, suggesting that acetate impairs the
turnover of harmful mitochondria.
Acetate inhibits basal autophagy and impairs autophagy
induction. To determine if the increased mitochondrial mass
resulting from acetate exposure could be due to autophagy
inhibition, we monitored how it affects the levels of Beclin-1, a
well-known autophagic player that is part of the class III PI3K
complex. Acetate lowered Beclin-1 levels in both RKO and
HCT-15 cells, consistent with inhibition of autophagy and
possibly explaining the increased levels of mitochondrial
proteins in acetate-treated cells (Figure 2a). We next
determined whether acetate affects autophagy induction.
We monitored starvation-induced autophagy (in HBSS
medium) by assessing an autophagy hallmark: conversion
of LC3-I to LC3-II20 (in the presence and absence of
bafilomycin A1 (Baf. A1), a specific inhibitor of vacuolar type
H+-ATPase used to inhibit the fusion of autophagosomes with
lysosomes).21 HCT-15 and RKO cell lines had high basal
autophagy levels and did not induce autophagy in response
to starvation, evidenced by the increased accumulation of
LC3-II in the presence of Baf. A1 already in control cells,
which was not altered in response to starvation (Figures 2b–d).
Therefore, we could not determine whether acetate affects
autophagy induction in these cells. For that purpose, we
instead used the HCT116 cell line, which displays increased
autophagic flux in response to starvation (Figures 2b–d).
We found that a 48 h exposure of HCT116 cells to IC50,
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intermediate concentration and 2× IC50 of acetate
(Supplementary Figure S4) decreased conversion of LC3-I
to LC3-II in the presence of Baf. A1, which was even more
pronounced under starvation conditions (Figures 2e and f).
Increasing doses of acetate also progressively decreased the
levels of Beclin1 and Atg5 proteins, essential for autophago-
some completion,22,23 in both complete and starvation media
(Figure 2g). Taken together, our results indicate not only that
exposure to acetate does not induce autophagy under our
experimental conditions but also that it can inhibit both basal
autophagy and autophagy induction.
Active CatD mediates mitochondrial degradation and
protects CRC cells from acetate-induced mitochondrial
dysfunction. The cellular event or signal that determines
whether mitochondrial degradation in cancer cells under-
going apoptosis occurs through selective or nonselective
autophagy or by an autophagy-independent process, and
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which are the consequences to cell fate, is still unclear. In a
previous study in S. cerevisiae, we showed that the yeast
CatD (Pep4p) has an antiapoptotic role in acetic acid-induced
cell death that depends on its proteolytic activity, and is
required for mitochondrial degradation independently of
autophagy.14 We therefore hypothesized that CatD, similarly
to Pep4p, is required for efficient degradation of damaged
mitochondria. To test this hypothesis, we assessed how CatD
affects mitochondrial dysfunctions induced by acetate in
CRC cells.
We first analyzed whether Pepstatin A (PstA), a known
specific pharmacological inhibitor of CatD, or transfection with
specific RNA interference (siRNA) targeting CatD interfered
with acetate-induced accumulation of ROS in RKO cells. We
found that PstA increased total O2
− and H2O2 accumulation in
cells exposed to the three acetate concentrations for 24 h
(Figures 3a and b). Downregulation of CatD was even more
effective, as it significantly increased total and mitochondrial
O2
− accumulation in cells treated with 110mMacetate (detected
with DHE or MitoSOX, respectively) (Figures 3c and d).
In contrast, inhibition of CatD did not significantly affect
etoposide-induced ROS accumulation (Figures 3c and d).
We next tested the effect of depleting CatD onmitochondrial
mass. Transfection with CatD siRNA clearly increased the
levels of the mitochondrial protein AIF in both acetate- and
etoposide-treated RKO cells, although not in untreated
controls (Figure 4a). Using the double-staining protocol
described above, we also found that depletion of CatD in
acetate-treated RKO cells significantly increased mitochon-
drial mass and decreased ΔΨm. In contrast, it had no significant
effect in cells treated with etoposide (Figures 4b and c).
Altogether, these data indicate that CatD protects RKO cells
from mitochondrial dysfunction induced by acetate through its
involvement in the degradation of damaged mitochondria.
To further analyze whether the role of CatD in mitochondrial
degradation depends on its proteolytic activity, we assessed
how this parameter was affected by inhibition with PstA. PstA
significantly increased the mitochondrial mass of RKO cells
exposed to 110 and 140mM acetate for 48 h, but decreased
the ΔΨm (Figures 4d and e). In contrast, inhibition of CatD in
RKO cells exposed to etoposide did not affect mitochondrial
mass or the ΔΨm. Moreover, E-64d, an inhibitor of CatB and
CatL (also overexpressed in CRC cells),24 had no effect on the
mitochondrial mass or ΔΨm of either acetate- or etoposide-
treated cells (Figures 4d and e). We confirmed that E-64d
was active under our experimental conditions because it
decreased caspase-3 activity in cells exposed to etoposide
(not shown), confirming the previously described proapoptotic
function of CatB and CatL in this process.25 These results
indicate that CatD, but not CatL or CatB, is involved in
mitochondrial degradation in response to acetate. Accord-
ingly, we found that only the active form of CatD, but not CatL
and only trace amounts of CatB, is released to the cytosol after
acetate treatment (Figure 5).
The aforementioned results indicate that the role of CatD in
mitochondrial degradation depends on its proteolytic activity.
To further support this conclusion and determine whether this
mechanism is conserved, we assessed if the same is true for
the yeast CatD, and if human and yeast CatD are functionally
equivalent. For this purpose, we constructed strains deficient
in Pep4p expressing the empty vector control, and equivalent
levels of FLAG-tagged wild-type Pep4p, a double-point mutant
form deficient in proteolytic activity, and human CatD
(Figure 6a). We then compared their sensitivity to acetic acid
with that of wild-type W303 cells expressing the empty vector.
In accordance with our previous data,14 expression of wild-
type Pep4p, but not of the catalytically inactive mutant,
reverted the sensitivity of Pep4p-deficient cells to acetic
acid-induced apoptosis. Now, we further show that expression
of human CatD also compensates for the loss of Pep4p,
indicating that the two proteins have a similar role in this
process (Figure 6b). All strains were then transformed with a
plasmid expressing mitochondrial GFP, and mitochondrial
degradation in response to acetic acid was assessed by
estimating the percentage of cells with preserved green
fluorescence, as described previously.14 While expression of
wild-type Pep4p and CatD reverted the delay in mitochondrial
degradation of Pep4p-deficient cells exposed to acetic acid,
expression of double-point mutant Pep4p did not (Figure 6c).
Although the precise mechanism underlying the role of Pep4p
in cell survival and in mitochondrial degradation is still elusive,
we have now determined that both depend on its proteolytic
activity and are complemented by CatD. Taken together, our
results show that Pep4p/CatD is involved in acetic acid/
acetate-induced mitochondrial degradation independently of
autophagy but dependently of its catalytic activity in both yeast
and CRC cells.
Discussion
CRC is one of the most common solid tumors worldwide.2,26
A diet rich in dietary fiber is associated with a reduction in CRC
incidence,1,27 indicating CRC may be amenable to prevention
through a dietary regimen.15,16,27 Some of the significant
health benefits of dietary fiber can be attributed to its microbial
Figure 2 Acetate impairs autophagy in CRC cells. (a) Levels of Beclin-1 in cells exposed to acetate for 48 h (110 and 220 mM; 70 and 140 mM for RKO and HCT-15 cells,
respectively) (b) Immunoblot analysis of LC3-I/II in HCT116, RKO and HCT-15 cell lines. Cells were maintained in complete medium or incubated in HBSS medium (starvation) for
6 h in the presence and absence of 20 nM bafilomycin A1 (Baf. A1). The HCT116 cell line exhibited the strongest autophagic response to nutrient limitation (starvation) and thus
was chosen to address the effect of acetate on starvation-induced autophagy. (c) LC3-II/actin ratios of HCT116, RKO and HCT-15 cells were determined using Quantity One
software (Bio-Rad manufacturer). (d) The autophagic flux was determined by subtracting the normalized LC3-II levels in the presence of Baf. A1 from the corresponding levels
obtained in the absence of Baf. A1. (e) Levels of LC3-I/II and (g) of Beclin-1 and Atg5 in HCT116 cells exposed to acetate. Cells were left untreated (Blank) or treated with 100, 150
or 200 mM acetate for 42 h. Later, cells were maintained in complete medium or HBSS medium (starvation) with acetate for another 6 h in the presence or absence of 20 nM Baf.
A1. These data demonstrate that acetate decreases the autophagic flux in CRC cells in a dose-dependent manner, as shown by the decrease in LC3-II delivery to the lysosome,
and in Beclin-1 and Atg5 protein levels. (f) The LC3-II/actin ratios of HCT116 cells were determined using Quantity One software (Bio-Rad manufacturer). Actin was used as a
loading control. Values are mean±S.E.M. of three independent experiments. Representative immunoblots are shown in (a, b, e and g). One-way ANOVA followed by Bonferroni’s
test, ##P≤ 0.01 and ###P≤ 0.001 compared with control cells treated with HBSS (starvation medium)
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fermentation, namely by Propionibacteria in the colon into
SCFAs (acetate, propionate and butyrate).1,6,15,16,28 Indeed,
many studies suggest these SCFAs protect against carcino-
genesis, as they reduce human colon cancer cell growth and
differentiation and stimulate apoptosis in CRC cells.4,6,27,29
Acetate is one of the most important SCFAs, but has been less
investigated than propionate and butyrate. Nonetheless,
previous studies proposed that acetate inhibits proliferation
and induces apoptosis in colon cancer cells3–6 and that
acetate-induced apoptosis in CRC cells involves different
biochemical events, includingmitochondrial alterations.3–5We
have also previously shown that acetate induces apoptosis in
CRC-derived cells in a dose-dependent manner, character-
ized by DNA fragmentation, caspase-3 activation, phospha-
tidylserine exposure to the outer leaflet of the plasma
membrane and the appearance of a sub-G1 population5. In
addition, we showed that this process is associated with
lysosomal alkalinization, LMP and CatD release into the
cytosol.5
It is well established that partial LMP followed by a release of
lysosomal hydrolases into the cytosol can activate intrinsic
caspase-dependent apoptosis or a caspase-independent
alternative cell death pathway.7,8 Of these, CatD has emerged
as an important molecular target in cancer therapy, as it is
overexpressed and secreted by cells of various tumor types,
including CRC.30,31 CatD has a vital role in extracellular matrix
degradation and cancer cell survival, and actively participates
in the invasion of carcinoma cells during both local invasion
and metastasis formation.32,33 However, its role in apoptosis
depends on cellular types, specific contexts, stimulus and
catalytic activity.10,33 Our data indicate that CatD has a
protective role in acetate-induced apoptosis in CRC cells,5
as we had shown for its ortholog Pep4p in Saccharomyces
cerevisiae.13 As SCFAs, and in particular acetate, have
garnered increased interest as potential prevention/therapeu-
tic agents in CRC, we sought to further understand the
mechanism underlying the antiapoptotic role of this lysosomal
protease under this specific cellular and stimulus context.
Based on data from our group and others, as well as on the
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Figure 4 CatD is involved in autophagy-independent mitochondrial degradation in CRC cells. (a) Western blot of CatD isoforms (Pro-CatD, intermediate form and mature
CatD) and AIF with or without CatD silencing in the absence or presence of acetate (110 mM) or etoposide (50 μM). As controls, RKO cells were not transfected (blank),
transfected with scrambled control siRNA or transfected with CatD siRNA. Actin was used as a loading control. (b and c) Effect of CatD silencing on mitochondrial dysfunction in
RKO cells treated with acetate (110 mM) or etoposide (50 μM) for 48 h. (b) Downregulation of CatD induces a significant increase in mitochondrial mass normalized to time 0 (T0)
in RKO cells treated with 110 mM acetate and (c) a significant mitochondrial membrane depolarization normalized to mitochondrial mass, in relation to T0. For each bar, the mean
value for at least three independent experiments is represented. Bonferroni’s test, *P≤ 0.05; **P≤ 0.01 and ***P≤ 0.001 compared with negative control cells. #P≤ 0.05,
##P≤ 0.01 comparing acetate treatment with acetate/CatD siRNA. (d and e) Effect of the specific CatD inhibitor (PstA) and the CatB and CatL inhibitor (E-64d) on mitochondrial
dysfunction in RKO cells treated with acetate (110 and 140 mM) or etoposide (50 μM) for 48 h. E-64d (10 μM) and PstA (100 μM) were pre-icubated for 1 or 16 h, respectively, and
then coincubated with acetate or etoposide for 48 h. Cells were incubated with fresh complete medium or with 50 μM CCCP as a negative and positive control, respectively. Cells
were then double stained with 400 nM MitoTracker Green and 200 nM MitoTracker Red CMXRos for 30 min at 37 ºC in the dark and analyzed by flow cytometry. Inhibition of CatD
activity with PstA induces an increase in mitochondrial mass (d) and membrane depolarization normalized to mitochondrial mass in relation to T0 in RKO cells (e). For each bar,
the mean value for at least three independent experiments is represented. Bonferroni’s test *P≤ 0.05; **P≤ 0.01, ***P≤ 0.001 and ****P≤ 0.0001 compared with negative
control cells. #P≤ 0.05 comparing acetate treatment with acetate/PstA
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present study, we propose that the lysosome and mitochon-
dria communicate during acetate-induced apoptosis in CRC
cells through permeabilization of both organelles and selective
leakage of proteins. Indeed, we show that acetate triggers
release of CatD to the cytosol, but not of CatL, and only a small
amount of CatB, which does not seem to have major
consequences. Besides lysosomal alterations, acetate triggered
mitochondrial dysfunction in a dose- and time-dependent-
manner, characterized by increased mitochondrial ROS,
changes in ΔΨm and an increase in mitochondrial mass,
which were enhanced when CatD was inhibited. This
mitochondrial dysfunction is in agreement with that reported
during apoptosis induction by acetate and a mixture of acetate
and propionate produced by Propionibacterium freudenreichii
in other CRC cells (HT-29), including increased ROS and ΔΨm
dissipation, as well as swelling in isolated mitochondria.4
However, the role of CatD or the lysosome in that context was
not evaluated.
The increase in mitochondrial mass observed after expo-
sure of cells to acetate led us to investigate whether the
presumed decrease in mitochondrial turnover was associated
with modulation of autophagy by this SCFA. Previous
studies demonstrated that apoptosis triggered by low doses
(1–10mM) of propionate and butyrate can be delayed
because autophagy is also induced, which can potentially
impair the therapeutic efficacy of SCFAs in colon cancer.15–17
Indeed, autophagy has been implicated in cancer progres-
sion, used by cells for autophagic degradation of damaged
organelles, long-lived proteins and pathogens, and in this way
maintain homeostasis.20,29,34 Further assays are required to
ascertain whether low concentrations of acetate can cause a
similar adaptive response in CRC cells. However, we
previously showed that autophagy is not induced during
acetic acid-induced apoptosis in yeast.13 In the present study,
we demonstrate that acetate impairs the autophagic flux of
HCT116 cells and decreases Beclin-1 levels in all three cell
lines. Therefore, we show that concentrations of acetate
normally present in the human intestine have a previously
uncharacterized effect in CRC cells: inhibition of autophagy,
most likely through impairment of autophagosome and
lysosome fusion during acetate-induced apoptosis.
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Figure 6 Cell survival and mitochondrial degradation in S. cerevisiae cells during
acetic acid treatment. The W303 strain transformed with the empty vector (pESC) and
pep4Δ strains, transformed with the empty vector (pESC), pESC-PEP4 (expressing
WT-Pep4p), pESC-DPM (expressing DPM-Pep4p) or pESC-CTSD (expressing
human CatD), were incubated with 120 mM acetic acid for up to 180 min.
(a) Immunoblot analysis of whole-cell extracts of pep4Δ cells expressing FLAG-
tagged WT-Pep4p, FLAG-tagged DPM-Pep4p, FLAG-tagged CatD and the
corresponding empty vector after 20 h of growth. Pgk1p was used as a loading
control. (b) Cell survival at time 180 min was determined by standard dilution plate
counts and expressed as a percentage of colony-forming units (CFU) in relation to time
0. Data represents means± S.D. (n= 3). (c) Mitochondrial degradation was
assessed by measuring the percentage of cells without loss of mtGFP fluorescence
(100% corresponds to the number of GFP positive cells at time 0). Data represent
means± S.D. (n= 4). *Po0.05, **Po0.01 and ***Po0.001
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Figure 5 Acetate induces specific CatD release to the cytosol in CRC cells. Effect
of acetate on the expression and release of CatL, CatB and CatD to the cytosol in
RKO cells. Cells were treated with 110 mM acetate or 50 μM etoposide for 48 h, or
with fresh medium as a negative control. Total and cytosolic fractions (Cyto) are
shown. Actin was used as a loading control
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It is known that malfunctioning mitochondria are selectively
targeted for autophagic degradation.16 However, it is con-
ceivable that cells use alternative pathways to clear damaged
mitochondria when autophagy is inactive. We therefore
investigated if CatD is involved in mitochondrial degradation,
similar to Pep4p in yeast, possibly having a prosurvival role
through elimination of dysfunctional mitochondria. We show
that CatD protects RKO cells from acetate-induced oxidative
stress and mitochondrial depolarization, as its inhibition with
PstA or downregulation with siRNA cause a significant
increase in the levels of H2O2 and O2
− and a decrease in
ΔΨm. Hah et al.10 have previously suggested that CatD has a
protective role in H2O2-induced cell death in M059J glioblas-
toma cells through its involvement in autophagy, which
enhances cell survival under oxidative stress.10 Accordingly,
we had shown that Pep4p deletion increased the sensitivity of
yeast cells to acetic acid associated with increased ROS
accumulation,14 although autophagy was not induced.13
These data, together with our results, support the notion that
reduced CatD activity leads to increased ROS accumulation
and mitochondrial depolarization. We therefore proceeded to
determine whether CatD is involved in the degradation of
damagedmitochondria, aswe presumed to be the case during
acetate-induced apoptosis in CRC cells. We found that
downregulation of CatD in acetate-treated RKO cells
increased mitochondrial mass, as well as the cellular pool of
AIF. These findings corroborate our hypothesis that CatD is
involved in the degradation of damaged mitochondria during
acetate-induced apoptosis through an autophagy-
independent process. Although not sufficiently efficient to
maintain mitochondrial mass homeostasis, as an acetate-
induced increase in mitochondrial mass is still observed, this
alternative degradation process allows the cell to dispose of
dysfunctional mitochondria and delay cell death. It will be
interesting in the future to determine if CatD is also released
and is involved in mitochondrial degradation in response to
other SCFAs, either directly or through downstream sub-
strates. Inhibition of CatD with PstA mimicked the results
obtained with CatD siRNA, indicating the catalytic activity of
CatD is required for this function, as we previously found for
the antiapoptotic role of both yeast and human CatD.5,14 We
now also show that the role of yeast CatD in acetic acid-
induced mitochondrial degradation depends on its proteolytic
activity and can be complemented by human CatD, indicating
this mechanism is conserved through evolution.
As discussed above, partial LMP followed by a release of
lysosomal hydrolases into the cytosol can activate intrinsic
caspase-dependent apoptosis or a caspase-independent
alternative cell death pathway.7,8 Thus, disabling lysosome
function is under investigation as an adjuvant therapeutic
approach to sensitize cells to apoptosis-inducing agents.7
Destabilization of the lysosomal membrane has been pro-
posed as a promising strategy, as it would promote apoptosis
through initiation of the lysosomal pathway in cancer cells.8
However, our results show that the release of lysosomal
proteases, in particular of CatD,5 may enable a degradation
process alternative to autophagy with a similar protective role
in cell survival, thus counteracting activation of the lysosomal
death pathway. This would negatively impact the efficacy of
acetate, and probably of other therapeutic compounds that
trigger LMPand impair autophagy, andwould require inhibiting
CatD in combination treatments.
In summary, our findings based on the clues provided by the
yeast system unveiled a novel prosurvival function of CatD in
autophagy-independent mitochondrial degradation, which
can enhance cell survival in CRC cells undergoing acetate-
induced apoptosis. These results offer new perspectives in the
intricate regulation of life and death, and suggest using CatD
inhibitors as adjunct therapy with SCFAs for prevention/
therapy of CRC.
Materials and Methods
Cell lines and culture. We used three cell lines derived from human CRC,
namely RKOBRAFV600E, HCT-15KRASG13D and HCT116KRASG13D; PI3KCA. Cells were
maintained at 37 °C under a humidified atmosphere containing 5% CO2. HCT-15
cells were grown in RPMI (Biowest, Nuaillé, France) medium with L-glutamine and
HEPES. RKO cells were grown in DMEM (Biowest) with high glucose and
supplemented with 1 mM sodium pyruvate and 1.5 g/l sodium bicarbonate. HCT116
cells were grown in McCoy’s 5 A (Biowest) medium. All culture media were
supplemented with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin.
For autophagy studies, we used HBSS (Gibco, Paisley, UK) medium supplemented
with 7.5% sodium bicarbonate.
Cell treatments with acetate. Cells were seeded and adhered onto
appropriate sterile plates for 24 h before treatments in all experiments.
We previously determined the IC50, IC intermediate (IC inter) and 2 × IC50 of
acetate after 48 h of treatment: 70, 100 and 140 mM for HCT-15; 110, 140 and
220 mM for RKO cell lines, respectively.5 The IC50, IC inter and 2 × IC50 values for
HCT116 (100, 150 and 200 mM, respectively) were calculated from the mean
values of sulforhodamine B reduction as described in Marques et al.5
(Supplementary Figure S3). For each bar, the mean value of at least three
independent experiments is represented. Bonferroni’s test: *P≤ 0.05, **P≤ 0.01
and ***P≤ 0.001 compared with negative control cells.
RNA interference-mediated inhibition of CatD. RKO cells were plated
in 6-well plates at a density of 3 × 104 cells per well. After 24 h, about 70%
confluence was confirmed before transfection with small interfering RNA (siRNA)
oligonucleotides. Cells were transfected with 100 nM on-target plus SMART pool
siRNA against CatD (A-003649-16; Thermo Fisher Scientific, Lafayette, CO, USA).
Transfection performance was monitored using a validated Silencer Select Negative
Control (scrambled siRNA control, no. 4390843; Life Technologies, Carlsbad, CA,
USA). Transfection was performed with 6 μl Lipofectamine 2000 (Invitrogen Corp.,
Paisley, UK). After 14 h, the transfection mixture was removed and cells were left
untreated (blank) or treated with acetate (110 mM) or etoposide (50 μM) and
incubated for a further 48 h in fresh medium. MitoSOx, DHE and double staining
with MitoTracker Green and Mitotracker Red CMXRos were performed as described
below. The experiments were carried out in three replicates, and CatD levels were
monitored by western blotting.
Determination of intracellular ROS
Dichlorofluorescein assay: Cells were seeded in a 12-well plate at a density
of 1.4× 105 and 1.8× 105 cells per well (RKO and HCT-15 cells, respectively).
When indicated, cells were preincubated with PstA (Sigma-Aldrich, St Louis, MO,
USA) for 16 h and then coincubated with PstA without and with different acetate
concentrations for 12, 24 and 48 h. After treatment, cells were washed two times
with 1x PBS and H2DCF-DA (Sigma-Aldrich) was added to the culture plates at a
final concentration of 100 μM. Plates were incubated at 37 °C for 30 min in the dark.
Then, cells were lysed with 500 μl of 90% DMSO/10% PBS (lysis solution) for
10 min at room temperature in the dark, with agitation. H2O2 (500 μM or 1 mM for
HCT-15 or RKO cell lines, respectively) was used as a positive control. H2DCF-DA
fluorescence intensity was detected with emission wavelength at 538 nm and
excitation wavelength at 485 nm using a fluorescence microplate reader
(Fluoroskan Ascent FL; Thermo Fisher Scientific Inc., Waltham, MA, USA). Values
are expressed as the mean fluorescence intensity normalized to the cell number in
each condition at the end of the experiment. Three independent experiments were
performed.
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DHE assay: Non-treated cells (negative control) or cells exposed to different
acetate concentrations for 12, 24 and 48 h were analyzed. When used, cells were
preincubated with PstA for 16 h and then coincubated with PstA without and with
different acetate concentrations for 24 h. Inhibition of CatD in RKO cells was
performed as described above. Approximately 1 × 106 floating and attached cells
were collected, washed with 1 × PBS, centrifuged at 1500 × g for 5 min and
incubated with 150 nM DHE (Molecular Probes, Eugene, OR, USA) (30 min, 37 °C,
in the dark) to detect superoxide anion (O2
−). Fluorescence emission of oxidized
DHE was analyzed by flow cytometry. H2O2 (500 μM or 1 mM for HCT-15 or RKO
cell lines, respectively) was used as a positive control. Values are expressed as the
mean of fluorescence intensity normalized to T0 (control for ROS level before the
treatment). Three independent experiments were carried out and data were
analyzed using the Flowing software (version 2.5.1, Turku Centre for Biotechnology,
Turku, Finland).
MitoSOX assay: MitoSOX Red (Molecular Probes) was used to detect
mitochondrial superoxide. Approximately 1 × 106 floating and attached cells were
collected, washed with 1x PBS, centrifuged at 1500 × g for 5 min and incubated with
2.5 μM MitoSOX Red for 30 min at room temperature. Fluorescence emission of
oxidized MitoSOX Red was analyzed by flow cytometry. H2O2 (1 mM) was used as a
positive control. Values are expressed as the percentage of cells with positive
staining normalized to T0 (control for ROS level before the treatment).
Analysis of mitochondrial alterations
Mitochondrial mass and ΔΨm analysis: MitoTracker Green FM (Molecular
Probes) was used to analyze the relative mitochondrial mass. MitoTracker Green is
a green fluorescent dye that localizes to the mitochondrial matrix regardless of the
ΔΨm and covalently binds to mitochondrial proteins by reacting with free thiol
groups of cysteine residues. MitoTracker Red CMXRos (Molecular Probes) was
used simultaneously, to monitor the changes in ΔΨm. MitoTracker Red CMXRos is
a red-fluorescent dye that stains mitochondria in live cells through accumulation in
mitochondria in a membrane potential-dependent manner. Untreated cells (negative
control), cells exposed to etoposide (50 μM), an inducer of LMP, or to different
acetate concentrations were analyzed at different time points. When used, cells
were preincubated with 10 μM (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methyl-
butane ethyl ester (E-64d; Sigma-Aldrich) (a CatB and CatL inhibitor) or 100 μM
PstA for 1 and 16 h, respectively, and then co-incubated with different acetate
concentrations or etoposide for 48 h. Both floating cells and attached cells were
collected, washed with 1x PBS, centrifuged at 1500 × g for 5 min and incubated with
400 nM MitoTracker Green FM and 200 nM MitoTracker Red CMXRos (30 min, 37 °
C, in the dark). The uncoupling agent CCCP (50 μM, 30 min) was used as positive
control for mitochondrial membrane depolarization. Fluorescence emission was
analyzed by flow cytometry. The values of mitochondrial mass for each time point
were expressed as the ratio between the mean green fluorescence intensity and the
one correspondent to time zero (T0). The values of the ΔΨm for each time point
were expressed as the ratio between the mean red fluorescence intensity and the
mean green fluorescence intensity normalized to the correspondent one at T0.
Three independent experiments were carried out.
Fluorescence microscopy studies: Cells were seeded in 6-well
plates containing glass coverslips and exposed to acetate for 48 h. At the
end of the experiment, cells were washed with 1x PBS and incubated with 20 nM
DiOC6(3) (Molecular Probes) or with 400 nM MitoTracker Green and
200 nM MitoTracker Red CMXRos for 30 min, at 37 °C, in the dark. CCCP
(50 μM, 30 min) was also used as a positive control for ΔΨm loss. Coverslips
were mounted in 1x PBS and immediately observed under the fluorescence
microscope (Leica DM 5000B; Leica Microsystems, Wetzlar, Germany).
Three coverslips were prepared for each experimental condition and representa-
tive images are shown.
Flow cytometry analysis: Samples were analyzed in a flow cytometer
(Epics XL; Beckman Coulter, Miami, FL, USA) equipped with an argon-ion laser
emitting a 488-nm beam at 15 mW. Detection of red fluorescence was performed
using FL-4 (488/620 nm) and detection of green fluorescence was performed using
FL-1 (488/525 nm). A total of 30 000 cells were acquired per sample and data were
analyzed using the Flowing software (version 2.5.1, Turku Centre for Biotechnology).
Assessing autophagy in CRC cell lines: Cell lines untreated (Blank) or
treated with IC50, IC inter or 2 × IC50 acetate concentrations were incubated for 42 h
in complete medium. Later, cells were incubated in HBSS medium for 6 h in the
presence or absence of 20 nM Baf. A1 (Acros Organics, Geel, Belgium), in the
absence or presence of acetate.
Cell survival and mitochondrial degradation assays in yeast: Sacchar-
omyces cerevisiae strain W303-1A was used as the wild-type strain. The pep4Δ
mutant was constructed in W303-1A by homologous recombination using a PEP4::
kanMX4 disruption cassette amplified from the respective Euroscarf deletion strain
by PCR. Correct integration of the cassette was confirmed by PCR. To construct
CatDFLAG, the insert was amplified by PCR from the plasmid pJP1520-CTSD
(containing human CatD cDNA) and integrated by homologous recombination into
the pESC-His vector. Correct integration was verified by sequencing. The W303-1A
strain was transformed with the empty vector (pESC) and the pep4Δ strain was
transformed with the empty vector (pESC), pESC-PEP4, pESC-DPM and pESC-
CTSD plasmids for expression of WT-Pep4, double-point mutant (DPM-Pep4p) or
human CatD, respectively. The strains were transformed with the pGAL-CLbGFP
(see Okamoto et al.35) vector for mitochondrial degradation studies. Strain growth
conditions, acetic acid treatments and mitochondrial degradation assays were
performed as described previously.14
Preparation of total/cytosolic protein extracts and western blotting:
Cell lysis of mammalian cells, protein sample preparation (total and cytosolic) and
western blotting were carried out as described previously5 with 25 μg of total or
cytosolic extracted proteins applied per lane before SDS-PAGE. Total yeast extracts
were prepared by suspending ~ 2 × 106 cells in 0.5 ml of water and adding 50 μl of a
mixture of 3.5% β-mercaptoethanol in 2 M NaOH. After a 15min incubation on ice,
proteins were precipitated with 50 μl of 3 M trichloracetic acid for 15 min on ice. After a
rapid centrifugation, the pellet was resuspended in Laemmli buffer for SDS-PAGE.
The primary antibodies used were anti-Beclin-1 (1 : 3000; Cell Signaling
Technology, Leiden, Netherlands), anti-LC3-II (1 : 5000; Sigma-Aldrich), anti-Atg5
(1 : 3000; Sigma-Aldrich), anti-CatD (1 : 100; Calbiochem, San Diego, CA, USA), anti-
CatB (1 : 300; Abcam, Cambridge, UK), anti-CatL (1 : 1000; Abcam), anti-AIF
(internal) rabbit polyclonal antibody (1 : 500; Chemicon International, Billerica, MA,
USA ), anti-VDAC1 (1 : 2000; MitoSciences, Eugene, OR, USA), anti-Tom22 (FL-145)
(1 : 1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-actin (Santa Cruz
Biotechnology, Santa Cruz), anti-FLAG (1 : 5000; Sigma-Aldrich) and anti-yeast
phosphoglycerate kinase (PGK1) antibody (1 : 5000; Molecular Probes). Secondary
antibodies used were peroxidase-conjugated AffiniPure goat anti-rabbit IgG (Jackson
ImmunoResearch, West Grove, PA, USA) and horseradish peroxidase-labeled goat
anti-mouse immunoglobulin IgG (Jackson ImmunoResearch). Subsequent chemilu-
minescence detection was performed using the ECL detection system (Amersham,
Biosciences, Buckinghamshire, UK) and a molecular imager by Chemi-Doc XRS
system (Bio-Rad, Laboratories Inc., Hercules, CA, USA). When performed,
densitometry analysis of protein bands was performed using the Quantity One
software (version 4.6.9, Bio-Rad manufacturer, Hercules, CA, USA) and levels of actin
used as a normalization control for protein loading.
Statistical analysis: Data are expressed as mean± S.D. of three independent
experiments. Statistical significance analysis was determined by one-way ANOVA
followed by Dunnett or Bonferroni’s test for multiple comparisons with the control
using Prism software (GraphPad, La Jolla, CA, USA). The differences were
considered significant for P-values lower than 0.05.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We thank Frank Madeo (University of Graz) for plasmids
pESC, pESC-PEP4 and pESC-DPM, and Elisabete Fernandes (University of Minho)
for the pESC-CTSD construct. This work was supported by FEDER through POFC –
COMPETE and by Fundação para a Ciência e Tecnologia through projects PEst-OE/
BIA/UI4050/2014 and FCTANR/BEX-BCM/0175/2012, as well as fellowships to CSF
Oliveira (SFRH/BD/77449/2011), H Pereira (SFRH/BD/73139/2010), L Castro
(SFRH/BD/93589/2013) and S Chaves (SFRH/ BPD/89980/2012).
1. Zhu Y, Michelle Luo T, Jobin C, Young HA. Gut microbiota and probiotics in colon
tumorigenesis. Cancer Lett 2011; 309: 119–127.
CatD mediates degradation of damaged mitochondria
CSF Oliveira et al
10
Cell Death and Disease
2. Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F. Colorectal cancer prevention in
Europe: burden of disease and status of screening programs. Preventive medicine 2014; 62:
132–141.
3. Jan G, Belzacq AS, Haouzi D, Rouault A, Metivier D, Kroemer G, et al. Propionibacteria
induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on
mitochondria. Cell Death Differ 2002; 9: 179–188.
4. Lan A, Lagadic-Gossmann D, Lemaire C, Brenner C, Jan G. Acidic extracellular pH shifts
colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate,
major end-products of the human probiotic propionibacteria. Apoptosis 2007; 12: 573–591.
5. Marques C, Oliveira CS, Alves S, Chaves SR, Coutinho OP, Corte-Real M, et al. Acetate-
induced apoptosis in colorectal carcinoma cells involves lysosomal membrane permeabi-
lization and cathepsin D release. Cell Death Dis 2013; 4: e507.
6. Comalada M, Bailon E, de Haro O, Lara-Villoslada F, Xaus J, Zarzuelo A, et al. The effects of
short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular
phenotype. J Cancer Res Clin Oncol 2006; 132: 487–497.
7. Repnik U, Stoka V, Turk V, Turk B. Lysosomes and lysosomal cathepsins in cell death.
Biochim Biophys Acta 2012; 1824: 22–33.
8. Groth-Pedersen L, Jaattela M. Combating apoptosis and multidrug resistant cancers by
targeting lysosomes. Cancer Lett 2013; 332: 265–274.
9. Margaryan NV, Kirschmann DA, Lipavsky A, Bailey CM, Hendrix MJ, Khalkhali-Ellis Z. New
insights into cathepsin D in mammary tissue development and remodeling. Cancer Biol Ther
2010; 10: 457–466.
10. Hah YS, Noh HS, Ha JH, Ahn JS, Hahm JR, Cho HY, et al. Cathepsin D inhibits oxidative
stress-induced cell death via activation of autophagy in cancer cells. Cancer Lett 2012; 323:
208–214.
11. Maynadier M, Vezenkov LL, Amblard M, Martin V, Gandreuil C, Vaillant O, et al. Dipeptide
mimic oligomer transporter mediates intracellular delivery of Cathepsin D inhibitors: a
potential target for cancer therapy. J Control Rel 2013; 171: 251–257.
12. Sagulenko V, Muth D, Sagulenko E, Paffhausen T, Schwab M, Westermann F. Cathepsin D
protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis
2008; 29: 1869–1877.
13. Pereira C, Chaves S, Alves S, Salin B, Camougrand N, Manon S, et al. Mitochondrial
degradation in acetic acid-induced yeast apoptosis: the role of Pep4 and the ADP/ATP
carrier. Mol Microbiol 2010; 76: 1398–1410.
14. Pereira H, Azevedo F, Rego A, Sousa MJ, Chaves SR, Corte-Real M. The protective role of
yeast cathepsin D in acetic acid-induced apoptosis depends on ANT (Aac2p) but not on the
voltage-dependent channel (Por1p). FEBS Lett 2013; 587: 200–205.
15. Tang Y, Chen Y, Jiang H, Nie D. The role of short-chain fatty acids in orchestrating two types
of programmed cell death in colon cancer. Autophagy 2011; 7: 235–237.
16. Tang Y, Chen Y, Jiang H, Nie D. Short-chain fatty acids induced autophagy serves as an
adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ
2011; 18: 602–618.
17. Adom D, Nie D. Regulation of Autophagy by Short Chain Fatty Acids in Colon Cancer Cells.
Intech, 2013, pp 522.
18. Iwase T, Tajima A, Sugimoto S, Okuda K, Hironaka I, Kamata Y, et al. A simple assay for
measuring catalase activity: a visual approach. Scientific Rep 2013; 3: 3081.
19. Handy DE, Loscalzo J. Redox regulation of mitochondrial function. Antioxidants Redox
Signal 2012; 16: 1323–1367.
20. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer
2007; 7: 961–967.
21. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1
prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes
and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23: 33–42.
22. Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of macroautophagy regulation in
mammalian cells. Cell Res 2010; 20: 748–762.
23. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell
Biol 2007; 9: 1102–1109.
24. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Expression of
cathepsin B and L antigen and activity is associated with early colorectal cancer progression.
Eur J Cancer 2004; 40: 1610–1616.
25. Oberle C, Huai J, Reinheckel T, Tacke M, Rassner M, Ekert PG, et al. Lysosomal membrane
permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of
apoptosis in fibroblasts and monocytes. Cell Death Differ 2010; 17: 1167–1178.
26. Goncalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Curr
Drug Metab 2013; 14: 994–1008.
27. Zeng H, Lazarova DL, Bordonaro M. Mechanisms linking dietary fiber, gut microbiota and
colon cancer prevention. World J Gastrointest Oncol 2014; 6: 41–51.
28. Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of
galacto-oligosaccharides and other prebiotics. J Appl Microbiol 2008; 104: 305–344.
29. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy.
Nat Rev Clin Oncol 2011; 8: 528–539.
30. Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, Arnogianaki N, Plataniotis G, et al.
Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to
carcinoma. Cancer Lett 2004; 205: 97–106.
31. Kirana C, Shi H, Laing E, Hood K, Miller R, Bethwaite P, et al. Cathepsin D expression in
colorectal cancer: from proteomic discovery through validation using western blotting,
immunohistochemistry, and tissue microarrays. Int J Proteom 2012; 2012: 245819.
32. Szajda SD, Snarska J, Jankowska A, Roszkowska-Jakimiec W, Puchalski Z, Zwierz K.
Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon
adenocarcinoma patients. Hepatogastroenterology 2008; 55: 388–393.
33. Carmona-Gutierrez D, Bauer MA, Ring J, Knauer H, Eisenberg T, Buttner S, et al. The
propeptide of yeast cathepsin D inhibits programmed necrosis. Cell Death Dis 2011; 2: e161.
34. Klionsky DJ. The molecular machinery of autophagy: unanswered questions. J Cell Sci
2005; 118(Part 1): 7–18.
35. Okamoto K, Perlman PS, Butow RA. The sorting of mitochondrial DNA and mitochondrial
proteins in zygotes: preferential transmission of mitochondrial DNA to the medial bud. J Cell
Biol 1998; 142: 613–623.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
CatD mediates degradation of damaged mitochondria
CSF Oliveira et al
11
Cell Death and Disease
  
 
 
OPEN ACCESS | www.microbialcell.com 225 Microbial Cell | July 2015 | Vol. 2 No. 7 
www.microbialcell.com 
Review 
ABSTRACT  Cathepsin D has garnered increased attention in recent years, 
mainly since it has been associated with several human pathologies. In partic-
ular, cathepsin D is often overexpressed and hypersecreted in cancer cells, 
implying it may constitute a therapeutic target. However, cathepsin D can 
have both anti- and pro-survival functions depending on its proteolytic activi-
ty, cellular context and stress stimulus. Therefore, a more detailed under-
standing of cathepsin D regulation and how to modulate its apoptotic func-
tions is clearly needed. In this review, we provide an overview of the role of 
cathepsin D in physiological and pathological scenarios. We then focus on the 
opposing functions of cathepsin D in apoptosis, particularly relevant in cancer 
research. Emphasis is given to the role of the yeast protease Pep4p, the vacu-
olar counterpart of cathepsin D, in life and death. Finally, we discuss how in-
sights from yeast cathepsin D and its role in regulated cell death can unveil 
novel functions of mammalian cathepsin D in apoptosis and cancer. 
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CATHEPSINS 
Cathepsins are members of a large protease family, which 
can be subdivided according to their structure and active-
site amino acid into cysteine (cathepsins B, C, F, H, K, L, O, S, 
V, W, and X), serine (cathepsins A and G), and aspartic ca-
thepsins (cathepsins D and E). While cathepsins B, L, H, C 
and D are ubiquitously expressed in human tissues, expres-
sion of cathepsins A, G, K, S, V, X and W is tissue and cell 
type specific [1-4]. In general, cathepsins are found in acid-
ic cellular organelles, lysosomes and endosomes. Initially, 
their function was thought to be limited to bulk degrada-
tion of proteins delivered to the lysosome by endocytosis 
or autophagocytosis. However, it was later demonstrated 
that cathepsins possess highly specific and directed proteo-
lytic activity, and that they can be found in other cellular 
compartments [5-10]. Numerous physiological functions of 
cathepsins have been uncovered, including a role in hor-
mone and antigen processing, bone and tissue remodeling, 
growth factor and proenzyme activation and, more recent-
ly, in the immune response [5, 6, 11-13]. Cathepsins also 
participate in apoptosis and are translocated from the ly-
sosomal lumen to the cytosol of mammalian cells through 
lysosomal membrane permeabilization (LMP) in response 
to a variety of apoptotic signals [14-16]. These lysosomal 
proteases can also be secreted from the cell and degrade 
extracellular matrix proteins such as collagen, fibronectin, 
proteoglycans and laminin [17]. 
In addition to their physiological function, cathepsins 
have also been associated with several pathologies such as 
cardiovascular diseases, osteoporosis, rheumatoid arthritis, 
atherosclerosis and cancer [6, 11, 17-19]. Elucidating the 
mechanisms underlying the involvement of cathepsins in 
the pathogenesis of these diseases, and how they can be 
modulated to develop new prevention and therapeutic 
strategies, has therefore taken center stage. Among ca-
thepsins, cathepsin D (CatD) has attracted increased atten-
tion in recent years due to its importance in the mediation 
of lysosomal cell death pathways and in cancer. In this re-
view, we will concentrate on both physiological and patho-
logical functions of CatD, as well as on yeast as a model 
system to study CatD pathophysiology. 
 
ROLE OF CATHEPSIN D IN CELLULAR PHYSIOLOGY AND 
PATHOLOGY 
CatD is a soluble aspartic endopeptidase found in the lyso-
somes of most mammalian cells. Like other cathepsins, 
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TABLE 1. Cellular roles of cathepsin D in physiological and pathological processes. 
Role Model References 
Limited proteolysis of proteins regulating cell growth and/or 
tissue homeostasis 
In vivo: CatD-deficient mice [43] 
Postnatal tissue homeostasis including tissue renewal, remod-
eling, aging and RCD 
In vivo: CatD-deficient mice; CatD-mutant mice [44-47] 
Neuronal ceroid lipofuscinosis in both animals and humans 
characterized by severe neurodegeneration, developmental 
regression, visual loss and epilepsy 
In vivo: CatD-deficient mice; CatD-mutant mice  
Human pathologies 
Animal diseases 
[45, 48-51] 
Wound healing, epidermal differentiation and pathological 
conditions such as psoriasis 
In vivo: CatD-deficient mice 
In vitro: normal and psoriatic keranocytes 
Human patients 
[52-54] 
Proliferation and regeneration in keratinocytes and possibly in 
skin regeneration 
In vitro: keratinocyte cell line HaCaT [38] 
Processing of proteins involved in Alzheimer disease pathogen-
esis, such as apolipoprotein E (apoE) and Tau protein 
Human patients 
Recombinant protein 
[55, 56] 
Post-partum cardiomyopathy resulting in heart failure In vivo: mutant mice [57] 
Autism pathogenesis  Autistic subjects [58] 
Innate immune responses and Parkinson disease 
In vivo: CatD-deficient mice  
Human patients  
[59, 60] 
Intracellular metabolism, transport of phospholipids and cho-
lesterol 
Human patients  [61] 
Atherosclerotic lesions associated with proCatD release from 
monocyte-derived macrophages 
Atherosclerosis patients 
In vitro: cultured atherosclerotic plaques 
[62] 
 
CatD is activated by proteolytic cleavage of the synthetized 
inactive zymogen (preproCatD), which is composed of an 
N-terminal signal peptide, a propeptide, and a catalytic 
domain [20-22]. The signal peptide directs the nascent 
chain to the endoplasmic reticulum, where it is cleaved in 
the lumen. ProCatD is then N-glycosylated and transported 
to the Golgi, where the N-glycan structures acquire man-
nose-6phosphate (Man-6P) residues that can bind to Man-
6P receptor(s) (Man-6PR), and the complex is directed to 
the lysosomal compartment [23]. In the acidic milieu, pro-
CatD (52 kDa) undergoes further proteolytic processing by 
cleavage of the proregion, resulting in the 48 kDa single 
chain intermediate active form. Finally, this chain is pro-
cessed into mature active CatD, composed of heavy (34 
kDa) and light (14 kDa) chains linked by non-covalent inter-
actions [24-26]. It has been shown that CatD processing 
involves cysteine cathepsins [26, 27] and, more recently, 
that it is independent of its own catalytic function and au-
to-activation but requires CatL and CatB [28]. Although 
proCatD and CatD are mostly intracellular, they can also 
localize in the extracellular matrix and synovial fluid of 
cartilage [29-31]. ProCatD/CatD are also found in human, 
bovine and rat milk [32-34], serum, sweat and urine [35, 
36], and extracellularly in macrophage-rich regions of ath-
erosclerotic lesions [37]. ProCatD secretion by human 
keranocytes [38], mammalian epithelial cells [39] and dif-
ferent types of cancer cells [18, 40] was also demonstrated. 
It is widely accepted that the major function of CatD is 
its involvement in general protein degradation and turno-
ver within the lysosomal compartment. However, CatD has 
also emerged as an important regulator and signaling mol-
ecule with numerous physiological functions. These include 
activation of enzymatic precursors, prohormones and 
growth factors, processing of brain-specific antigens, tissue 
homeostasis, and participation in apoptosis [18, 41]. CatD 
has also been associated with different pathological sce-
narios such as cancer progression and metastasis, Alz-
heimer’s disease, atherosclerosis and inflammatory disor-
ders [11, 12, 40, 42], and found to be a specific biomarker 
for several pathologies. The involvement of CatD in both 
physiological and pathological processes has been ad-
dressed in multiple studies, some of which are summarized 
in Table 1 [38, 43-62]. A more detailed description of the 
role of CatD in cancer is given below. 
 
THE ROLE OF CATHEPSIN D IN CANCER 
Numerous reports have demonstrated that CatD is overex-
pressed in several cancer types [18, 40, 42, 63-65], often 
correlating with poor prognosis. In particular, CatD is con-
sidered an independent prognostic marker in breast cancer 
associated with metastatic risk [66-68] and in colorectal 
cancer (CRC) [69, 70]. Mechanistically, the majority of re-
ports attribute its role in cancer to overexpression of pro-
CatD. As an example, transfection of rat tumor cells with 
human proCatD cDNA leads to increased proliferation, 
invasion and metastasis in vitro and in vivo [71]. According-
ly, anti-proCatD antibodies can inhibit tumor growth both 
in vitro and in vivo [72-74]. Overexpressed proCatD escapes 
normal targeting routes and is hypersecreted to the extra-
cellular milieu, where it can act in multiple fashions. On 
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one hand, it can exert an autocrine effect, inducing cancer 
cell growth by interacting with cell surface receptors [72, 
75-77]. This autocrine role has so far been observed in 
breast, prostate, ovarian and lung cancer cells [72-74, 78]. 
In addition, proCatD can play a crucial paracrine role in the 
tumor microenvironment by stimulating fibroblast out-
growth and tumor angiogenesis [71, 79], as well as inhibit-
ing anti-tumor responses [80]. When in the tumor micro-
environment, proCatD may also affect stromal cell behav-
ior and/or degrade components from the extracellular ma-
trix [81, 82], including the release of growth factors [83]. 
Although it has been suggested that proCatD can be pro-
cessed in the acidic extracellular space to catalytically ac-
tive CatD [84], the enzymatic activity of CatD is reportedly 
not required for its mitogenic role. Indeed, a proteolytically 
inactive mutant of CatD (D231N) is still mitogenic for fibro-
blasts [85], as well as for cancer cells both in vitro, in three-
dimensional matrices, and in athymic nude mice [71, 86]. 
Similarly, proCatD stimulates angiogenesis in tumor xeno-
grafts of athymic nude mice independently of its catalytic 
activity [85], also suggesting that CatD can signal through 
protein-protein interactions.  
Though less extensive, there are also examples of CatD 
roles in cancer cells that are not attributed to proCatD. For 
instance, intracellular CatD can stimulate cancer cell 
growth by inactivating secreted growth inhibitors [87, 88]. 
Moreover, mature CatD released into the cytosol as a con-
sequence of the reportedly higher susceptibility of cancer 
cells to LMP [15, 89] may interact with and/or degrade pro- 
and anti-apoptotic proteins, modulating cell death [41].  
Targeting CatD is a promising strategy in the clinic, but 
requires further detailed elucidation of its mechanisms of 
action. In the following section, we focus on the role of 
CatD in the apoptotic process, which is of particular rele-
vance for cancer research. These studies may however also 
offer clues into the function of CatD in other physiological 
and pathological scenarios. 
 
OPPOSING FUNCTIONS OF CATHEPSIN D IN APOPTOSIS 
In recent years, multiple studies have shown that CatD is a 
central player in the apoptotic response, both under physi-
ological and pathological conditions. In fact, depending on 
the cell type and context, CatD can induce or inhibit apop-
tosis, acting through different mechanisms [41]. On one 
hand, CatD can directly induce apoptosis triggered by sev-
eral stimuli such as staurosporine [90], etoposide, 5-
fluorouracil and cisplatin [91], as well as resveratrol [92] 
and others, possibly mediated by intrinsic or extrinsic 
pathways [41]. In the intrinsic pathway, the role of CatD is 
linked to the release of mature 34 kDa CatD into the cyto-
sol and cleavage of Bid to form tBid, triggering insertion of 
the pro-apoptotic protein Bax into the mitochondrial 
membrane [15]. Subsequent mitochondrial outer mem-
brane permeabilization leads to the release of pro-
apoptotic molecules such as cytochrome c and apoptosis 
inducing factor (AIF) to the cytosol [15]. For instance, it has 
been shown that CatD mediates cytochrome c release and 
caspase activation in human fibroblasts undergoing stauro-
sporine-induced apoptosis [90], and cleaves Bid and pro-
motes apoptosis via oxidative stress-induced LMP in hu-
man neutrophils [93]. In addition, Pepstatin A and/or 
knockdown of CatD expression by RNA interference pre-
vent resveratrol toxicity, impeding Bax oligomerization, 
mitochondrial membrane permeabilization, cytochrome c 
release and caspase 3 activation in DLD1 and HT29 CRC cell 
lines [92]. One study also reports that CatD mediates selec-
tive release of AIF in T lymphocytes entering the apoptosis 
early commitment phase through activation of Bax in a Bid-
independent manner [94]. This shows that CatD can be 
involved in caspase-independent apoptosis by activating 
Bax independently of Bid cleavage. Other studies strongly 
suggest that cytosolic CatD may have an additional role 
involving protein-protein interactions. As examples, it has 
been shown that overexpression of either catalytically ac-
tive or inactive CatD by cancer cells enhances apoptosis-
dependent chemo-sensitivity [95], and that stress-induced 
apoptosis is not affected in fibroblasts synthesizing a cata-
lytically inactive CatD [96]. Additionally, microinjection of 
inactive proCatD into the cytosol of both human fibroblasts 
and HeLa cells induces apoptosis [97]. Interestingly, one 
report also indicates that cytosolic mature CatD may reach 
the nucleus during cell death [98]. 
In contrast with the multiple studies showing CatD is 
pro-apoptotic, other studies describe an anti-apoptotic 
function of CatD. Most of these suggest it plays an anti-
apoptotic role in cancer cells. For example, CatD down-
regulation sensitizes human neuroblastoma cells to doxo-
rubicin-induced apoptosis, while CatD overexpression has 
the opposite effect [99]. Accordingly, inhibition of CatD 
with pepstatin A induces caspase-dependent apoptosis in 
neuroblastoma cell lines [100]. Moreover, overexpression 
of intracellular CatD in mouse xenografs using rat-derived 
cell lines inhibits apoptosis [71], and expression of wild 
type or a catalytic mutant of CatD promotes survival and 
invasive growth of CatD-deficient fibroblasts [85]. Another 
study in glioblastoma cells proposes that CatD stimulates 
autophagy induction, inhibiting apoptotic cell death under 
genotoxic conditions [101]. More recently, we showed that 
inhibition of CatD in CRC cells with small interfering RNA 
(siRNA) or pepstatin A enhances acetate-induced apoptosis 
associated with a decrease in mitochondria degradation 
independently of autophagy [102, 103]. An anti-apoptotic 
role of CatD has also been described under physiological 
conditions using CatD-deficient mice [43-45]. Indeed, mu-
tant mice developed apoptosis in the thymus, thalamus 
and retina. 
In summary, it is well documented that CatD plays an 
important role in apoptosis regulation, both with and 
without involvement of its proteolytic activity. However, 
the exact role of CatD in apoptosis, particularly what de-
termines whether this protease plays an anti- or pro-
apoptotic function remains poorly understood. In this re-
gard, a simpler model system would be particularly useful 
to offer additional clues into this dichotomy. 
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YEAST VACUOLAR PROTEASES 
The versatility of the yeast Saccharomyces cerevisiae to 
study several conserved cellular functions such as cell me-
tabolism, cell cycle, cell death and organelle biogenesis has 
justified the attractiveness of this system to study more 
complex mammalian physiological and pathological pro-
cesses [104-108]. Like other organelles, the yeast vacuole is 
functionally similar to its higher eukaryote counterpart, the 
lysosome. It harbors seven characterized proteases, name-
ly three aminopeptidases, three serine proteases and one 
aspartyl protease. Among these, two are endopeptidases: 
proteinase A (Pep4p), ortholog to human CatD, and pro-
teinase B (Prb1p). Five are exopeptidases: carboxypepti-
dase Y (CPY), ortholog to human CatA, carboxypeptidase S 
(CPS1), aminopeptidase I (Ape1) and Y (Ape3), and dipepti-
dylaminopeptidase B (Dap2).  
More recently, Hecht et al. reported an eighth vacuolar 
protease, a transmembrane metalloprotease (Pff1) [109], 
but although evidence of Pff1 vacuolar localization was 
shown, its proteolytic activity has yet to be demonstrated.  
The endopeptidases are responsible for the majority of 
bulk protein degradation, including of plasma membrane 
proteins. They are also fundamental for activation of the 
vacuolar proteolytic cascade, particularly Pep4p, since it is 
involved in proteolytic activation of Prb1p, CPY and Ape1 
[110, 111]. Prb1p, in turn, participates in the activation of 
Pep4p, CPY, CPS1, Ape1 and Ape3. Both carboxypeptidases 
and Ape1 are involved in peptide and glutathione degrada-
tion, respectively, but are not required for zymogen activa-
tion [111, 112].  
Substrates for the vacuolar proteases are mostly im-
ported via endocytosis (extracellular and cell surface pro-
teins) or autophagy (cytoplasmic material and organelles). 
Autophagy is activated under nutrient deprivation condi-
tions, and both Pep4p and Prb1p are implicated in the dis-
solution of autophagic bodies [113, 114].  
In addition, vacuolar proteases play a role in sporula-
tion. While absence of Prb1p activity alone results in partial 
reduction of sporulation, absence of Prb1p activity in a 
mutant lacking both CPY and CPS1 leads to almost com-
plete loss of sporulation ability [115]. In addition to ensur-
ing protein homeostasis under physiological conditions, 
vacuolar proteolysis therefore also appears to be a stress-
responsive process, particularly under nutrient stress con-
ditions and during sporulation. However, additional roles 
for vacuolar proteases have emerged in recent years, in 
particular for Pep4p. 
 
Pep4p PROTEASE - THE YEAST CATHEPSIN D 
Yeast CatD (Pep4p), like its lysosomal counterpart, is syn-
thesized as an inactive zymogen, traveling via the endo-
plasmic reticulum and Golgi to the acidic vacuoles, where it 
is activated through proteolytic removal of the inhibitory 
propeptide [116]. Although Pep4p is mainly located in the 
vacuole, different cell death stimuli can lead to its release 
to the cytosol, involving a selective vacuolar membrane 
permeabilization (VMP) typical of apoptotic death.  
Mason et al. were the first to report that Pep4p trans-
locates from the vacuole to the cytosol [117]. These au-
thors observed an increase in nuclear permeability associ-
ated with increased accumulation of reactive oxygen spe-
cies (ROS) during H2O2-induced cell death, and found that 
Pep4p is released into the cytosol and degrades nucleo-
porins during this process. However, Pep4p did not affect 
resistance to H2O2-induced cell death, probably because it 
migrates out of vacuoles after cells are effectively unviable. 
They further showed that the release of a Pep4p-EGFP 
(Enhanced Green Fluorescent Protein) fusion from the vac-
uole in H2O2-treated cells was not associated with major 
rupture of the vacuolar membrane, as cells maintained a 
vacuolar lumen morphologically distinct from the cytosol. 
Other authors reported that Pep4p is involved in protein 
degradation and removal of oxidized proteins during H2O2-
induced oxidative stress, but also did not ascribe a role for 
this protease in cell death induced by H2O2 [118].  
Another study showed that stabilization of the actin cy-
toskeleton caused by lack of the actin regulatory protein 
End3p leads to loss of mitochondrial membrane potential, 
accumulation of ROS, increase in VMP and consequent 
migration of Pep4p to the cytosol, as well as apoptotic cell 
death [119]. In that study, Pep4p-EGFP was visualized ex-
clusively in the vacuole lumen in wild type cells, but dis-
tributed throughout the entire cell in an END3-deficient 
strain. Again, no role was attributed to this protease in 
actin-stabilized dying cells.  
Pep4p is also involved in programmed nuclear destruc-
tion during yeast gametogenesis [120]. Using cells co-
expressing Pep4p-mCherry and Vma1-GFP, a GFP-tagged 
vacuolar membrane protein, Pep4p was shown to translo-
cate from the vacuole into the ascal compartment of early 
postmeiotic cells during sporulation, with preservation of 
vacuolar integrity.  
These observations show that VMP seems to mimic 
LMP in human cells. However, they do not indicate wheth-
er yeast vacuolar proteases play a role in cell survival and 
regulated death.  
In this regard, it has been shown that Pep4p has a pro-
survival role during chronological aging, since a Pep4p-
deficient mutant has a shortened lifespan associated with 
higher levels of carbonylated proteins [118]. Carmona-
Gutiérrez et al. further showed that deletion of PEP4 re-
sults in both apoptotic and necrotic cell death during 
chronological aging [121]. Using a panel of Pep4p mutants, 
they conclude that Pep4p plays a dual pro-survival role 
composed of both anti-apoptotic and anti-necrotic func-
tions, conferred by its proteolytic activity and its proteolyt-
ically inactive propeptide, respectively. We also previously 
found that Pep4p-EGFP translocates to the cytosol during 
acetic acid-induced apoptosis involving selective VMP in S. 
cerevisiae W303 cells, with preservation of both vacuolar 
and plasma membrane integrity [122]. Moreover, we 
demonstrated that Pep4p is required for increased cell 
survival and for efficient autophagy-independent mito-
chondrial degradation in response to this acid in a manner 
depending on its catalytic activity [122, 123]. This suggests 
that VMP associated with Pep4p release may act as an 
H. Pereira et al. (2015)  What can we learn from yeast about cathepsin D? 
 
 
OPEN ACCESS | www.microbialcell.com 229 Microbial Cell | July 2015 | Vol. 2 No. 7 
alternative mitochondrial degradation process, delaying 
cell death. In contrast, we recently demonstrated that ab-
sence of PEP4 resulted in increased resistance to acetic 
acid in S. cerevisiae BY4741 cells [124]. This prompted the 
hypothesis that Pep4p plays a dual function in acetic acid-
induced cell death depending on the genetic background, 
providing an interesting tool to explore the molecular de-
terminants of CatD function. 
 
YEAST AS A TOOL TO EXPLORE THE ROLE OF CATHEP-
SIN D IN APOPTOSIS AND CANCER 
It is widely established that the process of regulated cell 
death (RCD) involves a genetically encoded molecular ma-
chinery [125]. Core components of this machinery are con-
served in yeast, which can undergo RCD exhibiting typical 
markers of apoptosis, autophagy and necrosis [126-128]. 
Thus, this eukaryotic organism has been used extensively 
to study the molecular mechanisms of RCD pathways, re-
viewed elsewhere [126-129]. These studies encompass not 
only analysis of yeast endogenous death pathways but also 
heterologous expression of human proteins involved in 
apoptosis, such as caspases, Bcl-2 family proteins, PKC 
isoforms and the p53 tumor suppressor protein [130, 131]. 
As discussed above, the role of the lysosome-like vacu-
ole in the regulation of RCD has been investigated in yeast, 
where it has been shown to play a role similar to lysosomes 
[132, 133]. However, the use of this model organism to 
study lysosomal cell death pathways in general and ca-
thepsin function in particular is still underexplored. So far, 
only translocation of Pep4p to the cytosol during yeast 
apoptosis has been clearly demonstrated by different au-
thors [117, 119, 122]. One other study shows that the 
RNase T2 family member Rny1p is also released from the 
vacuole into the cytosol during oxidative stress, with 
preservation of vacuolar membrane integrity, directly 
promoting cell death [134]. The need for a comprehensive 
analysis of the VMP process and the vacuolar proteins re-
leased in response to different stimuli is therefore evident.  
Another approach that has not been sufficiently ex-
ploited is the heterologous expression of cathepsins in 
yeast. Two studies have shown that rat cathepsin L and D 
precursor polypeptides are recognized by mechanisms 
similar to those involved in the intracellular sorting of vac-
uolar proteins in yeast cells [135, 136]. We therefore 
sought to further explore this tool to understand the func-
tion of human CatD. As mentioned above, we previously 
 
 
 
FIGURE 1: Survival of S. cerevisiae cells expressing Bax during acetic acid treatment. The wild type W303-1A and pep4Δ mutant strains 
transformed with the empty vector (PYES2) and PYES2-Bax alpha were incubated with 120 mM acetic acid for up to 360 min. (A) Cell surviv-
al of W303-1A strain and (B) W303-1A pep4Δ strain for up to 360 min was determined by standard dilution plate counts and expressed as a 
percentage of c.f.u. in relation to time 0. Data represents means ± S.D. (n=2). (C) Cell survival at time 360 min was determined by standard 
dilution plate counts and expressed as a percentage of c.f.u. in relation to time 0. Data represents means ± S.D. (n=2). *P < 0.05, **P < 0.01, 
***P < 0.001. 
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showed the parallel between the role of human and yeast 
CatD in acetate/acetic acid-induced apoptosis and in the 
degradation of damaged mitochondria, which render 
CRC/yeast cells more resistant to apoptosis induced by 
acetate/acetic acid [102, 122]. We now found that heterol-
ogous expression of human CatD in yeast PEP4-deficient 
cells reverts their sensitivity to acetic acid-induced apopto-
sis and delays mitochondrial degradation [103], as previ-
ously observed for wild type Pep4p [122, 123]. These re-
sults provide evidence that the role of CatD in both apop-
tosis and mitochondrial degradation is conserved through 
evolution. Further elucidation of the molecular mecha-
nisms underlying the involvement of CatD in apoptosis and 
in mitochondrial degradation will now be crucial to devel-
op novel strategies to specifically inhibit this protease in 
apoptosis deficiency-associated diseases, such as cancer.  
Taking into account the multiple functions of CatD, one 
caveat of using CatD inhibitors could be a negative effect 
on Bax activation, release of cytochrome c and down-
stream caspase activation. To address this question, we 
exploited the well-established system of heterologous ex-
pression of Bax in yeast, which lacks obvious orthologs of 
the Bcl-2 family, and allows studying how absence of yeast 
CatD affects Bax activity without interference from other 
Bcl-2 family members. Using yeast cells heterologously 
expressing a cytosolic inactive form of human Bax, which 
was activated by exposure to acetic acid, we could discard 
this hypothesis since absence of Pep4p enhanced Bax-
induced cell death (Figure 1). It will be interesting to fur-
ther exploit this system with heterologous co-expression of 
Bax and human CatD, in order to dissect the role of this 
lysosomal protease in the regulation of Bax activity inde-
pendently of Bid. 
As a final conclusion, it becomes apparent that the ap-
proaches with yeast have already provided and can further 
offer new perspectives for an increased understanding of 
the role of CatD in mammalian apoptosis, and its implica-
tions in cancer. Indeed, studies with yeast further reinforce 
the use of this eukaryotic organism as a valuable model to 
identify and characterize novel RCD processes, and open 
the door to new clinical opportunities, with a substantial 
impact in public health. 
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Abstract     
Acetate is a short-chain fatty acid relevant in the regulation of colorectal cancer 
(CRC) cells survival. Monocarboxylate transporters (MCTs) have gained 
increased interest in cancer contributing to their metabolic phenotype and to the 
uptake of drugs such as 3-bromopyruvate (3BP). The mechanism by which 
acetate enters CRC cells is not well understood. Here, we aimed to investigate 
the mechanism of acetate transport as well as the role of acetate on MCTs 
expression and glucose metabolism. We further wanted to explore the use of 3BP 
and acetate as a possible therapeutic approach for CRC. 
Our results show that the transport of acetate occurs through the sodium 
dependent monocarboxylate transporter (SMCT-1) and by passive diffusion via 
aquaporins. MCT-1 is also involved in acetate uptake, indeed acetate increased 
the expression of MCT-1, MCT-4 and of the highly glycosylated CD147 
chaperone, promoting membrane re-localization of MCT-1 and changes in 
glucose metabolism. We further verified that 3BP potentiates acetate-induced 
apoptosis in CRC cells. Altogether we provide new evidences for the role of 
acetate in the regulation of MCTs expression and glycolytic profile, which 
influence acetate transport and increases the sensitivity of CRC cells to 3BP 
therapy. 
  
1. Introduction  
Colorectal cancer (CRC) is the most common malignancy and cause of cancer 
death in developed countries [1]. Dietary fiber and the gut microbial-derived short 
chain fatty acids (SCFA), namely acetate, propionate and butyrate, exert multiple 
beneficial effects on the colon energy metabolism [1-3]. SCFA are produced by 
colonic microbiota in a molar ratio of approximately 60:20:20 of acetate ˃ 
propionate ˃ butyrate respectively [4]. These microbial metabolites are a major 
source of energy for colonocytes, having the ability to prevent and inhibit colon 
carcinogenesis in vivo [1, 2]. We, and others, previously established that SCFA 
exert a role in the regulation of CRC cells survival [3, 5-8]. Indeed we showed 
that acetate inhibit cell proliferation, induce apoptosis and promote lysosomal 
membrane permeabilization with release of cathepsin D, which seems to protect 
CRC cells through an autophagy-independent degradation of damaged 
mitochondria [5, 8] 
Cancer cells, including CRC, exhibit profound metabolic adaptations, including 
the hyper-glycolytic phenotype which is characterized by production of high 
amounts of lactate, contributing to the acidification of the tumor microenvironment 
[9, 10]. MCTs (monocarboxylate transporters) have a central role in the 
maintenance of the cancer cell glycolytic metabolism, as lactate transporters as 
well as pH regulators [11, 12]. The MCT family is composed of 14 members [13], 
but only the first four (MCT-1, MCT-2, MCT-3 and MCT-4) have been 
demonstrated to catalyze the proton-linked transport of metabolically important 
monocarboxylates [11, 13]. MCT-1, MCT-2 and MCT-4 have been shown to be 
overexpressed in CRC cases [9, 14, 15], while SMCT-1 (sodium-linked) is usually 
silenced [16-19]. Interestingly MCT-1 and MCT-4, require the presence of a 
chaperone, CD147, which needs to be glycosylated to reach the plasma 
membrane [13, 20].  
SCFA exist almost entirely in their dissociated form in the colon and their 
transport across cell membranes may be dependent on a specific carrier protein 
[21]. Some mechanisms for SCFA absorption across the plasma membrane of 
colonocytes in various species have been postulated [7, 21-23]. SCFA seem to 
enter intestinal epithelial cells through passive diffusion of protonated SCFA or 
the transmembrane transport is mediated by monocarboxylate transporters 
(MCTs), especially SMCT-1 and MCT-1 [1, 23]. Studies regarding the 
involvement of MCTs in the transport of SCFA in CRC cells are scarce and 
contradictory. For instance MCT-1 was suggested to play a major role in transport 
of butyrate [1, 24, 25] but information on the transport of acetate or propionate is 
missing. Thus, additional studies are needed to understand the role of MCTs in 
SCFA transport, namely in the transport of acetate in CRC cells. 
The relevance of SCFA to normal human colon function has been well 
established namely as major energy source for colonocytes, as regulators of 
intracellular pH and in functions associated with ion absorption and gut motility of 
intestinal epithelial cells [23, 26]. Once absorbed, SCFA are converted by 
colonocytes into glucose, ketone bodies, and amino acids [24, 27]. They can also 
be used for de novo synthesis of lipids and glucose [2, 27, 28], but how SCFA, 
especially acetate, affect glucose metabolism of CRC cells is still elusive.  
MCTs are attractive targets in cancer therapy, as their elevated expression in 
cancer cells can mediate selectively the entry of chemotherapeutic agents into 
cancer cells [12]. 3-Bromopyruvate (3BP) is an anticancer compound that targets 
cancer cell metabolism presenting a high selectivity. 3BP activity is potentiated 
by butyrate in breast cancer cells through the increase of its uptake as 
consequence of an increase of MCTs expression [29, 30]. We described recently 
that 3BP uptake is mediated by MCT-1 in the presence of its glycosylated 
chaperone CD147, and that its selectivity towards cancer cells was dependent 
on the pH of acidic tumor microenvironment [31].  
Since acetate is the most relevant SCFA produced in the colon, we aimed to 
identify the mechanisms involved in its transport across the plasma membrane 
and the engagement of MCTs in such process. We further aimed to understand 
the role of acetate in the expression and localization of MCTs in CRC cells and 
in the glycolytic metabolism. We also intended to explore the combination of 3BP 
with acetate as a therapeutic strategy for CRC cells.  
 
2.  Material and Methods 
2.1 Material 
2.1.1 Reagents 
Acetic acid and HgCl2 were purchased from Merck. Radiolabelled [14C] acetate, 
with a specific activity of 55.2 mCi/mmol, was purchased from PerkinElmer. 
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), monensin, valinomycin 
and α-cyano-4-hydroxycinnamic acid (CHC) were purchased from Sigma. 4,4’-
Di-isothiocyano-2,2’-stilbenedisulfonic acid (DIDS) was obtained from Santa Cruz 
Biotechnology and AR-C155858 was a gift from AstraZeneca. 
 
2.1.2 Cell lines  
Human colorectal cancer (CRC) cell lines, RKOBRAFV600E and HCT-15 KRASG13D 
were cultured at 37 ºC under a humidified atmosphere containing 5% CO2. HCT-
15 cells were grown in RPMI (Biowest) medium with L-glutamine and HEPES. 
RKO cells were grown in DMEM (Biowest) with high-glucose and supplemented 
with 1 mM sodium pyruvate and 1.5 g/l sodium bicarbonate. All culture media 
were supplemented with 10% fetal bovine serum and 100 U/ml 
penicillin/streptomycin. Cells were seeded and adhered onto appropriate sterile 
plates for 24 hours before treatments in all experiments. 
 
2.2 Methods 
2.2.1 Measurement of acetate uptake 
The protocol for [14C] acetate uptake was adapted from Kobayashi et al. [32] as 
described in Azevedo-Silva et al. [31]. Briefly, cells were seeded in 24-well plates 
at 2–3×105 cells/well, incubated overnight at 37◦C with 5% CO2, washed twice 
and incubated with HEPES buffer (pH 7.4) for 10min at 37ºC. HEPES buffer was 
removed and cells were incubated in MES buffer (pH 6.0) with the radiolabelled 
[14C] acetate (4000 d.p.m./nmol) for the appropriate period of time at 37◦C. 
Afterwards, the [14C] acetate solution was removed, the plate was incubated on 
ice and the cultures washed with ice-cold HEPES buffer, pH 7.4. Cells were then 
solubilized with 1% SDS/0.2 M NaOH and mixed with scintillation liquid for 
measuring radioactivity in a Packard Tri-Carb 2200 CA liquid scintillation 
spectrophotometer with d.p.m. correction. For normalization, protein of all 
samples was quantified using a BCA Protein Assay Kit (Pierce). As [14C] acetate 
uptake was linear up to 5 min, 3 min of incubation of the cells with the 
radiolabelled substrate was adopted in the present study. The effect of distinct 
inhibitors AR-C155858, CHC, DIDS, CCCP, monensin, valinomycin and HgCl2 
was evaluated in cells incubated for 3 min with each compound in MES buffer, 
pH 6.0, prior to incubation with 1.0 mM [14C] acetate for 3 min.  
 
2.2.2 Preparation of total protein extracts and Western blotting 
Cells were seeded in 6-well plates and exposed to acetate for 48 hours: 45 mM, 
70 mM for HCT-15 and 75 mM, 110 mM for RKO cells (IC30 and IC50 acetate 
doses for both cell lines).  As negative control, cells with fresh medium were used. 
Cell lysis, total protein preparation and Western blotting were carried out as 
previously described [5] with 25 µg of total extracted proteins applied per lane 
before SDS-PAGE.  
The primary antibodies used were anti-MCT-1 (1:500, Santa Cruz 
Biotechnology), anti-MCT-2 (1:200, Santa Cruz Biotechnology), anti-MCT-4 
(1:500, Santa Cruz Biotechnology), anti-SMCT-1 (1:250, Santa Cruz 
Biotechnology), anti-CD147 (1:500, Santa Cruz Biotechnology), anti-GLUT 1 
(1:200, Abcam) and anti-actin (1:5000, Santa Cruz Biotechnology). Secondary 
antibodies used were peroxidase conjugated AffiniPure goat anti-rabbit IgG 
(Jackson ImmunoResearch, West Grove, PA, USA) and horseradish peroxidase-
labeled goat anti-mouse immunoglobulin IgG (Jackson ImmunoResearch). 
Subsequent chemiluminescence detection was performed using the ECL 
detection system (Amersham, Biosciences, Buckinghamshire, UK) and a 
molecular imager by Chemi-Doc XRS system (Bio-Rad, Laboratories Inc., 
Hercules, CA, USA). When performed, densitometry analysis of protein bands 
was performed using the Quantity One software (version 4.6.9) and levels of actin 
used as a normalization control for protein loading. 
 
2.2.3 Immunofluorescence microscopy analysis 
Cells were seeded in 12-well plates containing glass coverslips and exposed to 
acetate for 48 hours (IC30 and IC50 acetate doses for both cell lines). As negative 
control, cells with fresh medium were used. At the end of the experiment, cells 
were washed with 1x PBS and fixed with 4% paraformaldehyde for 15 min at RT. 
Then, coverslips were washed in 1x PBS and permeabilised with 0,1% Triton X-
100 in 1x PBS for 2 min. After this, coverslips were washed in 1x PBS and blocked 
with 5% BSA for 30 min. Coverslips were incubated with anti-MCT-1 (1:250, 
Santa Cruz Biotechnology) or anti-MCT-4 (1:500, Santa Cruz Biotechnology) or 
anti-CD147 (1:250, Santa Cruz Biotechnology) diluted in 5% BSA, overnight. At 
the end, coverslips were washed twice with 1x PBS and incubated with 
fluorescence anti-rabbit (for MCT-4, 1:500, Alexa Fluor® 488, Invitrogen A-
11008) and fluorescence anti-mouse (MCT-1 and CD147, 1:250, Alexa Fluor® 
594, Invitrogen A-11032) for 1 h. So, the coverslips were washed twice with 1x 
PBS and finally mounted on Vectashield Mounting Medium with DAPI and 
immediately observed under the fluorescence microscope (Olympus BX61 
fluorescence microscope, Tokyo, Japan). Three coverslips were prepared for 
each experimental condition and representative images are shown. 
 
2.2.4 Glucose consumption and lactate production assays 
Cells cultured in 48-well plates were pre-incubated in glucose-free media for 2 h. 
Then, cells were washed with 1x PBS and incubated with the doses of acetate - 
IC30 and IC50, as mentioned before). Non-treated cells (negative control) or 
exposed to acetate concentrations were analyzed. After incubation, conditioned 
medium was collected at 3, 6, 12, 24 and 48 hours. Glucose consumption and 
extracellular lactate were measured by the enzymatic colorimetric kits: Glucose 
Assay Kit (Roche, Mannheim, Germany) and Lactate Assay kit (SpinReact, Sant 
Esteve de Bas, Girona, Spain), following the manufacturer’s instructions. Glucose 
and lactate fluorescence intensity were detected with absorbance emission at 
490 nm using a fluorescence microplate reader. Values are expressed as the 
mean of fluorescence intensity normalized to T0 (control for glucose and lactate 
levels before the treatment with acetate) and the cell biomass for each condition 
(by Sulforhodamine (SRB) assay). The SRB protocol was performed as 
previously described [5]. 
 
2.2.5 Cell treatments with acetate and 3-bromopyruvate (3BP) 
Cells were treated during 48 hours, using the concentration (IC) of acetate 
previously determined [5]: 45 mM, 70 mM, for HCT-15 and 75 mM, 110 mM for 
RKO cell lines (values for the IC30 and IC50, respectively). The concentrations of 
3-bromopyruvate (3BP) used (17,5 µM, 35 µM and 75 µM, 150 µM; IC25 and IC50, 
respectively for HCT-15 and RKO cells) in the assay were calculated from the 
mean values obtained in the SRB assays. For the assays with acetate and 3BP, 
the 3BP was co-incubated 16 hours before completing 48 hours of acetate 
treatment.  
 
2.2.6 Cell proliferation assay using Sulforhodamine (SRB) 
Cells were seeded in 24-well before the treatments. Cells were incubated 48 
hours with 70 mM and 110 mM (IC50 acetate for HCT-15 and RKO cells, 
respectively) with and without 16 h of 3BP co-incubation. In these assays, the 
3BP IC25 and IC50 values were used for each cell line (as described above). 
H2O2 (500 M or 1 mM for HCT-15 or RKO cell lines, respectively) was used as 
positive control. The protocol preparation was performed as previously described 
[5]. All samples were measured in triplicates and the values were expressed 
relative to the negative control (cells incubated only with fresh completed 
medium). 
 
2.2.7 Assessment of cell proliferation by colony formation assay (CFA) 
Cells were seeded in 6-well plates at 600 cells/mL, 300 cells/mL (respectively for 
HCT-15 and RKO cell lines) and incubated 24 h at 37º C with 5% CO2 before the 
treatments. Cells were treated as described for the SRB assay (the same 
conditions). After 48 hours of treatment, the medium was replaced by fresh 
medium twice per week during 14 days. To evaluate the colony numbers formed 
for each condition, the cells were washed with 1x PBS and then fixed with 6% 
glutaraldehyde/0.5% crystal violet solution for 30 min, at room temperature (RT). 
The cells were then washed with water and air-dried.  
 
2.2.8 Analysis of apoptosis by flow cytometry 
Cells were seeded in 6-well plates and the percentage of cells undergoing 
apoptosis after 48 h of acetate treatment was determined using Annexin-V FITC 
(AV) (BD Biosciences) and Propidium iodide (PI) (Sigma Aldrich). Both CRC cell 
lines, with and without 16 h of 3BP co-incubation, were exposed to acetate (IC50). 
As negative control we used cells incubated with fresh medium and H2O2 as 
positive control (500 uM and 1 mM for HCT-15 and RKO cell lines, respectively). 
Both floating and attached cells were collected and prepared as described 
previously by us [5] and then analyzed by flow cytometry. Cell viability and cell 
death was assessed by double staining with Annexin-V FITC/ PI. Unstained and 
stained cells were classified as follows: viable cells (AV-/PI-), early apoptotic cells 
(AV+/PI-), late apoptotic cells (AV+/PI+) or necrotic cells (AV-/PI+). 
 
2.2.9 Statistical analysis 
Kinetic parameters were determined using GraphPad for the non-linear 
regression of the values of the initial uptake rates of acetate as a function of the 
acid concentration. Other statistical significance analyses were determined by 
two-way ANOVA or by one-way ANOVA followed by Dunnett or Bonferroni’s test 
for multiple comparisons using Prism software version 6 (GraphPad La Jolla, CA, 
USA). All results are presented as mean ± standard deviation (SD) of three 
independent experiments. Differences were considered significant for P values 
lower than 0.05. 
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3. Results 
3.1 Kinetics and energetics of acetate uptake across the plasma membrane 
of CRC cells 
The initial uptake rates of [14C] acetate were evaluated at pH 6.0 in HCT-15 and 
RKO cell lines (Figure 1a and b). The non-linear regression analysis shows that 
HCT-15 cells transport acetate follows a second order kinetics with an affinity 
constant (Km) of 1.97 ± 0.57 mM and a transport capacity (Vmax) of 62 ± 9 nmol/mg 
of protein/min. In RKO cells, acetate follows a first order kinetics with a diffusion 
constant of 5.19 ± 0.16 µL/mg of protein/min.  
To evaluate the energetics of [14C] acetate transport we tested the influence of 
agents known to disrupt different ion membrane electrochemical potentials 
(Figure 1c), such as CCCP (a protonophore which disrupts both the pH and the 
electric potentials), monensin (an ionophore that specifically disrupts a Na+ 
gradient) and valinomycin (an ionophore which preferentially affects a K+ gradient 
and, to a lesser extent, a Na+ gradient across biological membranes). We also 
tested the inhibition of acetate transport using monocarboxylate transporters 
(MCTs) inhibitors such as CHC (inhibitor of MCT-1 and SMCT-1), DIDS (inhibitor 
of MCTs and anion exchangers) and AR-C155858 (specific inhibitor of MCT-1 
and MCT-2). We also used HgCl2, which is described as an inhibitor of aquaporin 
activity [33, 34]. Our results showed that CCCP inhibited significantly acetate 
transport in both HCT-15 (71%) and RKO (52%) cells; monensin also inhibited 
acetate uptake in HCT-15 (78%) and RKO (36%) and valinomycin presented only 
a small inhibitory effect in both cell lines (22% inhibition in HCT-15 and 21% in 
RKO cells). Regarding MCT inhibitors, CHC inhibited both HCT-15 (30%) and 
RKO cells (35%) but DIDS and AR-C155858 did not prevent acetate uptake. 
Interestingly, HgCl2 (aquaporin inhibitor) inhibited acetate uptake in HCT-15 
(51%) and RKO (56%) cells indicating the contribution of aquaporins in acetate 
diffusion into CRC cells. 
We further investigated if this inhibition was independent of the inhibition detected 
for CCCP or monensin. HCT-15 and RKO cells were used to evaluate the 
inhibition of acetate uptake using double combinations of CCCP (1 µM), HgCl2 (5 
µM) and monensin (20 µM) (Figure 2a and b). However, in these assays lower 
concentrations than described above were used. We verified that in HCT-15 cells 
CCCP inhibited 34%, HgCl2 37% and monensin 69% of acetate transport. 
Combination of CCCP and HgCl2 resulted in a 56% inhibition of acetate uptake, 
HgCl2 and monensin in 76%, and CCCP with monensin inhibited 75%. In RKO 
cells acetate uptake was inhibited in 37% with CCCP, 28% with HgCl2 and 68% 
with monensin. Combination of CCCP with HgCl2 and monensin with HgCl2 
resulted in 46% inhibition of acetate transport while CCCP with monensin 
inhibited 81%.  
In conclusion, these results point for the involvement of at least two mechanisms 
of transport in CRC cells: a secondary active transport dependent on 
electrochemical Na+ gradient and diffusion mediated by aquaporins. 
 
 
Figure 1: Characterization of acetate uptake in CRC cells.  (a) and (b) Plots of the initial uptake 
rates of labeled acetate, as a function of the acid concentration at pH 6.0 in HCT-15 and RKO, 
respectively. Kinetic parameters, as affinity constant (Km) and transport capacity (Vmax) or 
Diffusion constant (Kd) for the uptake of acetate were based on the non-linear regression for the 
Michaelis-Menten equation f [V]=(Vmax x [Acetate])/(Km + [Acetate]) and Passive diffusion 
equation f[V] = Kd.[Acetate]. In HCT-15 a transporter system exists with a Km of 1.97 ± 0.57 mM 
and a Vmax of 62 ± 9 nmol/ mg of protein/ min. In RKO acetate enters cells by passive diffusion 
with a Kd of 5.19 ± 0.16. (c) Effect of CCCP (100 µM), Monensin (100 µM), Valinomycin (100 µM), 
AR-C155858 (1 µM), CHC (10 mM), DIDS (1 mM) and HgCl2 (100 µM) in the uptake of 1 mM of 
acetate. Statistical analysis was performed by two-way ANOVA: ***, ** and * indicate significant 
differences with a respective P-values of <0.001, <0.01 and <0.05 (n=3).  
 
 Figure 2: Inhibition of 1 mM of acetate uptake by CCCP (1 µM), HgCl2 (5 µM) and Monensin 
(20 µM) alone or in combination in HCT-15 (a) and RKO (b) cells. Statistical analysis was 
performed by two-way ANOVA: ***, ** and * indicate significant differences with a respective P-
values of <0.001, <0.01 and <0.05 (n=3).  
 
 
 
 
 
3.2 Acetate pre-treatment alters the kinetics and the energetics of acetate 
uptake by CRC cells  
To evaluate if acetate treatment could influence the kinetics and energetics of 
acetate, we tested the influence of CCCP, monensin, AR-C155858 and HgCl2 in 
the uptake of 1 mM of acetate in cells treated with IC30 of acetate for 48h (Figure 
3). Untreated cells of HCT-15 and RKO cell lines behaved as expected with 
acetate transport being inhibited with CCCP (HCT-15: 54%; RKO: 62%), 
monensin (HCT-15: 60%; RKO: 59%) and HgCl2 (HCT-15: 51%; RKO: 56%) but 
not with AR-C155858. Cell treated with the IC30 of acetate for 48 hours also 
presented inhibition for acetate uptake using CCCP (HCT-15: 52%; RKO: 53%), 
monensin (HCT-15: 60%; RKO: 38%) and HgCl2 (HCT-15: 60%; RKO: 55%). 
Acetate transport in HCT-15 (29%) and RKO (23%) cells treated with acetate was 
significantly inhibited by AR-C155858. These results led us to conclude that in 
cells treated with acetate, MCT-1, besides other transport mechanisms described 
above, is also involved in acetate transport. 
 
3.3 Acetate upregulates MCT-1, MCT-4 and CD147 expression in CRC cells  
We wanted to study if acetate influences the expression of MCTs as it was 
already reported by us for butyrate in breast cancer cells [30, 31]. We assessed 
the expression profile for the SMCT-1, MCT-1, MCT-2, MCT-4 and the chaperone 
CD147 (an important protein for MCT activity) in response to acetate by western 
blot analysis of cell extracts (Figure 4). We analyzed CRC cells treated with both 
IC30 and IC50 acetate doses (45 mM and 70 mM; 75 mM and 110 mM, respectively 
for HCT-15 and RKO) after 24 and 48 hours of incubation. We found that both 
CRC cell lines express SMCT-1 and MCT-2 but no difference in expression after 
acetate treatment was observed in both cell lines. We found an elevated 
expression of MCT-1 and MCT-4 after 48 hours but not after 24 hours acetate 
treatment in both cell lines compared to the negative control (Figure 4). The 
increase of MCT-1 and MCT-4 expression was accompanied by an increased 
expression of the chaperone cluster of differentiation (CD)147, important for 
MCT-1 and MCT-4 activity. The chaperone CD147, was present in both fully (FG) 
and core-glycosylated forms in both CRC cell lines after 48 hours of acetate 
treatment compared to the negative control. 
A higher level of CD147 expression was observed in RKO compared to HCT-15 
cells (Figure 4). We also evaluated the expression of GLUT-1 after acetate 
treatment. GLUT-1 is responsible for basal glucose transport across the plasma 
membrane into the cytosol in many cancer cells [35]. We observed that both cells 
expressed GLUT-1 transporter, but no difference in the expression of this 
transporter was observed after acetate treatment. Our results suggest that 
acetate regulates MCT-1, MCT-4 and CD147 expression in CRC cells. 
 
 
 
Figure 3: Inhibition of acetate (1 mM) uptake in HCT-15 and RKO cell lines treated with IC30 
of acetate for 48h with CCCP (100 µM), Monensin (100 µM), AR-C155858 (1 µM) and HgCl2 
(100 µM). Statistical analysis was performed by two-way ANOVA: ***, ** and * indicate significant 
differences with a respective P -values of <0.001, <0.01 and <0.05 (n=3).  
 
 Figure 4: Characterization of MCTs expression and other glycolytic markers in CRC cells 
after acetate treatment. HCT-15 and RKO cells were incubated with acetate (45 mM and 70 mM 
for HCT-15 cells; 75 mM and 110 mM for RKO cells, respective doses for the IC30 and IC50) or 
with fresh medium (as negative control) for 24 and 48 hours. Western blotting images of the 
SMCT-1, MCT-1, MCT-2, MCT-4, CD147 and GLUT-1 expression. β-actin was used as loading 
control. A representative experiment of at least three independent experiments is shown. 
 
 
 
3.4 Acetate induces MCT-1 plasma membrane localization in CRC cells  
We analyzed by immunofluorescence the cellular localization changes induced 
by acetate in MCT-1, MCT-4 and CD147. CRC cells were treated with acetate 
IC30 and IC50 doses during 48 hours, as described above for immunodetection. In 
agreement with the western blot analysis we could observe that acetate treatment 
leads to an elevated expression of these transporters and an increase in MCT-1 
localization at the plasma membrane in comparison to the cytoplasm in both cell 
lines (Figure 5), being more evident in HCT-15 than in RKO cells. Moreover, we 
found no differences between MCT-4 and CD147 co-localization after acetate 
treatment. Our results suggest that acetate treatment (in physiological 
concentrations) induces MCT-1 plasma membrane localization, which might 
explain that the plasma membrane transport of acetate also occurs by MCT-1 in 
CRC cells. 
  
Figure 5: Localization of MCT-1, MCT-4 and CD147 in CRC cells after acetate treatment. 
HCT-15 and RKO cells were incubated with acetate (45 mM and 70 mM for HCT-15 cells; 75 mM 
and 110 mM for RKO cells, respective doses for the IC30 and IC50) or with fresh medium (as 
negative control) for 48 hours. Representative images of immunofluorescence are shown (400× 
magnification). 
 
 
 3.5 Acetate treatment induces changes in the glycolytic metabolic profile 
in CRC cells 
MCTs are known to be overexpressed in cancer cells to maintain high glycolytic 
rates by performing lactate efflux from glycolysis as well as pH regulation by the 
co-transport of protons [9]. Herein, we showed that acetate increases MCT-1 
localization at the plasma membrane upon acetate treatment being accompanied 
by an increase in MCT-1, MCT-4 and CD147 expression. We therefore wonder if 
acetate might induce metabolic changes like glucose consumption and lactate 
production. To test this hypothesis, CRC cell lines were exposed to IC30 and IC50 
doses of acetate and the relative rate of glucose consumption and extracellular 
lactate production were measured at 3, 6, 12, 24 and 48 hours in triplicate and 
normalized to T0 (amount of glucose and lactate at time 0) and to cell biomass 
(by SRB assay). We found that CRC cells in response to acetate, exhibited a 
higher consumption of glucose (p ˂ 0.05) and lactate production (p ˂ 0.05; p ˂ 
0.01) up to 24 hours in a dose-dependent manner and then significantly 
decreased at 48 hours (Figure 6). RKO cells appear to be more glycolytic than 
HCT-15 cells since they exhibited a higher consumption of glucose (p ˂  0.01) and 
lactate production up to 12 hours after acetate treatment. 
Glycolytic metabolism is a well-known characteristic of cancer cells which 
contributes to their aggressive phenotype, such as increased proliferation, 
suppression of anti-cancer immune response, invasion, angiogenesis and 
metastasis [36, 37]. Our results indicate that there is an increase in the glycolytic 
metabolism in response to short incubation periods of acetate, although after 48 
hours of treatment, acetate induces a significant decrease in the glycolytic 
metabolism of CRC cells. 
 
3.6 3BP potentiates acetate-induced apoptosis 
It has been demonstrated that cancer cells exhibit the Warburg effect switching 
their metabolism to anaerobic glycolysis, characterized by glucose conversion 
into lactate even in the presence of oxygen [38]. Regarding our results on the 
metabolic profile and the elevated expression of MCT-1 and MCT-4 in CRC cells 
after acetate treatment we decided to study the effect of 3-bromopyruvate (3BP) 
in combination with acetate. 3BP is a small molecule analogue of lactate and 
pyruvate that acts as a glycolysis inhibitor and which is transported by MCTs in 
cancer cells [29, 31, 39]. It was previously described by us the capability of 
butyrate to sensitize breast cancer cells to 3BP by increasing the expression and 
activity of MCTs [30, 31]. Our present results indicate that acetate have a similar 
effect in CRC cells regarding the expression of MCTs and thus we hypothesize 
that acetate could also sensitize these cells to 3BP. 
To test this hypothesis, we used the colony formation assay (CFA) to analyze 
CRC cells treated with IC25 and IC50 values for the 3BP (17,5 µM, 35 µM and 75 
µM, 150 µM, respectively for HCT-15 and RKO cells) alone or in combination with 
acetate treatment (only with the IC50 value for acetate: 70 mM, for HCT-15 and 
110 mM for RKO cell lines) after 48 hours of incubation. We found that the 
combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of acetate) 
decreases cell proliferation (number of colonies formed) in both CRC cell lines in 
a 3BP dose-dependent manner in comparison to the negative control and to the 
same dose of 3BP or acetate alone (Figure 7a). The effect of the combined 
treatment was more evident in RKO cells compared to HCT15 cells.   
Analysis of cell proliferation by SRB assay (Figure 7b) showed that IC25 and IC50 
of 3BP reduced proliferation of HCT-15 and RKO cell being only significant with 
IC50 of 3BP. In addition, we found that combination of IC25 of 3BP/ IC50 of acetate 
and IC50 of 3BP/IC50 of acetate also reduced cell proliferation in both cell lines 
with a significant difference compared to the negative control. We also observed 
a significant difference between acetate treatment alone compared with the 
3BP+acetate combination in both CRC cell lines (p ˂ 0.01 and p ˂ 0.0001), being 
more evident in RKO cells as reported previously. 
We next analyzed cell death through AV/PI staining (Figure 7c) and found that 
the number of apoptotic (early and late) cells stained with AV (AV + PI - plus AV 
+ PI +) were 11%, 13% and 7% for IC25 of 3BP, IC50 of 3BP and IC50 of acetate, 
respectively for HCT-15 cells in comparison to 3% in the negative control.  In 
RKO cells the levels of apoptotic cells stained with AV were 4%, 13% and 18% 
for IC25 of 3BP, IC50 of 3BP and IC50 of acetate, respectively in comparison to 2% 
in the negative control. In addition, the treatment with 3BP alone induces a 
significant increase (p ˂ 0.05 and p ˂ 0.01) in cells stained with AV – PI + in a 
dose-dependent manner in both CRC cells. We could observe that the combined 
treatment of 3BP and acetate (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of 
acetate) potentiates apoptosis, as the number of cells stained with AV + PI - and 
AV + PI + showed a significant increase comparing with acetate alone (p ˂ 0.01 
and p ˂ 0.001) in both CRC cells, being more evident in RKO cells. In summary, 
our results show that the combination treatments (acetate in physiologic 
concentration + 3BP) potentiate apoptosis in CRC cells.  
 
 
 
 
 
 
Figure 6: Acetate induces metabolic changes in CRC cells. HCT-15 and RKO cells were 
incubated with acetate (45 mM and 70 mM for HCT-15 cells; 75 mM and 110 mM for RKO cells, 
respective doses for the IC30 and IC50) or with fresh medium (as negative control). Extracellular 
amounts of glucose consumption and lactate production overtimes 3, 6, 12, 24 and 48 hours are 
shown. Values are expressed as mean ± SD of at least three independent experiments. *P ≤ 0.05, 
**P ≤ 0.01 and ***P ≤ 0.001 compared with control cells and # P ≤ 0.05, ## P ≤ 0.01 and ### P ≤ 
0.001 comparing acetate treatment at 24 h with acetate treatment at 48 h. 
 
 
 
 
 
 
 Figure 7: Effect of acetate with 3-bromopyruvate (3BP; a glycolysis inhibitor) in CRC cells. 
(a, b and c) CRC cells were treated with IC25 and IC50 values for the 3BP (17,5 uM, 35 uM and 
75 uM, 150 uM, respectively for HCT-15 and RKO cells). The treatments were performed with 
3BP alone or with acetate treatment combination (only the IC50 value for the acetate: 70 mM for 
HCT-15 and 110 mM for RKO cell line) after 48 h of incubation. 3BP was added 16 hours before 
to complete 48 hours of the treatment. As negative control, cells were treated with fresh medium. 
H2O2 (500 uM or 1 mM for HCT-15 or RKO cell lines, respectively) was used as positive control. 
(a) Colony formation assay shows that the combined treatment (IC25 of 3BP/IC50 of acetate and 
IC50 of 3BP/IC50 of acetate) decreases cell proliferation (number of colony formed at the end of 
the assay) in both CRC cell lines in a dose-dependent manner compared to the negative control 
and with the same dose of the 3BP or acetate alone. (b) Sulforhodamine B (SRB) assay analyzes 
the cell proliferation of the same conditions. Values represent mean ± SD of at least three 
independent experiments. **P ≤ 0.01, ***P ≤ 0.001 and ***P ≤ 0.0001 compared with negative 
control cells and ## P ≤ 0.01 and #### P ≤ 0.0001 comparing acetate alone with combined 
treatment (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of acetate). (c) Quantitative analysis 
of AV/PI staining in HCT-15 and RKO cells. Values represent mean ± SD (AV – PI -, AV + PI -, 
AV + PI + and AV – PI +) of each condition (n=3). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ***P ≤ 
0.0001 compared with negative control cells and ## P ≤ 0.01 and #### P ≤ 0.0001 comparing 
acetate alone with combined treatment (IC25 of 3BP/IC50 of acetate and IC50 of 3BP/IC50 of 
acetate). 
 
 
 
4. Discussion  
Acetate is a monocarboxylic acid, which figures among the most abundant SCFA 
in the human organism and is absorbed at the intestinal level being able to reach 
distant organs [2, 40]. Acetate transport across biological membranes in the colon 
model is not well understood, thus here we deepen the study of the kinetics and 
energetics of acetate transport across CRC cells. Our results indicate the 
participation of sodium dependent transporters such as SMCT-1 or anion-
exchangers (AE-1 for example) in the uptake of acetate in CRC cells. These 
results are in accordance with several reports showing that SMCT-1 transport 
monocarboxylic acids such as butyrate, 3BP and dichloroacetate in cancer cells 
[18, 19, 41] and it has also been described that anion-exchangers might be 
involved in acetate transport in HT29-18-C1, a CRC cell line [42]. 
Our results also show that at pH 6.0 (similar to the gut environment) acetate 
transport across CRC cells membrane occurs preferentially via a sodium-
dependent mechanism possibly by SMCT-1. Indeed this is in agreement to the 
fact that monocarboxylate transport family members (MCT 1-4) are proton 
symporters, involved in the uptake and/or efflux of pyruvate, lactate, ketone 
bodies and SCFA through the plasma membrane [9, 23]. The literature on acetate 
transport is scarce and little is known about SCFA transport mediated by MCTs 
in CRC cells, being that the majority of the studies use butyrate as model to study 
SCFA transport, both in normal intestinal epithelial and CRC cells [1, 16, 24].  In 
this regard, some studies demonstrated that butyrate can be transported into 
colon cancer cells mainly by MCT-1 [1, 24, 25]. It has also been reported that 
MCT-1 is responsible for acetate transport in mouse cancer cells with an affinity 
constant of 3.7 mM [43]. Herein we showed for the first time that MCT-1 
participates actively in the transport of acetate into CRC cells. 
Interestingly our data suggest that other transport mechanisms such as passive 
diffusion through aquaporins might also contribute to acetate uptake. Aquaporins 
are important membrane proteins for cellular homeostasis, being known to be 
upregulated in different types of cancer including CRC [44], suggesting their 
capacity to transport not only water but other compounds. To the best of our 
knowledge, this is also the first report suggesting that aquaporins might play a 
novel role in acetate transport in colorectal cancer.   
Acetate is an important messenger in the symbiotic relationship between 
intestinal microbiota and colonocytes and is thus predictable that may play an 
important role in the regulation of transporters expression and metabolism of 
colon human cells [2, 40]. These issues are poorly understood and needed further 
understanding namely in CRC cells. Our data suggest that acetate might interfere 
with MCT-1 expression and with its cellular localization influencing the total 
acetate uptake/transport. Accordingly, it has been reported that butyrate and 
other SCFA, may modulate cell behavior by activation of several specific proteins 
depending of concentration and cell models used [2, 24, 45]. 
Despite the controversy in the literature concerning MCT expression in CRC, it 
has been shown that MCTs (especially MCT-1, MCT-2 and MCT-4) are usually 
upregulated in CRC tumors compared to normal epithelium samples [9, 14, 15]. 
We have previously shown that butyrate led to an increase in MCT-1, MCT-4 and 
CD147 expression with an increased localization of MCT-1 expression at the 
plasma membrane in breast cancer cells [30, 31]. Our results on CRC cells 
demonstrated that acetate is also capable of inducing the expression of MCT-1, 
MCT-4 and CD147 with an increase in plasma membrane localization of MCT-1. 
Our observations suggest that MCT-1 might be involved in acetate transport 
across the membrane by regulating MCT-1 expression and activation at the 
plasma membrane. 
The mechanisms involved in the regulation of MCTs in CRC cells in response to 
SCFA (especially acetate), are not well clarified, being the majority of the reports 
focused in the role of butyrate in CRC cells [1, 16, 24, 25]. Some studies have 
reported that MCT-1, MCT-4, MCT-5 and MCT-6 isoforms are also expressed in 
CRC cells [24]. In this regard, it has been shown that upon butyrate treatment, 
MCT-1 is the most abundant MCT isoform expressed in Caco-2, a CRC derived 
cell line [24]. Furthermore, some investigators have shown that SMCT-1 was 
silenced by DNA methylation in CRC cells [1, 16, 18, 19], which conferred a 
selective advantage to escape butyrate-induced cell death [16, 17]. Taking into 
account our results, we cannot exclude the involvement of SMCT-1 as the Na+-
linked symporter for acetate in CRC cells, since SMCT-1 was expressed after 
acetate treatment in CRC cells. To the best of our knowledge, this is the first 
report showing that the SCFA acetate leads to an increase in MCTs expression 
and to a cellular re-localization of MCT-1 in CRC cells. Our results put forward a 
possible regulatory role of acetate at both MCT-1 expression and localization in 
CRC cells, similarly to what was described by us with butyrate in breast cancer 
cells [31]. 
Our data also show that MCT-1 re-localization to the plasma membrane is 
associated with increased expression of MCT-1 and CD147 in response to 
acetate treatment. Indeed it has been described that MCT-1 and MCT-4 require 
the presence of CD147, for proper localization and function [13].  
MCT-4 expression has been associated with highly glycolytic tissues (including 
CRC), where it is essentially responsible for lactate efflux [9, 12]. We observed 
an elevated MCT-4 expression after 48 hours of acetate treatment that can be 
related with the increased glucose consumption and lactate production upon 24h 
of acetate treatment in CRC cells. Our findings are in agreement with Matthews 
and co-workers, which described that butyrate and propionate, alone or in 
combination, significantly increased glucose consumption at 24 hours with a 
considerable decrease 48 hours after treatment [6]. The authors explained the 
increased rate in glucose consumption as a way to provide energy efficiently and 
then the decreased rate in glucose consumption associated with the use of 
butyrate as second source of energy in CRC cells [6].  
It is known that CRC cells use 30 to 40 times more glucose for energy metabolism 
than normal colon cells [25]. As glucose becomes the primary source in CRC 
cells, we also evaluated the expression of GLUT-1, the main glucose transporter 
detected in colorectal cancer tissues [25, 36, 46]. Interestingly, we found that both 
CRC cells express GLUT-1 but the levels remain unchanged after acetate 
treatment over the time. Therefore the decrease in glucose consumption is not 
due to a decrease uptake and further studies are required to assess whether it 
relates to inhibition of the glycolytic flux as already reported in yeast in response 
to acetic acid [47].  
It is known that cancer cells usually express high levels of MCTs to maintain a 
highly glycolytic profile and an appropriate pH environment essential for tumor 
growth. MCTs became attractive targets in cancer therapy, especially in cancer 
with a hyper-glycolytic phenotype [11, 12]. Furthermore, MCTs can also be seen 
as Trojan horses and recent reports have demonstrated that MCTs are also 
involved in the transport of drugs such as 3BP [31, 39]. In this case, the elevated 
MCT expression is used to mediate the entry of the chemotherapeutic agent 3BP 
into the cells and then selectively kill cancer cells [12, 31]. 3BP is an anti-cancer 
agent that targets energy metabolism of cancer cells [31]. Our results showed 
that the combination of acetate and 3BP potentiates the effect of acetate or 3BP 
alone in cell proliferation inhibition and apoptosis induction in CRC cells. This 
result is in agreement with our previous data showing that butyrate also sensitize 
breast cancer cancer cells to 3BP treatment [30, 31].  
Summing up, here we show that acetate uptake involves at least two mechanisms 
of transport in CRC cells: mediated by MCTs and diffusion by aquaporins. Indeed, 
acetate induces changes in glycolytic metabolism, upregulation of MCT-1, MCT-
4 and CD147 and plasma membrane localization of MCT-1. These findings may 
provide a novel strategy for CRC therapy based on the elimination of CRC cells 
in the presence of acetate through their sensitization by 3BP or other glycolytic 
metabolism inhibitor whose transport is mediated by MCTs. 
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Abstract 
In Western societies, colorectal cancer (CRC) is a major cause of cancer-related 
death, the majority being CRC sporadic cases. These cases are rapidly 
increasing in developed countries, especially among populations that are 
adopting Western-style diets. Additionally, the environment, a sedentary 
lifestyle, medication, stress and intestinal diseases also influence the incidence 
of sporadic CRC. These risk factors are associated with alterations in the 
intestinal microbiota, accompanied by an increase of the colon pH due a 
decreased production of short chain fatty acids (SCFAs), influencing colorectal 
carcinogenesis. In this regard, many epidemiological studies have suggested 
the manipulation of colon microbiota, through the use of probiotics. These 
agents be used in the colorectal cancer prevention/treatment due to their ability 
to produce SCFAs, known as anti-neoplastic agents in CRC cells. In this review, 
we will describe the normal colon microbiota environment and its changes in 
CRC, as well as the concentration of SCFAs and the physiological effects these 
metabolites in the normal colon. Furthermore, we will focus on the anti-
neoplastic role of SCFAs, especially butyrate, propionate and acetate in CRC 
cells to discuss how a probiotic rich diet could improve the amount of SCFAs in 
the colon and provide one strategy to prevent or treat CRC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Normal colon microbiota and short-chain fatty acids 
The human intestine harbours as many as 1012 microorganisms from 500 - 1000 
different bacterial species, described by their variation in 16S ribosomal RNA 
genes (Sobhani, Amiot et al. 2013; Zeng, Lazarova et al. 2014; Cipe, Idiz et al. 
2015). Several studies have proposed that the normal human microbiota is 
formed mainly by strict anaerobes, such as Bacteroides, Eubacterium, 
Bifidobacterium, Fusobacterium, Peptostreptococcus, and Atopobium (Neish 
2009; Tiihonen, Ouwehand et al. 2010; Liu, Cao et al. 2013), representative of 
2 main divisions: Bacterodeites and Firmicutes (Neish 2009; Tiihonen, 
Ouwehand et al. 2010; Holmes, Li et al. 2011; Liu, Cao et al. 2013; Zeng, 
Lazarova et al. 2014). Proteobacteria, Actinobacteria, Fusobacteria and 
Verrucomicrobia were also found, but in minor proportions (Liu, Cao et al. 2013; 
Zeng, Lazarova et al. 2014). It is known that the intestinal microbiota is a very 
complex system with numerous beneficial roles to human health, including 
protection against pathogens, immune system maturation, degradation of toxic 
substances, digestion of complex carbohydrates and production of short-chain 
fatty acids (SCFAs) (Holmes, Li et al. 2011; Russell, Hoyles et al. 2013). 
In this case, although the main SCFAs (namely acetate, propionate and 
butyrate) exert multiple beneficial effects in the normal colon physiology, their 
role as cancer-preventing/treating agents has received special attention by 
several researchers (Scheppach, Bartram et al. 1995; Kim, Park et al. 2014; 
Kasubuchi, Hasegawa et al. 2015). These microbial compounds are produced 
by anaerobic microorganisms able to ferment polysaccharides, 
oligosaccharides, proteins, peptides and glycoproteins in the colon, including 
Firmicutes, Clostridium, Bifidobacterium, Propionibacterium, Bacteroides and 
Lactobacillus (Neish 2009; Adom and Nie 2013; Layden, Angueira et al. 2013; 
Kim, Park et al. 2014). The ability to produce butyrate requires a specific 
enzymatic process via butyryl-CoA: acetate CoA-transferase (mainly by 
Eubacterium, Roseburia, Anaerostipes and Faecalibacterium prausnitzii 
species) or via butyrate kinase (in certain Clostridium and Coprococcus species) 
(Russell, Hoyles et al. 2013; Kim, Park et al. 2014; Zeng, Lazarova et al. 2014). 
Firmicutes species are able to produce butyrate by both pathways (Russell, 
Hoyles et al. 2013; Kim, Park et al. 2014; Zeng, Lazarova et al. 2014). 
Propionate is generally produced by Bacteroides, Firmicutes and 
Propionibacterium species which involve the succinate, acrylate and 
propanediol pathways (Hosseini, Grootaert et al. 2011; Russell, Hoyles et al. 
2013; Kim, Park et al. 2014), while acetate is produced by acetogenic bacteria 
such as Acetobacterium species, Clostridium aceticum and Propionibacterium, 
able to perform reductive acetogenesis from formate (Russell, Hoyles et al. 
2013; Kim, Park et al. 2014). Normally, these bacteria exist in a mutually 
beneficial symbiotic relationship in the human colon, providing the proper 
amount of these SCFAs to help maintain colon homeostasis (Cipe, Idiz et al. 
2015).  
Indeed, it has recently been shown, that some changes in SCFAs production is 
directly associated with alterations in the intestinal microbiota modulated by 
numerous extrinsic factors such as diet, age, medication, treatment (drugs, 
radiation, surgery), stress and diseases (Zhu, Michelle Luo et al. 2011; Cipe, 
Idiz et al. 2015). These changes in the normal symbiotic state (normobiosis) can 
be associated with many intestinal disorders, such as obesity, inflammatory 
bowel disease and colorectal cancer (Chen, Liu et al. 2012; Di Mauro, Neu et 
al. 2013; Sobhani, Amiot et al. 2013; Zeng, Lazarova et al. 2014).  In this regard, 
the main challenge is to characterize the differences between a “healthy” 
intestinal microbiota and a CRC microbiota and its consequences on SCFAs 
production. This study would facilitate future studies towards the development 
of novel strategies for the diagnosis, treatment, and prevention of colorectal 
cancer (Cipe, Idiz et al. 2015). 
 
2. Intestinal microbiota and short-chain fatty acids in colorectal cancer 
patients 
Several factors (genetic and environmental) are involved in the transformation 
of normal colonic epithelium to adenoma and CRC (Keku, Dulal et al. 2015). It 
has been demonstrated that specific changes in human intestinal microbiota 
(dysbiosis) can also be associated with CRC development, especially in 
sporadic cases (Sobhani, Tap et al. 2011; Sobhani, Amiot et al. 2013; Gao, Guo 
et al. 2015). These changes support the hypothesis that “colon cancer may be 
a bacteria-related disease” (Sobhani, Amiot et al. 2013; Gao, Guo et al. 2015), 
and that specific bacterial species can be involved in CRC pathogenesis 
(Ohigashi, Sudo et al. 2013; Geng, Song et al. 2014; Cipe, Idiz et al. 2015; Gao, 
Guo et al. 2015)  (Figure 1). 
The majority of studies have shown a significant difference between the bacteria 
genera associated with cancerous and non-cancerous intestinal tissue or fecal 
samples (Sobhani, Amiot et al. 2013; Gao, Guo et al. 2015; Keku, Dulal et al. 
2015). The intestine microbial composition of CRC patients is usually increased 
in the following genera: Lactococcus, Fusobacterium, Prevotella, 
Streptococcus, Bacteroides (Sobhani, Tap et al. 2011; Gao, Guo et al. 2015; 
Keku, Dulal et al. 2015). It has been demonstrated that some bacteria have a 
complex arsenal of virulence factors which allow them to colonize and persist in 
the intestine, inducing chronic inflammation, accumulated mutations by DNA 
damage through superoxide radicals, genotoxin formation, increased T-cell 
proliferation and biosynthesis of procarcinogenic compounds that interfere with 
cell cycle regulation contributing to colorectal carcinogenesis (Yang and Jobin 
2014; Cipe, Idiz et al. 2015; Gao, Guo et al. 2015; Leung, Tsoi et al. 2015; Nistal, 
Fernandez-Fernandez et al. 2015).  
Escherichia coli (E. coli, a member of Enterobacteriaceae family) and 
Fusobacterium nucleatum  (F. nucleatum) are the main bacteria associated with 
CRC cases and commonly over-represented in many tumor tissues from CRC 
patients (Sobhani, Amiot et al. 2013; Yang and Jobin 2014; Gao, Guo et al. 
2015; Keku, Dulal et al. 2015; Leung, Tsoi et al. 2015). Interestingly, in healthy 
individuals, Enterobacteriaceae constitute only a small fraction (less than 1%) 
of the gut microbiota, but E. coli in particular becomes dominant in the gut 
microbiota of individuals with inflammatory bowel disease (IBD), in several 
animal models of gut inflammation and in CRC cases (Yang and Jobin 2014). 
An interesting fact is that, E. coli strains isolated from individuals with IBD and 
CRC are often adherent and invasive, displaying several pathogenic properties 
which modulate host cells and mediate carcinogenesis, and are in this way 
classified as inflammation drivers of the CRC formation (Leung, Tsoi et al. 
2015). Beyond that, F. nucleatum is an opportunistic bacterium able to induce 
chronic inflammation and interact directly or indirectly with colonocytes leading 
to uncontrolled cell proliferation, dysbiosis and intestinal tumorigenesis (Kostic, 
Chun et al. 2013; Leung, Tsoi et al. 2015). Recently, F. nucleatum has been 
considered as an indicator of disease progression and tumor severity (Leung, 
Tsoi et al. 2015). Likewise, it has also been shown that Streptococcus 
gallolyticus/bovis (involved with intestinal inflammatory disorders) is present in 
20-50% of CRC and in less than 5% of normal colon (Gao, Guo et al. 2015). 
 In contrast, patterns that preserve microbial intestinal homeostasis, such as 
Bifidobacterium, Lactobacillus, Clostridium and Ruminococcus are under-
represented in CRC patients compared to healthy individuals (Sobhani, Tap et 
al. 2011; Chen, Liu et al. 2012; Sobhani, Amiot et al. 2013; Nistal, Fernandez-
Fernandez et al. 2015). 
Changes in the intestinal microbial community of CRC patients affect the 
amount and types of metabolites produced by colonic microbes. In this regard, 
some studies have reported that changes in colon microbiota are associated 
with a decrease in SCFA concentrations accompanied by an elevated pH in 
patients with CRC compared to healthy individuals (Sobhani, Tap et al. 2011; 
Ohigashi, Sudo et al. 2013; Sobhani, Amiot et al. 2013) (Figure 5). However, it 
is not yet understood if the changes in colon microbiota are a cause or a 
consequence of CRC development. In this context, it is important to characterize 
the possible over- and under-represented bacteria, exploring the relationship 
between changes in the colon microbiota composition with the production of 
bacterial metabolites as well as the tumorigenesis process of CRC. The 
relationship between diet, intestinal microbiota, SCFA metabolism and 
colorectal cancer is very complex and remains an important area of research. 
In the following sections, the role of SCFAs in normal conditions is discussed 
(their concentrations, metabolism, beneficial effects, transporters and 
receptors), as well as how these microbial metabolites, namely butyrate, 
propionate and acetate, can be useful in the prevention and/or treatment of 
CRC. 
 
  
Figure 1: Schematic representation of the most important changes in the microbiota from 
normal to colorectal cancer (CRC).  
 
3. Short-chain fatty acid concentrations in colon 
Short chain fatty acids (SCFAs) are the major products of bacterial fermentation 
of undigested dietary fiber and of starches resistant to digestion in the human 
colon (Adom and Nie 2013; Zeng, Lazarova et al. 2014). Indeed, a diet rich in 
fiber, resistant starches and complex carbohydrates leads to increases the 
levels of colonic SCFAs (Adom and Nie 2013; Layden, Angueira et al. 2013). 
SCFAs are carboxylic acids with aliphatic tails ranging from formic (C1), acetic 
(C2), propionic (C3), butyric (C4), valeric (C5) and caproic (C6) acid (Layden, 
Angueira et al. 2013). SCFAs constitute approximately two-thirds of the colonic 
anions (~150 mM). At physiological pH, they predominate in a dissociated form, 
specifically acetate, propionate, butyrate, valerate and caproate (Nedjadi, 
Moran et al. 2014). The rate and amount of SCFAs produced depend on diet 
composition (which determines the type of the substrate fermented), on the 
microbiota present in the colon and on gut transit time (Mortensen and Clausen 
1996; Macfarlane and Macfarlane 2012; Zeng, Lazarova et al. 2014). SCFAs 
are usually generated by carbohydrate fermentation according to the following 
equation (Zeng, Lazarova et al. 2014) : 
59 C6H12O6 + 38 H2O = 60 CH3COO- (Acetate) + 22 CH5COO- (Propionate) + 18 CH7COO- 
(Butyrate) + 96 CO2 + 256 H+ + heat + gases 
Acetate, propionate and butyrate are the three major colonic SCFAs. They are 
found in the colon at considerably high concentrations, ranging from 40–80 mM 
to 10–25 mM, respectively (Scheppach, Bartram et al. 1995; Alles, Hartemink 
et al. 1999; Jenkins, Kendall et al. 1999; Topping and Clifton 2001). Although 
not constant, the ratio of SCFA concentrations in the colonic lumen is 
approximately 60% acetate, 25% propionate and 15% butyrate (Scheppach, 
Bartram et al. 1995; Canani, Costanzo et al. 2011). In addition, the 
concentration of acetate, propionate and butyrate vary along the human 
intestine as follows: approximately 130 ± 9 mmol/L in the cecum (where the 
amounts of fermentable substrates are higher), ~ 80 ± 11 mmol/L in the 
descending colon and ~ 13  ± 6 mmol/L in the rectum (Cummings, Pomare et 
al. 1987; Du, Shi et al. 2014).  This variation in acid concentration is linked with 
pH differences along the human colon, namely: ~ 5.5-6.8 in the cecum and ~ 
6.6-7 in the descending colon (Figure 2).  The higher acidity is associated with 
more active carbohydrate fermentation in the cecum than in the sigmoid/rectum, 
where the pH is more alkaline (Cummings, Pomare et al. 1987). 
 
 
 
 
Figure 2: Regions of the colon and rectum with respective total amount of SCFA 
concentrations and pH. 
 
4. Metabolism of short-chain fatty acids in the colon 
It has been demonstrated that SCFAs derived from microbial metabolism in the 
gut play a central role in colon homeostasis (den Besten, Lange et al. 2013; den 
Besten, van Eunen et al. 2013). SCFAs are substrates for energy metabolism 
by the epithelial cells, converted by colonocytes into glucose, ketone bodies, 
and amino acids (Hadjiagapiou, Schmidt et al. 2000; den Besten, Lange et al. 
2013; Kasubuchi, Hasegawa et al. 2015). Previous studies showed a 
preferential utilization of SCFAs in the order of butyrate ˃ propionate ˃ acetate 
by colonocytes (Adom and Nie 2013). Butyrate is the major energy source for 
colonocytes, but also for other cells from liver and muscle tissues (Ahmad, 
Krishnan et al. 2000; Adom and Nie 2013; Russell, Hoyles et al. 2013; Zeng, 
Lazarova et al. 2014). Butyrate is usually metabolized to acetyl-CoA by 
colonocytes (Donohoe, Collins et al. 2012) while propionate and acetate can 
modulate lipogenesis and gluconeogenesis (Comalada, Bailon et al. 2006). It 
has been demonstrated that propionate is largely metabolized in the liver 
(Russell, Hoyles et al. 2013) and also acts as substrate for gluconeogenesis 
inhibiting cholesterol synthesis in hepatic tissue (Adom and Nie 2013; Scott, 
Gratz et al. 2013). Acetate can be oxidized in the tricarboxylic acid (TCA) cycle, 
used as a substrate for the synthesis of cholesterol, long-chain fatty acids or as 
a co-substrate for glutamine and glutamate synthesis by colonocytes (Adom and 
Nie 2013; den Besten, Lange et al. 2013; Zeng, Lazarova et al. 2014). This 
compound also enters systemic circulation and can be used by many tissues, 
including heart, adipose, kidney, liver and muscle (den Besten, Lange et al. 
2013; Scott, Gratz et al. 2013). 
In contrast to normal colonocytes, CRC cells primarily undergo aerobic 
glycolysis instead of oxidative metabolism (Donohoe, Collins et al. 2012). In this 
case, it has been proposed that the preference of CRC cells for glucose 
metabolism instead SCFAs as an energy source explains the opposite effects 
on the growth of normal versus cancerous colonocytes (Donohoe, Collins et al. 
2012). However, this paradox is still poorly understood and more studies are 
needed to understand how the metabolic differences between normal and 
cancerous colonocytes can be used to inhibit tumorigenesis in CRC. 
 
5. Short-chain fatty acid transporters and receptors  
Production of total colonic SCFAs is difficult to determine because more than 
95% of these SCFAs are water soluble and rapidly absorbed and metabolized 
by colonocytes (Roy, Kien et al. 2006; Kim, Park et al. 2014; Zeng, Lazarova et 
al. 2014). Only a small amount of these SCFAs leave the colon intact and can 
be transported via the blood circulation to other organs (Roy, Kien et al. 2006; 
Ganapathy, Thangaraju et al. 2013; Kim, Park et al. 2014).  
Though distinct mechanisms for SCFAs absorption across the plasma 
membrane of colonocytes in various species have been postulated (Hijova and 
Chmelarova 2007; Nedjadi, Moran et al. 2014), most studies on SCFAs 
transporters both show in intestinal epithelial cells and CRC cells used butyrate 
transport as a model (Hadjiagapiou, Schmidt et al. 2000; Ganapathy, 
Thangaraju et al. 2013; Goncalves and Martel 2013) and information concerning 
other SCFAs like propionate or acetate transport is still rare. 
SCFAs enter intestinal epithelial cells through passive diffusion of protonated 
SCFAs or mediated transport by monocarboxylate transporters (MCTs) 
(Goncalves and Martel 2013). The MCT family comprises 14 members, 
however, only the first four (MCT-1 - 4) are known to mediate the proton-coupled 
transport of monocarboxylic acids across the plasma membrane (Pinheiro, 
Longatto-Filho et al. 2012; Halestrap 2013). The main function of  MCT has 
been associated with the uptake or efflux of monocarboxilic acids through the 
plasma membrane, according to the cell metabolic needs, characterized by a 
high affinity transport for L-lactate, pyruvate, acetate, propionate, D,L-β-
hydroxybutyrate and acetoacetate (Halestrap and Meredith 2004). 
SMCT-1 and MCT-1 have been identified as the main monocarboxylate 
transporters, responsible for the uptake of SCFAs across the membrane of 
intestinal cells (den Besten, Lange et al. 2013; Goncalves and Martel 2013; Kim, 
Park et al. 2014). SMCT-1 is a Na+-coupled transporter for a variety of SCFAs, 
especially butyrate (Canani, Costanzo et al. 2011; Ganapathy, Thangaraju et al. 
2013), while MCT-1 is a H+-coupled transporter for SCFAs and related organic 
acids, which transports these molecules across the plasma membrane 
depending on the H+  eletrochemical gradient (Kim, Park et al. 2014). MCT-1 is 
expressed widely in many different cell types and has been characterized as the 
primary butyrate transporter in colon epithelial cells (Canani, Costanzo et al. 
2011; Fung, Cosgrove et al. 2012).  
MCT-1 also exports lactate to the extracellular milieu, which is a potentially 
cytotoxic metabolic by-product of glycolysis, indicating that it plays a dual role 
to enhance CRC cell survival (Fung, Cosgrove et al. 2012). In contrast, it has 
been shown that CRC cells silence SMCT-1 by DNA methylation (Hadjiagapiou, 
Schmidt et al. 2000; Thangaraju, Cresci et al. 2008; Babu, Ramachandran et al. 
2011; Ganapathy, Thangaraju et al. 2013; Goncalves and Martel 2013) which 
confers a selective advantage to escape butyrate-induced cell death through 
limitation of butyrate uptake (Li, Myeroff et al. 2003; Ganapathy, Thangaraju et 
al. 2013). 
In addition to SCFA transporters, their receptors constitute a new and rapidly 
growing field of research, as more functions of SCFA receptors have been 
discovered. SCFAs are able to activate cells through several cell-surface G-
protein-coupled receptors (GPRs), especially GPR41 and GPR43 (Kim, Kang 
et al. 2013; Kuwahara 2014), involved in immune response regulation (Kim, 
Kang et al. 2013). These two GPRs are expressed not only by intestinal 
epithelial cells where SCFAs are produced, but also at multiple other sites 
considered to be metabolically important such as adipose tissue and pancreatic 
islets (Layden, Angueira et al. 2013). Recent studies have identified the cell-
surface receptors GPR41, GPR43 and GPR109A as essential for the biologic 
effects of SCFAs in the colon (Ganapathy, Thangaraju et al. 2013; Kim, Kang 
et al. 2013). GPR41 (also called free fatty acid receptor 3; FFA3) expressed in 
colon cells is activated by SCFAs, primarily by butyrate and propionate (Layden, 
Angueira et al. 2013; Kuwahara 2014), while GPR43 (free fatty acid receptor 2; 
FFA2) has a more potent affinity for propionate and acetate (Ganapathy, 
Thangaraju et al. 2013; Layden, Angueira et al. 2013). In addition, GPR109A 
(hydroxycarboxylic acid receptor 2), a receptor for niacin and vitamin B3, is also 
a receptor for butyrate in colon cells (Kim, Park et al. 2014; Kuwahara 2014). 
Nevertheless, the regulation of SCFA transporters and receptors in CRC cells 
is still poorly understood, and more studies are needed to grasp how these 
metabolites can influence the regulation of their transporters and receptors in 
CRC cells.  
6. Physiological effects of short-chain fatty acids in normal colon 
It is known that SCFAs play a significant role in maintaining the normal 
physiological functions of the colonic mucosa, serving as regulators of 
intracellular pH, cell volume and other functions associated with ion absorption 
and gut motility of intestinal epithelial cells (Kim, Park et al. 2014; Ohtani 2015). 
SCFAs are the major energy source for colonocytes and can also be used for 
de novo synthesis of lipids as referred before (Scharlau, Borowicki et al. 2009; 
Kim, Kang et al. 2013; Kasubuchi, Hasegawa et al. 2015). 
In addition, it has been demonstrated that SCFAs have a suppressive role in 
inflammation and cancer of the intestine (Kim, Park et al. 2014; Keku, Dulal et 
al. 2015). Though the anti-inflammatory mechanism of SCFAs is still not 
adequately clarified, a recent study showed that, once absorbed by intestinal 
epithelial cells and/or immune cells, SCFAs (especially butyrate and propionate) 
inhibit the activity of histone deacetylases (HDACs), promoting the 
hyperacetylation of histones and trans-activating gene expression, which results 
in downregulation of pro-inflammatory cytokines, such as interleukin-6 (IL-6) 
and IL-12 (Ohtani 2015). 
Interestingly, it has been demonstrated that total SCFAs and/or local differences 
in SCFA concentrations along the intestinal tract might be implicated in diseases 
of the colon, especially gastrointestinal disorders and colorectal cancer (Wong, 
de Souza et al. 2006). For example, a decreased level of butyrate in the 
environment of colonocytes has been suggested to contribute to the genesis of 
ulcerative colitis (UC) and to a significantly increased risk of colon cancer (Huda-
Faujan, Abdulamir et al. 2010). Therefore, increased production and greater 
distal delivery of SCFAs may result in a protective effect against these diseases 
(Wong, de Souza et al. 2006). 
SCFAs, especially butyrate, are involved not only in the regulation of expression 
of several genes, cell proliferation, differentiation and apoptosis to promote 
colonic wellbeing in epithelial cells, but in the prevention of colon cancer by 
promoting growth inhibition, cell-cycle arrest and apoptosis in transformed 
colonocytes (Sakata 1987; Comalada, Bailon et al. 2006; Fung, Cosgrove et al. 
2012; Ganapathy, Thangaraju et al. 2013; Kim, Park et al. 2014). Furthermore, 
as described in more detail below, it has been shown that SCFAs exhibit anti-
cancer activities acting through different mechanisms to induce cell death in 
CRC cells (Comalada, Bailon et al. 2006; Lan, Lagadic-Gossmann et al. 2007; 
Zhang, Zhou et al. 2010; Adom and Nie 2013; Marques, Oliveira et al. 2013; 
Oliveira, Pereira et al. 2015). 
 
7. Mechanisms of action of short-chain fatty acids in colorectal cancer 
cells: prevention and therapeutic implications 
A variety of biological effects of SCFA have been reported, and a vast number 
of experimental studies keep showing new aspects of these molecules.  Most 
notably, it has been shown that the SCFAs butyrate, propionate and acetate 
induce apoptosis in CRC cells but not in normal cells (Sakata 1987; Comalada, 
Bailon et al. 2006; Sauer, Richter et al. 2007; Zhang, Zhou et al. 2010; Tang, 
Chen et al. 2011; Imbernon, Whyte et al. 2014). The anti-cancer effect of SCFAs 
is also supported by epidemiological studies suggesting an inverse relation 
between the level of dietary fibers and the incidence of CRC (Scheppach, 
Bartram et al. 1995; Sengupta, Muir et al. 2006; Zeng, Lazarova et al. 2014). 
These dietary components influence the risk of human colon cancer through 
diverse mechanisms, which include activation of cell death through different 
processes depending on the concentration, pH and cell type. The mechanisms 
by which these SCFA are metabolized and regulate cell proliferation, 
differentiation, cell death and their role in inflammation in CRC cells will be 
discussed below. 
 
7.1 Butyrate 
Butyrate is considered the most potent of the SCFAs regarding prevention and 
inhibition of colon carcinogenesis, and its antitumor effects have been the most 
studied (Scheppach, Bartram et al. 1995; Comalada, Bailon et al. 2006; 
Scharlau, Borowicki et al. 2009; Zhang, Zhou et al. 2010; Matthews, Howarth et 
al. 2012; Goncalves and Martel 2013). Butyrate’s protective effects against 
human colon cancer cells involve inhibition of cell differentiation, promotion of 
cell-cycle arrest, apoptosis and of inhibition of histone deacetylases (HDACs) 
(Table 1) (Hinnebusch, Meng et al. 2002; Comalada, Bailon et al. 2006; Zhang, 
Zhou et al. 2010; Donohoe, Collins et al. 2012; Fung, Cosgrove et al. 2012; 
Matthews, Howarth et al. 2012).  
Previous studies in CRC cell lines showed that induction of apoptosis and cell 
cycle arrest in G0-G1 or G2-M by butyrate could occur via p53-dependent or 
p53- independent pathways (Archer, Meng et al. 1998; Mariadason, Velcich et 
al. 2001; Matthews, Howarth et al. 2012). Zhang and co-workers analyzed the 
cytotoxicity mechanism of butyrate (0-40 mM) in human colon cancer (RKO 
cells) and showed that it exhibited a strong growth inhibitory effect against RKO 
cells, inducing the intrinsic apoptosis pathway characterized by DNA 
fragmentation and activation of caspase-9 and caspase-3 (Zhang, Zhou et al. 
2010). The expression of anti-apoptotic protein Bcl-2 decreased, whereas the 
apoptotic protein Bax increased in a dose-dependent manner during butyrate-
induced apoptosis (Zhang, Zhou et al. 2010). 
Critical tumorigenesis signaling pathways that regulate cell proliferation, cell 
migration and apoptosis, including extracellular signal-regulated protein kinase 
1/2 (ERK1/2), C-Jun N-terminal kinase (JNK) and p38 MAPK (p38) were also 
studied (Zhang, Zhou et al. 2010). An important point is that a high levels of 
ERK1/2 activation/expression are associated with cell proliferation and survival 
in various cancer cells, including CRC (Davido, Richter et al. 2001; Zhang, Zhou 
et al. 2010). However, it was demonstrated that butyrate-induced growth 
inhibition occurs with inactivation or downregulation of ERKs in RKO and HT-29 
cells, respectively (Davido, Richter et al. 2001; Zhang, Zhou et al. 2010). 
Moreover, activation of the JNK MAPK pathway played an important role in 
butyrate-induced apoptosis in RKO cells (Zhang, Zhou et al. 2010). 
Matthews et al 2012, showed that butyrate (5 mM) induced apoptosis and G2-
M arrest mediated by alterations in the oxidative pentose pathway, reduction in 
glutathione availability and glucose consumption, and increased levels of 
reactive oxygen species (ROS) (Matthews, Howarth et al. 2012). He et al (2007) 
observed that downregulation of GLUT-1 expression was associated with 
apoptosis-induced by butyrate (5 mM) in HT-29 cells, also correlated with an 
increase in the expression and activity of MCT-1 as a mechanism to maximize 
intracellular availability of butyrate (He, Li et al. 2007). Some authors state that 
butyrate inhibits CRC cell proliferation and induces cell death due to its 
inefficient metabolism associated with the Warburg effect and nuclear 
accumulation in transformed colonocytes, where it acts as a HDAC inhibitor 
(Shao, Gao et al. 2004; Wong, de Souza et al. 2006; Donohoe, Collins et al. 
2012). Robert Li and co-workers (2006) confirmed accumulation of acetylated 
histone 3 (H3) as a reslt of butyrate treatment in CRC cells. Butyrate further 
contributes to hyperacetylation through conversion to acetyl-CoA and 
stimulation of histone acetyltransferase (HAT) activity (Barshishat, Polak-
Charcon et al. 2000; Li and Li 2006). However, the metabolic state of the cell 
influences the amount of intranuclear butyrate and acetyl-CoA levels 
determining whether butyrate functions as a HDAC inhibitor or stimulate HATs, 
thus epigenetically regulating the expression of different target genes 
(Mariadason, Velcich et al. 2001; Donohoe, Collins et al. 2012). Deregulation of 
the expression or activity of HATs and HDACs may lead to alterations in gene 
expression profiles, associated with reactivation or silencing of important genes 
for cancer progression, differentiation and apoptosis (Sambucetti, Fischer et al. 
1999; Iacomino, Tecce et al. 2001; Marchion and Munster 2007). In this context, 
Archer et al 1998, showed that butyrate (0-20 mM) increased p21 expression 
through a process involving histone hyperacetylation, and that p21 was required 
for butyrate-mediated growth arrest in colon cancer cells (HT-29 and HCT116). 
Furthermore, compared to propionate and acetate, butyrate has strong anti-
inflammatory properties, and this effect is mediated mainly by inhibition of TNF-
α production, nuclear factor-kappa B (NF-κB) activity and IL-8, 10 -12 
expression in immune and colonic epithelial cells (Tedelind, Westberg et al. 
2007; Kim, Park et al. 2014; Zeng, Lazarova et al. 2014). Yet, little is known 
about the role of butyrate on inflammation in CRC cells. 
The main conclusion is that the exposure of the human colon to butyrate might 
protect against CRC by reducing survival and inducing cell death in CRC cells 
by several mechanisms discussed above. It is worth noting that cells that 
metabolize butyrate at a higher rate, are usually less susceptible to its 
apoptosis-inducing effects. This may explain why normal colonocytes are 
unaffected by high levels of this SCFA in the colon, since they preferentially use 
butyrate as an energy source, in contrast with CRC cells which seem to prefer 
glucose.  
Table 1 - Effects of SCFA butyrate in colorectal cancer cells. 
  Butyrate  
Human 
colorectal 
cancer 
cell lines 
Concentration 
(mM) 
 
Effects 
 
Reference 
    
HCT116 
HT-29 
0 - 20 p21 is required for butyrate-mediated 
growth arrest  
Archer et 
al, 1998 
Caco-2 
SW620 
2 - 10 Cell cycle arrest and apoptosis more 
effective in undifferentiated cells, 
whereas differentiated cells were 
essentially resistant to butyrate effects 
Mariadason 
et al, 2001 
HT-29  Growth inhibition by the downregulation 
of ERK1/2 
Davido et 
al, 2001 
HCT116 
HT-29 
1 
5 
Cell growth arrest, differentiation, 
apoptosis, induction of histone H4 
hyperacetylation 
Hinnebusch 
et al, 2002 
HT-29 1 - 8 Inhibition of cell proliferation, induction 
of differentiation and apoptosis 
Comalada, 
2006 
HT-29 5 - 40 Modulation of histone acetylation Kiefer et al, 
2006 
HT-29 5 Downregulation of the GLUT-1 
expression mediates apoptosis  
He et al, 
2007 
LT92 
HT-29 
0 - 50 Induction of GSTs as a possible 
mechanism of chemoprevention 
Scharlau et 
al, 2009 
RKO 0 - 40 Inhibition of cell proliferation involving 
inactivation of ERK MAPK, induction of 
apoptosis via activation of caspase-9 
and caspase-3 
Zhang et al, 
2010 
Caco-2 5 Induction of apoptosis, G2-M arrest, 
alterations in the oxidative pentose 
pathway 
Matthews 
et al, 2012 
RAW264.7* 0 – 1.200 µmol/L Decrease of proinflammatory factors 
with an increase in the antiinflammatory 
cytokine 
 
 
Liu et al, 
2012 
 
*Murine macrophage cell line 
 
 
 
7.1   Propionate 
Though propionate exerts an anti-neoplastic effect in colorectal cancer cells and 
has a mechanisms of action similar to butyrate, there are less published studies 
with this SCFA than with butyrate (Kiefer, Beyer-Sehlmeyer et al. 2006; 
Hosseini, Grootaert et al. 2011) (Table 2). 
Jan and co-workers showed that propionate (10- 40 mM) induced typical signs 
of apoptosis in human CRC cell lines, with loss of mitochondrial membrane 
potential (∆ᴪm), generation of ROS, cytochrome c release, caspase-3-
processing and nuclear chromatin condensation (Jan, Belzacq et al. 2002). 
Matthews and co-workers demonstrated that at lower doses (5 mM) propionate 
also induced apoptosis, characterized by an elevated ROS production and 
decreased glucose oxidation after 48 h of treatment in the Caco-2 colon cancer 
cell line (Matthews, Howarth et al. 2012). Tang et al. showed that propionate 
treatment (3 -10 mM) induces ROS generation and loss of mitochondrial 
membrane potential (∆ᴪm) with autophagy induction to degrade damaged 
mitochondria in HCT116 cells, showing in this case that propionate-triggered 
autophagy serves as an adaptive strategy to delay mitochondria-mediated cell 
death in CRC cells (Tang, Chen et al. 2011).  
It has been demonstrated that propionate, like butyrate, also acts as an inducer 
of histone acetylation in CRC cells, which is possibly associated with a 
modulated growth response of tumorigenic lesions in the gut (Kiefer, Beyer-
Sehlmeyer et al. 2006; Hosseini, Grootaert et al. 2011; Kim, Park et al. 2014). 
In this regard, Kiefer et al showed that propionate alone (2.5 – 40 mM) or in 
combination with butyrate or acetate induced significant histone acetylation in 
HT-29 cells. In addition, another study demonstrated that propionate-induced 
growth inhibition, like butyrate, involves downregulation of ERK1/2 in HT-29 
cells (Davido, Richter et al. 2001). 
Furthermore, it has been shown that propionate has anti-inflammatory 
properties in the gut, comparable to those already described for butyrate 
(Tedelind, Westberg et al. 2007; Liu, Li et al. 2012; Kim, Park et al. 2014). 
Tedelind et al 2007, observed that the anti-inflammatory activity of propionate 
(0.3 - 30 mM) involves the inhibition of the NF-κB pathway and suppression of 
IL-6 release in Colo320DM cells. 
Taken together, these findings suggest that propionate could be effective in the 
prevention and treatment of some colon alterations, including CRC. 
Nevertheless, further studies both in vitro and in vivo are required to understand 
its real role alone and in combination with other SCFAs, as discussed below. 
 
 
Table 2- Effects of SCFA propionate in colorectal cancer cells. 
 
  Propionate  
Human 
colorectal 
cancer cell 
lines 
Concentration 
(mM) 
 
Effects 
 
Reference 
    
HT-29 
 
 Growth inhibition by the downregulation of 
ERK1/2 
Davido et 
al. 2002 
HT-29 
Caco-2 
0 - 40 Decrease of viability/apoptosis with 
mitochondrial alterations 
Jan et al. 
2002 
HT-29 20 - 40 Modulation of histone acetylation Kiefer et al, 
2006 
HT-29 2 - 16 Antiproliferative effect Comalada, 
2006 
HT-29 30 Apoptosis at pH 7.5 
Necrosis at pH 5.5 
Lan et al, 
2007 
Colo320DM 0,3 - 30 Inhibition of the NF-kB pathway Tedelind et 
al, 2007 
HCT116 0 - 10 Mitochondrial defects and autophagy Tang et al, 
2011b 
HCT116 
SW480 
0 - 3 Two types of programmed cell death 
(autophagy and apoptosis) 
Tang et al, 
2011a 
Caco-2 5 Induction of apoptosis, G2-M arrest, 
alterations in the oxidative pentose 
pathway. 
Matthews 
et al, 2012 
RAW264.7* 0 – 1.200 µmol/L Decrease of proinflammatory factors with an 
increase in the antiinflammatory cytokine 
Liu et al, 
2012 
*Murine macrophage cell line 
 
 
 
 
7.2 Acetate 
Acetate has been the least studied of the three most relevant SCFAs (table 5). 
Initially, Jan and co-workers showed that acetate (0-40 mM) decreased the 
viability and induced typical signs of apoptosis in the colon adenocarcinoma cell 
line HT-29, including loss of mitochondrial membrane potential, generation of 
ROS, caspase-3 processing and nuclear chromatin condensation (Jan, Belzacq 
et al. 2002).  
Studies in the yeast species Saccharomyces cerevisiae first demonstrated that 
acetic acid induced a mitochondria-mediated apoptotic process (Pereira, Silva et 
al. 2008; Guaragnella, Zdralevic et al. 2012) with several features similar to 
apoptosis mediated by SCFAs in CRC cells. Indeed, alterations in mitochondria 
were identified in yeast, including production of ROS, mitochondrial swelling, 
decrease of ΔΨm (Ludovico, Rodrigues et al. 2002), mitochondrial 
fragmentation/degradation (Fannjiang, Cheng et al. 2004), mitochondrial outer 
membrane permeabilization (MOMP) with consequent release of pro-apoptotic 
factors like cytochrome c, yeast apoptosis inducing factor 1 (Aif1p) and Nuc1p 
(yeast ortholog of EndoG) (Ludovico, Rodrigues et al. 2002; Wissing, Ludovico 
et al. 2004; Kroemer, Galluzzi et al. 2007). The yeast orthologs of the mammalian 
VDAC (voltage-dependent anion channel) and ANT (adenine nucleotide 
transporter) were shown to play a role in MOMP and cytochrome c release during 
acetic acid-induced apoptosis in yeast (Pereira, Camougrand et al. 2007) Later, 
vacuolar membrane permeabilization (VMP) and release of Pep4p, yeast 
cathepsin D (CatD), from the lysosome-like vacuole to the cytosol, were observed 
in yeast cells exhibiting apoptotic cell death induced by acetic acid (Pereira, 
Chaves et al. 2010). In that study, it was also shown that, once in the cytosol, 
Pep4p played an important role in mitochondrial degradation through an 
autophagic-independent process, which protected yeast cells from acetic acid-
induced apoptosis. Recently, it was demonstrated that both the protective 
function of Pep4p and its role in mitochondrial degradation during acetic acid-
induced apoptosis in yeast depend on Pep4p proteolytic activity, and is 
complemented by heterologous expression of human CatD (Pereira, Azevedo et 
al. 2013; Oliveira, Pereira et al. 2015). 
Taking into account the aforementioned results, we therefore hypothesized if 
similar events could occur in response to acetate in CRC cells (Figure 3). We 
showed that acetate treatment in CRC cells (0 - 140 mM and 0 - 220 mM, 
respectively to HCT-15 and RKO cells) decreased cell proliferation and induced 
apoptosis in CRC cells (Marques et al., 2013). We also demonstrated that the 
process was characterized by DNA fragmentation, caspase-3 activation and 
phosphatidylserine exposure to the outside leaflet of the plasma membrane with 
appearance of a sub-G1 population (Marques et al., 2013) (Figure 3). 
We also found that acetate induced lysosome membrane permeabilization (LMP) 
with cathepsin D (CatD) release to the cytosol. In this context, we showed that 
CatD, but not CatB and CatL (also overexpressed in CRC cells), has an anti-
apoptotic role in acetate-induced apoptosis (Marques et al., 2013). We next 
showed that acetate induced many mitochondrial dysfunctions as well as ROS 
(total and mitochondrial) production and an increase in mitochondrial mass 
accompanied by mitochondrial membrane depolarization (Oliveira et al., 2015). 
Additionally, we found an increase in the levels of mitochondrial proteins, namely 
the apoptosis inducing factor (AIF), the voltage dependent anion channel 
(VDAC1) and a subunit of the outer mitochondrial membrane translocator 
(TOM22) in CRC cells after acetate treatment (Oliveira et al., 2015). We could 
demonstrate that, like acetic acid in yeast, acetate-induced apoptosis is not 
associated with autophagy induction in CRC cells, but inhibition of CatD (with 
siRNA or pepstatin A) enhanced apoptosis associated with higher mitochondrial 
dysfunction and increased mitochondrial mass (Oliveira et al., 2015). This effect 
seems to be specific of CatD, since inhibition of Cathepsins B and L (using E-
64d, a well-known inhibitor of CaB and CatL) had no effect, nor were these 
proteases significantly released to the cytosol during acetate-induced apoptosis 
(Oliveira et al., 2015).  
The protective role of CatD demonstrated by our data can explains partly the 
CatD overexpression in some CRC clinical cases in comparison to normal colon 
mucosa. In summary, our group provided a novel CatD function in the 
degradation of damaged mitochondria when autophagy is impaired, which 
protects CRC cells from acetate-induced apoptosis and that CatD inhibitors could 
therefore enhance acetate-mediated cancer cell death, presenting a novel 
strategy for prevention or therapy of CRC. More recently, and aiming to get an 
overall picture of the effects of acetate on CRC cells, we focused the work in the 
transport mechanisms of acetate across the plasma membrane and its effects on 
the MCT expression and localization, as mentioned before (unpublished results) 
(Figure 3).  
As already referred for butyrate and propionate, the mechanism through which 
acetate mediates cell death and its anti-inflammatory effects are currently poorly 
understood. However, it has been shown that acetate also reduces the production 
of pro-inflammatory factors, including TNF-α, IL-1β, IL-6, while enhancing the 
production of the anti-inflammatory cytokine IL-10 (Tedelind, Westberg et al. 
2007; Liu, Li et al. 2012; Kim, Park et al. 2014) and induces inhibition of the NF-
κB pathway in CRC cells (Tedelind, Westberg et al. 2007). Although it has been 
demonstrated that acetate can affect the immune response in the colon, more 
studies are necessary in order to understand the precise role of this SCFA and 
its interaction with intestinal microbiota, host immune cells, colonocytes and CRC 
cells. In conclusion, as we previously reported, the idea of acetate, like butyrate 
and propionate, as chemopreventive agent should be also considered. However, 
more studies, especially using SCFA combinations, that mimic their relative 
concentrations in the colon, are necessary to support their combined use as a 
new strategy to potentiate their effects in CRC cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 - Effects of SCFA acetate in colorectal cancer cells. 
 
  Acetate  
Human 
colorectal 
cancer cell 
lines 
Concentration 
(mM) 
 
Effects 
 
Reference 
    
HT-29 
Caco-2 
0 - 40 Decrease of viability/Apoptosis with 
mitochondrial alterations 
Jan et al, 
2002 
HT-29 4 - 32 Ineffective in these concentrations Comalada, 
2006 
HT-29 80 Does not induce histone acetylation Kiefer et al, 
2006 
Colo320DM 2,4 Inhibition of the NF-kB pathway Tedelind et 
al, 2007 
HT-29 15 mM Apoptosis at pH 7.5 
Necrosis at pH 5.5 
Lan et al, 
2007 
RAW264.7* 0 – 1.200 µmol/L Decrease of proinflammatory factors with 
an increase in the antiinflammatory 
cytokine 
Liu et al, 
2012 
HCT-15 
RKO 
0 - 140 
0 - 220 
Induction of apoptosis/Inhibition of 
proliferation and partial lysosome 
permeabilization with CatD release to the 
cytosol 
Marques et 
al, 2013 
HCT-15 
RKO 
HCT116 
0 - 140 
0 - 220 
0 - 200 
Mitochondrial dysfunction/ inhibition of 
autophagy and active CatD involved in 
mitochondrial degradation independent of 
autophagy 
Oliveira et 
al, 2015 
HCT-15 
RKO 
0 - 70 
  0 - 110 
Acetate transport is mediated by SMCT-1 
or diffusion by aquaporins. Acetate 
treatment is involved with MCTs regulation 
and co-localization associated with 
changes in glucose metabolism. Acetate 
effects are potentiated by the combined 
treatment with 3BP (a well-known inhibitor 
of glycolysis) 
Oliveira et al 
(unpublished 
results) 
*Murine macrophage cell line 
 
 
 
 Figure 3: Schematic representation of different cell processes involved in apoptosis 
triggered by acetate in colorectal cancer cells. Different transporter systems which may 
mediate acetate uptake by CRC cells are represented. Acetate transport can be mediated by 
mocarboxylate transporters (MCT), such as SMCT-1 and MCT-1 (only in acetate pre-treated 
cells) or via passive diffusion by aquaporins. Acetate induces an increase in the expression of 
MCT-1, MCT-4 as well as of CD147 that after glycosylation leads to plasma membrane re-
localization of MCT-1 and glycolysis perturbation. Acetate also induces partial lysosome 
membrane permeabilization (LMP) with specific release of cathepspin D (CatD) into the cytosol, 
which protects cells from acetate-induced apoptosis. DNA fragmentation and mitochondrial 
dysfunctions (accumulation of reactive oxygen species ROS; increase of mitochondrial mass, 
decrease of mitochondrial membrane potential, ∆ᴪm; caspase 3 activation, and increase in the 
levels of different mitochondrial proteins such as apoptosis inducing factor, AIF; voltage 
dependent anion channel, VDAC1 and outer mitochondrial membrane translocator, TOM22) are 
other cellular events associated with acetate-induced apoptosis. Under these conditions 
autophagy is not induced and the inhibition of CatD (with pepstatin A or siRNA) enhanced 
acetate-induced apoptosis associated with a higher mitochondrial dysfunction. CatD plays a role 
in the degradation of damaged mitochondria when autophagy is impaired in CRC cells. 
Combined treatment (acetate + 3-bromopyruvate, 3BP, a well-known glycolysis inhibitor) 
potentiates the acetate effects, decreasing cell proliferation and inducing elevated rate of 
apoptosis.  
 
 
 
 
7.4. Combined effects of SCFAs 
Neither butyrate, propionate or acetate are available as the only metabolite 
present in the human colon, and therefore their combined effect should be taken 
into consideration.  Although there are few studies on the combined effect of 
SCFAs performed in CRC cells, Tang et al 2011a, using a combination of 
butyrate and propionate (1-3 mM), showed for the first time that SCFAs 
orchestrate two types of programmed cell death in colon cancer cells (HCT116 
and SW480). Butyrate and propionate treatment induced autophagy to dampen 
apoptosis, whereas inhibition of autophagy potentiated SCFA-induced 
apoptosis (Tang, Chen et al. 2011). Matthews and co-workers demonstrated 
that the combination (butyrate and propionate: 5 mM) induced cell cycle arrest 
in G2-M associated with a rapid and extensive apoptosis with changes in redox 
state and D-glucose metabolism in Caco-2 cells, compared to single treatments 
(Matthews, Howarth et al. 2012). In addition, Kiefer et al. showed that mixtures 
of acetate, butyrate and propionate (at molar ratios 75: 11 : 14, 69 : 16 : 15 and 
43 : 24 : 33, respectively) which mimic the relative concentrations occurring in 
the gut, modulated histone acetylation. However, they concluded that the 
histone acetylation was mainly due to additive effects of butyrate and 
propionate, but not due to acetate (Kiefer, Beyer-Sehlmeyer et al. 2006). Lan 
and co-workers showed that acetate and propionate (15 mM and 30 mM, 
respectively) produced by Propionibacterium freudereichii decreased 
proliferation and induced cell cycle arrest in G2/M, followed by a sequence of 
cellular events characteristic of apoptosis at pH 7.7, but induced necrosis at pH 
5.5 in colon cancer cells (HT-29) (Lan, Lagadic-Gossmann et al. 2007). This 
study demonstrated for the first time the impact of the extracellular pH prevailing 
within the colon (from 5.5 to 7.5) on the mode of cell death triggered by 
propionibacteria-produced SCFA in CRC cells (Lan, Lagadic-Gossmann et al. 
2007). In this regard, our group has recently characterized the potential of P. 
freudenreichii subsp. freudenreichii DSM 20271 as a producer of SCFAs 
(propionate and acetate) using several culture media to simulate the digestive 
stress process and the composition of digested products present in the colon 
(Marta et al unpublished results). Pure SCFAs, as well as the bacterial 
fermented broth, inhibited CRC cell proliferation and increased cell death. The 
results showed that co-culture of P. freudenreichii and CRC cells is possible and 
favourable for the bacteria and that P. freudenreichii could potentially be used 
as a probiotic in CRC prevention and/or treatment through its ability to produce 
SCFAs (Marta et al unpublished results).  
Although studies on the combined effects of SCFAs are still few, it seems that 
they have a greater effect in colorectal cancer cells compared with treatment 
with each SCFA separately. In summary, there is increasing evidence of the 
anti-neoplastic effects of SCFAs in CRC cells, which may be modulated by 
several aspects, namely the cell type, SCFA concentration/availability, 
extracellular pH, time of exposure to SCFAs, their absorption and metabolism. 
 
8. Final considerations 
The potential use of SCFAs in prevention and/or as adjuvants to conventional 
chemotherapy regimens of colorectal cancer is currently well supported by the 
data in the literature. Since the concentrations of SCFAs in colon cancer seem to 
be low, the generation of SCFAs in the colon could be improved with specific 
nutritional diet such as the intake of fibers and appropriate probiotics like 
Propionibacteria. It can be speculated that these microorganisms are able to 
metabolize complex fibers and produce high levels of SCFAs which function in 
vivo as tumor suppressor agents, resulting in the elimination of CRC cells and 
hence in the inhibition of colon tumor progression.  
In addition, as we reported previously that CatD protects CRC cells from acetate 
exposure, mediating a mitochondrial degradation process alternative to 
autophagy, suggesting that this could impact negatively the efficacy of acetate 
and probably of other therapeutics compounds. In this case, the use of CatD 
inhibitors in combination with strategies to increase acetate (or other SCFAs) 
concentrations in the colon, namely nutraceuticals, emerges as a novel strategy 
for prevention/ therapy of CRC. 
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